WO2012074126A1 - Bicyclic compound - Google Patents

Bicyclic compound Download PDF

Info

Publication number
WO2012074126A1
WO2012074126A1 PCT/JP2011/078010 JP2011078010W WO2012074126A1 WO 2012074126 A1 WO2012074126 A1 WO 2012074126A1 JP 2011078010 W JP2011078010 W JP 2011078010W WO 2012074126 A1 WO2012074126 A1 WO 2012074126A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
optionally substituted
ring
reaction
Prior art date
Application number
PCT/JP2011/078010
Other languages
French (fr)
Other versions
WO2012074126A9 (en
Inventor
Tsuneo Yasuma
Makoto Kamata
Tohru Yamashita
Hideki Hirose
Masataka Murakami
Asato Kina
Kazuko Yonemori
Ryo Mizojiri
Ikuo Fujimori
Takuya Fujimoto
Zenichi Ikeda
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2013006113A priority Critical patent/MX2013006113A/en
Priority to BR112013013417A priority patent/BR112013013417A2/en
Priority to SG2013041546A priority patent/SG190925A1/en
Priority to AU2011337565A priority patent/AU2011337565A1/en
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Priority to CA2819400A priority patent/CA2819400A1/en
Priority to CN201180066388.XA priority patent/CN103347872B/en
Priority to JP2013524677A priority patent/JP5824517B2/en
Priority to KR1020137016850A priority patent/KR20140001965A/en
Priority to ES11802168.2T priority patent/ES2536319T3/en
Priority to EA201390794A priority patent/EA201390794A1/en
Priority to EP11802168.2A priority patent/EP2649062B1/en
Publication of WO2012074126A1 publication Critical patent/WO2012074126A1/en
Priority to TNP2013000230A priority patent/TN2013000230A1/en
Priority to MA35965A priority patent/MA34713B1/en
Publication of WO2012074126A9 publication Critical patent/WO2012074126A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to a bicyclic compound having an acetyl-CoA carboxylase (in the present specification, sometimes to be abbreviated as ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity,
  • ACC acetyl-CoA carboxylase
  • diabetes hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like.
  • ACC is an enzyme, that converts acetyl-CoA to malonyl-CoA, and catalyzes a rate determining reaction in fatty acid
  • ACC plays a key role in controlling the balance between use of carbohydrate and fatty acid in the liver and skeletal muscle, and further, controlling insulin sensitivity in the liver, skeletal muscle and adipose tissue.
  • a reduced level of malonyl-CoA by ACC inhibition can promote a promotion in fatty acid oxidation, decreased
  • TG triglyceride
  • VLDL triglyceride-rich lipoprotein
  • long-term administration of a compound having an ACC inhibitory action can strikingly decrease the TG content of the liver and adipose tissues and selectively
  • a compound having an ACC inhibitory action is extremely useful for the prophylaxis or treatment of metabolic syndrome, obesity, hypertension, diabetes,
  • cardiovascular diseases associated with atherosclerosis and the like.
  • patent document 1 (WO 2010/050445) has reported the following compound.
  • A is an acyl group or an optionally substituted 5- or 6- membered aromatic ring group
  • ring M is an optionally condensed 5- to 7-membered ring which is . optionally further substituted;
  • ring P is an optionally further substituted 5-membered heterocycle
  • ring Q is an optionally further substituted 6- membered ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic heterocycle
  • ring P is an optionally further substituted 5-membered non-aromatic ring
  • ring Q is an optionally further substituted 6-membered aromatic ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic ring
  • R 1 is an optionally substituted Ci_ 6 alkyl group or an optionally substituted C 3 _ 6 cycloalkyl group
  • R A1 is a hydrogen atom or a Ci_ 6 alkyl group
  • R A2 , R A3 , R A4 , R A5 and R A7 are independently a hydrogen atom or a Ci_6 alkyl group; and R A6 is a hydrogen atom, a Ci-6 alkyl group or a hydroxy group,
  • non-patent document 1 (Analytical Sciences
  • patent document 2 (WO 2011/136385) has reported the following compound.
  • R 1 is a group represented by the formula: -COR 2 wherein R 2 is a hydrogen atom or a substituent, an optionally substituted 5- or 6-membered aromatic heterocyclic group or an optionally substituted phenyl group;
  • R 3 is a Ci-6 alkyl group optionally substituted by halogen atom(s), or an optionally substituted C 3 - 6 cycloalkyl group;
  • R 4 is a hydrogen atom or a substituent;
  • X is 0, CO , CR 5a R 5b wherein R 5a and R 5b are each independently a hydrogen atom, a halogen atom or an optionally substituted Ci_ 6 alkyl group, NR 5c wherein R 5c is a hydrogen atom or an
  • Ci-6 alkyl group optionally substituted Ci-6 alkyl group, S , SO or S(0) 2 ;
  • ring A is an optionally further substituted 4- to 7-membered non-aromatic ring (the ring is optionally crosslinked) ;
  • ring P is a 5-membered aromatic heterocycle
  • ring Q is an optionally further substituted 6-membered ring
  • ring P and ring Q are condensed to form an optionally further substituted bicyclic aromatic heterocycle
  • R 6 is an optionally substituted Ci- 6 alkyl group or an
  • R 1 is a group represented by the formula: -COR 2 wherein R 2 is a hydrogen atom or a substituent, or an optionally substituted 5- or 6-membered aromatic ring group;
  • R 3 is a C-6 alkyl group optionally substituted by halogen atom(s), or an optionally substituted C 3 _ 6 cycloalkyl group;
  • R a and R b are independently a hydrogen atom or a substituent;
  • X is 0, CO, CR 5a R 5b wherein R 5a and R 5b are independently a hydrogen atom or a substituent, NR 5c wherein R 5c is a hydrogen atom or an optionally substituted Ci_ 6 alkyl group, S, SO, or S(0) 2 ;
  • ring A is an optionally further substituted 5- or 6-membered aromatic ring
  • ring P is an optionally further substituted 5-membered aromatic ring
  • ring Q is an optionally further substituted 6- membered ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic ring, or
  • ring P is an optionally further substituted 5-membered non-aromatic ring
  • ring Q is an optionally further substituted 6-membered aromatic ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic ring
  • R 6 is an optionally substituted Ci_ 6 alkyl group or an
  • compound (I) has a superior ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic
  • the present invention relates to
  • Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • R 3 is a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • R a and R b are each a hydrogen atom
  • X is 0, CO or CH 2 ,
  • R 6 is a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • ring A is benzene, optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole, each of which is optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • [11A] a prodrug of the compound or salt of the above-mentioned [1], [2], [3], [4], [5], [6], [7], [8], [9], [10] or [11];
  • [15] a method of inhibiting acetyl-CoA carboxylase in a mammal, which comprises administering an effective amount of the compound or salt of the above-mentioned [1], [2], [3], [4],
  • Compound (I) has an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic
  • halogen atom in the present specification means, unless otherwise specified, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • Ci-6. alkyl group in the present specification means, unless otherwise specified, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1 , 1-dimethylbutyl, 2, 2-dimethylbutyl, 3, 3-dimethylbutyl, 2-ethylbutyl or the like.
  • Ci_6 alkoxy group in the present specification means, unless otherwise specified, methoxy, ethoxy, propoxy,
  • R 1 is a group represented by the formula: -COR 2 wherein R 2 is a hydrogen atom or a substituent, or an optionally
  • hydrocarbon group examples include a Ci-io alkyl group, a C 2 -io alkenyl group, a C 2 -io alkynyl group, a C3-10 cycloalkyl group, a C 3 _io cycloalkenyl group, a C4-10
  • Ci-10 alkyl group examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1, 1-dimethylbutyl, 2, 2-dimethylbutyl, 3, 3-dimethylbutyl, 2- ethylbutyl, heptyl, octyl, nonyl, decyl and the like. Of these, a Ci-6 alkyl group is preferable.
  • Examples of the C 2 -io alkenyl group include ethenyl, 1- propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3- hexenyl, 5-hexenyl, 1-heptenyl, 1-octenyl and the like. Of these, a C 2 -6 alkenyl group is preferable.
  • Examples of the C 2 -i 0 alkynyl group include ethynyl, 1- propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1- pentynyl, 2-pentynyl, 3-pentynyl,- 4-pentynyl, 1-hexynyl, 2- hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-heptynyl, 1- octynyl and the like.
  • a C 2 -6 alkynyl group is
  • Examples of .the C3-10 cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. Of these, a C3-6 cycloalkyl group is preferable.
  • Examples of the C3-10 cycloalkenyl group include 2- cyclopenten-l-yl, 3-cyclopenten-l-yl, 2-cyclohexen-l-yl, 3- cyclohexen-l-yl and the like. Of these, a C3_6 cycloalkenyl group is preferable.
  • Examples of the G4-10 cycloalkadienyl group include 2,4- cyclopentadien-l-yl, 2, -cyclohexadien-l-yl, 2,5- cyclohexadien-l-yl and the like. Of these, a C- 6
  • cycloalkadienyl group is preferable.
  • cycloalkenyl group and C4-10 cycloalkadienyl group are each optionally fused with a benzene ring to form a fused ring group.
  • fused ring group examples include indanyl, dihydronaphthyl, tetrahydronaphthyl, fluorenyl and the like.
  • C3-10 cycloalkyl group, C3-10 ' cycloalkenyl group and C4-10 cycloalkadienyl group may be - each a C 7 _i 0 bridged hydrocarbon group.
  • Examples of the C 7 _io . bridged hydrocarbon group include bicyclo [2.2.1] heptyl
  • cycloalkane a C3-10 cycloalkene or a C4-10 cycloalkadiene.
  • Examples of the C3-10 cycloalkane, C3-10 cycloalkene and C -10 cycloalkadiene include rings corresponding to the above- mentioned C3-10 cycloalkyl group, C3-10 cycloalkenyl group and C 4 _ 10 cycloalkadienyl group.
  • Examples of the spiro ring group include spiro [4.5] decan-8-yl and the like.
  • Examples of the C 6 -i 4 aryl group include phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, biphenylyl and the like. Of these, a C 6 -i2 aryl group is preferable.
  • Examples of the C 7 -i 3 aralkyl group include benzyl,
  • Examples of the Cg-i3 arylalkenyl group include styryl and the like.
  • Ci-io alkyl group, C 2 -io alkenyl group and C 2 -io alkynyl group which are exemplified as the above-mentioned
  • hydrocarbon . group optionally, have 1 to 7 (preferably 1 to 3) substituents at substitutable positions.
  • a C3-10 cycloalkyl group e.g., cyclopropyl, cyclohexyl
  • a C3-10 cycloalkyl group e.g., cyclopropyl, cyclohexyl
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy group optionally substituted by 1 to 3 halogen atoms
  • an aromatic heterocyclic group e.g., thienyl, furyl, pyridyl, pyrazolyl, imidazolyl, tetrazolyl, oxazolyl,
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy group optionally substituted by 1 to 3 halogen atoms
  • a halogen atom (d) a halogen atom; (4) a non-aromatic heterocyclic group (e.g., tetrahydrofuryl, morpholinyl, thiomorpholinyl, piperidyl, pyrrolidinyl,
  • a non-aromatic heterocyclic group e.g., tetrahydrofuryl, morpholinyl, thiomorpholinyl, piperidyl, pyrrolidinyl,
  • piperazinyl optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci_6 alkylsulfonyl group e.g., methylsulfonyl
  • halogen atoms e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., thienyl, furyl, pyridyl, pyrazolyl, imidazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl
  • an aromatic heterocyclic group e.g., thienyl, furyl, pyridyl, pyrazolyl, imidazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl
  • Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
  • a C6-1 aryl group e.g., phenyl
  • a heterocyclic group e.g., tetrahydrofuryl
  • a Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • Ci-6 alkoxy group optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 C6-14 aryl groups (e.g., phenyl),
  • a C 2 -6 alkenyloxy group e.g., ethenyloxy
  • a C 2 -6 alkenyloxy group e.g., ethenyloxy
  • 1 to 3 halogen atoms optionally substituted by 1 to 3 halogen atoms
  • a C 7 -i3 aralkyloxy group e.g., benzyloxy
  • a C 6 -i4 aryloxy group e.g., phenyloxy,' naphthyloxy
  • Ci-6 alkyl-carbonyloxy group e.g., acetyloxy, tert- butylcarbonyloxy
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • a non-aromatic heterocyclylcarbonyl group e.g.,
  • Ci_6 alkyl groups optionally substituted by 1 to 3 halogen atoms;
  • Ci-6 alkylthio group e.g., methylthio, ethylthio
  • substituents selected from
  • a C 6 -i4 arylthio group e.g., phenylthio, naphthylthio
  • Ci-3 alkyleneoxy group e.g., methyleneoxy, ethyleneoxy
  • an aromatic heterocyclylcarbonyl group e.g., an aromatic heterocyclylcarbonyl group
  • pyrazolylcarbonyl pyrazinylcarbonyl, isoxazolylcarbonyl, pyridylcarbonyl, thiazolylcarbonyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms;
  • a C 3 _io cycloalkoxy group e.g., cyclopropoxy
  • halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy
  • Ci_6 alkoxy-carbonyl group a Ci_6 alkoxy-carbonyl group
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • heterocyclic group of the above- mentioned “optionally substituted heterocyclic group” include an “aromatic heterocyclic group” and a “non-aromatic
  • aromatic heterocyclic group examples include a 4- to 7-membered (preferably 5- or 6-menbered) monocyclic aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atoms, 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom, and a fused aromatic heterocyclic group.
  • fused aromatic heterocyclic group examples include a group derived from a fused ring wherein a ring corresponding to the 4- to 7-membered
  • nitrogen atoms e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine
  • a 5-membered aromatic heterocycle containing one sulfur atom e.g., thiophene
  • a benzene ring fused, and the like.
  • aromatic heterocyclic group examples include
  • 2-furyl, 3-furyl) 2-furyl, 3-furyl
  • thienyl e.g., 2-thienyl, 3-thienyl
  • pyridyl e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl
  • pyrimidinyl e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl
  • pyridazinyl e.g., 3-pyridazinyl, 4-pyridazinyl
  • pyrazinyl e.g., 2-pyrazinyl
  • pyrrolyl e.g., 1-pyrrolyl, 2-pyrrolyl
  • imidazolyl e.g., 1-imidazoly.l, 2-imidazolyl, 4- imidazolyl, 5-imidazolyl
  • pyrazolyl e.g., 1-pyrazolyl, 3- pyrazolyl, 4-pyrazolyl
  • thiazolyl e.g., 2-thiazolyl, 4- thiazolyl, 5-thiazolyl
  • isothiazolyl e.g., 3-isothiazolyl
  • oxazolyl e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazo
  • triazol-4-yl tetrazolyl (e.g., tetrazol-l-yl, tetrazol-5-yl) , triazinyl (e.g., 1, 2, 4-triazin-l-yl, 1, 2, 4-triazin-3-yl) and the like;
  • quinolyl e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl, 6- quinolyl
  • isoquinolyl e.g., 3-isoquinolyl
  • quinazolyl e.g.,
  • 2-quinazolyl, 4-quinazolyl) quinoxalyl (e.g., 2-quinoxalyl, 6-quinoxalyl) , benzofuranyl (e.g., 2-benzofuranyl, 3- benzofuranyl) , benzothienyl (e.g., 2-benzothienyl, 3- benzothienyl) , benzoxazolyl (e.g., 2-benzoxazolyl) ,
  • benzisoxazolyl e.g., 7-benzisoxazolyl
  • benzothiazolyl e.g., 2-benzothiazolyl
  • benzimidazolyl e.g., benzimidazol-l-yl, benzimidazol-2-yl, benzimidazol-5-yl
  • benzotriazolyl e.g., lH-1, 2, 3-benzotriazol-5-yl
  • indolyl e.g., indol-l-yl, indol- 2-yl, indol-3-yl, indol-5-yl
  • indazolyl e.g., lH-indazol-3- yl
  • pyrrolopyrazinyl e.g., lH-pyrrolo [2, 3-b] pyrazin-2-yl, lH-pyrrolo [2, 3-b] pyrazin-2-y
  • thieno [2, 3-b] pyridin-3-yl) imidazopyrazinyl (e.g., 1H- imidazo [4, 5-b] pyrazin-2-yl) , pyrazolopyridinyl (e.g., 1H- pyrazolo [4, 3-c] pyridin-3-yl ) , pyrazolothienyl (e.g., 2H- pyrazolo [3, 4-b] thiophen-2-yl) , pyrazolotriazinyl (e.g.,
  • pyrazolo [5, 1-c] [1, 2, 4] triazin-3-yl) pyridopyridinyl (e.g., pyrido [2, 3-b] pyridin-3-yl)
  • thienopyridyl e.g., thieno [2,3- b] pyridin-3-yl
  • non-aromatic heterocyclic group examples include a 4- to 7-membered . (preferably 5- or 6-menbered) monocyclic non- aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atoms, 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom, and a fused aromatic heterocyclic group.
  • fused aromatic heterocyclic group examples include a group derived from a fused ring wherein a ring corresponding to the 4- to - 7-membered
  • nitrogen atoms e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine
  • a 5-membered aromatic heterocycle containing one sulfur atom e.g., thiophene
  • a benzene ring fused, a group wherein the above-mentioned group is partially saturated, and the like.
  • non-aromatic heterocyclic group examples include
  • azetidinyl e.g., 1- azetidinyl, 2-azetidinyl, 3-azetidinyl
  • pyrrolidinyl e.g., 1-pyrrolidinyl, 2-pyrrolidinyl
  • piperidyl e.g., piperidino, 2-piperidyl, 3-piperidyl, 4-piperidyl
  • morpholinyl e.g., morpholino
  • thiomorpholinyl e.g., thiomorpholino
  • piperazinyl e.g., 1-piperazinyl, 2- piperazinyl, 3-piperazinyl
  • hexamethyleniminyl e.g., hexamethylenimin-l-yl
  • oxazolidinyl e.g., oxazolidin-2-yl
  • thiazolidinyl e.g.
  • imidazolinyl e.g., imidazolin-2-yl, imidazolin-3-yl
  • - dioxolyl e.g., 1, 3-dioxol-4-yl
  • dioxolanyl e.g., 1,3- dioxolan-4-yl
  • dihydrooxadiazolyl e.g., 4, 5-dihydro-l, 2, - oxadiazol-3-yl
  • pyranyl e.g., 4-pyranyl
  • tetrahydropyranyl e . g .
  • tetrahydrofuryl e.g., tetrahydrofuran-3-yl, tetrahydrofuran- 2-yl
  • pyrazolidinyl e.g., pyrazolidin-l-yl, pyrazolidin-3- yl
  • pyrazolinyl e.g., pyrazolin-l-yl
  • tetrahydropyrimidin-l-yl e.g., 2,3- dihydro-lH-1, 2, 3-triazol-l-yl
  • tetrahydrotriazolyl e.g., 2,3- dihydro-lH-1, 2, 3-triazol-l-yl
  • dihydroindolyl e . g . , 2 , 3-dihydro-lH-indol-l-yl
  • dihydroisoindolyl e.g., 1, 3-dihydro-2H-isoindol-2-yl
  • dihydrobenzofuranyl e.g., 2, 3-dihydro-l-benzofuran-5-yl
  • dihydrobenzodioxinyl e.g., 2, 3-dihydro-l, 4-benzodioxinyl
  • dihydrobenzodioxepinyl e.g., 3, 4-dihydro-2H-l, 5- benzodioxepinyl
  • tetrahydrobenzofuranyl e.g., 4,5,6,7- tetrahydro-l-benzofuran-3-yl
  • chromenyl e.g., 4H-chromen-2- yl, 2H-chromen-3-yl
  • dihydrochromenyl e.g., 3, 4-dihydro-2H- chromen-2H- chromeny
  • heterocyclic group of the “optionally substituted heterocyclic group” optionally has 1 to 3 substituents at substitutable positions.
  • substituents include those similar to the substituents that the C 3 -i 0 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the above-mentioned "optionally substituted hydrocarbon group” optionally has.
  • the heterocyclic group is a "non-aromatic heterocyclic group”
  • the substituent further includes an oxo group.
  • the number of the substituents is not less than 2, the respective substituents may be the same or different.
  • optionally substituted hydroxy group examples include a hydroxy group optionally substituted by a substituent selected from a Ci-i 0 alkyl group, a C 2 -io
  • alkenyl group a C3-10 cycloalkyl group, a C3-10 cycloalkenyl group, a C 6 -u aryl group, a C 7 -i 3 aralkyl group, a C 8 -i 3
  • arylalkenyl group a Ci_ 6 alkyl-carbonyl group, a heterocyclic group and the like, each of which is optionally substituted.
  • Ci_i 0 alkyl group examples include those
  • hydrocarbon group of the above-mentioned “optionally substituted hydrocarbon group”.
  • heterocyclic group examples include those similar to the “aromatic heterocyclic group" and “non-aromatic heterocyclic group"
  • heterocyclic group exemplified as the "heterocyclic group” of the above-mentioned “optionally substituted heterocyclic group” .
  • Ci-io alkyl group, C 2 -io alkenyl group, C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C 6 -i4 aryl group, C 7 -i3 aralkyl group, C 8 -i3 arylalkenyl group, Ci_ 6 alkyl-carbonyl group and heterocyclic group optionally have.1 to 3
  • Ci-6 alkyl-carbonyl group include those similar to the substituent that the Ci-10 alkyl group and the like exemplified as the "hydrocarbon group" of the above- mentioned “optionally substituted hydrocarbon group"
  • Examples of the substituent for the C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C6-14 aryl group, C 7 _i 3 aralkyl group and Cs-13 arylalkenyl group include those similar to the substituent that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the above-mentioned "optionally
  • substituted hydrocarbon group optionally has.
  • substituent for the heterocyclic group include those similar to the substituent that the "heterocyclic group" of the above- mentioned “optionally substituted heterocyclic group”
  • heterocyclic group and the like, each of which is optionally substituted.
  • optionally substituted amino group examples include an amino group optionally mono- or di- substituted by substituent ( s ) selected from a Ci-10 alkyl group, a C2-10 alkenyl group, a C3-10 cycloalkyl group, a C3-10
  • cycloalkenyl group a Ce-14 aryl group, a C 7 -i 3 aralkyl group, a Ce-13 arylalkenyl group and a heterocyclic group, each of which is optionally substituted; an acyl group and the like.
  • Ci-10 alkyl group examples include those
  • hydrocarbon group of the above-mentioned “optionally substituted hydrocarbon group”.
  • heterocyclic group examples include those similar to the “aromatic heterocyclic group" and “non-aromatic heterocyclic group"
  • heterocyclic group exemplified as the "heterocyclic group” of the above-mentioned “optionally substituted heterocyclic group”.
  • a 5- or 6-membered monocyclic aromatic heterocyclic group is preferable.
  • the Ci-io alkyl group, C 2 -iq alkenyl group, C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C 6 -i4 aryl group, C7-13 aralkyl group, Cg-13 arylalkenyl group and heterocyclic group optionally have 1 to 3 substituents at substitutable positions. When the number of the substituents is not less than 2, the respective substituents may be the same or different.
  • Examples of the substituent for the Ci-10 alkyl group and C2-10 alkenyl group include those similar to the substituent that the Ci-10 alkyl group and the like exemplified as the
  • substituted hydrocarbon group optionally has.
  • C3-10 cycloalkenyl group, C 6 -i4 aryl group, C7-13 aralkyl group and CB-I3 arylalkenyl group include those similar to the substituent that the C3-10 cycloalkyl ' group and the like exemplified as the "hydrocarbon group" of the above-mentioned "optionally
  • substituted hydrocarbon group optionally has.
  • substituent for the heterocyclic group include those similar to the substituent that the "heterocyclic group" of the above- mentioned “optionally substituted heterocyclic group”
  • substituent for the "optionally substituted amino group” include those similar to the "acyl group” below, which is exemplified as the "substituent” for R 2 .
  • R A is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
  • R A ' and R B ' are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
  • R A ' and R B ' form, together with the adjacent nitrogen atom, an optionally substituted nitrogen- containing heterocycle, and the like.
  • R A , R A ' or R B ' examples include those similar to the "optionally substituted hydrocarbon group” and “optionally substituted heterocyclic group", which are exemplified as the "substituent" for R 2 .
  • nitrogen-containing heterocycle of the "optionally substituted nitrogen-containing heterocycle” formed by R A ' and R B ' together with the adjacent nitrogen atom
  • nitrogen-containing heterocycle include a 5- to 7-membered nitrogen-containing heterocycle containing, as a ring-constituting atom besides carbon atoms, at least one nitrogen atom and optionally further containing one or two hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom.
  • nitrogen- containing heterocycle include pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, morpholine,
  • the nitrogen-containing heterocycle optionally has 1 to 5 (preferably 1 or 2) substituents at substitutable positions.
  • substituents include those similar to the substituent that the "heterocyclic group" of the "optionally substituted heterocyclic group", which is exemplified as the "substituent" for R 2 , optionally has.
  • the number of the substituents is not less than 2, the respective substituents may be the same or different.
  • acyl group examples include
  • Ci-6 alkyl-carbonyl group e.g., acetyl
  • a Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci_6 alkoxy-carbonyl group e.g., methoxycarbonyl
  • a C3-10 cycloalkyl-carbonyl group e.g., cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl
  • a C3-10 cycloalkyl-carbonyl group e.g., cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl
  • a C 6 -i4 aryl-carbonyl group e.g., benzoyl, 1-naphthoyl, 2- naphthoyl
  • a C 6 -i4 aryl-carbonyl group e.g., benzoyl, 1-naphthoyl, 2- naphthoyl
  • optionally substituted by 1 to 3 halogen atoms e.g., benzoyl, 1-naphthoyl, 2- naphthoyl
  • Ci_6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclylcarbonyl group e.g., an aromatic heterocyclylcarbonyl group
  • furylcarbonyl, thienylcarbonyl optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms;
  • a non-aromatic heterocyclylcarbonyl group e.g.,
  • tetrahydrofurylcarbonyl, pyrrolidinocarbonyl optionally substituted by 1 to 3 substituents selected from a Ci- 6 alkyl group optionally substituted by 1 to 3 halogen atoms;
  • R 2 is preferably an optionally substituted Ci- 6 alkyl group, an optionally substituted Ci_ 6 alkoxy group, an
  • C 3 _io cycloalkyl group an optionally substituted Ce-u aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group,. an optionally substituted non-aromatic heterocyclic group or the like .
  • R 2 is preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci_6 alkoxy group e.g., methoxy, tert-butoxy
  • a C3-10 cycloalkyl group e.g., cyclopropyl, cyclopentyl
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl
  • isopropyl optionally substituted by 1 to 3 C 6 -i 4 aryl groups (e.g., phenyl),
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • Ci-6 alkyl groups e.g., methyl
  • an aromatic heterocyclic group e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl.
  • an aromatic heterocyclic group e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl.
  • substituents selected from a Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom);
  • a non-aromatic heterocyclic group e.g.,
  • R 2 is more preferably an optionally substituted Ci_ 6 alkyl group, an optionally substituted Ci_6 alkoxy group, an
  • R 2 is more preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci_6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl
  • isopropyl optionally substituted by 1 to 3 C6-14 aryl groups (e.g., phenyl),
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • Ci_ 6 alkyl groups e.g., methyl
  • R 2 is still more preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci- 6 alkyl group(s) e.g., methyl, ethyl, propyl, isopropyl
  • R 2 is particularly preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci_ 6 alkyl group(s) e.g., methyl, ethyl, propyl, isopropyl
  • the "group represented by the formula: -COR 2 " for R 1 is preferably a group represented by the formula: -COR 2 wherein R 2 is an optionally substituted Ci_ 6 alkyl group, an optionally substituted Ci_ 6 alkoxy group, an optionally substituted C 3 -i 0 cycloalkyl group, an optionally substituted C 6 -i 4 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group, an optionally substituted non- aromatic heterocyclic group or the like.
  • the "group represented by the formula: - COR 2 " for R 1 is preferably a group represented by the formula: -COR 2 wherein
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • a C3-10 cycloalkyl group e.g., cyclopropyl
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • aryl groups e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • Ci-6 alkyl groups e.g., methyl
  • an aromatic heterocyclic group e.g., furyl, . pyrazolyl, pyridyl, isoxazolyl, thiazolyl
  • an aromatic heterocyclic group e.g., furyl, . pyrazolyl, pyridyl, isoxazolyl, thiazolyl
  • 1 to 3 substituents selected from a Ci_ 6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) ;
  • a non-aromatic heterocyclic group e.g., tetrahydropyranyl
  • the "group represented by the formula: -COR 2 " for R 1 is more preferably a group represented by the formula: -COR 2 wherein R 2 is an optionally substituted Ci_ 6 alkyl group, an optionally substituted Ci_ 6 alkoxy group, an optionally
  • COR 2 " for R 1 is more preferably a group represented by the formula: -COR 2
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • 1 to 3 C 6 -i4 aryl groups e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • 1 to 3 Ci-6 alkyl groups e.g., methyl
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci- alkyl group(s) e.g., methyl, ethyl, propyl, isopropyl
  • the "group represented by the formula: -COR 2 " for R 1 is particularly preferably a group represented by the formula: - COR 2
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci- alkyl group(s) e.g., methyl, ethyl, propyl, isopropyl
  • Examples of the "5- or 6-membered aromatic group" of the "optionally substituted 5- or 6-membered aromatic group” for R include phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl (1,2,3-triazolyl, 1, 2, 4-triazolyl, 1, 3, 4-triazolyl) ,
  • tetrazolyl oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, furyl, thienyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like.
  • the "5- or 6-membered aromatic group” is preferably a 5- membered aromatic heterocyclic group, phenyl or the like, more preferably pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, phenyl or the like, particularly preferably isoxazolyl.
  • the "5- or 6-membered aromatic group" of the "optionally substituted 5- or 6-membered aromatic group” for R 1 optionally has 1 to 3 substituents at substitutable positions.
  • substituents include those similar to the substituents that the C 3 -i 0 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the “optionally substituted hydrocarbon group", which is exemplified as the "substituent” for R 2 , optionally has.
  • the "optionally substituted 5- or 6-membered aromatic group" for R 1 is preferably a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) or phenyl, each of which is optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • the "optionally substituted 5- or 6-membered aromatic group" for R 1 is more preferably a 5-membered aromatic
  • heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • phenyl each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci-6 alkyl group.
  • the "optionally substituted 5- or 6-membered aromatic group" for R 1 is still more preferably a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group.
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • R 1 is preferably
  • R 2 is an optionally substituted Ci- 6 alkyl group, an optionally
  • Ci- 6 alkoxy group an optionally substituted C 3 -i 0 cycloalkyl group, an optionally substituted C 6 -i4 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group, an optionally substituted non- aromatic heterocyclic group or the like; or
  • R 1 is preferably (1) a group represented by the formula: -COR 2
  • R 2 is ⁇
  • a C-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a C-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • a C3-10 cycloalkyl group e.g., cyclopropyl
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • 1 to 3 C 6 -i4 aryl groups e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • Ci- 6 alkyl groups e.g., methyl
  • an aromatic heterocyclic group e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl
  • an aromatic heterocyclic group e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl
  • 1 to 3 substituents selected from a Ci_ 6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • phenyl each of which is optionally substituted by 1 to 3 substituents selected from
  • Ci_6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci_ 6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • R 1 is more preferably
  • R 2 is an optionally substituted C-6 alkyl group, an optionally
  • Ci- 6 alkoxy group an optionally substituted, amino group or the like;
  • R 1 is more preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • a C6-1 aryl group e.g., phenyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • aryl groups e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • phenyl each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci-6 alkyl group.
  • R 1 is further more preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci- alkyl group(s) e.g., methyl, ethyl, propyl, isopropyl; or the like; or
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • R 1 is still more preferably
  • Ci_6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • Ci_6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci_ alkyl group (s) e.g., methyl, ethyl, propyl, isopropyl
  • R 1 is particularly preferably
  • Ci_6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci- 6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • ring P is an optionally further substituted 5-membered aromatic ring
  • ring Q is an optionally further substituted 6- membered ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic ring, or
  • ring P is an optionally further substituted 5-membered non-aromatic ring
  • ring Q is an optionally further substituted 6-membered aromatic ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic ring.
  • ring P is an optionally further substituted 5-membered aromatic ring
  • ring Q is an optionally further substituted 6- membered ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic ring
  • "optionally further substituted 5-membered aromatic ring" for ring P include pyrrole, pyrazole, imidazole, triazole (1,2,3- triazole, 1, 2, 4-triazole, 1, 3, 4-triazole) , tetrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, furan, thiophene and the like. Of these, oxazole, thiazole, pyrazole and 1, 2, 3-triazole are preferable, and pyrazole, oxazole and thiazole are particularly preferable.
  • the "5-membered aromatic ring" of the "optionally further substituted 5-membered aromatic ring” for ring P optionally has 1 or 2 substituents, besides ring A, at substitutable position.
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the “optionally substituted hydrocarbon group", which is exemplified as the "substituent” for R 2 , optionally has.
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • Examples of the "6-membered ring" of the "optionally further substituted 6-membered ring” for ring Q include benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine, cyclohexa-1, 3-diene, dihydropyridine and the like. Of these, benzene, 1, 2-dihydropyridine and cyclohexa-1, 3-diene are particularly preferable.
  • substituted 6-membered ring for ring Q optionally has, besides the group -O-R 6 , 1 to 3 substituents at substitutable positions.
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the "optionally substituted hydrocarbon ' group", which is exemplified as the "substituent” for R 2 , optionally has.
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "bicyclic aromatic ring" of the "optionally further substituted bicyclic aromatic ring” formed by fusion of ring P and ring Q optionally has, besides the group of R 6 -0-, 1 to 3 substituents at substitutable positions on the ring Q, and optionally has, besides ring A, . 1 or 2 substituents at substitutable positions on the ring P.
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the
  • hydrocarbon group of the "optionally substituted hydrocarbon group”, which is exemplified as the "substituent” for R 2 , optionally has.
  • substituted bicyclic aromatic ring formed by fusion of ring P and ring Q include
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "optionally further substituted bicyclic aromatic ring" formed by fusion of ring P and ring Q is preferably
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • halogen atoms e.g., a fluorine atom
  • C 3 -6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "optionally further substituted bicyclic aromatic heterocycle" formed by fusion of ring P and ring Q . is more preferably
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci- 6 alkyl group e.g., methyl
  • halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e .g. , methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • (2) ring P is an optionally further substituted 5-membered non-aromatic ring
  • ring Q is an optionally further substituted 6-membered aromatic ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic - ring.
  • ring P optionally further substituted 5-membered non-aromatic ring
  • ring P include cyclopentene, dihydrofuran,
  • the "5-membered non-aromatic ring" of the "optionally further substituted 5-membered non-aromatic ring" for ring P optionally has, besides ring A, 1 to 5 substituents at
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the “optionally substituted hydrocarbon group", which is exemplified as the "substituent” for R 2 ., optionally has.
  • substituted 5-membered non-aromatic ring for ring P include
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • ring Q optionally further substituted 6-membered aromatic ring
  • ring Q include benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like.
  • the "6-membered aromatic ring" of the "optionally further substituted 6-membered aromatic ring" for ring Q optionally has, besides the group R 6 -0-, 1 to 3 substituents at
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the “optionally substituted hydrocarbon group", which is exemplified as the "substituent” for R 2 , optionally has.
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • bicyclic non-aromatic ring of the "optionally further substituted bicyclic non-aromatic ring” formed by fusion of ring P and ring Q optionally has, besides ring A, 1 to 5 substituents at substitutable positions on the ring P, and optionally has, besides the group -O-R 6 , 1 to 3
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the “optionally substituted hydrocarbon group", which is exemplified as the "substituent” for R 2 , optionally has.
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci- 6 alkyl group e.g., methyl
  • halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q is preferably
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q is more preferably [0139] [0140]
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q is still more preferably
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • a C1-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl
  • a halogen atoms e.g., a fluorine atom
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci- 6 alkyl group e.g., methyl
  • halogen atoms e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • R 3 is a Ci-6 alkyl group optionally substituted by halogen atom(.s), or an optionally substituted C3-6 cycloalkyl group.
  • the "Ci-6 alkyl group" of the "Ci- 6 alkyl group optionally substituted by halogen atom(s)" for R 3 optionally has
  • C3-6 cycloalkyl group" of the “optionally substituted C3-6 cycloalkyl group” for R 3 include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • C3-6 cycloalkyl group" of the "optionally substituted C 3 -6 cycloalkyl group” for R 3 optionally has 1 to.7 substituents at substitutable positions.
  • substituents include those similar to the substituents that the C3-10
  • R 3 is preferably a Ci-6 alkyl group optionally substituted by 1 to 7 (preferably 1 to 3) halogen atoms (e.g., a fluorine atom) , or a C 3 _ 6 cycloalkyl group, more preferably a Ci_ 6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) , still more preferably a Ci-6 alkyl group, particularly preferably methyl.
  • 1 to 7 preferably 1 to 3 halogen atoms
  • C 3 _ 6 cycloalkyl group more preferably a Ci_ 6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) , still more preferably a Ci-6 alkyl group, particularly preferably methyl.
  • R a and R 4b are independently a hydrogen atom or a
  • Examples of the "substituent" for R 4a or R 5b include those similar to the "substituent" for R 2 .
  • R 4a is preferably a hydrogen atom or a fluorine atom, particularly preferably a hydrogen atom.
  • R 4b is preferably a hydrogen atom or a fluorine atom, particularly preferably a hydrogen atom.
  • X is 0, CO, CR 5a R 5b wherein R 5a and R 5b are independently a hydrogen atom or a substituent, NR 5c wherein R 5c is a hydrogen atom or an optionally substituted Ci-6 alkyl group, S, SO or S(0) 2 .
  • Examples of the "substituent" for R 5a or R 5b include those similar to the "substituent” for R 2 .
  • Ci-6 alkyl group of the "optionally substituted Ci_ 6 alkyl group” for R 5c optionally has 1 to 3 substituents at substitutable positions.
  • substituents include those similar to the substituents that the Ci-10 alkyl group and the like exemplified as the "hydrocarbon group" of the
  • X is preferably 0, CO or CR 5a R 5b wherein R 5a and R 5b are the same as above, more preferably 0, CO or CH 2 , particularly preferably 0.
  • R 6 is an optionally substituted Ci_ 6 alkyl group or an optionally substituted C 3 _ 6 cycloalkyl group.
  • Ci-6 alkyl group of the "optionally substituted Ci- 6 alkyl group” for R 6 optionally has 1 to 3 substituents at .
  • substituents include those similar to the substituents that the Ci_i 0 alkyl group and the like exemplified as the "hydrocarbon group" of the
  • R 6 is preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl, butyl
  • a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • halogen atom e.g., a fluorine* atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl, cyclobutyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • R 6 is more ' preferably a Ci_ 6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl) optionally substituted by 1 to 3 substituents selected from
  • halogen atom e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl, cyclobutyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • R 6 is still more preferably a Ci_ 6 alkyl group optionally substituted by 1 to 3 C 3 - 6 cycloalkyl groups optionally
  • R 6 is preferably a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms.
  • Ring A is an optionally further substituted 5- or 6- membered aromatic ring.
  • Examples of the "5- or 6-membered aromatic ring" of the "optionally further substituted 5- or 6-membered aromatic ring” for ring A include benzene, pyrrole, pyrazole, imidazole, triazole ( 1, 2 , 3-triazole, 1 ,2 , 4-triazole, 1, 3, -triazole) , tetrazole, oxazole, isoxazole, thiazole, isothiazole,
  • oxadiazole (1, 2, 4-oxadiazole, 1, 3, 4-oxadiazole)
  • thiadiazole (1, 2, -thiadiazole, 1, 3, 4-thiadiazole)
  • furan, thiophene pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like .
  • the "5- or 6-membered aromatic ring" of the "optionally further substituted 5- or 6-membered aromatic ring" for ring A is preferably benzene, optionally oxidized pyridine,
  • benzene optionally oxidized pyridine, pyrimidine, pyrazole, isoxazole or oxadiazole, still more preferably
  • benzene optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole.
  • the "5- or 6-membered aromatic ring" of the "optionally further substituted 5- or 6-membered aromatic ring" for ring A optionally has, besides group -X-CH (R 4a ) (R 4b ) -CH (R 3 ) -NH-R 1 and ring P, 1 to 4 substituents (preferably 1 to 3 substituents) at substitutable positions. Examples of the substituent
  • heterocyclic group which is exemplified as the "substituent" for R 2 , optionally has.
  • Ring A is preferably benzene, optionally oxidized
  • a halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group e.g., methyl
  • halogen atoms e.g., n-butane
  • Ci-6 alkoxy group e.g., methoxy
  • a C 7 -i3 aralkyl group e.g., benzyl
  • Ring A is more preferably benzene, optionally oxidized pyridine, pyrimidine, pyrazole, isoxazole or oxadiazole, each of which is optionally substituted by 1 to 3 substituents selected from
  • a halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group e.g., methyl
  • halogen atoms e.g., n-butane
  • Ci-6 alkoxy group e.g., methoxy
  • a C 7 -i3 aralkyl group e.g., benzyl
  • Ring A is still more preferably benzene, optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole, each of which is optionally substituted by 1 to 3 substituents
  • halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group e.g., methyl
  • Ci-6 alkoxy group e.g., methoxy
  • a C 7 -i3 aralkyl group e.g., benzyl
  • compound (I) include the following compounds .
  • R 2 is an optionally substituted Ci_ 6 alkyl group, an optionally
  • Ci_6 alkoxy group an optionally substituted C3-10 cycloalkyl group, an optionally substituted C 6 -i 4 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group or an optionally substituted non- aromatic heterocyclic group; or
  • R 3 is a Ci_6 alkyl group optionally substituted by 1 to 7 halogen atoms, or a C3-6 cycloalkyl group;
  • R a and R b are independently a hydrogen atom or a fluorine atom
  • X is 0, CO, CR 5a R 5b wherein R 5a and R 5b is as defined above, NR 5c wherein R 5c is as defined above, S, SO or S(0) 2 ;
  • ring A is benzene, pyridine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole or thiadiazole, each of which is optionally substituted by
  • a halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group e.g., methyl
  • halogen atoms optionally substituted by 1 to 3 halogen atoms
  • a halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group optionally substituted by halogen .
  • Ci-6 alkyl group optionally substituted by 1 to 3
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isdbutyl, isopentyl
  • a' Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isdbutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci_6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • aryl groups e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • Ci-6 alkyl groups e.g • r methyl
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl
  • phenyl each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci- 6 alkyl group;
  • R 3 is a Ci-6 alkyl group optionally substituted by 1 to 7
  • R a and R b are independently a hydrogen atom or a fluorine atom
  • X is 0 or CH 2 ;
  • ring A is benzene, pyridine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole or thiadiazole, each of which is optionally substituted by
  • a halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group e.g.> methyl
  • halogen atoms optionally substituted by 1 to 3 halogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Description

DESCRIPTION
BICYCLIC COMPOUND
Technical Field
[0001]
The present invention relates to a bicyclic compound having an acetyl-CoA carboxylase (in the present specification, sometimes to be abbreviated as ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity,
diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like.
[0002]
[Background of the Invention]
ACC is an enzyme, that converts acetyl-CoA to malonyl-CoA, and catalyzes a rate determining reaction in fatty acid
metabolism. Malonyl-CoA, which is produced by an ACC catalyst reaction, inhibits fatty acid oxidation in mitochondria based on the feedback inhibition of carnitine palmitoyl transferase- 1 (CPT-1) . Accordingly, ACC plays a key role in controlling the balance between use of carbohydrate and fatty acid in the liver and skeletal muscle, and further, controlling insulin sensitivity in the liver, skeletal muscle and adipose tissue.
[0003]
A reduced level of malonyl-CoA by ACC inhibition can promote a promotion in fatty acid oxidation, decreased
secretion of triglyceride (TG)-rich lipoprotein (VLDL) in the liver, regulation of insulin secretion in the pancreas, arid further, improvement in the insulin sensitivity in the liver, skeletal muscle and adipose tissue.
[0004]
In addition, long-term administration of a compound having an ACC inhibitory action can strikingly decrease the TG content of the liver and adipose tissues and selectively
decrease body fat in obese test subjects taking low fat diet, by promoting fatty acid oxidation and suppressing de novo synthesis of fatty acid. <
[0005]
Accordingly, a compound having an ACC inhibitory action is extremely useful for the prophylaxis or treatment of metabolic syndrome, obesity, hypertension, diabetes,
cardiovascular diseases associated with atherosclerosis and the like.
[0006]
On the other hand, patent document 1 (WO 2010/050445) has reported the following compound.
[0007]
A compound or a salt thereof represented by the formula:
[0008]
Figure imgf000004_0001
[0009]
wherein
A is an acyl group or an optionally substituted 5- or 6- membered aromatic ring group;
ring M is an optionally condensed 5- to 7-membered ring which is . optionally further substituted;
for ring P and ring Q
(1) ring P is an optionally further substituted 5-membered heterocycle, ring Q is an optionally further substituted 6- membered ring, and ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic heterocycle, or
(2) ring P is an optionally further substituted 5-membered non-aromatic ring, ring Q is an optionally further substituted 6-membered aromatic ring, and ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic ring; R1 is an optionally substituted Ci_6 alkyl group or an optionally substituted C3_6 cycloalkyl group; and
L1 and L2 are
(1) independently optionally substituted methylene, 0, S, SO or SO2, or
(2) L1 and L2 in combination form optionally substituted vinylene or ethynylene,
provided that
(a) a compound wherein A is an a-aminoisobutyroyl group; and (b) a compound wherein A is a 5- or 6-membered aromatic ring group substituted by
a group represented by the formula: -CO- (CH2) 3-C00RA1 wherein RA1 is a hydrogen atom or a Ci_6 alkyl group, or
a group represented by the formula: -CO-NRA2-CRA3RA-CRA5RA6- COORA7 wherein RA2, RA3, RA4, RA5 and RA7 are independently a hydrogen atom or a Ci_6 alkyl group; and RA6 is a hydrogen atom, a Ci-6 alkyl group or a hydroxy group,
are excluded.
[0010]
In addition, non-patent document 1 (Analytical Sciences
(1994), 10(1), pages 17-23) has reported the following
compound .
A compound represented by the formula:
[0011]
Figure imgf000005_0001
[0012]
or the formula:
[0013]
Figure imgf000006_0001
[0014]
In addition, patent document 2 (WO 2011/136385) has reported the following compound.
A compound or a salt thereof represented by the formula:
[0015]
Figure imgf000006_0002
[0016]
wherein
R1 is a group represented by the formula: -COR2 wherein R2 is a hydrogen atom or a substituent, an optionally substituted 5- or 6-membered aromatic heterocyclic group or an optionally substituted phenyl group;
R3 is a Ci-6 alkyl group optionally substituted by halogen atom(s), or an optionally substituted C3-6 cycloalkyl group; R4 is a hydrogen atom or a substituent;
X is 0, CO , CR5aR5b wherein R5a and R5b are each independently a hydrogen atom, a halogen atom or an optionally substituted Ci_6 alkyl group, NR5c wherein R5c is a hydrogen atom or an
optionally substituted Ci-6 alkyl group, S , SO or S(0)2;
ring A is an optionally further substituted 4- to 7-membered non-aromatic ring (the ring is optionally crosslinked) ;
ring P is a 5-membered aromatic heterocycle, ring Q is an optionally further substituted 6-membered ring, and ring P and ring Q are condensed to form an optionally further substituted bicyclic aromatic heterocycle; and
R6 is an optionally substituted Ci-6 alkyl group or an
optionally substituted C3-6 cycloalkyl group.
Summary of -the Invention
Problems to be Solved by the Invention
[0017]
There is a demand for the development of a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy.
Means of Solving the Problems
[0018]
The present inventors have found for the first time that a compound represented by the formula (I):
[0019]
Figure imgf000007_0001
[0020]
wherein
R1 is a group represented by the formula: -COR2 wherein R2 is a hydrogen atom or a substituent, or an optionally substituted 5- or 6-membered aromatic ring group;
R3 is a C-6 alkyl group optionally substituted by halogen atom(s), or an optionally substituted C3_6 cycloalkyl group; Ra and Rb are independently a hydrogen atom or a substituent; X is 0, CO, CR5aR5b wherein R5a and R5b are independently a hydrogen atom or a substituent, NR5c wherein R5c is a hydrogen atom or an optionally substituted Ci_6 alkyl group, S, SO, or S(0)2;
' ring A is an optionally further substituted 5- or 6-membered aromatic ring;
for ring P and ring Q,
(1) ring P is an optionally further substituted 5-membered aromatic ring, ring Q is an optionally further substituted 6- membered ring, and ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic ring, or
(2) ring P is an optionally further substituted 5-membered non-aromatic ring, ring Q is an optionally further substituted 6-membered aromatic ring, and ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic ring; and
R6 is an optionally substituted Ci_6 alkyl group or an
optionally substituted C3_6 cycloalkyl group,
or a salt thereof [hereinafter sometimes to be referred to as compound (I) ] has a superior ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic
complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. Based on this finding, the present inventors have conducted intensive studies and
completed the present invention.
[0021]
Accordingly, the present invention relates to
[1] compound (I) ;
[2] the compound or salt of the above-mentioned [1] , wherein R1 is a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms;
(b) a Ci-6 alkoxy group; or
(c) an amino group optionally mono- or di-substituted by Ci_6 alkyl group (s) ;
[3] the compound or salt of the above-mentioned [1] or [2], wherein the "optionally further substituted bicyclic aromatic ring" or "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q is
Figure imgf000009_0001
[0023]
each of which is optionally further substituted by 1 to 4 substituents selected from
(1) a halogen atom,
(2) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(3) a C3-6 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, and
(4) a cyano group;
[4] the compound or salt of the above-mentioned [1], [2] or [3], wherein R3 is a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms, and Ra and R4b are each a hydrogen atom;
[5] the compound or salt of the above-mentioned [1], [2], [3] or [4], wherein X is 0, CO or CH2;
[6] the compound or salt of the above-mentioned [1], [2], [3], [4] or [5], wherein R6 is a Ci-6 alkyl group optionally
substituted by 1 to 3 substituents selected from
(a) a halogen atom, and
(b) a C3-6 cycloalkyl group optionally substituted by 1 to 3 halogen atoms; [7] the compound or salt of the above-mentioned [1], [2], [3],
[4], [5] or [6], wherein ring A is benzene, optionally
oxidized pyridine, pyrimidine, pyrazole or isoxazole, each of which is optionally substituted by 1 to 3 substituents
selected from
(1) a halogen atom,
(2) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(3) a Ci-6 alkoxy group, and
(4) a C7-i3 aralkyl group;
[8] the compound or salt of the above-mentioned [1], wherein R1 is a group represented by the formula: -COR2
wherein .
R2 is
(a) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms;
(b) a Ci-6 alkoxy group; or
(c) an amino group optionally mono- or di-substituted by Ci-6 alkyl group (s) ,
the "optionally further substituted bicyclic aromatic ring" or
"optionally further substituted bicyclic non-aromatic ring formed by fusion of ring P and ring Q is
[0024]
Figure imgf000010_0001
[0025]
each of which is optionally further substituted by 1 to 4 substituents selected from
(1) a halogen atom,
(2) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(3) a C3-6 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, and
(4) a cyano group, .
R3 is a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
Ra and Rb are each a hydrogen atom,
X is 0, CO or CH2,
R6 is a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom, and
(b) a C3-6 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, and
ring A is benzene, optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole, each of which is optionally substituted by 1 to 3 substituents selected from
(1) a halogen atom,
(2) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(3) a Ci-6 alkoxy group, and
(4) a C7_i3 aralkyl group;
[9] N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) -1-methylethyl] acetamide or a salt thereof;
[10] N- [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] -5-fluoropyridin-3-yl } oxy) -1-methylethyl] acetamide or a salt thereof;
[11] N- [ (IS) -2-{ [6- (6-ethoxy-l, 3-benzoxazol-2-yl) pyridin-3- yl] oxy} -1-methylethyl] acetamide or a salt thereof;
[11A] a prodrug of the compound or salt of the above-mentioned [1], [2], [3], [4], [5], [6], [7], [8], [9], [10] or [11];
[12] a medicament comprising the compound or salt of the above-mentioned [1], [2], [3], [4], [5], [6], [7.], [8], [9],
[10] or [11] or a prodrug thereof;
[13] the medicament of the above-mentioned [12], which is an acetyl-CoA carboxylase inhibitor;
[14] the medicament of the above-mentioned [12], which, is an agent for the prophylaxis or treatment of obesity or diabetes;
[15] a method of inhibiting acetyl-CoA carboxylase in a mammal, which comprises administering an effective amount of the compound or salt of the above-mentioned [1], [2], [3], [4],
[5], [6], [7], [8], [9], [10] or [11] or a prodrug thereof to the mammal;
[16] a method for the prophylaxis or treatment of obesity or diabetes in a mammal, which comprises administering an
effective amount of the compound or salt of the above- mentioned [1], [2], [3], [4], [5], [6], [7], [8], [9], [10] or [11] or a prodrug thereof to the mammal;
[17] use of the compound or salt of the above-mentioned [1], [2], [3], [4], [5], [6], [7], [8], [9], [10] or [11] or a prodrug thereof for production of an agent for the prophylaxis or treatment of obesity or diabetes;
[18] the compound or salt of the above-mentioned [1], [2], [3], [4], [5], [6], [7], [8], [9], [10] or [11] or a prodrug
thereof for use in the prophylaxis or treatment of obesity or diabetes ;
and the like.
Effect of the Invention
[0026]
Compound (I) has an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic
complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy.
[0027] [Detailed Description of the Invention]
The definition of each symbol in the formula (I) is described in detail in the following.
The "halogen atom" in the present specification means, unless otherwise specified, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
The "Ci_3 alkylenedioxy group" in the present
specification means, unless otherwise specified,
methylenedioxy, ethylenedioxy or the like.
The "Ci-6. alkyl group" in the present specification means, unless otherwise specified, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1 , 1-dimethylbutyl, 2, 2-dimethylbutyl, 3, 3-dimethylbutyl, 2-ethylbutyl or the like.
[0028]
The "Ci_6 alkoxy group" in the present specification means, unless otherwise specified, methoxy, ethoxy, propoxy,
isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy or the like.
The "Ci-6 alkoxy-carbonyl group" in the present
specification means, unless otherwise specified,
methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert- butoxycarbonyl or the like.
The "Ci-6 alkyl-carbonyl group" in the present
specification means, unless otherwise specified, acetyl, propanoyl, butanoyl, isobutanoyl, pentanoyl, isopentanoyl, hexanoyl or the like.
[0029]
R1 is a group represented by the formula: -COR2 wherein R2 is a hydrogen atom or a substituent, or an optionally
substituted 5- or 6-membered aromatic group.
[0030]
Examples of the "substituent" for R2 include a "halogen atom", "nitro", "cyano", an "optionally substituted
hydrocarbon group", an "optionally substituted heterocyclic group", an "optionally substituted hydroxy group", an
"optionally substituted amino group", an "optionally
substituted mercapto group", an "acyl group" and the like.
[0031]
Examples of the "hydrocarbon group" of the above- mentioned "optionally substituted hydrocarbon group" include a Ci-io alkyl group, a C2-io alkenyl group, a C2-io alkynyl group, a C3-10 cycloalkyl group, a C3_io cycloalkenyl group, a C4-10
cycloalkadienyl group, a C6-i aryl group, a C7-i3 aralkyl group, a C8-i3 arylalkenyl group and the like.
[0032]
Examples of the Ci-10 alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1, 1-dimethylbutyl, 2, 2-dimethylbutyl, 3, 3-dimethylbutyl, 2- ethylbutyl, heptyl, octyl, nonyl, decyl and the like. Of these, a Ci-6 alkyl group is preferable.
[0033]
Examples of the C2-io alkenyl group include ethenyl, 1- propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3- hexenyl, 5-hexenyl, 1-heptenyl, 1-octenyl and the like. Of these, a C2-6 alkenyl group is preferable.
[0034]
Examples of the C2-i0 alkynyl group include ethynyl, 1- propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1- pentynyl, 2-pentynyl, 3-pentynyl,- 4-pentynyl, 1-hexynyl, 2- hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-heptynyl, 1- octynyl and the like. Of these, a C2-6 alkynyl group is
preferable .
[0035]
Examples of .the C3-10 cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. Of these, a C3-6 cycloalkyl group is preferable. [0036]
Examples of the C3-10 cycloalkenyl group include 2- cyclopenten-l-yl, 3-cyclopenten-l-yl, 2-cyclohexen-l-yl, 3- cyclohexen-l-yl and the like. Of these, a C3_6 cycloalkenyl group is preferable.
[0037]
Examples of the G4-10 cycloalkadienyl group include 2,4- cyclopentadien-l-yl, 2, -cyclohexadien-l-yl, 2,5- cyclohexadien-l-yl and the like. Of these, a C-6
cycloalkadienyl group is preferable.
[0038]
The above-mentioned C3-.10 cycloalkyl group, C3-10
cycloalkenyl group and C4-10 cycloalkadienyl group are each optionally fused with a benzene ring to form a fused ring group. Examples of the fused ring group include indanyl, dihydronaphthyl, tetrahydronaphthyl, fluorenyl and the like.
[0039]
In addition, the above-mentioned C3-10 cycloalkyl group, C3-10 ' cycloalkenyl group and C4-10 cycloalkadienyl group may be - each a C7_i0 bridged hydrocarbon group. Examples of the C7_io . bridged hydrocarbon group include bicyclo [2.2.1] heptyl
(norbornyl) , bicyclo [2.2.2] octyl, bicyclo [3.2.1] octyl,
bicyclo [3.2.2] nonyl, bicyclo [ 3.3.1] nonyl, bicyclo [4.2.1] nonyl, bicyclo [4.3.1] decyl, adamantyl and the like.
[0040]
Moreover, the above-mentioned C3-10 cycloalkyl group, C3-10 cycloalkenyl group and C4-10 cycloalkadienyl group each
optionally forms a spiro ring group together with a C3-10
cycloalkane, a C3-10 cycloalkene or a C4-10 cycloalkadiene.
Examples of the C3-10 cycloalkane, C3-10 cycloalkene and C -10 cycloalkadiene include rings corresponding to the above- mentioned C3-10 cycloalkyl group, C3-10 cycloalkenyl group and C4_ 10 cycloalkadienyl group. Examples of the spiro ring group include spiro [4.5] decan-8-yl and the like.
[0041] Examples of the C6-i4 aryl group include phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, biphenylyl and the like. Of these, a C6-i2 aryl group is preferable.
[0042]
Examples of the C7-i3 aralkyl group include benzyl,
phenethyl, naphthylmethyl, biphenylylmethyl and the like.
[0043]
Examples of the Cg-i3 arylalkenyl group include styryl and the like.
[0044]
The Ci-io alkyl group, C2-io alkenyl group and C2-io alkynyl group, which are exemplified as the above-mentioned
"hydrocarbon . group", optionally, have 1 to 7 (preferably 1 to 3) substituents at substitutable positions.
[0045]
Examples of the substituent include
(1) a C3-10 cycloalkyl group (e.g., cyclopropyl, cyclohexyl) ;
(2) a C6-i4 aryl group (e.g., phenyl, naphthyl) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a hydroxy group,
(c) a Ci-6 alkoxy group optionally substituted by 1 to 3 halogen atoms, and
(d) a halogen atom;
(3) an aromatic heterocyclic group (e.g., thienyl, furyl, pyridyl, pyrazolyl, imidazolyl, tetrazolyl, oxazolyl,
thiazolyl, oxadiazolyl, thiadiazolyl ) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a hydroxy group,
(c) a Ci-6 alkoxy group optionally substituted by 1 to 3 halogen atoms, and
(d) a halogen atom; (4) a non-aromatic heterocyclic group (e.g., tetrahydrofuryl, morpholinyl, thiomorpholinyl, piperidyl, pyrrolidinyl,
piperazinyl) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a hydroxy group,
(c) a Ci-6 alkoxy group optionally substituted by 1 to 3 halogen atoms,
(d) a halogen atom, and
(e) an oxo group;
(5) an amino group optionally mono- or di-substituted by, substituent (s) selected from
(a) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms,
(c) a Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 halogen atoms,
(d) a Ci_6 alkylsulfonyl group (e.g., methylsulfonyl) optionally substituted by 1 to 3 halogen atoms,
(e) a carbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms, and
(f) an aromatic heterocyclic group (e.g., thienyl, furyl, pyridyl, pyrazolyl, imidazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl) ;
(6) a Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms;
(7) a Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a Ci-6 alkoxy group,
.(c) a C6-1 aryl group (e.g., phenyl), and
(d) a heterocyclic group (e.g., tetrahydrofuryl); (8) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl,
ethylsulfonyl, isopropylsulfonyl) optionally substituted by 1 to 3 halogen atoms;
(9) a carbamoyl group optionally mono- or di-substituted by Ci_6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms ;
(10) a thiocarbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms;
(11) a sulfamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms;
(12) a carboxy group;
(13) a hydroxy group;
(14) a Ci-6 alkoxy group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a carboxy group,
(c) a Ci-6 alkoxy group,
(d) a Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 C6-14 aryl groups (e.g., phenyl),
(e) an amino group optionally mono- or di-substituted by substituent (s) selected from a Ci_6 alkyl group and a Ci_6 alkoxy-carbonyl group,
(f) a heterocyclic group (e.g., tetrahydrofuryl) , and
(g) a C3-10 cycloalkyl group;
(15) a C2-6 alkenyloxy group (e.g., ethenyloxy) optionally substituted by 1 to 3 halogen atoms;
(16) a C7-i3 aralkyloxy group (e.g., benzyloxy) ;
(17) a C6-i4 aryloxy group (e.g., phenyloxy,' naphthyloxy) ;
(18) a Ci-6 alkyl-carbonyloxy group (e.g., acetyloxy, tert- butylcarbonyloxy) ;
(19) a Ce-1 aryl-carbonyl group (e.g., benzoyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom, and
(b) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms;
(20) a non-aromatic heterocyclylcarbonyl group (e.g.,
pyrrolidinylcarbonyl, morpholinylcarbonyl) optionally
substituted by 1 to 3 Ci_6 alkyl groups optionally substituted by 1 to 3 halogen atoms;
(21) a mercapto group;
(22) a Ci-6 alkylthio group (e.g., methylthio, ethylthio) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom, and
(b) a Ci-6 alkoxy-carbonyl group;
(23) a C7-i3 aralkylthio group (e.g., benzylthio) ;
(24) a C6-i4 arylthio group (e.g., phenylthio, naphthylthio) ;
(25) a cyano group;
(26) a nitro group;
(27) a halogen atom;
(28) a Ci-3 alkylenedioxy group;
(29) a Ci-3 alkyleneoxy group (e.g., methyleneoxy, ethyleneoxy) ;
(30) an aromatic heterocyclylcarbonyl group (e.g.,
pyrazolylcarbonyl, pyrazinylcarbonyl, isoxazolylcarbonyl, pyridylcarbonyl, thiazolylcarbonyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms;
(31) a C3_io cycloalkoxy group (e.g., cyclopropoxy,
cyclopentyloxy) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (e.g., a fluorine atom), and
(b) a Ci-6 alkoxy group (e.g., methoxy)
and the like. When the number of the substituents is not less than 2, the respective substituents may be the same or
different.
[0046]
The C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C4-10 cycloalkadienyl group, C6-i4 aryl group, C7_i3 aralkyl group and Cs-13 arylalkenyl group, which are exemplified as the above- mentioned "hydrocarbon group", optionally have 1 to 3 substituents at substitutable positions.
[0047]
Examples of the substituent include
(1) the groups exemplified as the substituents for the above- mentioned Ci-io alkyl group and the like;
(2) a Ci-6 alkyl group optionally substituted by 1 to 3
substituents selected from
(a) a halogen atom,
(b) a carboxy group,
(c) a hydroxy group,
(d) a Ci-6 alkoxy-carbonyl group,
(e) a Ci-6 alkoxy group, and
(f) an amino group optionally mono- or di-substituted by Ci_6 alkyl group (s) ;
(3) a C2-6 alkenyl group (e.g., ethenyl, 1-propenyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a carboxy group,
(c) a hydroxy group,
'(d) a Ci_6 alkoxy-carbonyl group,
(e) a Ci-6 alkoxy group, and
'(f) an amino group optionally mono- or di-substituted by Ci-6 alkyl group (s);
(4) a C7_i3 aralkyl group (e.g., benzyl) optionally substituted by 1 to 3 substituents selected from
(a) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(b) a hydroxy group,
(c) a Ci-6 alkoxy group, and
(d) a halogen atom;
and the like. When the number of the substituents is not less than 2, the respective substituents may be the same or
different . . · '
[0048]
Examples of the "heterocyclic group" of the above- mentioned "optionally substituted heterocyclic group" include an "aromatic heterocyclic group" and a "non-aromatic
heterocyclic group".
[0049]
Examples of the aromatic heterocyclic group include a 4- to 7-membered (preferably 5- or 6-menbered) monocyclic aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atoms, 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom, and a fused aromatic heterocyclic group. Examples of the fused aromatic heterocyclic group include a group derived from a fused ring wherein a ring corresponding to the 4- to 7-membered
monocyclic aromatic heterocyclic group and 1 or 2 rings selected from a 5- or 6-membered aromatic heterocycle
containing 1 or 2 nitrogen atoms (e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine) , a 5-membered aromatic heterocycle containing one sulfur atom (e.g., thiophene) and a benzene ring are fused, and the like.
[0050]
Preferable examples of the aromatic heterocyclic group include
monocyclic aromatic heterocyclic groups such as furyl (e.g.,
2-furyl, 3-furyl) , thienyl (e.g., 2-thienyl, 3-thienyl) , pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl) , pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl) ,
pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl) , pyrazinyl (e.g., 2-pyrazinyl) , pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl,
3-pyrrolyl) , imidazolyl (e.g., 1-imidazoly.l, 2-imidazolyl, 4- imidazolyl, 5-imidazolyl) , pyrazolyl (e.g., 1-pyrazolyl, 3- pyrazolyl, 4-pyrazolyl) , thiazolyl (e.g., 2-thiazolyl, 4- thiazolyl, 5-thiazolyl) , isothiazolyl (e.g., 3-isothiazolyl,
4-isothiazolyl, 5-isothiazolyl) , oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl) , isoxazolyl (e.g., 3-isoxazolyl, 4- isoxazolyl, 5-isoxazolyl) , oxadiazolyl (e.g., 1, 2 , 4-oxadiazol- 5-yl, 1, 3, -oxadiazol-2-yl) , thiadiazolyl (e.g., 1,3,4- thiadiazol-2-yl) , triazolyl (e.g., 1,2, 4-triazol-l-yl, 1,2,4- triazol-3-yl, 1, 2, 3-triazol-l-yl, 1, 2, 3-triazol-2-yl, 1,2,3- . triazol-4-yl) , tetrazolyl (e.g., tetrazol-l-yl, tetrazol-5-yl) , triazinyl (e.g., 1, 2, 4-triazin-l-yl, 1, 2, 4-triazin-3-yl) and the like;
' fused aromatic heterocyclic groups such as
quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl, 6- quinolyl) , isoquinolyl (e.g., 3-isoquinolyl) , quinazolyl (e.g.,
2-quinazolyl, 4-quinazolyl) , quinoxalyl (e.g., 2-quinoxalyl, 6-quinoxalyl) , benzofuranyl (e.g., 2-benzofuranyl, 3- benzofuranyl) , benzothienyl (e.g., 2-benzothienyl, 3- benzothienyl) , benzoxazolyl (e.g., 2-benzoxazolyl) ,
benzisoxazolyl (e.g., 7-benzisoxazolyl) , benzothiazolyl (e.g., 2-benzothiazolyl) , benzimidazolyl (e.g., benzimidazol-l-yl, benzimidazol-2-yl, benzimidazol-5-yl) , benzotriazolyl (e.g., lH-1, 2, 3-benzotriazol-5-yl) , indolyl (e.g., indol-l-yl, indol- 2-yl, indol-3-yl, indol-5-yl) , indazolyl (e.g., lH-indazol-3- yl) , pyrrolopyrazinyl (e.g., lH-pyrrolo [2, 3-b] pyrazin-2-yl, lH-pyrrolo [2, 3-b] pyrazin-6-yl ) , imidazopyridinyl (e.g., 1H- imidazo [4, 5-b] pyridin-2-yl., lH-imidazo [4 , 5-c] pyridin-2-yl, 2H- imidazo [1, 2-a] pyridin-3-yl) , thienopyridinyl (e.g.,
thieno [2, 3-b] pyridin-3-yl) , imidazopyrazinyl (e.g., 1H- imidazo [4, 5-b] pyrazin-2-yl) , pyrazolopyridinyl (e.g., 1H- pyrazolo [4, 3-c] pyridin-3-yl ) , pyrazolothienyl (e.g., 2H- pyrazolo [3, 4-b] thiophen-2-yl) , pyrazolotriazinyl (e.g.,
pyrazolo [5, 1-c] [1, 2, 4] triazin-3-yl) , pyridopyridinyl (e.g., pyrido [2, 3-b] pyridin-3-yl) , thienopyridyl (e.g., thieno [2,3- b] pyridin-3-yl) and the like;
and the like.
[0051]
Examples of the non-aromatic heterocyclic group include a 4- to 7-membered. (preferably 5- or 6-menbered) monocyclic non- aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atoms, 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom, and a fused aromatic heterocyclic group. Examples of the fused aromatic heterocyclic group include a group derived from a fused ring wherein a ring corresponding to the 4- to - 7-membered
monocyclic non-aromatic heterocyclic group and 1 or 2 rings selected from a 5- or 6-membered aromatic heterocycle
containing 1 or 2 nitrogen atoms (e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine) , a 5-membered aromatic heterocycle containing one sulfur atom (e.g., thiophene) and a benzene ring are fused, a group wherein the above-mentioned group is partially saturated, and the like.
[0052]
Preferable examples of the non-aromatic heterocyclic group include
monocyclic non-aromatic heterocyclic groups such as
azetidinyl (e.g., 1- azetidinyl, 2-azetidinyl, 3-azetidinyl) , pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl) , piperidyl (e.g., piperidino, 2-piperidyl, 3-piperidyl, 4-piperidyl) , morpholinyl (e.g., morpholino) , thiomorpholinyl (e.g., thiomorpholino) , piperazinyl (e.g., 1-piperazinyl, 2- piperazinyl, 3-piperazinyl) , hexamethyleniminyl (e.g., hexamethylenimin-l-yl) , oxazolidinyl (e.g., oxazolidin-2-yl) , thiazolidinyl (e.g., thiazo.lidin-2-yl) , imidazolidinyl (e.g., imidazolidin-2-yl, imidazolidin-3-yl) , oxazolinyl (e.g., oxazolin-2-yl) , thiazolinyl (e.g., thiazolin-2-yl ) ,
imidazolinyl (e.g., imidazolin-2-yl, imidazolin-3-yl) , - dioxolyl (e.g., 1, 3-dioxol-4-yl) , dioxolanyl (e.g., 1,3- dioxolan-4-yl) , dihydrooxadiazolyl (e.g., 4, 5-dihydro-l, 2, - oxadiazol-3-yl) , pyranyl (e.g., 4-pyranyl) , tetrahydropyranyl (e . g . , 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4- tetrahydropyranyl), thiopyranyl (e.g., 4-thiopyranyl) , tetrahydrothiopyranyl (e.g., 2-tetrahydrothiopyranyl, 3- tetrahydrothiopyranyl, 4-tetrahydrothiopyranyl ) ,
tetrahydrofuryl (e.g., tetrahydrofuran-3-yl, tetrahydrofuran- 2-yl), pyrazolidinyl (e.g., pyrazolidin-l-yl, pyrazolidin-3- yl) , pyrazolinyl (e.g., pyrazolin-l-yl) , tetrahydropyrimidinyl „
(e.g., tetrahydropyrimidin-l-yl) , dihydrotriazolyl (e.g., 2,3- dihydro-lH-1, 2, 3-triazol-l-yl) , tetrahydrotriazolyl (e.g.,
2, 3, 4, 5-tetrahydro-lH-l, 2, 3-triazol-l-yl) and the like;
fused non-aromatic heterocyclic groups such as
dihydroindolyl (e . g . , 2 , 3-dihydro-lH-indol-l-yl) ,
dihydroisoindolyl (e.g., 1, 3-dihydro-2H-isoindol-2-yl) , dihydrobenzofuranyl (e.g., 2, 3-dihydro-l-benzofuran-5-yl) , dihydrobenzodioxinyl (e.g., 2, 3-dihydro-l, 4-benzodioxinyl) , dihydrobenzodioxepinyl (e.g., 3, 4-dihydro-2H-l, 5- benzodioxepinyl) , tetrahydrobenzofuranyl (e.g., 4,5,6,7- tetrahydro-l-benzofuran-3-yl) , chromenyl (e.g., 4H-chromen-2- yl, 2H-chromen-3-yl) , dihydrochromenyl (e.g., 3, 4-dihydro-2H- chromen-2-yl) , dihydroquinolinyl (e.g., 1, 2-dihydroquinolin-4- yl) , tetrahydroquinolinyl (e.g., 1, 2, 3, 4-tetrahydroquinolin-4- yl) , dihydroisoquinolinyl (e.g., 1, 2-dihydroisoquinolin-4-yl) , tetrahydroisoquinolinyl (e.g., 1, 2, 3, -tetrahydroisoquinolin- 4-yl) , dihydrophthalazinyl (e.g., 1, -dihydrophthalazin-4-yl) and the like;
and the like.
[0053]
The "heterocyclic group" of the "optionally substituted heterocyclic group" optionally has 1 to 3 substituents at substitutable positions. Examples of the substituent include those similar to the substituents that the C3-i0 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the above-mentioned "optionally substituted hydrocarbon group" optionally has. When the heterocyclic group is a "non-aromatic heterocyclic group", the substituent further includes an oxo group. When the number of the substituents is not less than 2, the respective substituents may be the same or different.
[0054]
Examples of the above-mentioned "optionally substituted hydroxy group" include a hydroxy group optionally substituted by a substituent selected from a Ci-i0 alkyl group, a C2-io
alkenyl group, a C3-10 cycloalkyl group, a C3-10 cycloalkenyl group, a C6-u aryl group, a C7-i3 aralkyl group, a C8-i3
arylalkenyl group, a Ci_6 alkyl-carbonyl group, a heterocyclic group and the like, each of which is optionally substituted.
[0055]
Examples of the Ci_i0 alkyl group, C2-io alkenyl group, C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C6-14 aryl group, C7_i3 aralkyl group and C8-i3 arylalkenyl group include those
exemplified as the "hydrocarbon group" of the above-mentioned "optionally substituted hydrocarbon group".
[0056]
Examples of the heterocyclic group include those similar to the "aromatic heterocyclic group" and "non-aromatic
heterocyclic group" exemplified as the "heterocyclic group" of the above-mentioned "optionally substituted heterocyclic group" .
[0057]
The above-mentioned Ci-io alkyl group, C2-io alkenyl group, C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C6-i4 aryl group, C7-i3 aralkyl group, C8-i3 arylalkenyl group, Ci_6 alkyl-carbonyl group and heterocyclic group optionally have.1 to 3
substituents at substitutable positions. When the number of the substituents is not less than 2, the respective
substituents may be the same or different.
[0058]
Examples of the substituent for the Ci_i0 alkyl group, C2_
10 alkenyl group and Ci-6 alkyl-carbonyl group include those similar to the substituent that the Ci-10 alkyl group and the like exemplified as the "hydrocarbon group" of the above- mentioned "optionally substituted hydrocarbon group"
optionally has.
[0059]
Examples of the substituent for the C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C6-14 aryl group, C7_i3 aralkyl group and Cs-13 arylalkenyl group include those similar to the substituent that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the above-mentioned "optionally
substituted hydrocarbon group" optionally has. Examples of the substituent for the heterocyclic group include those similar to the substituent that the "heterocyclic group" of the above- mentioned "optionally substituted heterocyclic group"
optionally, has.
[0060]
Examples of the above-mentioned "optionally substituted mercapto group" include a mercapto group optionally
substituted by a substituent selected from a Ci-io alkyl group, a C2-10 alkenyl group, a C3-10 cycloalkyl group,, a C3-10
cycloalkenyl group, a C6-i4 aryl group, a C7_i3 aralkyl group, a Ce-13 arylalkenyl group, a Ci-6 alkyl-carbonyl group, a
heterocyclic group and the like, each of which is optionally substituted.
[0061]
Examples of the substituent include those exemplified as the substituents of the above-mentioned "optionally
substituted hydroxy group".
[0062]
Examples of the above-mentioned "optionally substituted amino group" include an amino group optionally mono- or di- substituted by substituent ( s ) selected from a Ci-10 alkyl group, a C2-10 alkenyl group, a C3-10 cycloalkyl group, a C3-10
cycloalkenyl group, a Ce-14 aryl group, a C7-i3 aralkyl group, a Ce-13 arylalkenyl group and a heterocyclic group, each of which is optionally substituted; an acyl group and the like.
[0063]
Examples of the Ci-10 alkyl group, C2-10 alkenyl group, C3_i0 cycloalkyl group, C3-10 cycloalkenyl group, C6-i4 aryl group, C7-13 aralkyl group and C8-i3 arylalkenyl group include those
exemplified as the "hydrocarbon group" of the above-mentioned "optionally substituted hydrocarbon group".
[0064]
Examples of the heterocyclic group include those similar to the "aromatic heterocyclic group" and "non-aromatic
heterocyclic group" exemplified as the "heterocyclic group" of the above-mentioned "optionally substituted heterocyclic group". Of these, a 5- or 6-membered monocyclic aromatic heterocyclic group is preferable.
[0065]
The Ci-io alkyl group, C2-iq alkenyl group, C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C6-i4 aryl group, C7-13 aralkyl group, Cg-13 arylalkenyl group and heterocyclic group optionally have 1 to 3 substituents at substitutable positions. When the number of the substituents is not less than 2, the respective substituents may be the same or different.
[0066]
Examples of the substituent for the Ci-10 alkyl group and C2-10 alkenyl group include those similar to the substituent that the Ci-10 alkyl group and the like exemplified as the
"hydrocarbon group" of the above-mentioned "optionally
substituted hydrocarbon group" optionally has.
[0067]
Examples of the substituent for the C3-10 cycloalkyl group,
C3-10 cycloalkenyl group, C6-i4 aryl group, C7-13 aralkyl group and CB-I3 arylalkenyl group include those similar to the substituent that the C3-10 cycloalkyl' group and the like exemplified as the "hydrocarbon group" of the above-mentioned "optionally
substituted hydrocarbon group" optionally has. Examples of the substituent for the heterocyclic group include those similar to the substituent that the "heterocyclic group" of the above- mentioned "optionally substituted heterocyclic group"
optionally has .
[0068]
Examples of the "acyl group" exemplified as the
substituent for the "optionally substituted amino group" include those similar to the "acyl group" below, which is exemplified as the "substituent" for R2.
[0069] Examples of the "acyl group" exemplified as the
"substituent" for R2 include a group represented by the
formula:
Figure imgf000028_0001
-C0-0RA, -S03RA, -S(0)2RA, -SORA, -CO-NRA'RB', - CS-NRA'RB' or -S (0) 2NRA' RB' wherein RA is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, RA' and RB' are the same or different and each is a hydrogen atom, an optionally
substituted hydrocarbon group or an optionally substituted heterocyclic group, or RA' and RB' form, together with the adjacent nitrogen atom, an optionally substituted nitrogen- containing heterocycle, and the like.
[0070]
Examples of the "optionally substituted hydrocarbon group" and "optionally substituted heterocyclic group" for RA, RA' or RB' include those similar to the "optionally substituted hydrocarbon group" and "optionally substituted heterocyclic group", which are exemplified as the "substituent" for R2.
[0071]
Examples of the "nitrogen-containing heterocycle" of the "optionally substituted nitrogen-containing heterocycle" formed by RA' and RB' together with the adjacent nitrogen atom include a 5- to 7-membered nitrogen-containing heterocycle containing, as a ring-constituting atom besides carbon atoms, at least one nitrogen atom and optionally further containing one or two hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom. Preferable examples of the nitrogen- containing heterocycle include pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, morpholine,
thiomorpholine and the like.
[0072]
The nitrogen-containing heterocycle optionally has 1 to 5 (preferably 1 or 2) substituents at substitutable positions. Examples of the substituent include those similar to the substituent that the "heterocyclic group" of the "optionally substituted heterocyclic group", which is exemplified as the "substituent" for R2, optionally has. When the number of the substituents is not less than 2, the respective substituents may be the same or different.
[0073]
Preferable examples of the "acyl group" include
(1) a formyl group;
(2) a carboxy group;
(3) a Ci-6 alkyl-carbonyl group (e.g., acetyl) optionally substituted by 1 to 3 halogen atoms;
(4) a Ci_6 alkoxy-carbonyl group (e.g., methoxycarbonyl,
ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl )
optionally substituted by 1 to 3 halogen atoms;
(5) a C3-10 cycloalkyl-carbonyl group (e.g., cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl) ;
(6) a C6-i4 aryl-carbonyl group (e.g., benzoyl, 1-naphthoyl, 2- naphthoyl) optionally substituted by 1 to 3 halogen atoms;
(7) a carbamoyl group optionally mono- or di-substituted by substituent (s) selected from
(a) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from a halogen . atom, a Ci-6 alkoxy group, a Ci_6 alkoxy-carbonyl group and a carboxy group, and
(b) an amino group optionally mono- or di-substituted by Ci-6 alkoxy-carbonyl group (s);
(8) a Ci_6 alkylsulfonyl group (e.g., methylsulfonyl,
ethylsulfonyl, isopropylsulfonyl) optionally substituted by 1 to 3 halogen atoms;
(9) a C6-14 arylsulfonyl group (e.g., benzenesulfonyl) ;
(10) a sulfamoyl group;
(11) a thiocarbamoyl group;
(12) an aromatic heterocyclylcarbonyl group (e.g.,
furylcarbonyl, thienylcarbonyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms;
(13). a non-aromatic heterocyclylcarbonyl group (e.g.,
tetrahydrofurylcarbonyl, pyrrolidinocarbonyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms;
and the like.
[0074]
R2 is preferably an optionally substituted Ci-6 alkyl group, an optionally substituted Ci_6 alkoxy group, an
optionally substituted C3_io cycloalkyl group, an optionally substituted Ce-u aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group,. an optionally substituted non-aromatic heterocyclic group or the like .
[0075]
Specifically, R2 is preferably
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3
substituents selected from
(i) an amino group,
(ii) a carboxy group,
(iii) a Ci-6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl) ,
(iv) a C6-i4 aryl group (e.g., phenyl),
(v) a Ci-6 alkoxy group (e.g., methoxy), and
(vi) a halogen atom (e.g., a fluorine atom);
(b) a Ci_6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) a C3-10 cycloalkyl group (e.g., cyclopropyl, cyclopentyl);
(d) a C6-i4 aryl group (e.g., phenyl);
(e) an amino group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl,
isopropyl) optionally substituted by 1 to 3 C6-i4 aryl groups (e.g., phenyl),
(ii) a C6-14 aryl group (e.g., phenyl),
(iii) a C3-10 cycloalkyl group (e.g., cyclopentyl,
cyclohexyl) ,
(iv) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl) , and (v) an aromatic heterocyclic group (e.g., pyridyl)
optionally substituted by 1 to 3 Ci-6 alkyl groups (e.g., methyl) ;
(f) an aromatic heterocyclic group (e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl). optionally substituted by 1 to 3 substituents selected from a Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom);
(g) a non-aromatic heterocyclic group (e.g.,
tetrahydropyranyl) ;
or the like.
[0076]
R2 is more preferably an optionally substituted Ci_6 alkyl group, an optionally substituted Ci_6 alkoxy group, an
optionally substituted amino group or the like.
[0077]
Specifically, R2 is more preferably
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3
substituents selected from
(i) an amino group,
(ii) a carboxy group,
(iii) a Ci_6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl) ,
(iv) a C6-14 aryl group (e.g., phenyl),
(y) a Ci-6 alkoxy group (e.g., methoxy) , and
(vi) a halogen atom (e.g., a fluorine atom);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) an amino group optionally mono- or di-substituted by substituent ( s ) selected from
(i) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl,
isopropyl) optionally substituted by 1 to 3 C6-14 aryl groups (e.g., phenyl),
(ii) a C6-14 aryl group (e.g., phenyl),
(iii) a C3-10 cycloalkyl group (e.g., cyclopentyl,
cyclohexyl) , (iv) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl ) , and
- (v) an aromatic heterocyclic group (e.g., pyridyl)
optionally substituted by 1 to 3 Ci_6 alkyl groups (e.g., methyl) ;
or the like.
[0078]
R2 is still more preferably
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy);
(c) an optionally mono- or di-substituted amino group by Ci-6 alkyl group(s) (e.g., methyl, ethyl, propyl, isopropyl);
or the like.
[0079]
R2 is particularly preferably
(a) a Ci-6 alkyl group, (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) ;
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy);
(c) an amino group optionally mono- or di-substituted by Ci_6 alkyl group(s) (e.g., methyl, ethyl, propyl, isopropyl);
or the like.
[0080] "
The "group represented by the formula: -COR2" for R1 is preferably a group represented by the formula: -COR2 wherein R2 is an optionally substituted Ci_6 alkyl group, an optionally substituted Ci_6 alkoxy group, an optionally substituted C3-i0 cycloalkyl group, an optionally substituted C6-i4 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group, an optionally substituted non- aromatic heterocyclic group or the like.
[0081]
Specifically, the "group represented by the formula: - COR2" for R1 is preferably a group represented by the formula: -COR2 wherein
R2 is
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 substituents selected from
(i) an amino group,
(ii) a carboxy group,
(iii) a Ci-6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl) ,
(iv) a C6-i4 aryl group (e.g., phenyl),
(v) a Ci-6 alkoxy group (e.g., methoxy) , and
(vi) a halogen atom (e.g., a fluorine atom);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) a C3-10 cycloalkyl group (e.g., cyclopropyl,
cyclopentyl) ;
(d) a C6-1 aryl group (e.g., phenyl);
(e) an amino group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 C6-14 aryl groups (e.g., phenyl),
(ii) a C6-i4 aryl group (e.g., phenyl),
(iii) a C3-10 cycloalkyl group (e.g., cyclopentyl,
cyclohexyl) ,
(iv) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl ) , and
(v) an aromatic heterocyclic group (e.g., pyridyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (e.g., methyl) ;
(f) an aromatic heterocyclic group (e.g., furyl, . pyrazolyl, pyridyl, isoxazolyl, thiazolyl) optionally substituted by 1 to 3 substituents selected from a Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) ;
(g) a non-aromatic heterocyclic group (e.g., tetrahydropyranyl) ;
or the like.
[0082]
The "group represented by the formula: -COR2" for R1 is more preferably a group represented by the formula: -COR2 wherein R2 is an optionally substituted Ci_6 alkyl group, an optionally substituted Ci_6 alkoxy group, an optionally
substituted amino group or the like.
[0083]
Specifically,.. the "group represented by the formula: -
COR2" for R1 is more preferably a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 substituents selected from
(i) an amino group,
(ii) a carboxy group,
(iii) a Ci-6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl) ,
(iv) a C6-i4 aryl group (e . g ., phenyl) ,
(v) a Ci-6 alkoxy group (e.g., methoxy) , and
(vi) a halogen atom (e.g., a fluorine atom) ;
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) an amino group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 C6-i4 aryl groups (e.g., phenyl),
(ii) a C6-i4 aryl group (e.g., phenyl),
(iii) a C3-10 cycloalkyl group (e.g., cyclopentyl,
cyclohexyl) ,
(iv) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl) , and (v) an aromatic heterocyclic group (e.g., pyridyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (e.g., methyl ) ;
or the like.
[0084]
The "group represented by the formula: -COR2" for R1 is. still more preferably a group represented by the formula: -COR wherein
R2 is
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy);
(c) an amino group optionally mono- or di-substituted by Ci- alkyl group(s) (e.g., methyl, ethyl, propyl, isopropyl); or the like.
[0085]
The "group represented by the formula: -COR2" for R1 is particularly preferably a group represented by the formula: - COR2
wherein
R2 is
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) ;
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy);
(c) an amino group optionally mono- or di-substituted by Ci- alkyl group(s) (e.g., methyl, ethyl, propyl, isopropyl); or the like.
[0086]
Examples of the "5- or 6-membered aromatic group" of the "optionally substituted 5- or 6-membered aromatic group" for R include phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl (1,2,3-triazolyl, 1, 2, 4-triazolyl, 1, 3, 4-triazolyl) ,
tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, furyl, thienyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like.
[0087]
The "5- or 6-membered aromatic group" is preferably a 5- membered aromatic heterocyclic group, phenyl or the like, more preferably pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, phenyl or the like, particularly preferably isoxazolyl.
[0088]
The "5- or 6-membered aromatic group" of the "optionally substituted 5- or 6-membered aromatic group" for R1 optionally has 1 to 3 substituents at substitutable positions. Examples of the substituent include those similar to the substituents that the C3-i0 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group", which is exemplified as the "substituent" for R2, optionally has.
[0089]
The "optionally substituted 5- or 6-membered aromatic group" for R1 is preferably a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) or phenyl, each of which is optionally substituted by 1 to 3 substituents selected from
(1) a Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms;
(2) a Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a Ci-6 alkoxy group, and
(c) a C6-14 aryl group (e.g., phenyl);
(3) a carbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms;
(4) a carboxy group;
(5) a hydroxy group; (6) a halogen atom; and
(7) a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a carboxy group,
(c) a hydroxy group,
(d) a Ci-6 alkoxy-carbonyl group, and
(e) a Ci-6 alkoxy group.
[0090]
The "optionally substituted 5- or 6-membered aromatic group" for R1 is more preferably a 5-membered aromatic
heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) or phenyl, each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci-6 alkyl group.
[0091]
The "optionally substituted 5- or 6-membered aromatic group" for R1 is still more preferably a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group.
[0092]
R1 is preferably
(1) a group represented by the formula: -COR2 wherein R2 is an optionally substituted Ci-6 alkyl group, an optionally
substituted Ci-6 alkoxy group, an optionally substituted C3-i0 cycloalkyl group, an optionally substituted C6-i4 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group, an optionally substituted non- aromatic heterocyclic group or the like; or
(2) an optionally substituted 5- or 6-membered aromatic group.
[0093]
Specifically, R1 is preferably (1) a group represented by the formula: -COR2
wherein
R2 is ^
(a) a C-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 substituents selected from
(i) an amino group,
(ii) a carboxy group,
(iii) a Ci-6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl ) ,
(iv) a C6-i4 aryl group (e.g., phenyl),
(v) a Ci-6 alkoxy group (e.g., methoxy) , and
(vi) a halogen atom (e.g., a fluorine atom);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) a C3-10 cycloalkyl group (e.g., cyclopropyl,
cyclopentyl) ;
(d) a C6-14 aryl group (e.g., phenyl);
(e) an amino group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 C6-i4 aryl groups (e.g., phenyl),
(ii) a C6-i4 aryl group (e.g., phenyl),
(iii) a C3-10 cycloalkyl group (e.g., cyclopentyl,
cyclohexyl) ,
(iv) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl) , and
(v) an aromatic heterocyclic group (e.g., pyridyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (e.g., methyl) ;
(f) an aromatic heterocyclic group (e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl) optionally substituted by 1 to 3 substituents selected from a Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine
atom) ; (g) a non-aromatic heterocyclic group (e.g.,
tetrahydropyranyl) ;
or the like, or
(2) a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) or phenyl,, each of which is optionally substituted by 1 to 3 substituents selected from
(i) a Ci_6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms;
(ii) a Ci_6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a Ci-6 alkoxy group, and
(c) a C6-i4 aryl group (e.g., phenyl);
(iii) a carbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms;
(iv) a carboxy group;
(v) a hydroxy group;
(vi) a halogen atom; and
(vii) a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a carboxy group,
(c) a hydroxy group,
(d) a Ci-6 alkoxy-carbonyl group, and
(e) a Ci-6 alkoxy group.
[0094]
R1 is more preferably
(1) a group represented by the formula: -COR2 wherein R2 is an optionally substituted C-6 alkyl group, an optionally
substituted Ci-6 alkoxy group, an optionally substituted, amino group or the like; or
(2) an optionally substituted 5- or 6-membered aromatic ring group. [0095]
Specifically, R1 is more preferably
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 substituents selected from
(i) an amino group,
(ii) a carboxy group,
(iii) a Ci-6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl) ,
(iv) a C6-1 aryl group (e.g., phenyl),
(v) a Ci-6 alkoxy group (e.g., methoxy) , and
(vi) a halogen atom (e.g., a fluorine atom);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) an amino group optionally, mono- or di-substituted by substituent ( s ) selected from
(i) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 C6-14 aryl groups (e.g., phenyl),
(ii) a C6-i4 aryl group (e.g., phenyl), (
(iii) a C3-10 cycloalkyl group (e.g., cyclopentyl,
cyclohexyl) ,
(iv) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl ) , and
(v)' an aromatic heterocyclic group (e.g., pyridyl) optionally substituted by 1 to 3 Ci_6 alkyl groups (e.g., methyl) ;
or the like; or
(2) a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) or phenyl, each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci-6 alkyl group. [0096]
R1 is further more preferably
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) an amino group optionally mono- or di-substituted by Ci- alkyl group(s) (e.g., methyl, ethyl, propyl, isopropyl); or the like; or
(2) a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group.
[0097]
R1 is still more preferably
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci_6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom);
(b) a Ci_6 alkoxy group (e.g., methoxy, tert-butoxy);
(c) an amino group optionally mono- or di-substituted by Ci_ alkyl group (s) (e.g., methyl, ethyl, propyl, isopropyl); or the like.
[0098]
R1 is particularly preferably
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci_6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) ; (b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) an amino group optionally mono- or di-substituted by Ci-6 alkyl group (s) (e.g., methyl, ethyl, propyl, isopropyl) ;
or the like.
[0099]
For ring P and ring Q,
(1) ring P is an optionally further substituted 5-membered aromatic ring, ring Q is an optionally further substituted 6- membered ring, and ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic ring, or
(2) ring P is an optionally further substituted 5-membered non-aromatic ring, ring Q is an optionally further substituted 6-membered aromatic ring, and ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic ring.
[0100]
The case that ·
"(1) ring P is an optionally further substituted 5-membered aromatic ring, ring Q is an optionally further substituted 6- membered ring, and ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic ring".
[0101]
Examples of the "5-membered aromatic ring" of the
"optionally further substituted 5-membered aromatic ring" for ring P include pyrrole, pyrazole, imidazole, triazole (1,2,3- triazole, 1, 2, 4-triazole, 1, 3, 4-triazole) , tetrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, furan, thiophene and the like. Of these, oxazole, thiazole, pyrazole and 1, 2, 3-triazole are preferable, and pyrazole, oxazole and thiazole are particularly preferable.
[0102]
The "5-membered aromatic ring" of the "optionally further substituted 5-membered aromatic ring" for ring P optionally has 1 or 2 substituents, besides ring A, at substitutable position. Examples of the substituent include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group", which is exemplified as the "substituent" for R2, optionally has.
[0103]
Preferable examples of additional substituent for the "5- membered aromatic ring" of the "optionally further substituted 5-membered aromatic ring" for ring P include
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (4) a cyano group
and the like.
[0104]
Examples of the "6-membered ring" of the "optionally further substituted 6-membered ring" for ring Q include benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine, cyclohexa-1, 3-diene, dihydropyridine and the like. Of these, benzene, 1, 2-dihydropyridine and cyclohexa-1, 3-diene are particularly preferable.
[0105]
The "6-membered ring" of the "optionally further
substituted 6-membered ring" for ring Q optionally has, besides the group -O-R6, 1 to 3 substituents at substitutable positions. Examples of the substituent include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon' group", which is exemplified as the "substituent" for R2, optionally has.
[0106]
Preferable examples of additional substituent for the "6- membered ring" of the "optionally further substituted 6- membered ring" for ring Q include
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(4) a cyano group
and the like.
[0107]
Specific examples of the "bicyclic aromatic ring" of the "optionally further substituted bicyclic aromatic ring" formed by fusion of ring P and ring Q include
[0108]
Figure imgf000044_0001
[0109]
Figure imgf000045_0001
Figure imgf000045_0002
Figure imgf000045_0003
[0110]
and the like.
[0111]
The "bicyclic aromatic ring" of the "optionally further substituted bicyclic aromatic ring" formed by fusion of ring P and ring Q optionally has, besides the group of R6-0-, 1 to 3 substituents at substitutable positions on the ring Q, and optionally has, besides ring A,. 1 or 2 substituents at substitutable positions on the ring P. Examples of the substituent include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the
"hydrocarbon group" of the "optionally substituted hydrocarbon group", which is exemplified as the "substituent" for R2, optionally has.
[0112]
Preferable examples of additional substituent for the
"bicyclic aromatic ring" of the "optionally further
substituted bicyclic aromatic ring" formed by fusion of ring P and ring Q include
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) , .
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (4) a cyano group
and the like.
[0113]
The "optionally further substituted bicyclic aromatic ring" formed by fusion of ring P and ring Q is preferably
[0114]
Figure imgf000047_0001
Figure imgf000047_0002
[0115]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group.
[0116]
The "optionally further substituted bicyclic aromatic heterocycle" formed by fusion of ring P and ring Q . is more preferably
0117]
Figure imgf000048_0001
Figure imgf000048_0002
[0118]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci- 6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group.
[0119]
The "optionally further substituted bicyclic aromatic heterocycle" formed by fusion of ring P and ring Q is still more preferably
[0120]
Figure imgf000049_0001
[0121]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e .g. , methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) and
(4) a cyano group.
[0122]
The case that
"(2) ring P is an optionally further substituted 5-membered non-aromatic ring, ring Q is an optionally further substituted 6-membered aromatic ring, and ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic - ring".
[0123] Examples of the "5-membered non-aromatic ring" of the
"optionally further substituted 5-membered non-aromatic ring" for ring P include cyclopentene, dihydrofuran,
dihydrothiophene, dihydropyrrole, dihydroimidazole,
dihydropyrazole, dihydrotriazole, dihydrooxazole,
dihydrothiazole, dihydroisoxazole, dihydroisothiazole and the like.
[0124]
The "5-membered non-aromatic ring" of the "optionally further substituted 5-membered non-aromatic ring" for ring P optionally has, besides ring A, 1 to 5 substituents at
substitutable position. Examples of the substituent include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group", which is exemplified as the "substituent" for R2., optionally has.
[0125]
Preferable examples of additional substituent for the "5- membered non-aromatic ring" of the "optionally further
substituted 5-membered non-aromatic ring" for ring P include
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (4) a cyano group
and the like.
[0126]
Examples of the "6-membered aromatic ring" of the
"optionally further substituted 6-membered aromatic ring" for ring Q include benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like.
[0127]
The "6-membered aromatic ring" of the "optionally further substituted 6-membered aromatic ring" for ring Q optionally has, besides the group R6-0-, 1 to 3 substituents at
substitutable position. Examples of the substituent include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group", which is exemplified as the "substituent" for R2, optionally has.
[0128]
Preferable examples of additional substituent for the "6- membered aromatic ring" of the "optionally further substituted 6-membered aromatic ring" for ring Q include
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(4) a cyano group
and the like.
[0129].
Specific examples of the "bicyclic non aromatic ring" of the "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q include
[0130]
Figure imgf000051_0001
[0131]
Figure imgf000052_0001
[0132]
and the like.
[0133]
The "bicyclic non-aromatic ring" of the "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q optionally has, besides ring A, 1 to 5 substituents at substitutable positions on the ring P, and optionally has, besides the group -O-R6, 1 to 3
substituents at substitutable positions on the ring Q.
Examples of the substituent include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group", which is exemplified as the "substituent" for R2, optionally has.
[0134]
Preferable examples of additional substituent for the "bicyclic non-aromatic ring" of the "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q include
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci- 6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally , substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
( 4 ) a cyano group
and the like.
[0135]
The "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q is preferably
Figure imgf000053_0001
[0137]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group, (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group.
[0138]
The "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q is more preferably [0139] [0140]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group..
[0141]
The "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q is still more preferably
0142]
Figure imgf000054_0001
[0143]
each of which is optionally substituted by 1 to 4 substituents selected from
. (1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a C1-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group.
[0144]
The "optionally further substituted bicyclic aromatic heterocycle" or "optionally further, substituted" bicyclic non- aromatic ring" formed by fusion of ring P and ring Q is preferably
Figure imgf000055_0001
Figure imgf000055_0002
[0146]
Figure imgf000056_0001
Figure imgf000056_0002
[0147]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by' 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group.
[0148]
The "optionally further substituted bicyclic aromatic heterocycle" or "optionally further substituted bicyclic non- aromatic ring" formed by fusion of ring P and ring Q is more preferably
[0149]
Figure imgf000057_0001
Figure imgf000057_0002
Figure imgf000057_0003
[0151]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group.
[0152]
The "optionally further substituted bicyclic aromatic heterocycle" or "optionally further substituted bicyclic non- aromatic ring" formed by fusion of ring P and ring Q is still more preferably
[0153]
Figure imgf000058_0001
[0154]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci- 6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group.
[0155]
R3 is a Ci-6 alkyl group optionally substituted by halogen atom(.s), or an optionally substituted C3-6 cycloalkyl group.
The "Ci-6 alkyl group" of the "Ci-6 alkyl group optionally substituted by halogen atom(s)" for R3 optionally has
preferably 1 to 7, more preferably 1 to 3 halogen atoms, at substitutable positions.
[0156]
Examples of the "C3-6 cycloalkyl group" of the "optionally substituted C3-6 cycloalkyl group" for R3 include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The "C3-6 cycloalkyl group" of the "optionally substituted C3-6 cycloalkyl group" for R3 optionally has 1 to.7 substituents at substitutable positions. Examples of the substituent include those similar to the substituents that the C3-10
cycloalkyl group and the like exemplified as the "hydrocarbon group" of the "optionally substituted hydrocarbon group", which is exemplified as the "substituent" for R2, optionally has.
[0157] -
R3 is preferably a Ci-6 alkyl group optionally substituted by 1 to 7 (preferably 1 to 3) halogen atoms (e.g., a fluorine atom) , or a C3_6 cycloalkyl group, more preferably a Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) , still more preferably a Ci-6 alkyl group, particularly preferably methyl.
[0158]
Ra and R4b are independently a hydrogen atom or a
substituent.
Examples of the "substituent" for R4a or R5b include those similar to the "substituent" for R2.
R4a is preferably a hydrogen atom or a fluorine atom, particularly preferably a hydrogen atom.
R4b is preferably a hydrogen atom or a fluorine atom, particularly preferably a hydrogen atom.
[0159]
X is 0, CO, CR5aR5b wherein R5a and R5b are independently a hydrogen atom or a substituent, NR5c wherein R5c is a hydrogen atom or an optionally substituted Ci-6 alkyl group, S, SO or S(0)2.
[0160]
Examples of the "substituent" for R5a or R5b include those similar to the "substituent" for R2.
The "Ci-6 alkyl group" of the "optionally substituted Ci_6 alkyl group" for R5c optionally has 1 to 3 substituents at substitutable positions. Examples of the substituent include those similar to the substituents that the Ci-10 alkyl group and the like exemplified as the "hydrocarbon group" of the
"optionally substituted hydrocarbon group", which is
exemplified as the "substituent" for R2, optionally has.
[0161]
X is preferably 0, CO or CR5aR5b wherein R5a and R5b are the same as above, more preferably 0, CO or CH2, particularly preferably 0.
[0162]
R6 is an optionally substituted Ci_6 alkyl group or an optionally substituted C3_6 cycloalkyl group.
[0163]
The "Ci-6 alkyl group" of the "optionally substituted Ci-6 alkyl group" for R6 optionally has 1 to 3 substituents at.
substitutable positions. Examples of the substituent include those similar to the substituents that the Ci_i0 alkyl group and the like exemplified as the "hydrocarbon group" of the
"optionally substituted, hydrocarbon group", which is
exemplified as the "substituent" for R2, optionally has.
[0164]
Examples of the "optionally substituted C3_6 cycloalkyl group" for R6 include those similar to the "optionally
substituted C3-6 cycloalkyl group" for R3.
[0165]
R6 is preferably
(1) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (e.g., a fluorine* atom) , and
(b) a C3-6 cycloalkyl group (e.g., cyclopropyl, cyclobutyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) ; or
(2) a C3-6 cycloalkyl group (e.g., cyclopropyl).
[0166]
R6 is more' preferably a Ci_6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (e.g., a fluorine atom), and
(b) a C3-6 cycloalkyl group (e.g., cyclopropyl, cyclobutyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) .
[0167]
R6 is still more preferably a Ci_6 alkyl group optionally substituted by 1 to 3 C3-6 cycloalkyl groups optionally
substituted by 1 to 3 halogen atoms.
[0168]
In another embodiment, R6 is preferably a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms.
[0169]
Ring A is an optionally further substituted 5- or 6- membered aromatic ring.
Examples of the "5- or 6-membered aromatic ring" of the "optionally further substituted 5- or 6-membered aromatic ring" for ring A include benzene, pyrrole, pyrazole, imidazole, triazole ( 1, 2 , 3-triazole, 1 ,2 , 4-triazole, 1, 3, -triazole) , tetrazole, oxazole, isoxazole, thiazole, isothiazole,
oxadiazole (1, 2, 4-oxadiazole, 1, 3, 4-oxadiazole) , thiadiazole (1, 2, -thiadiazole, 1, 3, 4-thiadiazole) , furan, thiophene, pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like .
[0170]
The "5- or 6-membered aromatic ring" of the "optionally further substituted 5- or 6-membered aromatic ring" for ring A is preferably benzene, optionally oxidized pyridine,
pyrimidine, pyrazole, oxazole, isoxazole, thiazole,
isothiazole, oxadiazole, thiadiazole or the like, more
preferably benzene, optionally oxidized pyridine, pyrimidine, pyrazole, isoxazole or oxadiazole, still more preferably
benzene, optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole.
[0171] The "5- or 6-membered aromatic ring" of the "optionally further substituted 5- or 6-membered aromatic ring" for ring A optionally has, besides group -X-CH (R4a) (R4b) -CH (R3) -NH-R1 and ring P, 1 to 4 substituents (preferably 1 to 3 substituents) at substitutable positions. Examples of the substituent
include those similar to the substituents that the
"heterocyclic group" of the "optionally substituted
heterocyclic group", which is exemplified as the "substituent" for R2, optionally has.
[0172]
Ring A is preferably benzene, optionally oxidized
pyridine, pyrimidine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole or thiadiazole, each of which is optionally substituted by 1 to 3 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom),
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms,
(3) a Ci-6 alkoxy group (e.g., methoxy) , and
(4) a C7-i3 aralkyl group (e.g., benzyl).
[0173]
Ring A is more preferably benzene, optionally oxidized pyridine, pyrimidine, pyrazole, isoxazole or oxadiazole, each of which is optionally substituted by 1 to 3 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom),
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms,
(3) a Ci-6 alkoxy group (e.g., methoxy), and
(4) a C7-i3 aralkyl group (e.g., benzyl).
[0174]
Ring A is still more preferably benzene, optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole, each of which is optionally substituted by 1 to 3 substituents
selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom), (2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms,
(3) a Ci-6 alkoxy group (e.g., methoxy) , and
(4) a C7-i3 aralkyl group (e.g., benzyl).
[0175]
Preferable examples of compound (I) include the following compounds .
[0176]
[Compound A-l]
Compound (I) wherein
R1 is
(1) a group represented by the formula: -COR2 wherein R2 is an optionally substituted Ci_6 alkyl group, an optionally
substituted Ci_6 alkoxy group, an optionally substituted C3-10 cycloalkyl group, an optionally substituted C6-i4 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group or an optionally substituted non- aromatic heterocyclic group; or
(2) an optionally substituted 5- or 6-membered aromatic group; R3 is a Ci_6 alkyl group optionally substituted by 1 to 7 halogen atoms, or a C3-6 cycloalkyl group;
Ra and Rb are independently a hydrogen atom or a fluorine atom;
X is 0, CO, CR5aR5b wherein R5a and R5b is as defined above, NR5c wherein R5c is as defined above, S, SO or S(0)2;
ring A is benzene, pyridine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole or thiadiazole, each of which is optionally substituted by
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom) ; or
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms;
ring P and ring Q are fused to form
[0177]
Figure imgf000064_0001
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom),
(2) a Ci-6 alkyl group optionally substituted by halogen .
atom(s) (e.g., methyl, trifluoromethyl ) , and
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by halogen atom(s) and
R6 is
(1) a Ci-6 alkyl group optionally substituted by 1 to 3
substituents selected from a halogen atom and a C3-6 cycloalkyl group; or
(2) a C3-6 cycloalkyl group (e.g., cyclopropyl).
[0180]
[Compound B-l]
Compound (I) wherein
R1 is
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) a' Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isdbutyl, isopentyl) optionally substituted by 1 to 3 substituents selected from
(i) an amino group,
(ii) a carboxy group,
(iii) a Ci-6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl) ,
(iv)' a C6-1 aryl group (e.g., phenyl), and
(v) a Ci-6 alkoxy group (e.g., methoxy);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) an amino group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci_6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 C6-i4 aryl groups (e.g., phenyl),
(ii) a C6-i4 aryl group (e.g., phenyl),
(iii) a C3-10 cycloalkyl group (e.g., cyclopentyl,
cyclohexyl) , (iv) a Ci-6 alkylsulfonyl group (e.g methylsulfonyl) , and
(v) an aromatic heterocyclic group (e.g., pyridyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (e.g • r methyl) ;
or the like; or
(2) a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl) or phenyl, each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci-6 alkyl group;
R3 is a Ci-6 alkyl group optionally substituted by 1 to 7
halogen atoms, or a C3-6 cycloalkyl group;
Ra and Rb are independently a hydrogen atom or a fluorine atom;
X is 0 or CH2;
ring A is benzene, pyridine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole or thiadiazole, each of which is optionally substituted by
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom) ; or
' (2) a Ci-6 alkyl group (e.g.> methyl) optionally substituted by 1 to 3 halogen atoms;
ring P and ring Q are fused to form
[0181]
Figure imgf000067_0001
[0183]
each of which is optionally substituted by 1 to 4 substituents selected from (1) a halogen atom (e.g., a fluorine atom),
(2) a Ci-6 alkyl group optionally substituted by halogen atom(s) (e.g., methyl, trifluoromethyl) , and
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by halogen atom(s) and
R6 is
(1) a Ci-6 alkyl group optionally substituted by 1 to 3
substituents selected from a halogen atom and a C3_6 cycloalkyl group; or
(2) a C3-6 cycloalkyl group (e.g., cyclopropyl).
[0184]
[Compound C-l]
Compound (I) wherein
R1 is
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl)
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) an amino group optionally mono- or di-substituted by Ci-6 alkyl group(s) (e.g., methyl, ethyl, propyl, isopropyl) ;
or the like; or
(2) a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl ) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group;
R3 is a Ci-6 alkyl group optionally substituted by 1 to 7 halogen atoms, or a C3-6 cycloalkyl group;
Ra and R4b are independently a hydrogen atom or a fluorine atom;
X is 0 or CH2;
ring A is benzene, pyridine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, oxadiazole or thiadiazole, each of which is optionally substituted by (1) a halogen atom (e.g., a fluorine atom, a chlorine atom) ; or
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms;
ring P and ring Q are fused to form
[0185]
Figure imgf000069_0001
[0186]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom) ,
(2) a Ci- 6 alkyl group optionally substituted by halogen atom(s) (e.g., methyl, trifluoromethyl) , and
(3) a C3- 6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by halogen atom(s); and
R6 is
(1) a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a C3-.6 cycloalkyl group; or
(2) a C3-.6 cycloalkyl group (e.g., cyclopropyl).
[0187]
[Compound A-2] Compound (I) wherein
R1 is
(1) a group represented by the formula: -COR2 wherein R2 is an optionally substituted Ci-6 alkyl group, an optionally
substituted Ci_6 alkoxy group, an optionally substituted C3-10 cycloalkyl group, an optionally substituted C6-i4 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group or an optionally substituted non- aromatic heterocyclic group; or
(2) an optionally substituted 5- or 6-membered aromatic ring group;
R3 is a Ci-6 alkyl group optionally substituted by 1 to 7 halogen atoms, or a C3-6 cycloalkyl group;
Ra and R4b are independently a hydrogen atom or a fluorine atom;
X is 0, CO, CR5aR5b wherein R5a and R5b is as defined above, NR5c wherein R5c is as defined above, S, SO, or S(0)2;
ring A is benzene, pyridine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole or thiadiazole, each of which is optionally substituted by
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom) ; or
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms;
ring P and ring Q are fused to form
[0188]
Figure imgf000071_0001
Figure imgf000071_0002
[0190]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom),
(2) a Ci-6 alkyl group optionally substituted by halogen atom(s) (e.g., methyl, trifluoromethyl ) , and
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by halogen atom(s) and
R6 is
(1) a Ci_6 alkyl group optionally substituted by 1 to 3
substituents selected from
(a) a halogen atom, and
(b) a C3-6 cycloalkyl group optionally substituted by 1 to 3 halogen atoms; or
(2) a C3-6 cycloalkyl group (e.g., cyclopropyl).
[0191]
[Compound B-2]
Compound (I) wherein
R1 is
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci_6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 substituents selected from
(i) an amino group,
(ii) a carboxy group,
(iii) a Ci-6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl) ,
(iv) a C6-i4 aryl group (e.g., phenyl), and
(v) a Ci-6 alkoxy group (e.g., methoxy);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) an amino group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 Ce-u aryl groups (e.g., phenyl), (ii) a C6-i4 aryl group (e.g., phenyl),
(iii) a C3-10 cycloalkyl group (e.g., cyclopentyl, cyclohexyl) ,
(iv) a Ci-6 alkylsulfonyl group (e.g., methylsulfonyl ) , and
(v) an aromatic heterocyclic group (e.g., pyridyl) optionally substituted by 1 to 3 Ci_6 alkyl groups (e.g., methyl) ;
or the like; or
(2) a 5-membered aromatic heterocyclic group (e . g. , pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl ) or phenyl, each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci-6 alkyl group;
R3 is a Ci-6 alkyl group optionally substituted by 1 to 7 halogen atoms, or a C3-6 cycloalkyl group;
Ra and R4b are independently a hydrogen atom or a fluorine atom;
X is 0 or CH2;
ring A is benzene, pyridine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole or thiadiazole, each of which is optionally substituted by
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom) ; or
(2) a Ci_6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms;
ring P and ring Q are fused to form
[0192]
Figure imgf000074_0001
selected from
(1) a halogen atom (e.g., a fluorine atom),
(2) a Ci-6 alkyl group optionally substituted by halogen atom(s) (e.g., methyl., trifluoromethyl) , and
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by halogen atom(s); and
R6 is
(1) a Ci-6 alkyl group optionally substituted by 1 to 3
substituents selected from
(a) a halogen atom, and
(b) a C3-6 cycloalkyl group optionally substituted by 1 to 3 halogen atoms; or
(2) a C3_6 cycloalkyl group (e.g., cyclopropyl).
[0195]
[Compound C-2]
Compound (I) wherein
R1 is
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) ;
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) an amino group optionally mono- or di-substituted by Ci-6 alkyl group(s) (e.g., methyl, ethyl, propyl, isopropyl) ;
or the like; or
(2) a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group;
R3 is a Ci-6 alkyl group optionally substituted by 1 to 7 halogen atoms, or a C3-6 cycloalkyl group;
R4a and R4b are independently a hydrogen atom or a fluorine atom;
X is 0 or CH2; ring A is benzene, pyridine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole or thiadiazole, each of which is optionally substituted by
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom) ; or
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms;
ring P and ring Q are fused to form
[0196]
Figure imgf000076_0001
[0197]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom),
(2) a Ci-6 alkyl group optionally substituted by halogen atom(s) (e.g., methyl, trifluoromethyl ) , and
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by halogen atom(s); and
R6 is
(1)- a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom, and (b) a C3-6 cycloalkyl group optionally substituted by ' 1 to 3 halogen atoms; or
(2) a C3-6 cycloalkyl group (e.g.,. cyclopropyl) .
[0198]
[Compound A-3]
Compound (I) wherein
R1 is
(1) a group represented by the formula: -COR2 wherein R2 is an optionally substituted . Ci-6 alkyl group, an optionally
substituted Ci_6 alkoxy group, an optionally substituted C3-10 cycloalkyl group, an optionally substituted C6-1 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group or an optionally substituted non- aromatic heterocyclic group; or
(2) an optionally substituted 5- or 6-membered aromatic ring group
(preferably
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 substituents selected from
(i) an amino group,
(ii) a carboxy group,
(iii) a Ci_6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl) ,
(iv) a C6-1 aryl group (e.g., phenyl),
(v) a Ci-6 alkoxy group (e.g., methoxy) , and
(vi) a halogen atom (e.g., a fluorine atom);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) a C3-10 cycloalkyl group (e.g., cyclopropyl,
cyclopentyl) ;
(d) a C6-i4 aryl group (e.g., phenyl);
(e) an amino group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci_6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 C6-i4 aryl groups (e.g., phenyl),
(ii) a C6-i4 aryl group (e.g., phenyl),
(iii) a C3-10 cycloalkyl group (e.g., cyclopentyl,
cyclohexyl) ,
(iv) a C1-6 alkylsulfonyl group (e.g., methylsulfonyl) , and
(v) an aromatic heterocyclic group (e.g., pyridyl) optionally substituted by 1 to 3 Ci_6 alkyl groups (e.g., methyl) ;
(f) an aromatic heterocyclic group (e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.,g., a fluorine atom) ;
(g) a non-aromatic heterocyclic group (e.g.,
tetrahydropyranyl) ;
or the like; or
(2) a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) or phenyl, each of which is optionally substituted by 1 to 3 substituents selected from
(i) a C1-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms;
(ii) a Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a Ci_6 alkoxy group, and
(c) a C6-i4 aryl group (e.g., phenyl);
(iii) a carbamoyl group optionally mono- or di-substituted by Ci-6 alkyl group (s) optionally substituted by 1 to 3 halogen atoms;
(iv) a carboxy group; (v) a hydroxy group;
(vi) a halogen atom; and
(vii) a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a carboxy group,
(c) a hydroxy group,
■(d) a Ci-6 alkoxy-carbonyl group, and
(e) a Ci-6 alkoxy group) ;
R3 is a Ci-6 alkyl group optionally substituted by 1 to 7
halogen atoms, or a C3_6 cycloalkyl group;
Ra and Rb are independently a hydrogen atom or a fluorine atom;
X is 0, CO, CR5aR5b wherein R5a and R5b is as defined above, NR5c wherein R5c is as defined above, S, SO, or S(0)2;
ring A is benzene, optionally oxidized pyridine, pyrimidine, pyrazole, oxazole, isoxazole, thiazole, isothiazole,
oxadiazole or thiadiazole, each of which is optionally
substituted by 1 to 3 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom),
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms,
(3) a Ci-6 alkoxy group (e.g., methoxy) , and
(4) a C7-i3 aralkyl group (e.g., benzyl);
ring P and ring Q are fused to form
[0199]
Figure imgf000080_0001

Figure imgf000081_0001
Figure imgf000081_0002
[0201]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group; and
R6 is
(1) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (e.g., a fluorine atom), and
(b) a C3-6 cycloalkyl group (e.g., cyclopropyl, cyclobutyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) ; or
(2) a C3-6 cycloalkyl group (e.g., cyclopropyl).
[0202]
[Compound B-3]
Compound (I) wherein
R1 is
(1) a group represented by the formula: -COR2, wherein R2 is an optionally substituted Ci_6 alkyl group, an optionally substituted Ci-6 alkoxy group or an optionally substituted amino group; or
(2) an optionally substituted 5- or 6-membered aromatic ring group
(preferably
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 substituents selected from
(i) an amino group,
(ii) a carboxy group,
(iii) a C-6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl ) ,
(iv) a C6-i4 aryl group (e.g., phenyl).,
(v) a.. Ci-6 alkoxy group (e.g., methoxy) , and
(vi) a halogen atom (e.g., a fluorine atom);
(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;
(c) an amino group optionally mono- or di-substituted by substituent (s) selected from
(i) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl) optionally substituted by 1 to 3 C6-1 aryl groups (e.g., phenyl),
(ii) a C6-i4 aryl group (e.g., phenyl),
(iii) a C3-.10 cycloalkyl group (e.g., cyclopentyl,
cyclohexyl) ,
(iv) a Ci_6 alkylsulfonyl group (e.g., methylsulfonyl) , and
(v) an aromatic heterocyclic group (e.g., pyridyl) optionally substituted by 1 to 3 Ci-6 alkyl groups (e.g., methyl) ;
or the like; or
(2) a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) or phenyl, each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci-6 alkyl group) ;
R3 is a Ci-6 alkyl group optionally substituted by 1 to 7
halogen atoms, or a C3-6 cycloalkyl group;
Ra and Rb are independently a hydrogen atom or a fluorine atom;
X is 0, CO or CH2;
ring A is benzene, optionally oxidized pyridine, pyrimidine, pyrazole, isoxazole or oxadiazole, each of which is optionally substituted by 1 to 3 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom),
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms,
(3) a Ci_6 alkoxy group (e.g., methoxy) , and'
(4) a C7-13 aralkyl group (e.g., benzyl);
ring P and ring Q are fused to form
Figure imgf000083_0001
Figure imgf000083_0002
[0205] each of which is optionally substituted by 1 to 4 substituents selected from .
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group; and
R6 is '
(1) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (e.g., a fluorine atom), and
(b) a C3-6 cycloalkyl group (e.g., cyclopropyl, cyclobutyl) optionally substituted byl to 3 halogen atoms (e.g., a fluorine atom) ; or
(2) a C3-6 cycloalkyl group (e.g., cyclopropyl).
[0206] .
[Compound C-3]
Compound (I) wherein
R1 is
(1) a group represented by the formula: -COR2
wherein
R2 is
(a) Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) ;
(b) a Ci-6 alkoxy group (e.g., "methoxy, tert-butoxy) ;
(c) an amino group optionally mono- or di-substituted by Ci-6 alkyl group(s) (e.g., methyl, ethyl, propyl, isopropyl);
or the like;
R3 is a Ci_6 alkyl group optionally substituted by 1 to 7
halogen atoms; Ra and R4b are independently a hydrogen atom;
X is .0, CO or CH2;
ring A is benzene, optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole, each of which is optionally substituted by 1 to 3 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom),
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms,
(3) a C-6 alkoxy- group (e.g., methoxy) , and
(4) a C7-13 aralkyl group (e.g., benzyl);
ring P and ring Q are fused to form
Figure imgf000085_0001
[0208]
each of which is optionally substituted by 1 to 4 substituents selected from
(1) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom) ,
(2) a Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
(3) a C3-6 cycloalkyl group (e.g., cyclopropyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and
(4) a cyano group; and R6 is a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom (e.g., a fluorine atom), and
* (b) a C3-6 cycloalkyl group (e.g., cyclopropyl, cyclobutyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) .
[0209]
[Compound D-3]
N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide or a salt thereof. N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -5- fluoropyridin-3-yl } oxy) -1-methylethyl] acetamide or a salt thereof.
N- [ (IS) -2- { [6- ( 6-ethoxy-l, 3-benzoxazol-2-yl) pyridin-3-yl] oxy} - 1-methylethyl] acetamide or a salt thereof.
[0210]
A salt of the compound represented by the formula (I) is preferably a pharmacologically acceptable salt. Examples of such salt include salts with inorganic base, salts with
organic base, salts with inorganic acid, salts with organic acid, salts with basic or acidic amino acid, and the like.
[0211]
Preferable examples of the salt with inorganic base include alkali metal salts such as sodium salt, potassium salt and the like; alkaline earth metal salts such as calcium salt, magnesium salt and the like; aluminum salt; ammonium salt and the like.
[0212]
Preferable examples of the salt with organic base include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine,
, tromethamine [tris (hydroxymethyl)methylamine] , tert-butylamine, cyclohexylamine, benzylamine, dicyclohexylamine, N,N- dibenzylethylenediamine and the like. [0213]
Preferable examples of the salt with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
[0214]
Preferable examples of the salt with organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid,
methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.
[0215]
Preferable examples of the salt with basic amino acid include salts with arginine, lysine, ornithine and the like.
[0216]
Preferable examples of the salt with acidic amino acid include salts with aspartic acid, glutamic acid and the like.
[0217]
A prodrug of compound (I) means a compound which is converted to compound (I) with a reaction due to an enzyme, an gastric acid, etc. under the physiological condition in the living body, that is, a compound which is converted to
compound (I) by oxidation, reduction, hydrolysis, etc. due to an enzyme; a compound which is converted to compound (I) by hydrolysis etc. due to gastric acid, etc.
[0218]
Examples of the prodrug of compound (I) include a compound obtained by subjecting an amino group in compound (I) to an acylation, alkylation or phosphorylation (e.g., a compound obtained by subjecting an amino group in compound (I) to an eicosanoylation, alanylation, pentylaminocarbonylation, (5-methyl-2-oxo-l, 3-dioxolen-4-yl)methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation,
pivaloyloxymethylation or tert-butylation) ; a compound
obtained by subjecting a hydroxy group in compound (I) to an acylation, alkylation, phosphorylation or boration (e.g., a compound obtained by subjecting a hydroxy group in compound (I) to an acetylation, palmitoylation, propanoylation,
pivaloylation, succinylation, fumarylation, alanylation or dimethylaminomethylcarbonylation) ; a compound obtained by subjecting a carboxy group in compound (I) to an
esterification or amidation (e.g., a compound obtained by subjecting a carboxy group in compound (I) to an ethyl
esterification, phenyl esterification, carboxymethyl
esterification, dimethylaminomethyl esterification,
pivaloyloxymethyl esterification, ethoxycarbonyloxyethyl esterification, phthalidyl esterification, (5-methyl-2-oxo- • 1, 3-dioxolen-4-yl) methyl esterification,
cyclohexyloxycarbonylethyl esterification or methyl amidation etc.) and the like. These compounds can be produced from compound (I) according to a method known per se.
[0219]
A prodrug for compound (I) may also be one which is converted to compound '(I) under a physiological condition, such as those described in IYAKUHIN no KAIHATSU, Development of Pharmaceuticals, Vol. 7, Design of Molecules, p. 163-198,
Published by HIROKAWA SHOTEN, 1990.
In the present specification, a prodrug may be in the form of a salt. Examples of the salt include those exemplified as the salt of the compound represented by the aforementioned formula (I) .
[0220]
Compound (I) may be labeled with an isotope (e.g., 3H, 13C, 14C, 18F, 35S, 125I) and the like.
Compound (I) may be a hydrate or a non-hydrate, and a solvate or a non-solvate.
Compound (I) also encompasses a deuterium conversion form wherein 1H is converted to 2H(D).
Compound (I) may be a pharmaceutically acceptable cocrystal or cocrystal, salt. Here, the cocrystal or cocrystal salt means a crystalline substance consisting of two or more particular substances which are solids at room temperature, each having different physical properties (e.g., structure, melting point, heat of melting, hygroscopicity, solubility, stability etc.). The cocrystal and cocrystal salt can be produced by cocrystallization known per se.
[0221]
Compound (I) or a prodrug thereof (hereinafter sometimes to be abbreviated simply as the compound of the present
invention) has low toxicity, and can be used as an agent for the prophylaxis or treatment of various diseases mentioned below in a mammal (e.g., human, mouse, rat, rabbit, dog, cat, bovine, horse, swine, monkey) directly or in the form of a pharmaceutical composition by admixing with a
pharmacologically acceptable carrier and the like.
[0222]
Here, examples of the pharmacologically acceptable carrier include various organic or inorganic carrier
substances conventionally ised as preparation materials, which are added as excipient, lubricant, binder or disintegrant for solid preparations; as solvent, solubilizing agent, suspending agent, isotonicity agent, buffer or soothing agent for liquid preparation, and the like. Where necessary, preparation
additives such as preservative, antioxidant, colorant,
sweetener and the like can also be used.
[0223]
Preferable examples of the excipient include lactose, sucrose, D-mannitol, D-sorbitol, starch, pregelatinized starch, dextrin, crystalline cellulose, low-substituted
hydroxypropylcellulose, sodium carboxymethylcellulose, gum arabic, pullulan, light anhydrous silicic acid, synthetic aluminum silicate and magnesium aluminometasilicate.
[0224]
Preferable examples of the lubricant include magnesium stearate, calcium stearate, talc and colloidal silica. [0225]
Preferable examples of the binder include pregelatinized starch, sucrose, gelatin, gum arabic, methylcellulose,
carboxymethylcellulose, sodium carboxymethylcellulose,
crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, pullulan, . hydroxypropylcellulose, hydroxypropylmethylcellulose and polyvinylpyrrolidone.
[0226]
Preferable examples of the disintegrant include lactose, sucrose, starch, carboxymethylcellulose, calcium
carboxymethylcellulose, sodium croscarmellose, sodium
carboxymethylstarch, light anhydrous silicic acid and low- substituted hydroxypropylcellulose .
[0227]
Preferable examples of the solvent include water for injection, physiological brine, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil and cottonseed oil.
[0228]
Preferable examples of the solubilizing agent include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate and sodium acetate.
[0229]
Preferable examples of the suspending agent include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate and the like; hydrophilic polymers such as polyvinyl alcohol,
polyvinylpyrrolidone, sodium carboxymethylcellulose,
methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and the like; polysorbates and
polyoxyethylene hydrogenated castor oil.
[0230] Preferable examples of the isotonicity agent include sodium chloride, glycerol, D-mannitol, D-sorbitol and glucose.
[0231]
Preferable examples of the buffer include buffers such as- phosphate, acetate, carbonate, citrate and the like.
Preferable examples of the soothing agent include benzyl alcohol.
[0232]
Preferable examples of the preservative include
paraoxybenzoates , chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid and sorbic acid.
Preferable examples of the antioxidant include sulfite, ascorbate and the like.
[0233]
Preferable examples of the colorant include aqueous food tar colors (e.g., food colors such as Food Red No. 2 and No. 3, Food Yellow No. 4 and No. 5, Food Blue No. 1 and No. 2, etc.), water insoluble lake dye (e.g., aluminum salt of the above- mentioned aqueous food tar color) and natural dye (e.g., β- carotene, chlorophyll, ferric oxide red) .
[0234]
Preferable examples of the sweetening agent include sodium saccharin, dipotassium glycyrrhizinate, aspartame and stevia .
[0235]
The medicament containing the compound of the present invention can be safely administered solely or by mixing with a pharmacologically acceptable carrier according to a method known per se (e.g., the method described in the Japanese
Pharmacopoeia etc.) as the production method of a
pharmaceutical preparation, and in the form of, for example, tablet (including sugar-coated tablet, film-coated tablet, sublingual tablet, orally disintegrating tablet, buccal and the like) , pill, powder, granule, capsule (including soft capsule, microcapsule) , troche, syrup, liquid, emulsion, suspension, release control preparation (e.g., immediate- release preparation, sustained-release preparation, sustained- release microcapsule), aerosol, film (e.g., orally
disintegrating film, oral mucosa-adhesive film) , injection (e.g., subcutaneous injection, intravenous injection,
intramuscular injection, intraperitoneal injection), drip infusion, transdermal absorption type preparation, ointment, lotion, adhesive preparation, suppository (e.g., rectal suppository, vaginal suppository) , pellet, nasal preparation, pulmonary preparation (inhalant) , eye drop and the like, orally or parenterally (e.g., intravenous, intramuscular, subcutaneous, intraorgan, intranasal, intradermal,
instillation, intracerebral, intrarectal, intravaginal, intraperitoneal and intratumor administrations, administration to the vicinity of tumor, and direct administration to the lesion) .
[0236]
A pharmaceutical composition can be produced by a method conventionally used in the technical field of pharmaceutical preparation, for example, the method described in the Japanese Pharmacopoeia and the like.
[0237]
While the content of the compound of the present
invention in the pharmaceutical composition varies depending on the dosage form, dose of the compound of the present invention, and the like, it is, for example, about 0.1 to 100 wt% .
[0238]
During production of an oral preparation, coating may be applied as necessary for the purpose of masking of taste, enteric property or durability.
[0239]
Examples of the coating base to be used for coating include sugar coating base, aqueous film coating base, enteric film coating base and sustained-release film coating base. [0240]
As the sugar coating base, sucrose is used. Moreover, one or more kinds selected from talc, precipitated calcium carbonate, gelatin, gum arabic, pullulan, carnauba wax and the like may be used in combination.
[0241] -.
Examples of the aqueous film coating base include cellulose polymers such as hydroxypropyl cellulose,
hydroxypropylmethyl cellulose, hydroxyethyl cellulose, methylhydroxyethyl cellulose etc.; synthetic polymers such as polyvinylacetal diethylaminoacetate, aminoalkyl methacrylate copolymer E [Eudragit E (trade name) ] , polyvinylpyrrolidone etc.; and polysaccharides such as pullulan etc.
[0242]
Examples of the enteric film coating base include cellulose polymers such as hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, carboxymethylethyl cellulose, cellulose acetate phthalate etc.; acrylic polymers such as methacrylic acid copolymer L [Eudragit L (trade name)], methacrylic acid copolymer LD
- [Eudragit L-30D55 (trade name) ] , methacrylic acid copolymer S [Eudragit S (trade name)] etc.; and naturally occurring substances such as shellac etc.
[0243]
Examples of the sustained-release film coating base include cellulose polymers such as ethyl cellulose etc.; and acrylic polymers such as aminoalkyl methacrylate copolymer RS [Eudragit RS (trade name) ] , ethyl acrylate-methyl methacrylate copolymer suspension [Eudragit NE (trade name) ] etc.
[0244]
The above-mentioned coating bases may be used after mixing with two or more kinds thereof at appropriate ratios. For coating, for example, a light shielding agent such as titanium oxide, red ferric oxide and the like can be used.
[0245] The compound of the present invention shows low toxicity
(e.g., acute toxicity, chronic toxicity, genetic toxicity, reproductive toxicity, pneumotoxicity, carcinogenicity and the like) and a few side effects. Therefore, it can be used as an agent for the prophylaxis or treatment or a diagnostic of various diseases in a mammal (e.g., human, bovine, horse, dog, cat, monkey, mouse, rat) .
[0246]
The compound of the present invention has a superior ACC (acetyl-CoA carboxylase) inhibitory action. Examples of ACC include liver, adipose tissue, pancreas-specific isozyme
(ACC1) ; and muscle specific isozyme (ACC2) .
The compound of the present invention has ACC2
selectivity. Particularly, the compounds of Examples of the present invention have high ACC2 selectivity.
The compound of the present invention is superior in the metabolism stability and has advantages such as long half-life of compound, difficult in vivo metabolism and the like.
Moreover, the compound of the present invention is superior in the in vivo kinetics (e.g., oral absorbability, bioavailability) .
[0247]
The compound of the present invention can be used as an agent for the prophylaxis or treatment of obesity, diabetes (e.g., type 1 diabetes, type 2 diabetes, gestational diabetes, obese diabetes), hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, high LDL-cholesterolemia, hypoHDL-emia, postprandial hyperlipemia) , hypertension, cardiac failure, diabetic complications [e.g., neuropathy, nephropathy, retinopathy, diabetic cardiomyopathy, cataract,
macroangiopathy, osteopenia, hyperosmolar diabetic coma, infections (e.g., respiratory infection, urinary tract
infection, gastrointestinal infection, dermal soft tissue infections, inferior limb infection) , diabetic gangrene, xerostomia, hypacusis, cerebrovascular disorder, peripheral blood circulation disorder] , metabolic syndrome (pathology having three or more selected from hypertriglyceridemia (TG) , low HDL cholesterol (HDL-C) , hypertension, abdomen obesity and impaired glucose tolerance), sarcopenia, cancer and the like.
[0248]
For diagnostic criteria of diabetes, Japan Diabetes Society reported diagnostic criteria in 1999.
[0249]
According to this report, diabetes is a condition showing any of a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 126 mg/dl, a 75 g oral glucose tolerance test (75 g OGTT) 2 hr. level (glucose
concentration of intravenous plasma) of not less than 200 mg/dl, and a non-fasting blood glucose level (glucose
concentration of intravenous plasma) of not less than 200 mg/dl. A condition not falling under the above-mentioned diabetes and different from "a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of less than 110 mg/dl or a 75 g oral glucose
tolerance test (75 g OGTT) 2 hr level (glucose concentration of intravenous plasma) of less than 140 mg/dl" (normal type) is called a "borderline type".
[0250]
In addition, ADA (American Diabetes Association) in 1997 and WHO in 1998 reported new diagnostic criteria of diabetes.
[0251]
According to these reports, diabetes is a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 126 mg/dl and a 75 g oral glucose tolerance test 2 hr level (glucose concentration of intravenous plasma) of not less than 200 mg/dl.
[0252]
According to the above-mentioned reports, impaired glucose tolerance is a condition showing fasting blood sugar level (glucose concentration of intravenous plasma) of less than 126 mg/dl and a 75 g oral glucose tolerance test 2 hr level (glucose concentration of intravenous plasma) of not less than 140 mg/dl and less than 200 mg/dl. According to the report of ADA, a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of not' less than 110 mg/dl and less than 126 mg/dl is called IFG (Impaired Fasting Glucose) . According to the report of WHO, among the IFG (Impaired Fasting Glucose) , a condition showing a 75g oral glucose tolerance test 2 hr level (glucose
concentration of intravenous plasma) of less than 140 mg/dl is called IFG (Impaired Fasting Glycemia) .
[0253]
The compound of the present invention can be also used as an agent for the prophylaxis or treatment of diabetes,
borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) and IFG (Impaired Fasting Glycemia), as determined according to the above-mentioned diagnostic
criteria. Moreover, the compound of the present invention can prevent progress of borderline type, impaired glucose
tolerance, IFG (Impaired Fasting Glucose) or IFG (Impaired Fasting Glycemia) into diabetes.
[0254]
Since the compound of the present invention has an activity of inhibiting body weight gain, it can be used as a body weight gain inhibitor to mammals . Target mammals may be any mammals of which body weight gain is to be avoided. The mammals may have a risk of body weight gain genetically or may be suffering from lifestyle-related diseases such as diabetes, hypertension and/or hyperlipidemia and the like. The body weight gain may be caused by excessive feeding or diet without nutrient balance, or may be derived from concomitant drug (e.g., agents for enhancing insulin sensitivity having PPARy-agonistic activity such as troglitazone, rosiglitazone, englitazone, ciglitazone, pioglitazone and the like) . In addition, body weight gain may be preliminary to obesity, or may be body weight gain of obesity patients. Here, obesity is defined that BMI (body mass index; body weight (kg) /[height (m)]2) is not less than 25 for Japanese
(criterion by Japan Society for the Study of Obesity) , or not less than 30 for westerner (criterion by WHO) .
[0255]
The compound (I) is also useful as an agent for the prophylaxis or treatment of metabolic syndrome. Because patients with metabolic syndrome have an extreme high
incidence of cardiovascular diseases as compared to patients with single lifestyle-related disease, the prophylaxis or treatment of metabolic syndrome is quite important to prevent cardiovascular diseases.
Criteria for diagnosis of metabolic syndrome are announced by WHO in 1999, and by NCEP in 2001. According to the criterion of WHO, patients with at least two of abdominal obesity, dyslipidemia (high TG or low HDL) and hypertension in addition to hyperinsulinemia or impaired glucose tolerance are diagnosed as metabolic syndrome (World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications .' Part I: Diagnosis and Classification of Diabetes Mellitus, World Health Organization, Geneva, 1999) . According to the criterion of Adult Treatment Panel III of National Cholesterol Education Program, that is an indicator for managing ischemic heart diseases in America, patients with at least three of abdominal obesity, high triglycerides, low HDL cholesterol, hypertension and impaired glucose tolerance are diagnosed as metabolic syndrome (National Cholesterol Education Program: Executive Summary of the Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III) . The Journal of the American Medical Association, Vol. 285, 2486-2497, 2001) .
[0256]
The compound of the present invention can also be used, for example, as an agent for the prophylaxis or treatment of osteoporosis, cachexia (e.g., carcinomatous cachexia,
tuberculous cachexia, diabetic cachexia, hemopathic cachexia, endocrinopathic cachexia, infectious cachexia or cachexia induced by acquired immunodeficiency syndrome) , fatty liver, polycystic ovary syndrome, renal disease (e.g., diabetic nephropathy, glomerulonephritis, glomerulosclerosis, nephrosis syndrome, hypertensive nephrosclerosis, terminal renal disorder) , muscular dystrophy, myocardial infarction, angina pectoris, cerebrovascular disorder (e.g., cerebral infarction, cerebral apoplexy), Alzheimer's disease, Parkinson's disease, anxiety, dementia, insulin resistance syndrome, syndrome X, hyperinsulinemia, sensory abnormality in hyperinsulinemia, irritable bowel syndrome, acute or chronic diarrhea,
inflammatory disease (e.g., rheumatoid arthritis, spondylitis deformans, osteoarthritis, lumbago, gout, postoperative or posttraumatic inflammation, swelling, neuralgia,
pharyngolaryngitis, cystitis, hepatitis (including
nonalcoholic steatohepatitis) , pneumonia, pancreatitis, enteritis, inflammatory bowel disease (including inflammatory colitis) , ulcerative colitis, stomach mucosainjury (including stomach mucosainjury caused by aspirin) ) , small intestine mucosainjury, malabsorption, testis dysfunction, visceral obesity syndrome or sarcopenia.
[0257]
In addition, the compound of the present invention can also be used as an agent for the prophylaxis or treatment of various carcinomas (particularly breast cancer (e.g., invasive ductal carcinoma, ductal carcinoma in situ, inflammatory breast cancer and the like), prostate cancer (e.g., hormone- dependent prostate cancer, non-hormone dependent prostate cancer and the like), pancreatic cancer (e.g., pancreatic duct cancer and the like), gastric cancer (e.g., papillary
adenocarcinoma, mucinous adenocarcinoma, adenosquamous carcinoma and the like), lung cancer . (e . g. , non-small cell lung cancer, small cell lung cancer, malignant mesothelioma and the like), colorectal cancer (e.g., gastrointestinal stromal tumor and the like), rectal cancer (e.g.,
gastrointestinal stromal tumor and the like) , colorectal cancer (e.g., familial colorectal cancer, hereditary
nonpolyposis colorectal cancer, gastrointestinal stromal tumor and the like), small intestinal cancer (e.g., non-Hodgkin lymphoma, gastrointestinal stromal tumor and the like) , esophagus cancer, duodenal cancer, cancer of the tongue, pharyngeal cancer (e.g., nasopharyngeal. cancer, mesopharyngeal cancer, hypopharyngeal cancer and the like) , salivary gland cancer, brain tumor (e.g., pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma and the like), schwannoma, liver cancer (e.g., primary liver cancer, Extrahepatic Bile Duct Cancer and the like) , kidney cancer (e.g., renal cell carcinoma, transitional carcinoma of kidney pelvis and urinary duct, and the like) , biliary tract cancer, endometrial carcinoma, cervical cancer, ovarian cancer (e.g., ovarian epithelial carcinoma, extragonadal germ cell tumor ovarian germ cell tumor ovarian low malignant potential tumor and the like) , urinary bladder cancer, urinary tract cancer, skin cancer (e.g., intraocular (ocular) melanoma, Merkel cell carcinoma and the like) , Hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer (e.g., medullary thyroid carcinoma and the like) , parathyroid cancer, nasal cavity cancer, paranasal sinus cancer, bone tumor (e.g., osteosarcoma, Ewing' s tumor uterus sarcoma, soft tissue sarcoma and the like) , vascular fibroma, retinoblastoma, penile cancer, testis tumor solid. cancer in childhood (e.g., Wilms' tumor childhood kidney tumor and the like), Kaposi's sarcoma, Kaposi's sarcoma derived from AIDS, maxillary tumor fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, ■ leukemia (e.g., acute myeloid leukemia, acute lymphoblastic leukemia and the like) etc.).
[0258]
The compound of the present invention can also be used for secondary prevention or suppression of progression of the above-mentioned various diseases (e.g., cardiovascular events such as myocardial infarction and the like) .
[0259]
While the dose of the compound of the present invention varies depending on the subject of administration,
administration route, target disease, symptom and the like, for example, for oral administration to an adult obese patient, it is generally about 0.01 to 100 mg/kg body weight,
preferably 0.05 to 30 mg/kg body weight, further preferably 0.5 to 10 mg/kg body weight for one dose, which is desirably administered once to 3 times a day.
[0260]
With the aim of enhancing the action of the compound of the present invention or decreasing the dose of the compound and the like, the compound can be used in combination with medicaments such as therapeutic agents for diabetes,
therapeutic agents for diabetic complications, therapeutic agents for hyperlipidemia, antihypertensive agents,
antiobesity agents, diuretics, antithrombotic agents and the like (hereinafter to be abbreviated as concomitant drug) . The time of administration of the compound of the present
invention and that of the concomitant drug are not limited, and these concomitant drugs may be low-molecular-weight
compounds or high-molecular-weight protein, polypeptide, antibody, vaccine and the like. They may be administered simultaneously or in a staggered manner to the administration subject. In addition, the compound of the present invention and the concomitant drug may be administered as two kinds of preparations containing respective active ingredients or a single preparation containing both active ingredients.
[0261]
The dose of the concomitant drug can be appropriately determined based on the dose employed clinically. In -addition, the mixing ratio of the compound of the present invention and the concomitant drug can be appropriately determined according to the administration subject, administration route, target disease, condition,- combination, and the like. For example, when the administration subject is a human, the concomitant drug may be used in an amount of 0.01 to 100 parts by weight per 1 part by weight of the compound of the present invention.
[0262]
Examples of the therapeutic agents for diabetes include insulin preparations (e.g., animal insulin preparations
extracted from pancreas of bovine or swine; human insulin preparations genetically synthesized using Escherichia coli or yeast; zinc insulin; protamine zinc insulin; fragment or derivative of insulin (e.g., INS-1) , oral insulin preparation), insulin sensitizers (e.g., pioglitazone or a salt thereof
(preferably hydrochloride) , rosiglitazone or a salt thereof (preferably maleate) , etaglidasen, AMG-131, Balaglitazone, MBX-2044, Rivoglitazone, Aleglitazar, Chiglitazar,
Lobeglitazone, PLX-204, PN-2034, GFT-505, THR-0921, compound described in WO 2007/013694, WO 2007/018314, WO 2008/093639 or WO 2008/099794), -glucosidase inhibitors (e . g . , voglibose, acarbose, miglitol, emiglitate) , biguanides (e.g., metformin, buformin or a salt thereof (e.g., hydrochloride, fumarate, succinate)), insulin secretagogues [sulfonylureas (e.g., tolbutamide, glibenclamide, gliclazide, chlorpropamide,
tolazamide, acetohexamide, glyclopyramide, glimepiride,
glipizide, glybuzole) , repaglinide, nateglinide, mitiglinide or a calcium salt hydrate thereof] , dipeptidyl peptidase IV inhibitors (e.g., Alogliptin, Vildagliptin, Sitagliptin,
Saxagliptin, BI1356, GRC8200, MP-513, PF-00734200, PHX1149, SK-0403, ALS2-0426, TA-6666, TS-021, KRP-104, 2- [ [ 6- [ (3R) -3- amino-l-piperidynyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-l (2H) - pyrimidinyl] methyl] -4-fluorobenzonitrile or a salt thereof), β3 agonists (e.g., N-5984), GPR40 agonists (e.g., compound described in WO 2004/041266, WO 2004/106276, WO.2005/063729, WO 2005/063725, WO 2005/087710, WO 2005/095338, WO 2007/013689 or WO 2008/001931), GPR119 agonists (e.g., MBX-2982, PSN821,
GSK1292263A, APD597), GLP-1 receptor agonists [e.g., GLP-1, GLP-1MR preparation, Liraglutide, Exenatide, AVE-0010, BIM- 51077, Aib (8, 35) hGLP-1 (7, 37)NH2, CJC-1131, Albiglutide] , amylin agonists (e.g., pramlintide) , phosphotyrosine phosphatase inhibitors (e.g., sodium vanadate), gluconeogenesis inhibitors (e.g., glycogen phosphorylase inhibitors glucose-6-phosphatase inhibitors, glucagon antagonists, FBPase inhibitors) , SGLT2 (sodium-glucose cotransporter 2) inhibitors (e.g.,
Depagliflozin, AVE2268, TS-033, YM543, TA-7284, Remogliflozin, ASP1941), SGLT1 inhibitors, Ιΐβ-hydroxysteroid dehydrogenase inhibitors (e.g., BVT-3498) , adiponectin or an agonist thereof, IKK inhibitors (e.g., AS-2868), leptin resistance improving drugs, somatostatin receptor agonists, glucokinase activators (e.g., N- (5- (2-methoxyethoxy) -2-{ 5- [ (1- oxidethiomorpholino) methyl] -4, 5-dihydro-l, 3-thiazol-2-yl } -1H- indol-7-yl) -N-methylpyridine-2-sulfonamide, AZD1656, AZD6370, AZD6714, TPP355, PSN010, MK-0599, ARRY-403/AMG-151, PF- 04937319, compound described in WO 2006/112549, WO 2007/028135, WO 2008/047821, WO 2008/050821, WO 2008/136428 or
WO2008/156757 ) , GIP (Glucose-dependent insulinotropic peptide) and the like.
[0263]
Examples of the therapeutic agents for diabetic
complications include aldose reductase inhibitors (e.g., tolrestat, epalrestat, zopolrestat, fidarestat, CT-112,
ranirestat (AS-3201) , lidorestat) , neurotrophic factor and increasing drugs thereof (e.g., NGF, NT-3, BDNF, neurotrophic factors and increasing drugs thereof (e.g., 4- (4- .
chlorophenyl) -2- (2-methyl-l-imidazolyl) -5- [3- (2- methylphenoxy) propyl] oxazole) described in WO 01/14372, a compound described in WO 2004/039365) , nerve regeneration promoters (e.g., Y-128) , PKC inhibitors (e.g., ruboxistaurin mesylate), AGE inhibitors (e.g., ALT946, pyratoxanthine, N- phenacylthiazolium bromide (ALT766) , ALT-711, EXO-226, Pyridorin, pyridoxamine) , GABA receptor agonists (e.g.,
gabapentin, Pregabalin) , serotonin noradrenaline re-uptake inhibitors (e.g., duloxetine) , sodium channel inhibitors (e.g., lacosamide) , active oxygen scavengers (e.g., thioctic acid), cerebral vasodilators (e.g., tiapuride, mexiletine) ,
somatostatin receptor agonists (e.g., BIM23190) , apoptosis signal regulating kinase-1 (ASK-1) inhibitors and the like.
[0264]
Examples of the therapeutic agent for hyperlipidemia include statin compounds (e.g., pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin,
pitavastatin or a salt thereof (e.g., sodium salt, calcium salt)), squalene synthase inhibitors (e.g., a compound
described in WO 97/10224, for example, N- [ [ (3R, 5S) -1- (3- acetoxy-2, 2-dimethylpropyl) -7-chloro-5- (2, 3-dimethoxyphenyl) - 2-oxo-l, 2, 3, 5-tetrahydro-4, l-behzoxazepin-3- yl] acetyl] piperidine-4-acetic acid), fibrate compounds (e.g., bezafibrate, clofibrate, simfibrate, clinofibrate) , anion exchange resins (e.g., colestyramine) , probucol, nicotinic acid drugs (e.g., nicomol, niceritrol, niaspan) , ethyl
icosapentate, phytosterols (e.g., soysterol) , γ-oryzanol) , cholesterol absorption inhibitors (e.g., Zetia) , CETP
inhibitors (e.g., dalcetrapib, anacetrapib) , co-3 fatty acid preparations (e.g., ω-3-acid ethyl esters 90) and the like.
[0265]
Examples of the antihypertensive agent include
angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, delapril etc.), angiotensin II antagonists (e.g., candesartan cilexetil, candesartan, losartan, losartan
potassium, eprosartan, valsartan, telmisartan, irbesartan, tasosartan, olmesartan, olmesartan medoxomil, azilsartan, azilsartan medoxomil), calcium antagonists (e.g., manidipine, nifedipine, efonidipine, nicardipine, amlodipine, cilnidipine and the like), β blockers (e.g., metoprolol, atenolol,
propranolol, carvedilol, pindolol), clonidine and the like. [0266]
Examples of the antiobesity agent include monoamine uptake inhibitors (e.g., phentermine, sibutramine, mazindol, fluoxetine, tesofensine) , serotonin 2C receptor agonists (e.g., lorcaserin) , serotonin 6 receptor antagonists, histamine H3 receptor GABA modulators (e.g., topiramate) , MCH receptor antagonists (e.g., SB-568849; SNAP-7941; compound described in WO 01/82925 or Wp 01/87834), neuropeptide Y antagonists (e.g., velneperit) , cannabinoid receptor antagonists (e.g.,
rimonabant, taranabant) , ghrelin antagonists, ghrelin receptor antagonists, ghrelinacylation enzyme inhibitors, opioid
receptor antagonists (e.g., GSK-1521498 ) , orexin receptor antagonists, melanocortin 4 receptor agonists (e.g., Palatin, AP-1030) , Ιΐβ-hydroxysteroid dehydrogenase inhibitors (e.g., AZD-4017), pancreatic lipase inhibitors (e.g., orlistat, cetilistat) , β3 agonists (e.g., N-5984), diacylglycerol
acyltransferase 1 (DGAT1) inhibitors, acetylCoA carboxylase (ACC) inhibitors, stearoyl-CoA desaturated enzyme inhibitors, microsomal triglyceride transfer protein inhibitors (e.g., R- 256918), Na-glucose cotransporter inhibitors (e.g., JNJ-
28431754, remogliflozin<) , N FK inhibitors (e.g., HE-3286) , PPAR agonists (e.g., GFT-505, DRF-11605) , phosphotyrosine
phosphatase inhibitors (e.g., sodium vanadate, Trodusquemin) , glucokinase activators (e.g., AZD-1656) , leptin, leptin
derivatives (e.g., metreleptin) , CNTF (ciliary neurotrophic factor) , BDNF (brain-derived neurotrophic factor) ,
cholecystokinin agonists, glucagon-like peptide-1 (GLP-1) preparations (e.g., animal GLP-1 preparations extracted from the pancreas of bovine and pig; human GLP-1 preparations genetically synthesized using Escherichia coli or yeast;
fragments or derivatives of GLP-1 (e.g., exenatide,
liraglutide) ) , amylin preparations (e.g., pramlintide, AC- 2307), neuropeptide Y agonists (e.g., PYY3-36, derivatives of PYY3-36, obineptide, T -30339, T -30335), oxyntomodulin
preparations: FGF21 preparations (e.g., animal FGF21 preparations extracted from the pancreas of bovine and pig;
human FGF21 preparations genetically synthesized using
Escherichia coli or yeast; fragments or derivatives of FGF21)), anorexigenic agents (e.g., P-57) and the like.
[0267]
Examples of the diuretics include xanthine derivatives (e.g., theobromine sodium salicylate, theobromine calcium salicylate), thiazide preparations (e.g., ethiazide,
cyclopenthiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penflutizide, polythiazide, methyclothiazide) , antialdosterone preparations (e.g., spironolactone, triamterene)., carbonic anhydrase
inhibitors (e.g., acetazolamide) , chlorobenzenesulfonamide agents (e.g., chlortalidone, mefruside, indapamide) , azosemide, isosorbide, ethacrynic acid, piretanide, bumetanide,
furosemide and the like.
[0268]
Examples of the antithrombotic agent include heparins (e.g., heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium), warfarins (e.g., warfarin potassium), anti-thrombin drugs (e.g., argatroban, dabigatran) ,
thrombolytic agents (e. g. , urokinase, tisokinase, alteplase, nateplase, monteplase, pamiteplase) , platelet aggregation inhibitors (e.g., ticlopidine hydrochloride, clopidogrel,
E5555, SHC530348, cilostazol, ethyl icosapentate, beraprost sodium, sarpogrelate hydrochloride, prasugrel, E5555,
SHC530348), FXa inhibitors (e.g., rivaroxaban, apixaban, edoxaban, Y 150, compound described in WO 02/06234, WO
2004/048363, WO 2005/030740, WO 2005/058823 or WO 2005/113504) and the like.
[0269]
The administration time of the aforementioned concomitant drug is not limited, and the compound of the present invention and the concomitant drug may be administered to an
administration subject simultaneously, or may be administered at different times. The dosage of the concomitant drug may be determined according to the dosage clinically used, and can be appropriately selected depending on the administration subject, administration route, diseases, combination thereof and the like.
The administration mode of the concomitant drug is not particularly limited,, and the compound of the present
invention and the concomitant drug only need to be combined on administration. Examples of such administration mode include the following:
(1) administration of a single preparation obtained by
simultaneously processing the compound of the present
invention and the concomitant drug,
(2) simultaneous administration of two kinds of preparations of the compound of the present invention and the concomitant drug, which have been separately produced, by the same
administration route,
(3) administration of two kinds of preparations of the
compound of the present invention and the concomitant drug, which have been separately produced, by the same
administration route in a staggered manner,
(4) simultaneous administration of two kinds of preparations of the compound of the present invention and the concomitant drug, which have been separately produced, by different
administration routes,
(5) administration of two kinds of preparations of the
compound of the present invention and the concomitant drug, which have been .separately produced, by different
administration routes in a staggered manner (e.g.,
administration in the order of the compound of the present invention and the concomitant drug, or in the reverse order) and the like.
The compounding ratio of the compound of the present invention to the concomitant drug can be appropriately
selected depending on the administration subject, administration route, diseases and the like.
[0270]
The production method of the compound of the present invention is explained in the following.
In the following Reaction Schemes, starting compounds may be each in the form of a salt as long as it inhibits the reaction. Examples of the salt include those exemplified as the above-mentioned salt of the compound represented by formula (I) .
When a specific production method is not described, the starting compound may be easily commercially available, or can also be produced according to a method known per se, or a method analogous thereto.
In each reaction of the following Reaction Schemes, the product can be used for the next reaction as the reaction mixture or as a crude product, or can also be isolated
according to a conventional method from the reaction mixture, and can also be easily purified according to a conventional separation means (e.g., recrystallization, distillation, chromatography) .
When alkylation reaction, hydrolysis, amination reaction, esterification reaction, amidation reaction, esterification reaction, etherification reaction, oxidation reaction,
■ reduction reaction and the like are to be performed in the following Reaction Schemes, these reactions are performed according to a method known per se. Examples of such method include the methods described in ORGANIC FUNCTIONAL GROUP PREPARATIONS, 2nd ed. , ACADEMIC PRESS, INC., 1989;
Comprehensive Organic Transformations, VCH Publishers Inc., 1989 and the like, and the like.
[0271]
The following are explanations of the solvents in generic terms, which are used for the following reactions.
. Examples of the "nitrile solvents" include acetonitrile, propionitrile and the like. Examples of the "amide solvents" include N,N- dimethylformamide (DMF) , N, -dimethylacetamide, N- methylpyrrolidone and the like.
Examples of the "halogenated hydrocarbon solvents" include dichloromethane, chloroform, 1, 2-dichloroethane, carbon tetrachloride and the like.
Examples of the "ether solvents" include diethyl ether, diisopropyl ether, tert-butyl methyl ether, tetrahydrofuran (THF) , 1,4-dioxane, 1 , 2-dimethoxyethane and the like.
Examples of the "aromatic solvents" include benzene, toluene, xylene, chlorobenzene, (trifluoromethyl) benzene, pyridine and the like.
Examples of the "aliphatic hydrocarbon solvents" include hexane, pentane, cyclohexane and the like.
Examples of the "sulfoxide solvents" include dimethyl sulfoxide (D SO) and the like.
Examples of the "alcohol solvents" include methanol, ethanol, propanol, 2-propanol, butanol, isobutanol, tert- butanol and the like.
Examples of the "ester solvents" include methyl acetate, ethyl acetate, n-butyl acetate, tert-butyl acetate and the like.
Examples of the "ketone solvents" include acetone, methyl ethyl ketone and the like.
Examples of the "organic acid solvents" include formic acid, acetic acid, propionic acid, trifluoroacetic acid, methanesulfonic acid and the like.
[0272]
The following are explanations of the bases in generic terms, which are used for the following reactions.
Examples of the "inorganic bases" include sodium
hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide and the like.
Examples of the "basic salt" include sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, tripotassium
phosphate and the like.
Examples of the "aromatic amines" include pyridine, imidazole, 2,6-lutidine and the like.
Examples of the "tertiary amines" include triethylamine, diisopropylethylamine, N-methylmorpholine, DBU (1,8- diazabicycio [5. .0] undec-7-ene) , DBN (1,5- diazabicyclo [ .3.0] non-5-ene) and the like.
Examples of the "hydrides of an alkali metal or alkaline earth metal" include lithium hydride, sodium hydride,
potassium hydride, calcium hydride and the like.
Examples of the "metal amides" include lithium amide, sodium amide, lithium diisopropylamide, lithium
dicyclohexylamide, lithium hexamethyldisilazide, sodium
hexamethyldisilazide, potassium hexamethyldisilazide and the like.
Examples of the "alkyl metals" include n-butyllithium, sec-butyllithium, tert-butyllithium, methylmagnesium bromide and the like.
Examples of the "aryl metals" include phenyllithium, phenylmagnesium bromide and the like.
Examples of the "metal alkoxides" include sodium
methoxide, sodium ethoxide, potassium tert-butoxide, sodium tert-butoxide and the like.
[0273]
In the following production methods, when the starting compound has an amino group, a carboxyl group, a hydroxy group, a carbonyl group or a sulfanyl group as a substituent, a protecting group generally used in peptide chemistry and the like may be introduced into these groups. By removing the protecting group as necessary after the reaction, the object compound can be obtained.
Examples of the amino-protecting group include a formyl group, a Ci_6 alkyl-carbonyl group, a Ci_6 alkoxy-carbonyl group, a benzoyl group, a C7-10 aralkyl-carbonyl group (e.g., benzylcarbonyl), a C7_i4 aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl) , a. 9-fluorenylmethoxycarbonyl group, a trityl group, a phthaloyl group, a N, N-dimethylaminomethylene group, a substituted silyl group (e.g., trimethylsilyl,
triethylsilyl, dimethylphenylsilyl, tert-butyldimethylsilyl, tert-butyldiethylsilyl) , a C2-6 alkenyl group (e.g., 1-allyl), a substituted C7_io aralkyl group (e.g., 2, 4-dimethoxybenzyl) and the like. These groups are optionally substituted by 1 to 3 substituents selected from a halogen atom, a Ci-6 alkoxy group and a nitro group.
Examples of the carboxyl-protecting group include a Ci_6 alkyl group, a C7_io aralkyl group (e.g., benzyl), a phenyl group, a trityl group, a substituted silyl group (e.g.,
trimethylsilyl, triethylsilyl, dimethylphenylsilyl, tert- butyldimethylsilyl, tert-butyldiethylsilyl) , a C2-6 alkenyl group (e.g., 1-allyl) and the like. These groups are
optionally substituted by 1 to 3 substituents selected from a halogen atom, a Ci-6 alkoxy group and a nitro group.
Examples of the hydroxy-protecting group include a Ci-6 alkyl group, a phenyl group, a trityl group, a C7-.10 aralkyl group (e.g., benzyl), a formyl group, a Ci_6 alkyl-carbonyl group, a benzoyl group, a C7-10 aralkyl-carbonyl group (e.g., benzylcarbonyl) , a 2-tetrahydropyranyl group, a 2- tetrahydrofuranyl group, a substituted silyl group (e.g., trimethylsilyl, triethylsilyl, dimethylphenylsilyl, tert- butyldimethylsilyl, tert-butyldiethylsilyl) , a C2_6 alkenyl group (e.g., 1-allyl) and the like. These groups are
optionally substituted by 1 to 3 substituents selected from a halogen atom, a Ci_6 alkyl group, a Ci_6 alkoxy group or a nitro group.
[0274]
Examples of the protected carbonyl group include a cyclic acetal (e.g., 1, 3-dioxane) , a non-cyclic acetal (e.g., a di-Ci_6 alkylacetal) and the like.
Examples of the sulfanyl-protecting group include a Ci-6 alkyl group, a phenyl group, a trityl group, a C7_io aralkyl group (e.g., benzyl), a Ci-6 alkyl-carbonyl group, a benzoyl group, a C7_i0 aralkyl-carbonyl group (e.g., benzylcarbonyl) , a Ci-6 alkoxy-carbonyl group, a Ce-1 aryloxy-carbonyl group (e.g., phenyloxycarbonyl) , a C7-14 aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl) , a 9-fluorenylmethoxycarbonyl group, . a 2- tetrahydropyranyl group, a Ci-6 alkylamino-carbonyl group (e.g., methylaminocarbonyl, ethylaminocarbonyl) and the like. These groups are optionally substituted by 1 to 3 substituents selected from a halogen atom, a Ci-6 alkyl group, a Ci_6 alkoxy group and a nitro group.
[0275]
The removal method of the protecting group can be carried out according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis,
John Wiley and Sons (1980) or the like. Specifically, a method using acid, base/ ultraviolet rays, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate, trialkylsilyl halide (e.g., trimethylsilyl iodide, trimethylsilyl bromide) and the like, a reduction method, and the like can be employed.
[0276]
<Reaction Scheme 1>
Figure imgf000111_0001
[0278]
wherein each symbol is as defined above.
[0279]
Compound (I) can be produced, for example, by subjecting compound (1) to an alkylation reaction.
Examples of the alkylation reaction include the following "method using a base and an alkyl halide or sulfonate corresponding to R6", "method employing the Mitsunobu reaction" and the like.
[0280]
The "method using a base and an alkyl halide or sulfonate corresponding to R6" can be performed according to a method known per se, for example, the method described in Journal of the Chemical Society, 1530-1534 pages, 1937 or the like, or a method analogous thereto.
This reaction is performed by reacting compound (1) with an alkyl halide or sulfonate corresponding to R6 in the
presence of a base, in an inert solvent.
Examples of the above-mentioned "alkyl halide
corresponding to R6" include optionally substituted Ci_6 alkyl halides and optionally substituted C3-6 cycloalkyl halides. The amount of the "alkyl halide corresponding to R6" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (1) .
Examples of the above-mentioned "sulfonate corresponding to R6" include optionally substituted Ci_6 alkyl esters of sulfonic acid, and optionally substituted C3-6 cycloalkyl esters of sulfonic acid. Examples of the "sulfonic acid" include methanesulfonic acid, p-toluenesulfonic acid,
trifluoromethanesulfonic acid and the like. The amount of the "sulfonate corresponding to R6" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound ( 1) .
Examples of the above-mentioned "base" include "inorganic bases", "basic salts", "aromatic amines", "tertiary amines", "hydrides of an alkali me.tal or alkaline earth metal", "alkyl metals", "aryl metals", "metal alkoxides" and the like. The amount of the "base" to be used is generally 1 to 10
equivalents, preferably 1 to 5 equivalents, relative to compound (1) .
Examples of the above-mentioned "inert solvent" include nitrile solvents, amide solvents, halogenated hydrocarbon solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an
appropriate ratio. Among them, THF, DMF and the like are preferable .
The reaction temperature is generally -100°C to 150°C, preferably 0°C to 100°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0281]
The "method employing the itsunobu reaction" can be performed according to a method known per se, for example, the method described in Tetrahedron Letters, 769-770 pages, 1980 or the like, or a method analogous thereto.
This reaction is performed by reacting compound (1) with the compound R6OH in the presence of a hydroxy group-activator, in an inert solvent.
The amount of the above-mentioned "compound R6OH" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (1) .
Examples of the above-mentioned "hydroxy group-activator" include cyanomethylenetri-n-butylphosphorane, a combination of diisopropyl azodicarboxylate and triphenylphosphine, and the like. The amount of the "hydroxy group-activator" to be used is generally 1 to 10 equivalents, preferably 1 to 5
equivalents, relative to compound (1) .
Examples of the above-mentioned "inert solvent" include aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, ester solvents, amide solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 48 hr.
[0282] Compound (I) wherein X is an oxidized sulfur atom, which is a sulfone derivative or sulfoxide derivative, can be produced by subjecting compound (I) wherein X is sulfur atom to an oxidation reaction.
This reaction can be performed according to the method described in Jikken Kagaku Kouza, 4th Edition, vol.20 (The Chemical Society of Japan ed. ) , 276-278 pages, 503 or a method analogous thereto, or the like.
[0283]
<Reaction Scheme 2>
[0284]
Figure imgf000114_0001
Figure imgf000114_0002
[0285]
wherein M1 is an amino-protecting group, and the other symbols are as defined above.
[0286]
Compound (3) can be produced, for example, by subjecting compound (2) to a deprotection. reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0287]
Compound (1-1) can be produced, for example, by
subjecting compound (3) to an acylation reaction.
[0288]
The above-mentioned "acylation reaction" encompasses, for example, reactions for production of amide derivatives,, carbamate derivatives and urea . derivative, and the like.
The production of the "amide derivative" is performed according to the following "method using a carboxylic acid corresponding to R2C0 and a dehydrating condensing agent" or "method using a reactive derivative of a carboxylic acid corresponding to R2CO".
i) the method using a dehydrating condensing agent
The method is performed by reacting compound (3) with a carboxylic acid corresponding to R2CO in the presence of a dehydrating condensing agent, in an inert solvent. Where necessary, the reaction can be performed in the presence of 1- hydroxybenzotriazole (HOBt) in a catalytic amount to 5
equivalents relative to the carboxylic acid corresponding to R2CO, a base in a catalytic amount to 5 equivalents relative to the carboxylic acid corresponding to R2C0, and the like.
The amount of the above-mentioned "carboxylic acid corresponding to R2CO" to be used is generally 0.5 to 5 equivalents, preferably 0.8 to 1.5 equivalents, relative to compound (3) .
Examples of the above-mentioned "dehydrating condensing agent" include dicyclohexylcarbodiimide (DCC) , l-ethyl-3- ( 3- dimethylaminopropyl) carbodiimide hydrochloride (WSC) and the like. Among them, WSC is preferable. The amount of the
"dehydrating condensing agent" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (3) .
Examples of the above-mentioned "inert solvent" include nitrile solvents, amide solvents, halogenated hydrocarbon solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an
appropriate ratio. Among them, amide solvents are preferable.
Examples of the above-mentioned "base" include "aromatic amines", "tertiary amines" and the like.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 1 hr to 48 hr.
ii) the method using a reactive derivative of a carboxylic acid corresponding to R2C0
The method is performed by reacting compound (3) with 0.5 to 5 equivalents (preferably 0.8 to 3 equivalents) of a reactive derivative of a carboxylic acid corresponding to R2C0 in an inert solvent. Where necessary, the reaction can be performed in the presence of a base in 1 to 10 equivalents, preferably 1 to 3 equivalents, relative to the carboxylic acid corresponding to R2CO.
Examples of the above-mentioned "reactive derivative of the carboxylic acid corresponding to R2CO" include acid halides (e.g., acid chlorides, acid bromides), mixed acid anhydrides (e.g., acid . anhydrides with a Ci-6 alkyl-carboxylic acid, a C6-io aryl-carboxylic acid, a Ci_6 alkylcarbonate etc.), activate esters (e.g., esters with a phenol optionally having
substituent (s) , HOBt, N-hydroxysuccinimide etc.), activate amides (e.g., amides with imidazole, triazole etc.) and the like.
Examples of the above-mentioned "phenol optionally having substituent (s) " include phenols such as phenol,
pentachlorophenol, pentafluorophenol, p-nitrophenol and the like.
The above-mentioned "reactive derivative of the
carboxylic acid corresponding to R2CO" is preferably an acid anhydride.
Examples of the above-mentioned "inert solvent" include ether solvents, halogenated hydrocarbon solvents, aromatic solvents, aliphatic hydrocarbon solvents, nitrile solvents, amide solvents, sulfoxide solvents and the like. These
solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, pyridine, acetonitrile, THF, dichloromethane, chloroform and the like are preferable. Examples of the above-mentioned "base" include "aromatic amines", "tertiary amines" and the like.
The reaction temperature is generally -20°C to 100°C, preferably -20°C to 50°C.
The reaction time is generally 5 min to 40 hr, preferably
30 min to 18 hr.
[0289]
The production of the above-mentioned "carbamate
derivative" is performed by reacting compound (3) with 0.5 to 5 equivalents (preferably 0.8 to 3 equivalents) of a
dicarbonate or chloroformate corresponding to R2CO in an inert solvent. Where necessary, the reaction can be performed in the presence of a base in a catalytic amount to 5 equivalents relative to the dicarbonate or chloroformate corresponding to R2CO.
Examples of the above-mentioned "inert solvent" include ether solvents, halogenated hydrocarbon solvents, aromatic solvents, aliphatic hydrocarbon solvents, nitrile solvents, amide solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, pyridine, acetonitrile, THF, DMF, dichloromethane, chloroform and the like are preferable.
Examples of the above-mentioned "base" include "aromatic amines", "tertiary amines" and the like.
The reaction temperature is generally -20°C to 100°C, preferably -20°C to 50°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 18 hr.
[0290]
The production of the above-mentioned "urea derivative" is performed by reacting compound (3) with 0.5 to 5
equivalents (preferably 0.8 to 3 equivalents) of an isocyanate or carbamoyl chloride corresponding to R2CO in an inert solvent. Where necessary, the reaction can be performed in the presence of a base in a catalytic amount to 5 equivalents relative to the isocyanate or carbamoyl chloride corresponding to R2CO.
Examples of the above-mentioned "inert solvent" include ether solvents, halogenated hydrocarbon solvents, aromatic solvents, aliphatic hydrocarbon solvents, nitrile solvents, amide solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, pyridine, acetonitrile, THF, DMF, dichloromethane, chloroform and the like are preferable.
Examples of the above-mentioned "base" include "aromatic amines", "tertiary amines" and the like.
The reaction temperature is generally -20°C to 100°C, preferably -20°C to 50°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 18 hr.
[0291] .
<Reaction Scheme 3>
Figure imgf000118_0001
[0293]
wherein L1 is a halogen atom, and the other symbols are as defined above.
[0294]
Compound (2) can be produced, for example, by subjecting compound (4) to a coupling reaction with compound (5) .
The above-mentioned "coupling reaction" is performed by reacting compound (4) with compound (5) in the presence of a metal catalyst, a ligand and a base, in an inert solvent. This reaction is preferably performed under an inert gas atmosphere.
The amount of compound (4) to be used is generally 0.5 to 5 equivalents, preferably 0.8 to 1.5 equivalents, relative to compound (5) .
Examples of the above-mentioned "metal catalyst" include palladium (II) acetate, copper (I) iodide and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents,
relative to compound (5) .
Examples of the above-mentioned "ligand" include butyldi-
(1-adamantyl) phosphine, (1R, 2R) -Ν,Ν' -dimethylcyclohexane-1, 2- diamine and the like. The amount of the "ligand" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (5) .
Examples of the above-mentioned "base" include "basic salts" and the like. Among them, tripotassium phosphate, cesium carbonate and the like are preferable. The amount of the "base" to be used is generally 1 to 10 equivalents,
preferably 1 to 5 equivalents, relative to compound (5) .
Examples of the above-mentioned "inert solvent" include amide solvents, aromatic solvents, halogenated hydrocarbon solvents and the like.
Examples of the above-mentioned "inert gas" include argon gas, nitrogen gas and the like.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0295]
Compound (2) can also, be produced, for example, by
subjecting compound (6) to an alkylation reaction.
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0296]
<Reaction Scheme 4> [0297]
Figure imgf000120_0001
[0298]
wherein L2 is a hydroxyl group, a sulfonyloxy group or a halogen atom, M2 is a hydroxyl-protecting group, an amino- protecting group or a sulfanyl-protecting group, Y1 is an oxygen atom, a nitrogen atom substituted by R5c or a sulfur atom, and the other symbols are as defined above.
[0299]
Compound (8) can be produced, for example, by subjecting compound (5) to a coupling reaction. with compound (7).
This reaction is performed in the same manner as in the production method of compound (2) from compound (4) and compound (5) in Reaction Scheme 3.
[0300]
Compound (9) can be produced, for example, by subjecting compound (8) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0301]
Compound (2-1) can be produced, for example, by
subjecting compound (9) to a coupling reaction with compound (10) .
Examples of the above-mentioned "coupling reaction" include a "method employing the Mitsunobu reaction" and the like in the case that L2 of compound (10) is a hydroxy1 group, a "method using a base" and the like in the case that L2 of compound (10) is a sulfonyloxy group or a halogen atom.
[0302]
The "method employing the Mitsunobu reaction" can be performed according to a method known per se, for example, the method described in Tetrahedron Letters, 769-770 pages, 1980 or the like, or a method analogous thereto.
This reaction is performed by reacting compound (9) with compound (10) wherein L2 is a hydroxyl group in the presence of a hydroxy group-activator, in an inert solvent.
The amount of compound (10) wherein L2 is a hydroxyl group to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (9).
Examples of the above-mentioned "hydroxy group-activator" include cyanomethylenetri-n-butylphosphorane, a combination of diisopropyl azodicarboxylate and triphenylphosphine, and the like. The amount of the "hydroxy group-activator" to be used is generally 1 to 10 equivalents, preferably 1 to 5
equivalents, relative to compound (9).
Examples of the above-mentioned "inert solvent" include aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, ester solvents, amide solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 48 hr.
[0303]
The "method using a base" can be performed according to a method known per se, for example, the method described in
Journal of the Chemical Society, 1530-1534 pages, 1937 or the like, or a method analogous thereto. This reaction is performed by reacting compound (9) with compound (10) wherein L2 is a sulfonyloxy group or a halogen atom in the presence of a base, in an inert solvent.
Examples of the above-mentioned "base" include "inorganic bases", "basic salts", "aromatic amines", "tertiary amines", "hydrides of an alkali metal or alkaline earth metal", "alkyl metals", "aryl. metals", "metal alkoxides" and the like. The amount of the "base" to be used is generally 1 to 10
equivalents, preferably 1 to 5 equivalents, relative to compound ( 9) .
Examples of the above-mentioned "inert solvent" include nitrile solvents, amide solvents,, halogenated hydrocarbon solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an
appropriate ratio. Among them, THF, DMF and the like are preferable .
The reaction temperature is generally -100°C to 150°C, preferably 0°C to 100°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0304]
<Reaction Scheme 5>
Figure imgf000122_0001
[0306] wherein M3 is a carboxy-protecting group, and the other symbols are as defined above.
[0307]
Compound (12) can be produced, for example, by subjecting compound (11) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0308]
Compound (13) can be produced, for example, by subjecting compound (12) to an acylation reaction.
This reaction is performed in the same manner as in the production method of compound (1-1) in Reaction Scheme 2.
[0309] .
Compound (14) can be produced, for example, by subjecting - compound (13) to hydrolysis.
This reaction is performed by reacting compound (13) with a base in an inert solvent.
Examples of the above-mentioned "base" include "inorganic bases" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (13) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents are
preferably used in a mixture with water in an appropriate ratio. Among them, alcohol solvents containing water are preferable.
The reaction temperature is generally -78°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 5 min to 100 hr,
preferably 30 min to 24 hr.
[0310]
The production method of compound (14) by the removal of the carboxy-protecti g group of compound (13) can also be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0311]
Compound (16) can be produced, for example, by subjecting compound (14) to an amidation reaction with compound (15) .
The above-mentioned "amidation reaction" is performed by reacting compound (14) with compound (15) in the presence of a dehydrating condensing agent, in an inert solvent. Where necessary, the reaction can be performed in the presence of 1- hydroxybenzotriazole (HOBt) in a catalytic amount to 5
equivalents relative to compound (14), a base in a catalytic amount to 5 equivalents relative to compound (14), and the like.
The amount of compound (15) to be used is generally 0.5 to 5 equivalents, preferably 0.8 to 1.5 equivalents, relative to compound (14) .
Examples of the above-mentioned "dehydrating condensing agent" include dicyclohexylcarbodiimide (DCC) , l-ethyl-3- (3- dimethylaminopropyl) carbodiimide hydrochloride (WSC) , N- [ (dimethylamino) (3H- [1,2,3] triazolo [4, 5-b] pyridin-3- yloxy) methylidene] -N-methylmethanaminium hexafluorophosphate (HATU) and the like. Among them, HATU is preferable. The amount of the "dehydrating condensing agent" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (14).
Examples of the above-mentioned "inert solvent" include nitrile solvents, amide solvents, halogenated hydrocarbon solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an
appropriate ratio. Among them, amide solvents are preferable.
Examples of the above-mentioned "base" include "aromatic amines", "tertiary amines" and the like.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr, preferably 1 hr to 48 hr.
[0312]
Compound (1-1) can be produced, for example, by
subjecting compound (16) to a cyclization reaction.
The above-mentioned "cyclization reaction" is performed by reacting compound (16) in the presence of an activator, in an inert solvent.
Examples of the above-mentioned "activator" include p- toluenesulfonic acid, a combination of diethyl
azodicarboxylate and triphenylphosphine, a combination of hexachloroethane, triphenylphosphine and a base, and the like. The amount of the "activator" to be used is generally 0.001 to 10 equivalents, preferably 0.01 to 8 equivalents, relative to compound (16) .
Examples of the above-mentioned "inert solvent" include aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, ester solvents, amide solvents, nitrile solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
Examples of the above-mentioned "base" include "aromatic amines", "tertiary amines" and the like.
The reaction temperature is generally -70°C to 200°C, preferably -20°C to 150°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0313]
<Reaction Scheme 6>
[0314]
Figure imgf000126_0001
[0315]
wherein L3 is a halogen atom or a sulfonyloxy group, M4 is a hydroxyl-protecting group, R7 is a substituent, and the other symbols are as defined above.
[0316]
Compound (19) can be produced, for example, by subjecting compound (17) to a coupling reaction with compound (18) .
The above-mentioned "coupling reaction" is performed by reacting compound (17) with a base in an inert solvent to convert the hydrogen atom to a metal atom, and then reacting the resulting compound with compound (18) .
The amount of compound (18) to be used is generally 0.5 to 5 equivalents, preferably 0.8 to 1.5 equivalents, relative to compound (17) .
Examples of the above-mentioned "base" include "alkyl metals", "metal amides", "inorganic bases", "basic salts", "aryl metals", "metal alkoxides" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents
relative to compound (17) .
Examples of the above-mentioned "inert solvent" include aliphatic hydrocarbon solvents, aromatic solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
[0317]
Compound (20) can be produced, for example, by subjecting compound (19) to a cyclization reaction.
The above-mentioned "cyclization reaction" is performed by reacting compound (19) in the presence of a metal catalyst, a ligand and a base, in an inert solvent. This reaction is preferably performed under an inert gas atmosphere.
Examples of the above-mentioned "metal catalyst" include palladium (II) acetate and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (19).
Examples of the above-mentioned "ligand" include 1,1'- bis (diphenylphosphino) ferrocene and the like. The amount of the "ligand" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (19).
Examples of the above-mentioned "base" include "metal alkoxides" and the like. Among them, sodium tert-butoxide and the like are preferable.' The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5
equivalents, relative to compound (19).
Examples of the above-mentioned "inert solvent" include aromatic solvents, halogenated hydrocarbon solvents and the like. Among them, aromatic solvents are preferable.
Examples of the above-mentioned "inert gas" include argon gas, nitrogen gas and the like. The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0318]
Compound (21) can be produced, for example, by subjecting compound (20) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0319]
Compound (22) can be produced, for example, by subjecting compound (21) to a coupling reaction with compound (10) .
This reaction is performed in the same manner as in the production method of compound (2-1) in Reaction Scheme 4.
[0320]
Compound (23) can be produced, for example, by subjecting compound (22) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in
Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0321]
Compound (24) can be produced, for example, by subjecting compound (23) to an acylation reaction.
This reaction is performed in the same manner as in the production method of compound (1-1) in Reaction Scheme 2.
[0322]
Compound (1-2) can. be produced, for example, by
subjecting compound (24) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in' Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like. [0323]
<Reaction Scheme 7>
[0324]
Figure imgf000129_0001
6-1
[0325]
wherein each symbol is as defined above.
[0326]
Compound (4-1) can be produced, for example, by subjecting compound (28) to a coupling reaction with compound
(10).
This reaction is performed in the same manner as in the production method of compound (2-1) in Reaction Scheme 4.
[0327]
Compound (11-1) can be produced, for example, by
subjecting compound (25) to a coupling reaction with compound (10).
This reaction is performed in the same manner as in the production method of compound (2-1) in Reaction Scheme 4.
[0328]
Compound (11-1) can also be produced, for example, by subjecting compound (4-1) to a carbon monoxide-insertion reaction.
The above-mentioned "carbon monoxide-insertion reaction" is performed by reacting compound (4-1) with a hydroxide corresponding to M3 in the presence of a metal catalyst and a carbon monoxide source, in an inert solvent. Where necessary, a ligand and base may be used.
Examples of the above-mentioned "hydroxide corresponding to M3" include optionally substituted alkyl alcohols and optionally substituted cycloalkyl alcohols. The amount of the "hydroxide corresponding to 3" to be used is generally 1 equivalent relative to compound (4-1) to a solvent amount.
Examples of the above-mentioned "metal catalyst" include
1, 1' -bis (diphenylphosphino) ferrocene-palladium(II) dichloride dichloromethane complex and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (4-1).
Examples of the above-mentioned "ligand" include 1,1'- bis (diphenylphosphino) ferrocene and the like. The amount of the "ligand" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (4-1).
Examples of the above-mentioned "carbon monoxide source" include carbon monoxide gas and the like. Examples of the above-mentioned "base" include "aromatic amines", "tertiary amines" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (4-1) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, amide solvents, aromatic solvents,
halogenated hydrocarbon solvents, ether solvents and the like. Among them, alcohol solvents corresponding to M3 are preferable. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0329]
Compound (26) can be produced, for example, by subjecting compound (11-1) to hydrolysis.
This reaction is performed in the same manner as in the production method of compound (14) in Reaction Scheme 5.
[0330]
Compound (27) can be produced, for example, by subjecting compound (26) to an amidation reaction with compound (15) .
This reaction is performed in the same manner as in the production method of compound (16) in Reaction Scheme 5.
[0331]
Compound (6-1) can be produced, for example, by
subjecting compound (27) to a cyclization reaction.
This reaction is performed in the same manner as in the production method of compound (1-1) in Reaction Scheme 5.
[0332]
<Reaction Scheme 8>
[0333]
Figure imgf000132_0001
[0334]
wherein each symbol is as defined above.
[0335]
Compound (30) can be produced, for example, by subjecting compound (29) to an amidation reaction with compound (15) .
This reaction is performed in the same manner as in the production method of compound (16) in Reaction Scheme 5.
[0336]
Compound (31) can be produced, for example, by subjecting compound (30) to a cyclization reaction.
This reaction is performed in the same manner as in the production method of compound (1-1) in Reaction Scheme 5.
[0337]
Compound (32) can be produced, for example, by subjecting compound (31) to an alkylation reaction.
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0338]
Compound (33) can be produced, for example, by subjecting compound (32) to a boration reaction.
The above-mentioned "boration reaction" is performed by reacting compound (32) with an alkyl metal in an inert solvent to convert the halogen atom to a metal atom, and then reacting the resulting compound with an organic boron compound.
Examples of the above-mentioned "alkyl metal" include alkyllithiums, alkylmagnesium halides and the like. The amount of the "alkyl metal" to be used is generally 1 to 10
equivalents relative to compound (32) .
Examples of the above-mentioned "organic boron compound" include trialkoxyborane and the like. The amount of the
"organic boron compound" to be used is generally 1 to 10 equivalents relative to compound (32).
Examples of the above-mentioned "inert solvent" include aliphatic hydrocarbon solvents, aromatic solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably ,-100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
[0339]
Compound (9-1) can be produced, for example, by
subjecting compound (33). to an oxidation reaction.
The above-mentioned "oxidation reaction" is performed by reacting compound (33) with an oxidant in an inert solvent.
Where necessary, a base may be used.
Examples of the above-mentioned "oxidant" include oxygen, hydrogen peroxide, organic peroxides (e.g., m-chloroperbenzoic acid), inorganic peroxides (e.g., sodium perborate) and the like. The amount of the "oxidant" to be used is generally 1 to 10 equivalents relative to compound (33) .
Examples of the above-mentioned "base" include "inorganic bases" and the like. The amount of the "base" to be used is generally 1 to 100. equivalents, preferably 1 to 50 equivalents, relative to compound (33) .
Examples of the above-mentioned "inert solvent" include water, aliphatic hydrocarbon solvents, aromatic -solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
[0340]
<Reaction Scheme 9>
Figure imgf000134_0001
• [0342]
wherein each symbol is as defined above.
[0343]
Compound ( 11-3 ) can be produced, for example, by
subjecting compound (11-2) to a substitution reaction.
This reaction is performed by reacting compound (11-2) with a halide corresponding to R7 in the presence of a base, in an inert solvent.
Examples of the above-mentioned "halide corresponding to
R7" include optionally substituted alkyl halides, optionally substituted cycloalkyl halides, optionally substituted
cycloalkylalkyl halides and optionally substituted aralkyl halides. The amount of the "halide corresponding to R7" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (11-2) .
Examples of the above-mentioned "base" include "inorganic bases", "basic salts", "aromatic amines", "tertiary amines", "hydrides of an alkali metal or alkaline earth metal", "alkyl metals", "aryl metals", "metal alkoxides" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (11-2) .
Examples of the above-mentioned "inert solvent" include nitrile solvents, amide solvents, halogenated hydrocarbon solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an
appropriate ratio. Among them, THF, D F and the like are preferable.
The reaction temperature is generally -100°C to 150°C, preferably 0°C to 100°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0344]
<Reaction Scheme 10>
Figure imgf000135_0001
34 35
[0346]
wherein R8 is a substituent, Y2 is a nitrogen atom when Y3 is an oxygen atom, Y2 is an oxygen atom or a nitrogen atom when Y3 is a nitrogen atom, the nitrogen is optionally substituted by R7, Z1 is M1 or R1, and the other symbols are as defined above.
[0347]
Compound (35) can be produced, for example, by subjecting compound (34) to a substitution reaction.
[0348]
The above-mentioned "substitution reaction" is performed by reacting compound (34) with an alkyl metal in an inert solvent to convert the hydrogen atom to a metal atom, and then reacting the resulting compound with, for example, a
halogenating agent or halide.
Examples of the above-mentioned "alkyl metal" include alkyllithiums, alkylmagnesium halides and the like. The amount of the "alkyl metal" to be used is generally 1 to 10 equivalents relative to compound (34).
Examples of the above-mentioned "halogenating agent" include N-fluoro-N- (phenylsulfonyl ) benzenesulfonamide, bromine, iodine and the like. The amount of the "halogenating agent" to be used is generally 2 to 10 equivalents relative to compound (34).
Examples of the above-mentioned "halide" include
optionally substituted alkyl halides, optionally substituted cycloalkyl halides, optionally substituted cycloalkylalkyl halides and optionally substituted aralkyl halides. The amount of the "halide" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (34).
Examples of the above-mentioned "inert solvent" include aliphatic hydrocarbon solvents, aromatic solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably
5 min to 24 hr.
[0349]
The above-mentioned "substitution reaction" is also performed by reacting compound (34) with a halogenating agent in an inert solvent.
Examples of the above-mentioned "halogenating agent" include 1- (chloromethyl) -4-fluoro-1, 4- diazoniabicyclo [2.2.2 ] octane ditetrafluoroborate, bromine, iodine and the like. The amount of the "halogenating agent" to be used is generally 2 to 20 equivalents relative to compound (34).
Examples of the above-mentioned "inert solvent" include nitrile solvents, aliphatic hydrocarbon solvents, aromatic solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
[0350]
<Reaction Scheme 11>
[0351]
Figure imgf000137_0001
(1-2) (1-3)
[0352]
wherein M5 is a protecting group such as an aralkyl group, a tetrahydropyranyl group and the like, and the other symbols are as defined above.
[0353]
Compound (1-3) can be produced,, for example, by
subjecting compound (1-2) to a deprotection . reaction .
[0354]
The above-mentioned "deprotection reaction" is performed by reacting compound (1-2) in the presence of a metal catalyst and a hydrogen source, in an inert solvent. Where necessary, the reaction can be performed in the presence of an organic acid in a catalytic amount to a solvent amount, or hydrogen chloride in 1 to 50 equivalents relative to compound (1-2) .
Examples of the above-mentioned "metal catalyst" include palladium-carbon, palladium black, palladium chloride,
palladium hydroxide, rhodium-carbon, platinum oxide, platinum black, platinum-palladium, Raney-nickel, Raney-cobalt and the like. The amount of the "metal catalyst" to be used is
generally 0.001 to 1000 equivalents, preferably 0.01 to 100 equivalents, relative to compound (1.-2) .
-Examples of the above-mentioned "hydrogen source" include hydrogen gas and the like.
Examples of the above-mentioned "organic acid" include acetic acid and the like.
Examples of the above-mentioned "inert solvent" include alcohol solvents, nitrile solvents, aromatic solvents,
aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0355]
The above-mentioned "deprotection reaction" is also performed by reacting compound (1-2) in the presence of an acid, in an inert solvent.
Examples of the above-mentioned "acid" include
hydrochloric acid, p-toluenesulfonic acid, trifluoroacetic acid and the like. The amount of the "acid" to be used is a catalytic amount to a solvent amount.
Examples of the above-mentioned "inert solvent" include alcohol solvents, ether solvents, halogenated hydrocarbon solvents, ester solvents and the like. These solvents may be used in a mixture with water in an appropriate ratio.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0356]
<Reaction Scheme 12>
Figure imgf000138_0001
36 5 [0358]
wherein each symbol is as defined above.
[0359]
Compound (5) can be produced, for example, by subjecting compound (36) to an alkylation reaction.
This reaction is performed. in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0360]
<Reaction Scheme 13>
[0361]
Figure imgf000139_0001
3 38
[0362]
wherein Lla is. a halogen atom, and the other symbols are as defined above.
[0363]
Compound (38) can be produced, for example, by subjecting compound (37) to a boronation reaction.
This reaction is performed in the same manner as in the production method of compound (33) in Reaction Scheme 8.
[0364]
Compound (28-1) can be produced, for example, by
subjecting compound (38) to an oxidation reaction.
This reaction is performed in the same manner as in the production method of compound (9-1) in Reaction Scheme 8.
[0365]
<Reaction Scheme 14>
[0366]
Figure imgf000140_0001
Figure imgf000140_0002
[0367]
wherein each symbol is as defined above.
[0368]
Compound (40) can be produced, for example, by subjecting compound (39) to an amidation reaction with N,0- dimethylhydroxylamine .
The above-mentioned "amidation reaction" is performed in the same manner as in the production method of "amide
derivative" which is described as one of the production methods of compound (1-1) in Reaction Scheme 2.
[0369]
Compound (4-2) can be produced, for example, by
subjecting compound (40) to a coupling reaction with compound (37).
This reaction is performed by reacting compound (37) with an alkyl metal in an inert solvent to convert the halogen atom to a metal atom, and then reacting the resulting compound "with compound (40) .
Examples of the above-mentioned "alkyl metal" include alkyllithiums, alkylmagnesium halides and the like. The amount of the "alkyl metal" to be used is generally 1 to 10 equivalents relative to compound (37).
Examples of the above-mentioned "inert solvent" include aliphatic hydrocarbon solvents, aromatic solvents, ether solvents and the like. These solvents may be used in a mixture 5 of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
10 [0370]
Compound (4-3) can be produced, for example, by reacting . compound (4-2) with an organic metal reagent corresponding to R8 in an inert solvent.
Examples of the above-mentioned "organic metal reagent 15 corresponding to R8" include organic Grignard reagents (e.g., methylmagnesium bromide, methylmagnesium chloride) , organic lithium reagents (e.g., methyllithium) and the like. The amount of the "organic metal reagent corresponding to R8" to be used is generally 1 to 20 equivalents, preferably 1 to 5
20 equivalents, relative to compound (4-2).
Examples of the above-mentioned "inert solvent" include aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture of two or 25 more kinds thereof in an appropriate ratio. Among them, THF
and the like are preferable.
The reaction temperature is generally -78°C to 150°C, preferably -20°C to 100°C.
The .reaction time is generally 5 min to 48 hr, preferably 30 30 min to 24 hr.
[0371]
Compound (4-4) can be produced, for example, by
subjecting compound (4-2) to a fluorination reaction.
This reaction is performed by reacting compound (4-2) 35 with a fluorinating agent in an inert solvent. Examples of the above-mentioned "fluorinating agent" include (diethylamino) sulfur trifluoride and the like. The amount of the "fluorinating agent" to be used is generally 2 to 10 equivalents relative to compound (4-2) .
Examples of the above-mentioned "inert solvent" include aliphatic hydrocarbon solvents, aromatic solvents, ether solvents, nitrile solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
[0372]
<Reaction Scheme 15>
Figure imgf000142_0001
32 42 2-2
[0374]
wherein each symbol is as defined above.
[0375]
Compound (42) can be produced, for example, by subjecting compound (32) to the Sonogashira coupling reaction with compound (41) .
The above-mentioned "Sonogashira coupling reaction" is performed by reacting compound (32) with compound (41) in the presence of a metal catalyst and a base, in an inert solvent. This reaction is preferably performed under an inert gas atmosphere.
The amount of compound (41) to be used is generally 0.5 to 5 equivalents, preferably 0.8 to 2 equivalents, relative to compound (32).
Examples of the above-mentioned "metal catalyst" include a combination of bis (triphenylphosphine) palladium ( II )
dichloride and copper (I) iodide, and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (32) .
Examples of the above-mentioned "base" include "aromatic amines", "tertiary amines" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (32) .
Examples of the above-mentioned "inert solvent" include amide solvents, aromatic solvents, halogenated hydrocarbon solvents and the like.
Examples of the above-mentioned "inert gas" include argon gas, nitrogen gas and the like.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0376]
Compound (2-2) can be produced, for example, by
subjecting compound (42) to a reduction reaction.
This reaction is performed by reacting compound (42) in the presence of a metal catalyst and a hydrogen source, in an inert . solvent . Where necessary, the reaction can be performed in the presence of an organic acid in a catalytic amount to a solvent amount, or hydrogen chloride in 1 to 50 equivalents relative to compound (42) .
Examples of the above-mentioned "metal catalyst" include palladium-carbon, palladium black, palladium chloride,
palladium hydroxide, rhodium-carbon, platinum oxide, platinum black, platinum-palladium, Raney-nickel, Raney-cobalt and the like. The amount of the "metal catalyst" to be used is
generally 0.001 to 1000 equivalents, preferably 0.01 to 100 equivalents, relative to compound (42) .
Examples of the above-mentioned "hydrogen source" include hydrogen gas and the like.
Examples of the above-mentioned "organic acid" include acetic acid and the like.
Examples of the above-mentioned "inert solvent" include alcohol solvents, nitrile solvents, aromatic solvents,
aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0377]
<Reaction Scheme 16>
Figure imgf000144_0001
[0379]
wherein Rla is an optionally substituted 5- or 6-membered aromatic ring, and the other symbols are as defined above.
[0380]
Compound (43) can be produced, for example, by subjecting compound (9) to an alkylation reaction with a haloacetate, or by reacting compound (9) with a diazoacetate .
[0381]
The above-mentioned "alkylation reaction with a
haloacetate" is performed by reacting compound (9) with a haloacetate in the presence of a base, in an inert solvent. Where necessary, the reaction can be performed in the presence of a phase-transfer catalyst.
Examples of the above-mentioned "haloacetate" include ethyl bromoacetate, tert-butyl bromoacetate and the like. The amount of the "haloacetate" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (9) .
Examples of the above-mentioned "base" include "inorganic bases", "basic salts", "aromatic amines", "tertiary amines", "hydrides of an alkali metal or alkaline earth metal", "metal alkoxides" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5
equivalents, relative to compound (9) .
Examples of the above-mentioned "inert solvent" include aromatic solvents, amide solvents, halogenated hydrocarbon solvents, ether solvents and the like. These solvent may be used in a mixture with water in an appropriate ratio, or in a mixture of two or more kinds thereof in an appropriate ratio. Among them, THF, DMF and the like are preferable.
Examples of the above-mentioned "phase-transfer catalyst" include quaternary ammonium salts (e.g., tetrabutylammonium bromide, benzyltrioctylammonium chloride, tetrabutylammonium hydrogensulfate) and the like. The amount of the "phase- transfer catalyst" to be used is generally 0.001 to 10
equivalents, preferably 0.01 to 1 equivalents, relative to compound ( 9) . The reaction temperature is generally -100°C to 150°C, preferably 0°C to 100°C.
The reaction time is generally 5 min to 100 hr,
preferably 30 min to 48 hr.
[0382]
The above-mentioned "reaction with a diazoacetate" is performed by reacting compound (9) with a diazoacetate in the presence of a metal catalyst, in an inert solvent.
Examples of the above-mentioned "diazoacetate" include diazoethyl acetate and the like. The amount of the
"diazoacetate" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (9).
Examples of the above-mentioned "metal catalyst" include rhodium acetate dimer and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 10 equivalents, preferably 0.01 to 1 equivalents, relative to compound (9).
Examples of the . above-mentioned "inert solvent" include aromatic solvents, aliphatic hydrocarbon solvents, nitrile solvents, amide solvents, halogenated hydrocarbon solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, toluene, dichloromethane and the like are
preferable.
The reaction temperature is generally -100°C to 150°C, preferably 0°C to 100°C.
The reaction time is generally 5 min to 48 hr, preferably 5 min to 24 hr.
[0383]
Compound (44) can be produced, for example, by subjecting compound (43) to a substitution reaction.
This reaction is performed by reacting compound (43) with a base in an inert solvent to convert the hydrogen atom to a metal atom, and then reacting the resulting compound with, for example, a halogenating agent or halide.
Examples of the above-mentioned "base" include "hydrides of an alkali metal or alkaline earth metal", "metal amides",
"metal alkoxides" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents relative to compound (43).
Examples of the above-mentioned "halogenating agent" include N-fluoro-N- (phenylsulfonyl) benzenesulfonamide and the like. The amount of the "halogenating agent" to be used is generally 2 to 10 equivalents relative to compound (43) .
Examples of the above-mentioned "halide" include
optionally substituted alkyl halides, optionally substituted cycloalkyl halides, optionally substituted cycloalkylalkyl halides, optionally substituted aralkyl halides and the like. The amount of the "halide" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (43) .
Examples of the above-mentioned "inert solvent" include aliphatic hydrocarbon solvents, aromatic solvents, ether solvents, amide solvents, alcohol solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
[0384]
Compound (45) can be produced, for example, by subjecting compound (44) to a substitution reaction.
This reaction is performed in the same manner as in the production method of compound (44) in Reaction Scheme 16.
[0385]
Compound (45) can also be produced, for example, by subjecting compound (9) to an alkylation reaction.
This reaction can be produced, for example, by subjecting compound (9) to an alkylation reaction with an optionally substituted haloacetate. [0386]
The above-mentioned "alkylation reaction" is performed by reacting compound (9) with an optionally substituted
haloacetate in the presence of a base, in an inert solvent. Where necessary, the reaction can be performed in the presence of a phase-transfer catalyst.
Examples of the above-mentioned "optionally substituted haloacetate" include ethyl bromoacetate, tert-butyl
bromoacetate and the like. The amount of the "optionally substituted haloacetate" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound ( 9) .
Examples of the above-mentioned "base" include "inorganic bases", "basic salts", "aromatic amines", "tertiary amines", "hydrides of an alkali metal or alkaline earth metal", "metal alkoxides" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5
equivalents, relative to compound (9).
Examples of the above-mentioned "inert solvent" include aromatic solvents, amide solvents, halogenated hydrocarbon solvents, ether solvents and the like. These solvent may be used in a mixture with water in an appropriate ratio, or in a mixture of two or more kinds thereof in an appropriate ratio. Among them, THF, D F and the like are preferable.
Examples of the above-mentioned "phase-transfer catalyst" include quaternary ammonium salts (e.g., tetrabutylammonium bromide, benzyltrioctylammonium chloride, tetrabutylammonium hydrogensulfate) and the like. The amount of the "phase- transfer catalyst" to be used is generally 0.001 to 10
equivalents, preferably 0.01 to 1 equivalents, relative to compound (9) .
The reaction temperature is generally -100°C to 150°C, preferably 0°C to 100°C.
The reaction time is generally 5 min to 100 hr,
preferably 30 min to 48 hr. [0387]
Compound (46) can be produced, for example, by subjecting compound (45) to hydrolysis.
This reaction is performed in the same manner as in the production method of compound (14) in Reaction Scheme 5.
[0388]
Compound (47) can be produced, for example, by subjecting compound (46) to an amidation reaction with N,0- dimethylhydroxylamine .
The above-mentioned "amidation reaction" is performed in the same manner as in the production method of compound (40) in Reaction Scheme 14.
[0389]
Compound (48) can be produced, for example, by reacting compound (47) with an organic metal reagent in an inert solvent.
This reaction is performed in the same manner as in the production method of compound (4-2) in Reaction Scheme 14.
[0390]
Compound (49) can be produced, for example, by subjecting compound (48) to a reductive amination reaction.
The reductive amination reaction can be performed according to a method known per se, for example, the method described in Tetrahedron Letters, 8345-8349 pages, 2001 or the like, or a method analogous thereto.
This reaction is performed by reacting compound (48) with the compound RlaNH2 in the presence of a reducing agent, in an inert solvent. Where necessary, the reaction can be performed in the presence of an organic acid in 1 equivalent relative to compound (48) to a solvent amount.
The amount of the above-mentioned "compound RlaNH2" to be used is generally 1 to 5 equivalents, preferably 1 to 4 equivalents, relative to compound (48).
Examples of the above-mentioned "reducing agent" include metal hydrogen compounds (e.g., diisobutylaluminum hydride), metal hydride complex compounds (e.g., sodium bis(2- methoxyethoxy) aluminum . hydride, sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, lithium
aluminum hydride, sodium aluminum hydride) , decaborane and the like. The amount of the "reducing agent" to be used is
generally 0.1 to 20 equivalents, preferably 1 to 5 equivalents, relative to compound (48) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, amide solvents, halogenated hydrocarbon solvents, ester solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, methanol, THF,
dichloroethane, dichloromethane and the like are preferable.
Examples of the above-mentioned "organic acid" include acetic acid and the like.
The reaction temperature is generally -78°C to 100°C, preferably -20°C to 50°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0391]
Compound (1-3) can be produced, for example, by
subjecting compound (49) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in
Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0392]
<Reaction Scheme 17>
[0393]
Figure imgf000151_0001
[0394]
wherein L4 is a sulfonyloxy group, and the other symbols are as defined above.
[0395]
Compound (50) can be produced, for example, by subjecting compound (48) to a reduction reaction.
This reaction is performed by reacting compound (48) with a reducing agent in an inert solvent.
Examples of the above-mentioned "reducing agent" include metal hydrogen compounds (e.g., diisobutylaluminum hydride), metal hydride complex compounds (e.g., sodium borohydride, sodium cyanoborohydride, lithium aluminum hydride, sodium aluminum hydride, sodium bis (2-methoxyethoxy) aluminum hydride) and the like. The amount of the "reducing agent" to be used is generally 0.1 to 20 equivalents, preferably 1 to 5 equivalents, relative to compound (48) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated
hydrocarbon solvents and the like. These solvents may be. used in a mixture of two or more kinds thereof in an appropriate 5 ratio. Among them, THF, ethanol, methanol and the like are
. preferable .
The reaction temperature is generally -78°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 5 min to 48 hr, preferably 10 30 min to 24 hr.
[0396]
Compound (51) can be produced, for example, by subjecting the hydroxyl group of compound (50) to a sulfonylation
reaction.
15 This reaction is- performed by reacting compound (50) with a sulfonylating agent in the presence of a base, in an inert solvent.
Examples of the above-mentioned "sulfonylating agent" include methanesulfonyl chloride, p-toluenesulfonyl chloride 20 and the like. The amount of the "sulfonylating' agent" to be used is generally 1 to 10 equivalents, preferably 1 to 1.5 equivalents, relative to compound (50) .
Examples of the above-mentioned "base" include "aromatic amines", "tertiary amines" and the like are preferable. The 25 amount of the "base" to be used is generally 1 to 20
equivalents, preferably 1 to 10 equivalents, relative to compound ( 50 ) .
Examples of the above-mentioned "inert solvent" include aromatic solvents, aliphatic hydrocarbon solvents, ether
30 solvents, ester solvents, amide solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
35 The reaction time is generally 0.1 hr to 100 hr, preferably 0.1 hr to 48 hr.
[0397]
Compound (52) can be produced, for example, by subjecting compound (51) to an azidation reaction.
This reaction is performed by reacting compound (51) with an azidating agent in an inert solvent.
Examples of the above-mentioned "azidating agent" include sodium azide, lithium azide, trimethylsilyl azide and the like. The amount of the "azidating agent" to be used is generally 1 to 20 equivalents, preferably 1 to 10 equivalents, relative to compound (51) .
Examples of the above-mentioned "inert solvent" include ether solvents, amide solvents, sulfoxide solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70°C to 200°C, preferably 0°C to 15.0°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 48 hr.
[0398]
Compound (53) can be produced, for example, by subjecting compound (52) to a reduction reaction.
This reaction is performed by reacting compound (52) in the presence of a metal catalyst and a hydrogen source, in an inert solvent.
Examples of the above-mentioned "metal catalyst" include palladium-carbon, palladium black, palladium chloride,
palladium hydroxide, platinum oxide, platinum black, Raney- nickel, Raney-cobalt and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (52).
Examples of the above-mentioned "hydrogen source" include hydrogen gas, formic acid, formic acid amine salt,
phosphinates, hydrazine and the like.
Examples of the above-mentioned "inert solvent" include alcohol solvents, ester solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture with water in an appropriate ratio. Among them, alcohol solvent. is preferable.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 to 100 hr, preferably 0.1 to 48 hr.
[0399]
This reaction can also be performed by reacting compound
(52) with triphenylphosphine and water in an inert solvent.
Examples of the above-mentioned "inert solvent" include aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, sulfoxide solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture with water in an appropriate ratio. Among them, ether solvents are preferable.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 to 100 hr, preferably
0.1 to 40 hr.
[0400]
Compound (54) can be produced, for example, by subjecting compound (53) to an acylation reaction.
This reaction is performed in the same manner as in the production method of compound (1-1) in Reaction Scheme 2.
[0401]
Compound (1-4) can be produced, for example, by
subjecting compound (54) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0402]
<Reaction Scheme 18>
Figure imgf000155_0001
[0404]
wherein each symbol is as defined above.
[0405]
Compound (56) can be produced, for example, by subjecting compound (55) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0406]
Compound (57) can be produced, for example, by subjecting compound (56) to an alkylation reaction.
Examples of the alkylation reaction include the following
"method using a base and an alkyl halide or sulfonate
corresponding to R6" and the like. [0407]
The "method using a base and an alkyl halide or sulfonate corresponding to R6" can be performed according to a method known per se, for example, the method described in Journal of the Chemical Society, 1530-1534 pages, 1937 or the like, or a method analogous thereto.
This reaction is performed by reacting compound (56) with an alkyl halide or sulfonate corresponding to R6 in the
presence of a base, in an inert solvent.
Examples of the above-mentioned "alkyl halide
corresponding to R6" include optionally substituted Ci_6 alkyl halides and optionally substituted C3_6 cycloalkyl halides. The amount of the "alkyl halide corresponding to R6" to be used is generally 2 to 10 equivalents, preferably 2 to 5 equivalents, relative to compound (56) .
Examples of the above-mentioned "sulfonate corresponding to R6" include optionally substituted Ci_6 alkyl esters of sulfonic acid, and optionally substituted C3_6 cycloalkyl esters of sulfonic acid. Examples of the "sulfonic acid" include methylsulfonic acid, p-methylphenylsulfonic acid,
trifluoromethylsulfonic acid and the like. The amount of the "sulfonate corresponding to R6" to be used is generally 2 to 10 equivalents, preferably 2 to 5 equivalents, relative to compound (56) .
Examples of the above-mentioned "base" include "inorganic bases", "basic salts", "aromatic amines", "hydrides of an alkali metal or alkaline earth metal", "alkyl metals", "aryl metals", "metal alkoxides" and the like. The amount of the "base" to be used is generally 2 to 10 equivalents, preferably 2 to 5 equivalents, relative to compound (56) .
Examples of the above-mentioned "inert solvent" include nitrile solvents, amide solvents, halogenated hydrocarbon solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an
appropriate ratio. Among them, THF, D F and the like are preferable .
The reaction temperature is generally -100°C to 150°C, preferably 0°C to 100°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0408]
Compound (58) can be produced, for example, by subjecting compound (57) to hydrolysis.
This reaction is performed by reacting compound (57) with a base in an inert solvent.
Examples of the above-mentioned "base" include "inorganic bases" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 1.5 equivalents, relative to compound (57) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents are
preferably used in a mixture with water in an appropriate ratio. Among them, alcohol solvents containing water are preferable.
The reaction temperature is generally -78°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 5 min to 100 hr,
preferably 30 min to 24 hr.
[0409]
Compound (59) can be produced, for example, by subjecting compound (58) to an amidation reaction with N,0- dimethylhydroxylamine .
The above-mentioned "amidation reaction" is performed in the same manner as in the production method of compound (40) in Reaction Scheme 14.
[0410]
Compound (60) can be produced, for example, by reacting compound (7) with an alkyl metal in an inert solvent to
convert the halogen atom of compound (7) to a metal atom, and then reacting the resulting compound with compound (59) .
Examples of the above-mentioned "alkyl metal" include alkyllithiums, alkylmagnesium halides and the like. The amount of the "alkyl metal" to be used is generally 1 to 10
equivalents relative to compound (7) .
Examples of the above-mentioned "inert solvent" include aliphatic hydrocarbon solvents, aromatic solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
[0411] ·
Compound (61) can be produced, for example, by subjecting compound (60) to a reduction reaction.
This reaction is performed by reacting compound (60) with a reducing agent in an inert solvent.
Examples of the above-mentioned "reducing agent" include metal hydrogen compounds (e.g., diisobutylaluminum hydride), metal hydride complex compounds (e.g., sodium borohydride, sodium cyanoborohydride, lithium aluminum hydride, sodium aluminum hydride, sodium bis (2-methoxyethoxy) aluminum hydride) and the like. The amount of the "reducing agent" to be used is generally 0.1 to 20 equivalents, preferably 1 to 5 equivalents, relative to compound (60) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated
hydrocarbon solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, THF, ethanol, methanol and the like are preferable .
The reaction temperature is generally -78°C to 150°C, preferably -20°C to 100°C. The reaction time is generally 5 min to 48 hr, preferably
30 min to 24 hr.
[0412]
Compound (8-1) can be produced, for example, by 5 subjecting compound (61) to a cyclization reaction.
This reaction is performed by reacting compound (61) in the presence of a base and a metal catalyst in an inert solvent.
Examples of the above-mentioned "base" include "inorganic
10 bases", "basic salts", "aromatic amines", "tertiary amines", "hydrides of an alkali metal or alkaline earth metal", "alkyl metals", "aryl metals" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative, to compound (61).
15 Examples of the above-mentioned "metal catalyst" ' include copper halides such as copper (I) chloride, copper (I) bromide, copper (II) chloride and the like and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to
20 compound (61) .
Examples of the above-mentioned "inert solvent" include aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture of two or
25 more kinds thereof in an appropriate ratio. Among them, THF, toluene and the like are preferable.
The reaction temperature is generally -78°C to 200°C, preferably -20°C to 150°C.
The reaction time is generally 5 min to 48 hr, preferably
30 30 min to 24 hr.
[0413]
<Reaction Scheme 19>
[0414]
Figure imgf000160_0001
(I)
[0415]
wherein each symbol is as defined above.
[0416]
Compound (I) can be produced, for example, by subjecting compound (4-5) to a coupling reaction with compound (5) .
This reaction is performed in the same manner as in the production method of compound (2) from compound (4) and compound (5) in Reaction Scheme 3.
[0417]
<Reaction Scheme 20>
Figure imgf000160_0002
[0419]
wherein each symbol is as defined above.
[0420]
Compound (2-3) can be produced, for example, by
subjecting compound (62) to a dehydration-condensation reaction with compound (63), and then subjecting the resulting compound to a cyclization reaction.
The above-mentioned "dehydration-condensation . reaction" is performed by reacting compound (62) with compound (63) in the presence of a dehydrating agent, in an inert solvent.
The amount of compound (63) to be used is generally 0.01 to 5 equivalents relative to compound (62) .
Examples of the above-mentioned "dehydrating agent" include magnesium sulfate and the like. The amount of the "dehydrating agent" to be used is generally 1 to 1000 equivalents relative to compound (62) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, aromatic solvents, aliphatic hydrocarbon 5 solvents, ether solvents, amide solvents, halogenated
hydrocarbon solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, alcohol solvent is preferable.
The reaction temperature is generally -78°C to 200°C, 10 preferably 50°C to 150°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0421]
The above-mentioned "cyclization reaction" is performed 15 by reacting the compound obtained in the above-mentioned
dehydration-condensation reaction of compound (62) with compound (63) in the presence of an activator.
Examples of the above-mentioned "activator" include . trimethylphosphite, triethylphosphite and the like. The amount 20 of the "activator" to be used is generally 5 equivalents to an excess amount relative to compound (62).
The reaction temperature is generally -78°C to 200°C, preferably 50°C to 150°C.
The reaction time is generally 5 min to 48 hr, preferably 25 30 min to 24 hr.
[0422]
<Reaction Scheme 21>
[0423]
Figure imgf000161_0001
64 65 66 62
30 [0424]
wherein each symbol is as defined above.
[0425]
Compound (65) can be produced, for example, by subjecting compound (64) to an alkylation reaction.
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0426]
Compound (66) can be produced, for example, by subjecting compound (65) to a bromination reaction.
The above-mentioned "bromination reaction" is performed by reacting compound (65) in the presence of a brominating agent and a radical initiator, in an inert solvent.
Examples of the above-mentioned "brominating agent" include bromine, N-bromosuccinimide and the like.. The amount of the "brominating agent" to be used is generally 1 to 10 equivalents relative to compound (65) .
Examples of the above-mentioned "radical initiator" include 2, 2' -azobis (2-methylpropionitrile) and the like. The amount of the "radical initiator" to be used is generally 0.01 to 10 equivalents relative to compound (65).
Examples of the above-mentioned "inert solvent" include nitrile solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated
hydrocarbon solvents and the like. Among them, nitrile
solvents, aromatic solvents and halogenated hydrocarbon solvents are preferable.
The reaction temperature is generally -78°C to 200°C, preferably 50°C to 150°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0427]
Compound (62) can be produced, for example, by subjecting compound (66) to an oxidation reaction.
The above-mentioned "oxidation reaction" is performed by reacting compound (66) in the presence of an oxidant and a dehydrating agent, in an inert solvent. This reaction is preferably performed under an inert gas atmosphere.
Examples of the above-mentioned "oxidant" include 4- methylmorpholine N-oxide and the like. The amount of the
"oxidant" to be used is generally 1 to 100 equivalents, preferably 1 to 10 equivalents, relative to compound (66) .
Examples of the above-mentioned "dehydrating agent" include molecular sieves 4A and the like. The amount of the "dehydrating agent" to be used is generally 0.1- to 100-fold amount, preferably 0.5- to 10-fold amount, relative to the weight of compound (66) .
Examples of the above-mentioned "inert solvent" include nitrile solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated
hydrocarbon solvents and the like. Among them, nitrile
solvents and halogenated hydrocarbon solvents are preferable.
Examples of the above-mentioned "inert gas" include argon gas, nitrogen gas and the like.
The reaction temperature is generally -78°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 5 min- to 48 hr, preferably 30 min to 24 hr.
[0428]
<Reaction Scheme 22>
[0429]
Figure imgf000163_0001
[0430]
wherein each symbol is as defined above.
[0431]
Compound (68) can be produced, for example, by subjecting compound (67) to a coupling reaction with compound (10) .
This reaction is performed in the same manner as in the production method of compound (2-1) in Reaction Scheme 4.
[0432]
Compound (63-1) can be produced, for example, by subjecting compound (68) to a hydrogenation reaction.
The above-mentioned "hydrogenation reaction" is performed by reacting compound (68) in the presence of a metal catalyst and a hydrogen source, . in an inert solvent. Where necessary, the reaction can be performed in the presence of an organic acid in a catalytic amount to an excess amount relative to compound (68), or hydrogen chloride in 1 to 50 equivalents relative to compound (68) .
Examples of the above-mentioned "metal catalyst" include palladium-carbon, palladium black, palladium chloride,
palladium hydroxide, rhodium-carbon, platinum oxide, platinum black, platinum-palladium, Raney-nickel, Raney-cobalt and the like. The amount of the "metal catalyst" to be used is
generally 0.001 to 1000 equivalents, preferably 0.01 to 100 equivalents, relative to compound (68) .
Examples of the above-mentioned "hydrogen source" include hydrogen gas and the like.
Examples of the above-mentioned "organic acid" include acetic acid and the like.
Examples of the above-mentioned "inert solvent" include alcohol solvents, nitrile solvents, aromatic solvents,
aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0433]
<Reaction Scheme 23>
[0434]
Figure imgf000164_0001
[0435]
wherein each symbol is as defined above.
[0436]
Compound (70) can be produced, for example, by subjecting compound (69) to an alkylation reaction.
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0437]
Compound (72) can be produced, for example, by subjecting compound (70) to a diazocoupling reaction with compound (71).
The. above-mentioned "diazocoupling reaction" is performed by reacting compound (70) with a diazotizating agent under an acidic condition, and then reacting the resulting diazonium salt with compound (71) under a basic condition.
[0438]
The production reaction of the above-mentioned "diazonium salt" is performed by reacting compound (70) with a
diazotizating agent in an acidic aqueous solution such as hydrochloric acid, sulfuric acid and the like.
Examples of the above-mentioned "diazotizating agent" include sodium nitrite and the like. The amount of the
"diazotizating agent" to be used is generally 1 to 100
equivalents, preferably 1 to 10 equivalents, relative to compound (70) .
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 30°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0439]
The reaction of the above-mentioned "diazonium salt" with compound (71) is performed by reacting the "diazonium salt" with compound (71) in an basic aqueous solution such as an aqueous sodium hydroxide solution and the like.
The amount of compound (71) to be used is generally 0.5 to 10 equivalents, preferably 0.8 to 5 equivalents, relative to compound (70) .
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 50°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0440]
Compound (9-2) can be produced, for example, by
subjecting compound (72) to a cyclization reaction.
The above-mentioned "cyclization reaction" is performed by reacting compound (72) in the presence of an activator, in an inert solvent.
Examples of the above-mentioned "activator" include trimethylphosphite, triethylphosphite and the like. The amount of the "activator" to be used is 1 to 100 equivalents (an excess amount) relative to compound (72) .
The reaction temperature is generally -78°C to 200°C, preferably 50°C to 150°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0441]
<Reaction Scheme 24>
[0442]
Figure imgf000166_0001
[0443]
wherein each symbol is as defined above.
[0444]
Compound (74) can be produced, for example, by subjecting compound (6) to a coupling reaction with compound (73) .
This reaction is performed in the same manner as in the production method of compound (2-1) in Reaction Scheme 4.
[0445]
Compound (2-4) can be produced, for example, by
subjecting compound (74) to a fluorination reaction. The above-mentioned "fluorination reaction" is performed by reacting compound (74) in the presence of a fluorinating agent, in an inert solvent.
Examples of the above-mentioned "fluorinating agent" include diethylaminosulfur trifluoride, bis (2- methoxyethyl) aminosulfur trifluoride and the like. The amount of the "fluorinating agent" to be used is generally 3 to 100 equivalents, . preferably 3 to 10 equivalents, relative to compound (74 ) .
Examples of the above-mentioned "inert solvent" include nitrile solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, halogenated hydrocarbon solvents and the like. Among them, aromatic solvents and halogenated hydrocarbon solvents are preferable.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0446] .
<Reaction Scheme 25>
Figure imgf000167_0001
79 80 81 26
[0448]
wherein M6 and M7 are each a nitrogen atom-protecting group, or M6 is a hydrogen atom and M7 is a nitrogen atom-protecting group, and the other symbols are as defined above.
[0449]
Compound (76) can be produced, for. example, by. subjecting compound (75) to a coupling reaction with compound (10-1) .
This reaction is performed in the same manner as in the production method of compound (2-1) in Reaction Scheme 4.
[0450]
Compound (77) can be produced, for example, by subjecting compound (76) to a bromination reaction.
This reaction is performed in the same manner as in the production method of compound (66) in Reaction Scheme 21.
[0451]
Compound (78) can be produced, for example, by subjecting compound (77) to a substitution reaction.
- The above-mentioned "substitution reaction" is performed by reacting compound (77) in a mixed solvent of water and an inert solvent.
Examples of the above-mentioned "inert solvent" include amide solvents and the like. Among them, N-methylpyrrolidone is preferable.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 120°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0452]
Compound (79) can be produced, for example, by subjecting compound (78) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0453]
Compound (80) can be produced, for example, by subjecting compound (79) to a protection reaction.
The protection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0454]
Compound (81) can be produced, for example, by subjecting compound (80) to an oxidation reaction.
The above-mentioned "oxidation reaction" is performed by reacting compound (80) with an oxidant in an inert solvent.
Examples of the above-mentioned "oxidant" include manganese dioxide, tetrapropylammonium perruthenate, chromium trioxide, Dess-Martin reagent and the like. The amount of the "oxidant" to be used is generally 1 to 5 equivalents,
preferably 1 to 2 equivalents, relative to compound (80) .
Examples of the above-mentioned ,"inert solvent" include alcohol solvents, nitrile solvents, amide solvents,
halogenated hydrocarbon solvents, ether solvents, aromatic solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, nitrile solvents, halogenated hydrocarbon solvents and the like are preferable.
The reaction temperature is generally -100°C to 50°C, preferably -78°C to 30°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
The above-mentioned "oxidation reaction" can also be performed according to a method known per se, for example, the method described in Journal of the Medicinal Chemistry, 5282- 5290 pages, 2006 or the like, or a method analogous thereto.
[0455]
Compound (26) can be produced, for example, by subjecting compound (81) to an oxidation reaction.
The above-mentioned "oxidation reaction" is performed by reacting compound (81) with an oxidant in an inert solvent.
Examples of the above-mentioned "oxidant" include sodium dihydrogen phosphate, chromium trioxide and the like. Where necessary, an additive such as 2-methylbut-2-ene and the like may be added. The amount of the "oxidant" to be used is generally 1 to 5 equivalents, preferably 1 to 2 equivalents, relative to compound (81) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, ketone solvents and the like. These solvents are preferably used in a mixture with water in an appropriate ratio.
The reaction temperature is generally -100°C to 100°C, preferably -78°C to 50°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0456]
<Reaction Scheme 26>
Figure imgf000170_0001
[0458]
wherein Z2 is R6 or a hydroxyl-protecting group, and the other symbols are as defined above.
[0459]
Compound (84) can be produced, for example, by subjecting compound (83) to an alkylation reaction..
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0460]
Compound (84) can also be produced, for example, by subjecting compound (83) to a protection reaction.
The protection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0461]
Compound (86) can be produced, for example, by subjecting compound (84) to a substitution reaction with compound (85).
This reaction is performed in the same manner as in the
"method using a base", from among the production methods of compound (2-1) in Reaction Scheme 4.
[0462]
Compound (87) can be produced, for example, by subjecting compound (.86) to a hydrogenation reaction.
[0463]
The above-mentioned "hydrogenation reaction" is performed by reacting compound (86) in the presence of a metal and a hydrogen source, in an inert solvent. Where necessary, the reaction can be performed in the presence of an organic acid in a catalytic amount to a solvent amount, or hydrogen
chloride in 1 to 50 equivalents relative to compound (86) .
Examples of the above-mentioned "metal" include
palladium-carbon, palladium black, palladium chloride,
palladium hydroxide, rhodium-carbon, platinum oxide, platinum black, platinum-palladium, Raney-nickel, Raney-cobalt and the like. The amount of the "metal", to be used is generally 0.001 to 1000 equivalents, preferably 0.01 to 100 equivalents, relative to compound (86) .
Examples of the above-mentioned "hydrogen source" include hydrogen gas, ammonium formate and the like.
Examples of the above-mentioned "organic acid" include acetic acid and the like.
Examples of the above-mentioned "inert solvent" include alcohol solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated
hydrocarbon solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0464]
The above-mentioned "hydrogenation reaction" is also performed by reacting compound (86) in the presence of a metal and a hydrochloric acid source, in an inert solvent.
Examples of the above-mentioned "metal" include iron, zinc, tin and the like. The amount of the "metal" to be used is generally 0.1 to 1000 equivalents, preferably 1 to 100 equivalents, relative to compound (86) .
Examples of the above-mentioned "hydrochloric acid
source" include hydrochloric acid, hydrogen chloride gas, ammonium chloride and the like. The amount of the
"hydrochloric acid source" to be used is generally 1
equivalent to an excess amount relative to compound (86) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated
hydrocarbon solvents and the like. These solvents may be used in a mixture with water in an appropriate ratio.
The reaction temperature is generally -70°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 0.1 hr to 100 hr,
preferably 0.1 hr to 40 hr.
[0465]
Compound (88) can be produced, for example, by subjecting compound (87) to an amidation reaction with compound (14) .
This reaction is -performed in the same manner as in the production method of compound (16) in Reaction Scheme 5.
[0466]
Compound (82) can be produced, for example, by subjecting compound (88) to a cyclization reaction.
The above-mentioned "cyclization reaction" can be
produced by reacting compound (88) with a base in an inert solvent, and then reacting the resulting compound with an acid.
Examples of the above-mentioned "base" include "metal alkoxides" and the like. The amount of the "base" to be used is generally 2 to 100 equivalents, preferably 2 to 10
equivalents, relative to compound (88) .
Examples of the above-mentioned "acid" include "organic acids" and the like. The amount of the "acid" to be used is generally 3 to 1000 equivalents, preferably 3 to 100
equivalents, relative to compound (88) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, halogenated hydrocarbon solvents, ether solvents and the like.
The reaction temperature is generally -100°C to 150°C, preferably 0°C to 100°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0467]
<Reaction Scheme 27>
0468]
Figure imgf000173_0001
[0469]
wherein each symbol is as defined above.
[0470]
Compound (11-5) can be produced, for example, by
subjecting compound (11-2) to a substitution reaction.
The above-mentioned "substitution reaction" is performed by reacting compound (11-2) with a halogenating agent in an inert solvent.
Examples of the above-mentioned "halogenating agent" include 1- (chloromethyl) -4-fluoro-1, 4- diazoniabicyclo [2.2.2] octane ditetrafluoroborate, N- bromosuccinimide, N-iodosuccinimide and the like. The amount of the "halogenating agent" to be used is generally 2 to 20 equivalents relative to compound (11-2) .
Examples of the above-mentioned "inert solvent" include nitrile solvents, aliphatic hydrocarbon solvents, aromatic solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an
appropriate ratio. The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
[0471]
Compound (11-6) can be produced, for example, by
subjecting compound (11-5) to a substitution reaction.
This reaction is performed in the same manner as in the production method of compound (11-3) in Reaction Scheme 9.
[0472]
Compound (11-4) can be produced, for example, by
subjecting compound (11-6) to a coupling reaction.
The above-mentioned "coupling reaction" is performed, for example, by reacting compound (11-6) and a boron compound corresponding to R8 in the presence of a metal catalyst, a ligand and a base, in an inert solvent. This reaction is preferably performed under an inert gas atmosphere.
Examples of the above-mentioned "boron compound
corresponding to R8" include trimethylboroxin, phenylboronic acid and the like. The amount of the "boron compound
corresponding to R8" to be used is generally 0.5 to 5
equivalents, preferably 1 to 3 equivalents, relative to compound (11-6) .
Examples of the above-mentioned "metal catalyst" include palladium(II) acetate, [1,1'- bis (diphenylphosphino) ferrocene] palladium ( II ) dichloride and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (11-6) .
Examples of the above-mentioned "ligand" include
triphenylphosphine, 1, 1' -bis (diphenylphosphino) ferrocene and the like. The amount of the "ligand" to be used is generally 0.0001 to 100 equivalents, preferably 0.001 to 10 equivalents, relative to compound (11-6) .
Examples of the above-mentioned "base" include "basic salts" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (11-6) .
Examples of the above-mentioned "inert solvent" include amide solvents, aromatic solvents, halogenated hydrocarbon solvents, ether solvents and the like.
Examples, of the above-mentioned "inert gas" include argon gas, nitrogen gas and the like.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0473]
<Reaction Scheme 28>
[0474]
Figure imgf000175_0001
[0475]
wherein each symbol is as defined above.
[0476]
Compound (90) can be produced, for example, by subjecting compound (25) to a substitution reaction with compound (89) .
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0477]
Compound (91) can be produced, for example, by subjecting compound (90) to hydrolysis.
This reaction is performed in the same manner as in the production method of compound (14) in Reaction Scheme 5. [0478]
Compound (92) can be produced, for example, by subjecting compound (90) to a sulfonylation reaction.
This reaction is performed in the same manner as in the production method of compound (51) in Reaction Scheme 17.
[0479]
Compound (93) can be produced, for example, by subjecting compound (91) to a sulfonylation reaction.
This reaction is performed in the same manner as in the production method of compound (51) in Reaction Scheme 17.
[0480]
Compound (93) can also be produced, for example, by subjecting compound (92) to hydrolysis.
This reaction is performed in the same manner as in the production method of compound (14) in Reaction Scheme 5.
[0481]
Compound (94) can be produced, for example, by subjecting compound (93) to an amidation reaction with compound (15).
This reaction is performed in the same manner as in the production method of compound (16) in Reaction Scheme 5.
[0482]
Compound (95) can be produced, for example, by subjecting compound (94) to a cyclization reaction.
This reaction is performed in the same manner as in the production method of compound (1-1) in Reaction Scheme 5.
[0483]
Compound (51-1) can be produced, for example, by
subjecting compound (95) to an alkylation reaction.
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0484]
Compound (52-1) can be produced, for example, by
subjecting compound (51-1) to an azidation reaction.
This reaction is performed in the same manner as in the production method of compound (52) in Reaction Scheme 17. [0485]
Compound (3-1) can be produced, for example, by
subjecting compound (52-1) to a reduction reaction.
This reaction is performed in the same manner as in the production, method of compound (53) in Reaction Scheme
[0486]
<Reaction Scheme 29>
[0487]
Figure imgf000177_0001
[0488]
wherein each symbol is as defined above.
[0489]
Compound (98) can be produced, for example, by subjecting compound (97) to a protection reaction.
The protection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0490]
Compound (99) can be produced, for example, by subjecting compound (98) to an oxidative cleavage or ozone oxidation.
This reaction is performed by reacting compound (98) with an oxidant in an inert solvent. Where necessary, a re-oxidant may be used.
Examples of the above-mentioned "oxidant" include osmium tetraoxide, potassium permanganate, ozone and the like. The amount of the "oxidant" to be used is generally 0.001 to 10 equivalents, preferably.0.01 to 3 equivalents, relative to compound (98) .
Examples of the above-mentioned "re-oxidant" include sodium periodate and the like. The amount of the "re-oxidant" to be used is generally 1 to 10 equivalents, preferably 1 to 3 equivalents, relative to the "oxidant". Examples of the above-mentioned "inert solvent" include ketone solvents, nitrile solvents, . amide solvents, halogenated hydrocarbon solvents, ether solvents, aromatic solvents and the like. These solvent may be used in a mixture with water in 5 an appropriate ratio, or in a mixture of two or more kinds
thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 48 hr, preferably 10 30 min to 24 hr.
[0491] ■
Compound (100) can be produced, for example, by subjecting compound (99) to a fluorination reaction.
This reaction is performed by reacting compound (99) with 15 a fluorinating agent in an inert solvent.
Examples of the above-mentioned "fluorinating agent" include (diethylamino) sulfur trifluoride and the like. The amount of the "fluorinating agent" to be used is generally 1 to 10 equivalents, preferably 1 to 3 equivalents, relative to 20 compound (99) .
Examples of the above-mentioned "inert solvent" include nitrile solvents, amide solvents, halogenated hydrocarbon solvents, ether solvents, aromatic solvents and the like.
These solvents may be used in a mixture of two or more kinds 25 thereof in an appropriate ratio. Among them, toluene,
dichloromethane and the like are preferable.
The reaction temperature is generally -100°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 48 hr, preferably 30 30 min to 24 hr.
[0492]
Compound (96) can be produced, for example, by subjecting compound (100) to a deprotection reaction.
The deprotection reaction can be performed according to a 35 method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons
(1980) or the like.
[0493]
<Reaction Scheme 30>
[0494]
Figure imgf000179_0001
[0495]
wherein each symbol is as defined above.
[0496]
Compound (102) can be produced, for example, by
subjecting compound (101) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like."
[0497]
Compound (103) can be. produced, for example, by
subjecting compound (102) to an acylation reaction.
This reaction is performed in the same manner as in the production method of compound (1-1) in Reaction Scheme 2.
[0498]
Compound (1-5) can be produced, for example, by
subjecting compound (103) to a reduction1 reaction.
This reaction is performed in the same manner as in the production method of compound (2-2) in Reaction Scheme 15.
[0499]
Reaction Scheme 31>
[0500]
Figure imgf000179_0002
[0501]
wherein each symbol is as defined above. [0502]
Compound (104) can be produced, for example, by
subjecting compound (74) to a reduction reaction.
This reaction is performed in the same manner as in the production method of compound (50) in Reaction Scheme 17.
[0503].
Compound (2-5) can be produced, for example, by
subjecting compound (104) to a fluorination reaction.
This reaction is performed in the same manner as in the production method of compound (2-4) in Reaction Scheme 24.
[0504]
<Reaction Scheme 32>
[0505]
Figure imgf000180_0001
2-10
[0506]
wherein each symbol is as defined above.
[0507]
Compound (2-8) can be produced, for example, by
subjecting compound (2-7) to an oxidation reaction.
The above-mentioned "oxidation reaction" can be produced by reacting compound (2-7) in the presence of an oxidant, in an inert solvent. Where necessary, the reaction can be performed in the presence of an organic acid in a catalytic amount to an excess amount.
Examples of the above-mentioned "oxidant" include m- chloroperbenzoic acid, hydrogen peroxide and the like. The amount of the "oxidant" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (2-7 ) .
Examples of the above-mentioned "organic acid" include acetic acid and the like.
Examples of the above-mentioned "inert solvent" include nitrile solvents, halogenated hydrocarbon solvents, aromatic solvents and the like. Among them, toluene, dichloromethane and the like are preferable.
The reaction temperature is generally -100°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 48 hr, preferably
30 min to 24 hr.
[0508]
Compound (2-9) can be produced, for example, by
subjecting compound (2-8) to a rearrangement reaction.
The above-mentioned "rearrangement reaction" can be produced, for example, by reacting compound (2-8) with acetic anhydride in an inert solvent. The amount of the acetic anhydride to be used is generally 1 equivalent to an excess amount, relative to compound (2-8).
Examples of the above-mentioned "inert solvent" include nitrile solvents, halogenated hydrocarbon solvents, aromatic solvents and the like.
The reaction temperature is generally -100°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally.5 mih to 48 hr, preferably
30 min to 24 hr.
[0509]
Compound (2-10) can be produced, for example, by
subjecting compound (2-9) to hydrolysis.
This reaction is performed in the same manner as in the production method of compound (14) in Reaction Scheme 5.
[0510]
Compound (2-6) can be produced, for example, by
subjecting compound (2-10) to an alkylation reaction.
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0511]
<Reaction Scheme 33>
[0512]
Figure imgf000182_0001
105 8-1
[0513]
wherein each symbol is as defined above.
[0514]
Compound (8-1) can be produced, for example, by
subjecting compound (105) to a coupling reaction with compound
(106) .
The above-mentioned "coupling reaction" is performed by reacting compound (105) with compound (106) in the presence of a metal catalyst, a ligand and a base, in an inert solvent. This reaction is preferably performed under an inert gas atmosphere.
The amount of compound (106) to be used is generally 0.5 to 100 equivalents, preferably 0.8 to 20 equivalents, relative to compound (105) .
Examples of the above-mentioned "metal catalyst" include tris (dibenzylideneacetone) dipalladium ( 0 ) , palladium(II) acetate, copper (I) iodide and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 100
equivalents, preferably 0.01 to 10 equivalents, relative to compound (105) .
Examples of the above-mentioned "ligand" include (1R,2R)- N, N' -dimethylcyclohexane-1, 2-diamine, 1, 10-phenanthroline, triphenylphosphine, 1, 1' -bis (diphenylphosphino) ferrocene and the like. The amount of the "ligand" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (105) .
Examples of the above-mentioned "base" include salts" and the like. Among them, tripotassium .phosphate, cesium carbonate and the like are preferable. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (105) .
Examples of the above-mentioned "inert solvent" include amide solvents, aromatic solvents, halogenated hydrocarbon solvents and the like.
Examples of the above-mentioned "inert gas" include argon gas, nitrogen gas and the like.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0515]
<Reaction Scheme 34>
Figure imgf000183_0001
107 108 2-11
[0517]
wherein each symbol is as defined above.
[0518]
Compound (108) can be produced, for example, by
subjecting compound (107) to an alkylation reaction.
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0519]
Compound (2-11) can be produced, for example, by
subjecting compound (108) to a dehydration-condensation reaction with compound (63), and then subjecting the resulting compound to a condensation pyrazole ring-formation reaction.
The above-mentioned "dehydration-condensation reaction" is performed by reacting compound (108) with compound (63) in an inert solvent. Where necessary, a dehydrating agent may be used. The amount of compound (63). to be used is generally 1 to
5 equivalents relative to compound (108) .
Examples of the above-mentioned "dehydrating agent" include magnesium sulfate and the like. The amount of the
5 "dehydrating agent" to be used is generally 1 to 1000
equivalents relative to compound (108) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated
10 hydrocarbon ' solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -78°C to 200°C, preferably 50°C to 150°C.
15 The reaction time is generally 5 min to 48 hr, preferably
30 min to 24 hr.
[0520]
The above-mentioned "condensation pyrazole ring-formation reaction" is performed by reacting subjecting the above- 20 mentioned compound (108) to dehydration-condensation reaction with compound (63) , and then reacting the resulting compound with an azidating agent in an inert solvent.
Examples of the above-mentioned "azidating agent" include sodium azide and the like. The amount of the "azidating agent" 25 to be used is generally 1 equivalent to an excess amount
relative to compound (108) .
The reaction temperature is generally -78°C to 200°C, preferably 50°C to 150°C.
The reaction time is generally 5 min to 48 hr, preferably 30 30 min to 24 hr.
[0521]
<Reaction Scheme 35>
[0522]
Figure imgf000185_0001
[0523]
wherein each symbol is as defined above.
[0524]
Compound (110) can be produced, for example, by
subjecting compound (109) to a protection reaction.
The protection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0525]
Compound (8-2) can be produced, for example, by
subjecting compound (110) to a dehydration-condensation reaction with compound (62), and then subjecting the resulting compound to a cyclization reaction.
This reaction is performed in the same manner as in the production method of compound (2-3) in Reaction Scheme 20.
[0526]
<Reaction Scheme 36>
[0527]
Figure imgf000185_0002
[0528]
wherein each symbol is as defined above.
[0529]
Compound (8-3) can be produced, for example, by
subjecting compound (8) to a substitution reaction.
[0530]
The above-mentioned "substitution reaction" is performed by reacting compound (8) with an alkyl metal, a metal amide or the like in an inert solvent to convert the hydrogen atom to a metal atom, and then reacting the resulting compound with, for example, a halogenating agent or a halide corresponding to R7.
Examples of the above-mentioned "alkyl metal" include alkyllithiums, alkylmagnesium halides and the like. The amount of the "alkyl metal" to be used is generally 1 to 10
equivalents relative to compound (8) .
Examples of the above-mentioned "metal amides" include lithiumdiisopropylamide, lithiumhexamethyl disilazide and the like. The amount of the "metal amides" to be used is generally 1 to 10 equivalents relative to compound (8) .
Examples of the above-mentioned "halogenating agent" include N-fluoro-N- (phenylsulfonyl) benzenesulfonamide, N- chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, bromine, iodine and the like. The amount of the "halogenating agent" to be used is generally 2 to 10 equivalents relative to compound ( 8 ) .
Examples of the above-mentioned "halide corresponding to R7" include optionally substituted alkyl halides, optionally substituted cycloalkyl halides, optionally substituted
cycloalkylalkyl halides and optionally substituted aralkyl halides. The amount of the "halide corresponding' to R7" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (8).
Examples of the above-mentioned "inert solvent" include aliphatic hydrocarbon solvents, aromatic solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
[0531]
The above-mentioned "substitution reaction" is also performed by reacting compound (8) with a halogenating agent in an inert solvent. Where necessary, a radical initiator may be used.
Examples of the above-mentioned "halogenating agent" include 1- (chloromethyl) -4-fluoro-l, 4-'
diazoniabicyclo [2.2.2 ] octane ditetrafluoroborate, N- chlorosuccinimide, N-bromosuccinimide, N-iodosucci-nimide, bromine, iodine and the like. The amount of the "halogenating agent" to be used is generally 2 to.20 equivalents relative to compound (8) .
Examples of the above-mentioned "radical initiator" include 2, 2' -azobis (2-methylpropionitrile) and the like. The amount of the "radical initiator" to be used is generally 0.01 to 10 equivalents relative, to compound (8) .
Examples of the above-mentioned "inert solvent" include nitrile solvents, aliphatic hydrocarbon solvents, aromatic solvents, ether solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an
appropriate ratio.
The reaction temperature is generally -100°C to 200°C, preferably -100°C to 100°C.
The reaction time is generally 1 min to 48 hr, preferably 5 min to 24 hr.
[0532]
<Reaction Scheme 37>
[0533]
Figure imgf000187_0001
[0534]
wherein each symbol is as defined above.
[0535]
Compound (8-4) can be produced, for example, by
subjecting compound (8) to a substitution reaction.
This reaction is performed in the same manner as in the production method of compound (8-3) in Reaction Scheme 36.
[0536]
<Reaction Scheme 38>
Figure imgf000188_0001
8-5
[0538]
wherein each symbol is as defined above.
[0539]
Compound (8-6) can be produced, for example, by
subjecting compound (8-5) to a trifluoromethylation reaction.
The above-mentioned "trifluoromethylation reaction" is performed by reacting compound (8-5) with a
trifluoromethylating agent in the presence of a metal catalyst, in an inert solvent.- This reaction is preferably performed under an inert gas atmosphere.
Examples of the above-mentioned "trifluoromethylating agent" include methyl difluoro (fluorosulfonyl) cetate and the like. The amount of the "trifluoromethylating agent" to be used is generally 0.5 to 100 equivalents, preferably 1 to 20 equivalents, relative to compound (8-5) .
Examples of the above-mentioned "metal catalyst" include copper (I) iodide and the like. The amount of the "metal
catalyst" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (8-5).
Examples of the above-mentioned "inert solvent" include amide solvents, aromatic solvents, halogenated hydrocarbon solvents and the like.
Examples of the above-mentioned "inert gas" include argon gas, nitrogen gas and the like.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0540]
<Reaction Scheme 39>
0541]
Figure imgf000189_0001
8-8 8-7
[0542]
wherein each symbol is as defined above.
[0543]
Compound (8-7) can be produced, for example, by
subjecting compound (8-8) to a cyanation reaction.
The above-mentioned "cyanation reaction" is performed by reacting compound (8-8) with a cyanating agent in the presence of a metal catalyst and a ligand, in an inert solvent. Where necessary, zinc may be used in a catalytic amount to an excess amount as an additive. This reaction is preferably performed under an inert gas atmosphere.
Examples of the above-mentioned "cyanating agent" include zinc cyanide and the like. The amount of the "cyanating agent" to be used is generally 0.5 to 100. equivalents, preferably 1 to 20 equivalents, relative to compound (8-8).
Examples of the above-mentioned "metal catalyst" include tris (dibenzylideneacetone) dipalladium(O) and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents,
relative to compound (8-8).
Examples of the above-mentioned "ligand" include
triphenylphosphine, 1, 1' -bis (diphenylphosphino) ferrocene and the like. The amount of the "ligand" to be used is generally 0.0001 to 100 equivalents, preferably 0.001 to 10 equivalents, relative to compound (8-8).
Examples of the above-mentioned "inert solvent" include amide solvents, aromatic solvents, halogenated hydrocarbon solvents and the like.
Examples of the above-mentioned "inert gas" include argon gas, nitrogen, gas and the like.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0544]
<Reaction. Scheme 40>
[0545]
Figure imgf000190_0001
[0546]
wherein each symbol is as defined above.
[0547]
Compound (111) can be produced, for example, by
subjecting compound (112) to a substitution reaction.
This reaction is performed in the same manner as in the production method of compound (8-3) in Reaction Scheme 36.
[0548]
<Reaction Scheme 41>
[0549]
Figure imgf000190_0002
[0550]
wherein Q1 is a 6-membered ring heterocycle such as the above- mentioned ring shown in the reaction scheme, and the like, and the other symbols are as defined above.
[0551]
Compound (114) can be produced, for example, by subjecting compound (113) to ah alkylation reaction.
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0552]
Compound (115) can be produced, for example, by
subjecting compound (114) to an amination reaction.
The above-mentioned "amination reaction" is performed by reacting compound (114) with an aminating agent in the
presence of a metal catalyst, a ligand and a base, in an inert solvent. This reaction is preferably performed under an inert gas atmosphere.
Examples of the above-mentioned "aminating agent" include 1, 1-diphenylmethanimine, ammonia and the like. The amount of the "aminating agent" to be used is generally 0.5 to 100 equivalents, preferably 1 to 10 equivalents, relative to compound . (114) .
Examples of the above-mentioned "metal catalyst" include tris (dibenzylideneacetone) dipalladium ( 0 ) , palladium(II) acetate, copper (I) iodide and the like. The amount of the "metal catalyst" to be used is generally 0.001 to 100
equivalents, preferably 0.01 to 10 equivalents, relative to compound ( 114 ) .
Examples of the above-mentioned "ligand" include 2,2'- bis (diphenylphosphino) -1,1' -binaphthyl, butyldi- (1- adamantyl) phosphine, (1R, 2R) -Ν,Ν' -dimethylcyclohexane-1, 2- diamine, 1, 10-phenanthroline, triphenylphosphine, 1,1'- bis (diphenylphosphino) ferrocene and the like. The amount of the "ligand" to be used is generally 0.001 to 100 equivalents, preferably 0.01 to 10 equivalents, relative to compound (114).
Examples of the above-mentioned "base" include "basic salts", "metal alkoxides" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (114) .
Examples of the above-mentioned "inert solvent" include amide solvents, aromatic solvents, ' halogenated hydrocarbon solvents and the like.
Examples of the above-mentioned "inert gas" include argon gas, nitrogen gas and the like.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0553]
Compound (9-3) can be produced, for example, by
subjecting compound (115) to a condensation imidazole ring- formation reaction with compound (116) .
The above-mentioned "condensation imidazole ring- formation reaction" is performed by reacting compound (115) with compound (116) in an inert solvent.
The amount of compound (116) to be used is generally 0.5 to 100 equivalents, preferably 0.8 to 5 equivalents, relative to compound (115) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, aromatic solvents, halogenated hydrocarbon solvents and the like.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0554]
<Reaction Scheme 42>
[0555]
Figure imgf000192_0001
[0556] wherein L3b is a halogen atom, and the other symbols, are as defined above.
[0557]
Compound (118) can be produced, for example, by
subjecting compound (114) to the Sonogashira coupling reaction with compound (117) .
This reaction is performed in the same manner as in the production method of compound (42) in Reaction Scheme 15.
[0558]
Compound (119) can be produced, for example, by
subjecting compound (118) to a desilylation reaction.
The desilylation reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0559]
Compound (120) can be produced, for example, by
subjecting compound (4-1) to the Sonogashira coupling reaction with compound (117) .
This reaction is performed in the same manner as in the production method of compound (42) in Reaction Scheme 15.
[0560]
Compound (121) can be produced, for example, by
subjecting compound (120) to a desilylation reaction.
The desilylation reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0561]
Compound (122) can be produced, for example, by
subjecting compound (4-1) to the Sonogashira coupling reaction with compound (119) .
This reaction is performed in the same manner as in the production method of compound (42) in Reaction Scheme 15.
[0562] Compound (122) can also be produced, for example, by subjecting compound (121) to the Sonogashira coupling reaction with compound (114) .
This reaction is performed in the same manner as in the production method of compound (42) in Reaction Scheme 15.
[0563]
Compound (2-12) can be produced, for example, by
subjecting compound (122) to an amination reaction and
subsequent cyclization reaction.
The above-mentioned "amination reaction and subsequent cyclization reaction" is performed by reacting compound (122) with an aminating agent in an inert solvent, and then reacting the resulting compound with a base.
Examples of the above-mentioned "aminating agent" include 2- [ (aminooxy) sulfonyl] -1, 3, 5-trimethylbenzene,
(aminooxy) (hydroxy) sulfane dioxide and the like. The amount of the "aminating agent" to be used is generally 0.5 to 100 equivalents, preferably 1 to 10 equivalents, relative to compound (122) .
Examples of the above-mentioned "base" include "basic salts" and the like. The amount of the "base" to be used is ■generally 1 to 100 equivalents, preferably 1 to 10 equivalents, relative to compound (122) .
Examples of the above-mentioned "inert solvent" include ether solvents, amide solvents, alcohol solvents, aromatic solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture with water in an appropriate ratio.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0564]
<Reaction Scheme 43>
[0565]
Figure imgf000195_0001
[0566]·
wherein each symbol is as defined above.
[0567]
Compound (111-1) can be produced, for example, by subjecting compound (112) to a substitution reaction.
This reaction is performed in the same manner as in the production method of compound (8-3) in Reaction Scheme 36.
[0568]
<Reaction Scheme 44>
Figure imgf000195_0002
[0570]
wherein each symbol is as defined above.
[0571]
Compound (8-9) can be produced, for example, by
subjecting compound (115) to an amination reaction, and then subjecting the resulting compound to dehydration-condensation and cyclization reaction with compound (123) .
[0572]
The above-mentioned "amination reaction" is performed by reacting . compound (115) with an aminating agent in an inert solvent.
Examples of the above-mentioned "aminating agent" include 2- [ (aminooxy) sulfonyl] -1,3, 5-trimethylbenzene,
(aminooxy) (hydroxy) sulfane dioxide and the like. The amount of the "aminating agent" to be used is generally 0.5 to 100 equivalents, preferably 1 to 10 equivalents, relative to compound ( 115) . Examples of the above-mentioned "inert solvent" include ether solvents, amide solvents, alcohol solvents, aromatic solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture with water in an appropriate ratio.
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably 30 min to 24 hr.
[0573]
The above-mentioned "dehydration-condensation reaction and cyclization reaction" is performed, for example, by
reacting the compound obtained in the above-mentioned
"amination reaction" with compound (123) in the presence of a base, in an inert solvent.
The amount of compound (123) to be used is generally 0.5 to 100 equivalents, preferably 1 to 10 equivalents, relative to compound (115) . .
Examples of the above-mentioned "base" include "basic salts" and the like. The amount of the "base" to be used is generally 1 to 100 equivalents, preferably 1 to 10 equivalents, relative to compound (115) .
Examples of the above-mentioned "inert solvent" include ether solvents, amide solvents, alcohol solvents, aromatic solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture with water in an appropriate ratio. '
The reaction temperature is generally -20°C to 200°C, preferably 0°C to 150°C.
The reaction time is generally 5 min to 40 hr, preferably
30 min to 24 hr.
[0574]
<Reaction Scheme 45>
[0575]
Figure imgf000197_0001
125
[0576]
wherein each symbol is as defined above.
[0577]
Compound (125) can be produced, for example, by
subjecting compound (11-1) to a reduction reaction.
This reaction is performed by reacting compound (11-1) in the presence of a reducing agent, in an inert solvent.
Examples of the above-mentioned "reducing agent" include metal hydrogen compounds (e.g., sodium bis (2- methoxyethoxy) aluminum hydride, diisobutylaluminum hydride), metal hydride complex compounds (e.g., sodium borohydride, lithium borohydride, lithium aluminum hydride, sodium aluminum hydride) and the like. The amount of the "reducing agent" to be used is generally 0.1 to 20 equivalents, preferably 1 to 5 equivalents, relative to compound (11-1) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, ester solvents, amide solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70 to 150°C, preferably -20 to 100°C.
The reaction time is generally 0.1 to 100 hr, preferably 0.1 to 40 hr.
[0578]
Compound (124) can be produced, for example, by subjecting compound (11-1) to a reduction reaction.
The reduction reaction can be performed according to a method known per se, for example, the method described in Journal of the Medicinal Chemistry, 3434-3442 pages, 2000 or the like, or a method analogous thereto.
This reaction is performed by reacting compound (11-1) with a reducing agent in an inert solvent.
Examples of the above-mentioned "reducing agent" include metal hydrogen compounds (e.g., sodium bis (2- methoxyethoxy) aluminum hydride, diisobutylaluminum, hydride) , metal hydride complex compounds (e.g., sodium borohydride, sodium cyanoborohydride, lithium aluminum hydride, sodium aluminum hydride) and the like. The amount of the "reducing agent" to be used is generally 0.1 to 20 equivalents,
preferably 1 to 5 equivalents, relative to compound (11-1) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, ester solvents, amide solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70 to 150°C, preferably -20 to 100°C.
The reaction time is generally 0.1 to 100 hr, preferably 0.1 to 40 hr.
[0579]
Compound (124) can also be produced for example, by subjecting compound (125) to an oxidation reaction.
The oxidation reaction can be performed according to a method known per se, for example, the method described in Journal of the Medicinal Chemistry, 5282-5290 pages, 2006 or the like, or a method analogous thereto.
This reaction is performed by reacting compound (125) with an oxidant in an inert solvent.
Examples of the above-mentioned "oxidant" include manganese dioxide, tetrapropylammonium perruthenate, chromium trioxide, Dess-Martin reagent and the like. The amount of the
"oxidant" to be used is generally 1 to 5 equivalents,
preferably 1 to 1.5 equivalents, relative to compound (125).
Examples of the above-mentioned "inert solvent" include alcohol solvents, nitrile solvents, amide solvents,
halogenated hydrocarbon solvents, ether solvents, aromatic solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, halogenated hydrocarbon solvents and the like are preferable.
The reaction temperature is generally -100°C to 50°C, preferably -78°C to 30°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0580]
<Reaction Scheme 46>
[0581]
Figure imgf000199_0001
127 126
[0582]
wherein each symbol is as defined above.
[0583]
Compound (126) can be produced, for example, by
subjecting compound (127) to an amination reaction, and then subjecting the resulting compound to a dehydration- condensation reaction and cyclization reaction with compound (124).
This reaction is performed in the same manner as in the production method of compound (8-9) in Reaction Scheme 45.
[0584]
<Reaction Scheme 47>
[0585]
Figure imgf000200_0001
8
9
[0586]
wherein each symbol is as defined above.
[0587]
Compound (8) can be produced, for example, by subjecting compound (9) to a protection reaction.
The protection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0588]
<Reaction Scheme 48>
0589]
Figure imgf000200_0002
128
[0590]
wherein each symbol is as defined above.
[0591] .
Compound (6) can be produced, for example, by subjecting compound (128) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0592]
<Reaction Scheme 49>
[0593] R7-OH ► R7-L R7-CN R7-C02H
130 131
Figure imgf000201_0001
[0594]
wherein each symbol is as defined above.
[0595]
Compound (130) can be produced, for example, by
subjecting compound (129) to a sulfonylation reaction.
This reaction is performed in the same manner as in the production method of compound (51) in Reaction Scheme 17.
[0596]
Compound (131) can be produced, for example, by
subjecting compound (130) to a cyanation reaction.
The above-mentioned "cyanation reaction" is performed, for example, by reacting compound (130) with a cyanating agent in an inert solvent. Where necessary, a base may be used in a catalytic amount to an excess amount.
Examples of the above-mentioned "cyanating agent" include sodium cyanide, potassium cyanide and the like. The amount of the "cyanating agent" to be used is generally 1 to 5
equivalents, preferably 1 to 3 equivalents, relative to compound (130) .
Examples of the above-mentioned "base" include "basic amines", "aromatic amines", "tertiary amines" and the like.
Examples of the above-mentioned "inert solvent" include nitrile solvents, amide solvents, halogenated hydrocarbon solvents, ether solvents, aromatic solvents and the like.
The reaction temperature is generally -100°C to 150°C, preferably -78°C to 120°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0597] Compound (132) can be produced, for example, by
subjecting compound (131) to hydrolysis.
[0598]
This reaction is performed by reacting compound (131) with a base in an inert solvent.
Examples, of the above-mentioned "base" include "inorganic bases" and the like. The amount of the "base" to be used is generally 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (131) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents are
preferably used in a mixture with water in an appropriate ratio. Among them, alcohol solvents containing water are preferable.
The reaction temperature is generally -78°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 5 min to 100 hr,
preferably 30 min to 24 hr.
[0599]
This reaction is also performed by reacting compound (131) with an acid in an inert solvent.
Examples of the above-mentioned "acid" include
hydrochloric acid, sulfuric acid and the like. The amount of the "acid" to be used is generally 1 equivalent to an excess amount, preferably 1 to 10 equivalents, relative to compound (131).
Examples of the above-mentioned "inert solvent" include alcohol solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents are
preferably used in a mixture with water in an appropriate ratio. Among them, alcohol solvents containing water are preferable.
The reaction temperature is generally -78°C to 150°C, preferably -20°C to 100°C. . The reaction time is generally 5 min to.100 hr, preferably 30 min to 24 hr.
[0600]
Compound (133) can be produced, for example, by subjecting compound (132) to a reduction reaction.
This reaction is performed in the same manner as in the production method of compound (125) in Reaction Scheme 45.
[0601]
Compound (134) can be produced, for example, by subjecting compound (133) to a sulfonylation reaction.
This reaction is performed in the same manner as in the production method of compound (51) in Reaction Scheme 17.
[0602]
<Reaction Scheme 50>
[0603]
Figure imgf000203_0001
[0604]
wherein R9 is a substituent, and the other symbols are as defined above.
[0605]
Compound (135) can be produced, for example, by subjecting compound (56) to an amidation reaction with N,0- dimethylhydroxylamine . The above-mentioned "amidation reaction" is performed in the same manner as in the production method of compound (40) in Reaction Scheme 14.
[0606]
Compound (136) can be produced,, for example, by
subjecting compound (135) to an alkylation reaction.
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0607]
Compound (137) can be produced, for example, by
subjecting compound (136) to a reduction reaction.
The above-mentioned "reduction reaction" is performed by reacting compound (136) with a reducing agent in an inert solvent .
Examples of the above-mentioned "reducing agent" include metal hydrogen compounds (e.g., sodium bis (2-,
methoxyethoxy) aluminum hydride, diisobutylaluminum hydride), metal hydride complex compounds (e.g., sodium borohydride, sodium cyanoborohydride, lithium aluminum hydride, sodium aluminum hydride) and the like. The amount of the "reducing agent" to be used is generally 0.1 to 20 equivalents,
preferably 1 to 5 equivalents, relative to compound (136) .
Examples of the above-mentioned "inert solvent" include alcohol solvents, aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, ester solvents, amide solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio.
The reaction temperature is generally -70 to 150°C, preferably -20 to 100°C.
The reaction time' is generally 0.1 to 100 hr, preferably
0.1 to 40 hr.
[0608]
Compound (138) can be produced, for example,- by reacting compound (7) with an alkyl metal in an inert solvent to convert the halogen atom of compound (7) to a metal atom, and then reacting the resulting compound with compound (137) .
This reaction is performed in the same manner as in the production method of compound (60) in Reaction Scheme 18. , [0609]
Compound (139) can be produced, for example, by
subjecting compound (138) to an oxidation reaction.
The oxidation reaction can be performed according to a method known per se, for example, the method described in Journal of the Medicinal Chemistry, 5282-5290 pages, 2006 or the like, or a method analogous thereto.
This reaction is performed by reacting. compound (138) with an oxidant in an inert solvent,.
Examples of the above-mentioned "oxidant" include manganese dioxide, tetrapropylammonium perruthenate, chromium trioxide, Dess-Martin reagent and the like. The amount of the "oxidant" to be used is generally 1 to 5 equivalents,
preferably 1 to 1.5 equivalents, relative to compound (138).
Examples of the above-mentioned "inert solvent" include alcohol solvents, nitrile solvents, amide solvents,
halogenated hydrocarbon solvents, ether solvents, aromatic solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, halogenated hydrocarbon solvents and the like are preferable .
The reaction temperature is generally -100°C to 50°C, preferably -78°C to 30°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
[0610]
Compound (139) can also be produced, for example, by reacting compound (7) with an alkyl metal in an inert solvent to convert the halogen atom of compound (7) to a metal atom, and then reacting the resulting compound with compound (136) .
This reaction is performed in the same manner as in the production method of compound (60) in Reaction Scheme 18. [0611]
Compound (140) can be produced, for example, by reacting compound (137) with an organic metal reagent corresponding to R9 in an inert solvent.
Examples of the above-mentioned "organic metal reagent corresponding to R9" include organic Grignard reagents (e.g., methylmagnesium bromide, methylmagnesium chloride) , organic lithium reagents (e.g., methyllithium) and the like. The amount of the "organic metal reagent corresponding to R9" to be used is generally 1 to 20 equivalents, preferably 1 to 5 equivalents, relative to compound (137).
Examples of the above-mentioned "inert solvent" include aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, THF and the like are preferable.
The reaction temperature is generally -78°C to 150°C, preferably -20°C to 100°C.
The reaction time -is generally 5 min to 48 hr, preferably
30 min to 24 hr.
[0612]
Compound (140) can also be produced, for example, by subjecting compound (137) to a perfluoroalkylation reaction.
This reaction is performed by reacting compound (137) with a perfluoroalkylating agent in the presence of a fluoride, in an inert solvent. Where necessary, a desilylation reaction may be performed after completion of the reaction.
Examples of the above-mentioned "perfluoroalkylating agent" include trimethyl (perfluoroalkyl) silane (e.g.,
trimethyl (trifluoromethyl) silane) and the like. The amount of the "perfluoroalkylating agent" to be used is generally 1 to 20 equivalents, preferably 1 to 5 equivalents, relative to compound ( 137 ) .
Examples of the above-mentioned "fluoride" include tetraalkylammonium fluorides (e.g., tetrabutylammonium
fluoride), metal fluorides (e.g., potassium fluoride) and the like. The amount of the "fluoride" to be used is generally catalytic amount to 20 equivalents, preferably 0.1 to 5 equivalents, relative to compound (137) .
Examples of the above-mentioned "inert solvent" include aromatic solvents, aliphatic hydrocarbon solvents, ether solvents, amide solvents, halogenated hydrocarbon solvents and the like. These solvents may be used in a mixture of two or more kinds thereof in an appropriate ratio. Among them, THF and the like are preferable.
The reaction temperature is generally -78°C to 150°C, preferably -20°C to 100°C.
The reaction time is generally 5 min to 48 hr, preferably 30 min to 24 hr.
The above-mentioned "desilylation reaction" can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0613]
Compound (141) can be produced, for example, by reacting compound (136) with an organic metal reagent corresponding to R9 in an inert solvent.
This reaction is performed in the same manner as in the production method of compound (4-3) in Reaction Scheme 14.
[0614]
Compound (141) can also be produced, for example, by subjecting compound (140) to an oxidation reaction.
This reaction is performed in the same manner as in the "oxidation reaction", from among the production methods of compound (139) in Reaction Scheme 50.
[0615]
Compound (142) can be produced, for example, by reacting compound (7) with alkyl metal an in an inert solvent to convert the halogen atom of compound (7) to a metal atom, and then reacting the resulting compound with compound (141) .
This reaction is performed in the . same manner as in the production method of compound (60) in Reaction Scheme 18.
[0616]
Compound (142) can also be produced, for example, by reacting compound (139) with an organic metal reagent corresponding to R9 in an inert solvent.
This reaction is performed in the same manner as in the method using "organic metal reagent", from among the
production methods of compound (140) in Reaction Scheme 50.
[0617]
Compound (142) can also be produced, for example, by subjecting compound (139) to a perfluoroalkylation reaction.
This reaction is performed in the same manner as in the method using "perfluoroalkylating agent", from among the production methods of compound (140) in Reaction Scheme 50.' [0618]
Compound (8-10) can be produced, for example, by subjecting compound (142) to a cyclization reaction.
This reaction is performed in the same manner as in the production method of compound (8-1) in Reaction Scheme 18.
[0619]
<Reaction Scheme 51>
[0620] .
Figure imgf000209_0001
Figure imgf000209_0002
Figure imgf000209_0003
[0621]
wherein each symbol is as defined above.
[0622]
Compound (136-1) can be produced, for example, by subjecting compound (135) to a protection reaction.
The protection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0623]
Compound (137-1) can be produced, for example, by subjecting compound (136-1) to a reduction reaction.
This reaction is performed in the same manner as in the production - method of compound (137) in Reaction Scheme 50.
[0624] Compound (138-1) can be produced, for example, by
reacting compound (7) with an alkyl metal in an inert solvent to convert the halogen atom of compound (7) to a metal atom, and then reacting the resulting compound with compound (137-1) .
This reaction is performed in the same manner as in the production method of compound (60) in Reaction Scheme 18.
[0625]
Compound (139-1) can be produced, for example, by
subjecting compound (138-1) to an oxidation reaction.
This reaction is performed in the same manner as in the method using "oxidation reaction", from among the production methods of compound (139) in Reaction Scheme 50.
[0626]
Compound (139-1) can also be produced, for example, by reacting compound (7) with an alkyl metal in an inert solvent to convert the halogen atom of compound (7) to a metal atom, and then reacting the resulting compound with compound (136-1) .
This reaction is performed in the same manner as in the production method of compound (60) in Reaction Scheme 18.
[0627]
Compound (140-1) can be produced, for example, by
reacting compound (137-1) with an organic metal reagent
corresponding to R9 in an inert solvent.
This reaction is performed in the same manner as in the method using "organic metal reagent", from among the
production methods of compound (140) in Reaction Scheme 50.
[0628]
Compound (140-1) can also be produced, for example, by subjecting compound (137-1) to a perfluoroalkylation reaction.
This reaction is performed in the same manner as in the method using "perfluoroalkylating agent", from among the
production methods of compound (140) in Reaction Scheme 50.
[0629]
Compound (141-1) can be produced, for example, by
reacting compound (136-1) with an organic metal reagent corresponding to R9 in an inert solvent.
This reaction is performed in the same manner as in the production method of compound (4-3) in Reaction Scheme 14.
[0630]
Compound (141-1) can also be produced, for example, by subjecting compound (140-1) to an oxidation reaction.
This reaction is performed in the same manner as in the "oxidation reaction", from among the production methods of compound (139) in Reaction Scheme 50.
[0631]
Compound (142-1) can be produced, for example, by
reacting compound (7) with an alkyl metal in an inert solvent to convert the halogen atom of compound (7) to a metal atom, and then reacting the resulting compound with compound (141-1).
This1 reaction is performed in the same manner as in the production method of compound (60) in Reaction Scheme 18.
[0632]
Compound (142-1) can also be produced, for example, by reacting compound (139-1) with an organic metal reagent
corresponding to R9 in an inert solvent..
This reaction is performed in the same manner as in the method using "organic metal reagent", from among the
production methods of compound (140) in Reaction Scheme 50.
[0633]
Compound (142-1) can also be produced, for example, by subjecting compound (139-1) to a perfluoroalkylation reaction.
This reaction is performed in the same manner as in the method using "perfluoroalkylating agent", from among the
production methods of compound (140) in Reaction Scheme 50.
[0634]
Compound (143) can be produced, for example, by
subjecting compound (14.2) to a cyclization reaction.
This reaction is performed in the same manner as in the production method of compound (8-1) in Reaction Scheme 18.
[0635] Compound (144) can be produced, for example, by
subjecting compound (143) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, .for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0636]
Compound (145) can be produced, for example, by
subjecting compound (10) to a substitution reaction with compound (144) .
This reaction is performed in the same manner as in the production method of compound (2-1) in Reaction Scheme 4.
[0637]
Compound (146) can be produced, for example, by
subjecting compound (145) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the. like.
[0638]
Compound (147) can be produced, for example, by
subjecting compound (146) to an acylation reaction.
This reaction is performed in the same manner as in the production method of compound (1-1) in Reaction Scheme 2.
[0639]
Compound (148) can be produced, for example, by
subjecting compound (145) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in
Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0640]
Compound (149) can be produced, for example, by
subjecting compound (148) to an acylation reaction.
This reaction is performed in the same manner as in the production method of compound (1-1) in Reaction Scheme 2.
[0641]
Compound (149) can also be produced, for example, by subjecting compound (147) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0642]
Compound (150) can be produced, for example, by
subjecting compound (145) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0643]
Compound (151) can be produced, for example, by
subjecting compound (150) to an alkylation reaction.
This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0644]
Compound (152) can be produced, for. example, by
subjecting compound (151) to a deprotection reaction.
The deprotection reaction can be performed according to a method known per se, for example, the method described in Protective Groups. in Organic Synthesis, John Wiley and Sons (1980) or the like.
[0645]
Compound (153) can be produced, for example, by
subjecting compound (152) to an acylation reaction.
This reaction is performed in the same manner as in the production method of compound (1-1) in Reaction Scheme 2.
[0646]
Compound (153) can also be produced, for example, by subjecting compound (149) to an alkylation reaction. This reaction is performed in the same manner as in the production method of compound (I) in Reaction Scheme 1.
[0647]
<Reaction Scheme 52>
[0648]
Figure imgf000214_0001
59 154 0 1
[0649]
wherein each symbol is as defined above.
Compound (154) can be produced, for example, by
subjecting compound (59) to a reduction reaction.
This reaction is performed in the same manner as in the production method of compound (137) in Reaction Scheme 50.
[0650]
Compound (61) can be produced, for example, by reacting compound (7) with an alkyl metal in an inert solvent to convert the halogen atom of compound (7) to a metal atom, and then reacting the resulting compound with compound (154).
This reaction is performed in the same manner as in the production method of compound (60) in Reaction Scheme 18.
[0651]
In compound (I) thus obtained, a functional group in a molecule can also be converted to a desired functional group by a combination of chemical reactions known per se. Examples of the chemical reaction include oxidation reaction, reduction reaction, alkylation reaction, acylation reaction, ureation reaction, hydrolysis reaction, amination reaction,
esterification reaction, aryl coupling reaction, deprotection reaction and the like.
[0652]
Compound (I) obtained by the above-mentioned production methods can be isolated and purified according to a known means, for example, solvent extraction, liquid conversion, phase transfer, crystallization, recrystallization,
chromatography and the like.
[0653]
When compound (I) contains an optical isomer, a
stereoisomer, a regioisomer or a rotamer, these are also encompassed in compound (I) , and can be obtained as a single product according to synthesis and separation methods known per se . For example, when compound (I) contains an optical isomer, an optical isomer resolved from this compound is also encompassed in compound (I) .
The optical isomer can be produced according to a method known per se.
[0654]
Compound (I) may be a crystal.
Crystals of compound (I) (hereinafter sometimes to be abbreviated as the crystals of the present invention) can be produced according to crystallization methods known per se .
In the present specification, the melting point means that measured using, for example, a micromelting point apparatus (Yanako, P-500D or Buchi, B-545) , a DSC
(differential scanning calorimetry) device (SEIKO, EXSTAR6000) or the like.
In general, the melting points vary depending on the measurement apparatuses, the measurement conditions and the like. The crystal in the present specification may show different values from the melting point described in the present specification, as long as they are within each of a general error range.
The crystal of the present invention is superior in physicochemical properties (e.g., melting point, solubility, stability) and biological properties (e.g., pharmacokinetics (absorption, distribution, metabolism, excretion) , efficacy expression) ,· and thus it is extremely useful as a medicament. Examples [0655]
The present invention is explained in detail in the following by referring to Examples, Experimental Examples and Formulation Examples, which are not to be construed as limitative, and the invention may be changed within the scope of the present invention. .
In the following Examples, the "room temperature" generally means about 10°C to about 35°C. The ratios indicated for mixed solvents are volume mixing ratios, unless otherwise specified. % means wt%, unless otherwise specified.
In silica gel column chromatography, NH means use of aminopropylsilane-bound silica gel. In HPLC (high performance liquid chromatography) , CI8 means use of octadecyl-bound silica gel. The ratios of elution solvents are volume mixing ratios, unless otherwise specified.
[0656]
In .the following Examples, the following abbreviations are used,
mp: melting point
THF: tetrahydrofuran
DMF: N, N-dimethylformamide
WSC: l-ethyl-3- ( 3-dimethylaminopropyl) carbodiimide
hydrochloride
HOBt : 1-hydroxybenzotriazole monohydrate
HATU: N-[ (dimethylamino) (3H- [1, 2, 3] triazolo [4, 5-b] pyridin-3- yloxy) methylidene] -N-methylmethanaminium hexafluorophosphate [0657]
1H NMR (proton nuclear magnetic resonance spectrum), was measured by Fourier-transform type NMR. For the analysis, ACD/SpecManager (trade name) and the like were used. Peaks with very mild protons such as hydroxyl group, amino group and the like are not described.
Other abbreviations used in the specification mean the following.
s: singlet d: doublet
t: triplet
q: quartet
m: multiplet
br : broad
J: coupling constant
Hz: hertz
CDC13: deuterated chloroform
DMSO-d6: d6~dimethyl sulfoxide
1H-NMR: proton nuclear magnetic resonance
TFA: trifluoroacetic acid
[0658]
MS (mass spectrum) was measured by LC/MS (liquid
chromatography mass spectrometer) . As the ionization method, ESI (ElectroSpray Ionization) method, or APCI (Atomospheric Pressure Chemical Ionization) method was used. The data indicates those found. Generally, a molecular ion peak is observed. In the case of a compound having a tert- butoxycarbonyl group (-Boc) , a peak after elimination of a tert-butoxycarbonyl group or tert-butyl group may be observed as a fragment ion. In the case of a compound having a hydroxyl group (-OH) , a peak after elimination of H20 may be observed as a fragment ion. In the case of a salt, a molecular ion peak or fragment ion peak of free form is generally observed.
The unit of reagent concentration (c) in optical rotation
( [ a] D ) is g/100 mL.
The elemental analysis value (Anal.) shows Calculated (Calcd) and Found.
[0659]
Example 1
N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) -1-methylethyl] acetamide
[0660]
A) 6- (cyclopropylmethoxy) -1, 3-benzoxazole
A mixture of 1, 3-benzoxazol-6-ol (2.31 g), (bromomethyl) cyclopropane (3.46 g) , potassium carbonate (3.54 g) and DMF (25 mL) was stirred at 60°C for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound (2.88 g) .
XH NMR (300 MHz, DMSO-d6) 50.23-0.41 (2H, m) , 0.51-0.66 (2H, m) , 1.18-1.37 (1H, m) , 3.88 (2H, d, J = 7.2 Hz), 6.99 (1H, dd, J = 8.7, 2.3 Hz), 7.35 (1H, d, J = 2.3 Hz), 7.65 (1H, d, J = 8.7 Hz), 8.58 (1H, s) .
[0661]
B) tert-butyl { (IS) -2- [ (6-bromopyridin-3-yl) oxy] -1- methylethyl } carbamate
To a solution of 6-bromopyridin-3-ol (4.90 g) , tert-butyl [ (IS) -2-hydroxy-l-methylethyl] carbamate (4.93 g) and
triphenylphosphine (11.06 g) in THF (100 mL) was added
dropwise a toluene solution (1.9 M, 22 mL) of diisopropyl azodicarboxylate, and the mixture was stirred at room
temperature for 3 hr. To the reaction mixture was added ethyl acetate, and the mixture was washed with. water and saturated aqueous sodium hydrogen carbonate solution, dried over
anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (5.35 g) .
XH NMR (300 MHz, DMSO-d6) δ 1.11 (3H, d, J = 6.4 Hz), 1.37 (9H, s), 3.73-4.00 (2H, m) , 4.69-5.01 (1H, m) , 6.90 (1H, d, J = 7.6 Hz), 7.39 (1H, dd, J = 8.7, 3.0 Hz), 7.53 (1H, d, J = 8.7 Hz), 8.11 (1H, d, J = 3.0 Hz) .
[0662]
C) tert-butyl [ (IS) -2- ({ 6- [ 6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] pyridin-3-yl } oxy) -1-methylethyl] carbamate
A mixture of 6- (cyclopropylmethoxy) -1, 3-benzoxazole (500 mg) , tert-butyl { ( IS) -2- [ ( 6-bromopyridin-3-yl) oxy] -1- methylethyl } carbamate (1.31 g) , palladium ( II ) acetate "(29 mg) , butyldi (l-adamantyl)phosphine (93 mg) , tripotassium phosphate (1.12 g) and N-methylpyrrolidone (12 mL) was stirred under an argon atmosphere at 125°C for 15 hr. The reaction mixture was allowed to cool to room temperature, and filtered through celite. The filtrate was diluted with ethyl acetate and water, and the organic layer was separated. The combined organic layer was washed with saturated brine, and dried over
anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (400 mg) .
¾ NMR (300 MHz, DMSO-d6) δ 0.31-0.40 (2H, m) , 0.53-0.67 (2H, m) , 1.15 (3H, d, J = 6.4 Hz), 1.21-1.32 (1H, m) , 1.38 (9H, s) , 3.81-3.96 (3H, m) , 3.96-4.13 (2H, m) , 6.96 (1H, d, J = 7.6 Hz), 7.02 (1H, dd, J = 8.7, 2.3 Hz), 7,.39 (1H, d, J = 2.3 Hz), 7.61 (1H, dd, J = 9.0, 2.7 Hz), 7.68 (1H, d, J = 8.7 Hz), 8.20 (1H, d, J = 9.0 Hz), 8.45 (1H, d, J = 2.7 Hz).
MS (ESI+) : [M+H]+ 440.5.
[0663]
D) N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) -1-methylethyl] acetamide
To a solution of tert-butyl [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl]pyridin-3-yl}oxy) -1- methylethyl] carbamate (350 mg) in ethyl acetate (20 mL) was added 4M hydrogen chloride/ethyl acetate (10 mL) , and the mixture was stirred at room temperature for 2 hr. The solvent was evaporated under reduced pressure, and the residue was dissolved in pyridine (15 mL) . Acetic anhydride (163 mg) was added thereto, and the mixture was stirred at room temperature for 15 hr. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl- acetate/methanol) , and recrystallized (hexane/ethyl acetate) to give the title compound (201 mg) . ΧΗ NMR (300 MHz, DMSO-d6) δ 0.29-0.43 (2H, m) , 0.53-0.67 (2H, m) , 1.18 (3H, d, J = 6.4 Hz), 1.21-1.38 (1H, m) , 1.83 (3H, s) ,
3.91 (2H, d, J = 6.8 Hz), 3.98-4.06 (1H, m) , 4.06-4.21 (2H, m) ,
7.02 (1H, dd, J = 8.8, 2.3 Hz), 7.39 (1H, d, J = 2.3 Hz), 7.63 (1H, dd, J = 8.8, 2.7 Hz), 7.68 (1H, d, J = 8.8 Hz), 7.99 (1H, d, J = 7.5 Hz), 8.21 (lH, d, J = 8.8 Hz), 8.47 (1H, d, J = 2.7
Hz) .
mp 179-180 °C
Anal. Calcd for C21H23N3O4 : C, 66.13; H, 6.08; N, 11.02. Found: C, 66.09; H, 6.18; N, 11.02.
[0664]
Example 2
N- [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl }oxy) -1-methylethyl] acetamlde
[0665]
A) methyl 3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) isoxazole-5-carboxylate
' o a solution of methyl 3-hydroxyisoxazole-5-carboxylate (20 g) , tert-butyl [ (IS) -2-hydroxy-l-methylethyl] carbamate (25 g) and triphenylphosphine (55.1 g) in THF (800 mL) was added dropwise a toluene solution (1.9 M, 110 mL) of diisopropyl azodicarboxylate, and the mixture was refluxed for 5 hr. The reaction mixture was allowed to cool to room temperature, and ethyl acetate was added thereto. The mixture was washed with water and saturated aqueous sodium hydrogen carbonate solution, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (25 g) .
lR NMR (300 MHz, DMSO-d6) δ 1.09 (3H, d, J = 6.8 Hz), 1.37 (9H, s), 3.77-3.93 (4H, m) , 4.11 (2H, d, J = 6.4 Hz), 6.94 (1H, d, J = 8.0 Hz) , 7.08 (1H, s) .
[0666]
B) 3-({ (2S)-2-[ (tert- butoxycarbonyl) amino] propyl } oxy) isoxazole-5-carboxylic acid 2M Aqueous sodium hydroxide solution (20 mL) was added to a solution of methyl 3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) isoxazole-5-carboxylate (4.0. g) in THF/methanol (20 mL/20 mL) , and the mixture was stirred at room temperature for 15.hr. The solvent was evaporated under reduced pressure, and the residue was neutralized with 6M hydrochloric acid and extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium . sulfate, and the solvent was evaporated under reduced pressure to give the title compound (3.5 g) .
MS (ESI+) : [M+H]+ 287.2.
[0667]
C) tert-butyl [ (IS) -2- ( {5- [ (2, 5- dihydroxyphenyl) carbamoyl] isoxazol-3-yl}oxy) -1- methylethyl] carbamate
To a solution of 3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) isoxazole-5-carboxylic acid (1.5 g) , 2-aminobenzene-l, 4-diol hydrochloride (0.847 g) and HATU (1.99 g) in DMF (20 mL) was added N,N- diisopropylethylamine (1.80 mL) , and the mixture was stirred at room temperature for 5 hr. The solvent was evaporated under reduced pressure, 0.1M hydrochloric acid was added thereto, and the mixture was extracted with ethyl acetate. The combined - organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (hexane/ethyl acetate) to give the title
compound (1.11 g).
1H NMR (300 MHz, DMSO-d6) δ 1.10 (3H, d, J = 6.8 Hz), 1.38 (9H, s), 3.81-3.93 (lH, m), 4.11 (2H, d, J = 6.0 Hz), 6.46 (1H, dd, J = 8.7, 2.6 Hz), 6.73 (1H, d, J = 8.7 Hz), 6.88-7.08 (2H, m) , 7.27 (1H, d, J = 2.6 Hz), 8.90 (1H, s) , 9.27 (1H, brs) , 9.45 (1H, brs) .
[0668] D) tert-butyl [ (IS) -2-{ [5- (5-hydroxy-l, 3-benzoxazol-2- yl) isoxazol-3-yl] oxy} -1-methylethyl] carbamate
Triethylamine (2.83 mL) was added to a solution of triphenylphosphine (2.0 g) and hexachloroethane (1.5 g) in acetonitrile (25 mL) , and the mixture was stirred at room temperature for 20 min. To the reaction mixture was further added a solution of tert-butyl [ ( IS) -2- ( { 5- [ (2 , 5- dihydroxyphenyl) carbamoyl] isoxazol-3-yl } oxy) -1- methylethyl] carbamate (1.0 g) in acetonitrile (5 mL) , and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound (503 mg) . XH N R (300 MHz, DMSO-d6) δ 1.11 (3H,'d, J = 6.8 Hz), 1.38 (9H, s), 3.76-3.99 (1H, m) , 4.16 (2H, d, J = 6.0 Hz), 6.96 (1H, d, J = 2.3 Hz), 6.99 (1H, d, J = 2.6 Hz), 7.16 (1H, d, J = 2.3 Hz) ,.7.21 (1H, s) , 7.66 (1H, d, J = 9.1 Hz) , 9.76 (1H, s) .
[0669]
E) tert-butyl [ ( IS) -2- ( { 5- [ 5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] isoxazol-3-yl}oxy) -1-methylethyl] carbamate
(Bromomethyl ) cyclopropane (0.388 mL) was added to a mixture of tert-butyl [ (IS) -2-{ [5- (5-hydroxy-l, 3-benzoxazol-2- yl) isoxazol-3-yl] oxy} -1-methylethyl] carbamate (500 mg) , potassium carbonate (552 mg) and DMF (13 mL) , and the mixture was stirred at 60°C for 5 hr. The solvent was evaporated under reduced pressure, water was added thereto, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was washed with hexane-ethyl acetate to give the title compound (510 mg) .
XH NMR (300 MHz, DMSO-d6) δ 0.30-0.39 (2H, m) , 0.54-0.65 (2H, m) , 1.12 (3H, d, J = 6.8 Hz), 1.21-1.30 (1H, m) , 1.38 (9H, s) ,
3.84-3.97 (3H, m) , 4.17 (2H, d, J = 6.1 Hz), 6.97 (1H, d, J =
8.0 Hz), 7.14 (1H, dd, J = 8.9, 2.5 Hz), 7.23 (1H, s) , 7.40
(1H, d, J = 2.3 Hz), 7.76 (1H, d, J = 9.1 Hz).
[0670]
F) N- [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl }oxy) -1-methylethyl] acetamide
To a solution of tert-butyl [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] isoxazol-3-yl } oxy) -1- methylethyl] carbamate (510 mg) in ethyl acetate (11 mL) was added 4M hydrogen chloride/ethyl acetate (12 mL) , and the mixture was stirred at room temperature for 5 hr. The solvent was evaporated under reduced pressure, and the residue was dissolved in pyridine (1.5 mL) . Acetic anhydride (1.5 mL) was added thereto, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate/methanol) , and
recrystallized (hexane/ethyl acetate) to give the title
compound (182 mg) .
XH NMR (300 MHz, DMS0-d6) δ 0.29-0.42 (2H, m) , 0.54-0.66 (2H, m) , 1.15 (3H, d, J = 6.4 Hz), 1.20-1.31 (1H, m) , 1.82 (3H, s) , 3.90 (2H, d, J = 7.2 Hz), 4.08-4.31 (3H, m) , 7.14 (1H, dd, J = 9.1, 2.3 Hz), 7.25 (1H, s) , 7.40 (1H, d, J = 2.3 Hz), 7.76 (1H, d, J = 8.7 Hz), 8.00 (1H, d, J = 6.4 Hz),
mp 156-157 °C
Anal. Calcd for C19H22 3O5: C, 61.28; H, 5.95; N, 11.28. Found: C, 61.49; H, 5.76; N, 11.14.
[0671]
Example 3
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] phenoxy} -1-methylethyl] acetamide
[0672]
A) methyl 4- { [ (2S) -2- (acetylamino) propyl] oxy}benzoate
To a solution of methyl 4-hydroxybenzoate (4.77 g) , tert- butyl [( IS) -2-hydroxy-l-methylethyl] carbamate (5.00 g) and triphenylphosphine (11.2 g) in THF (70 mL) was added dropwise a toluene solution (2.2 M, 20 mL) of diethyl azodicarboxylate, and the mixture was stirred at room temperature for 1 hr. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate) . Using the obtained residue, and in the same manner as in Example 1, step D, the title compound (3.80 g) was obtained.
XH NMR (300 MHz, CDC13) δ 1.32 (3H, d, J = 6.8 Hz), 2.00 (3H, s), 3.89 (3H, s), 3.95-4.09 (2H, m) , 4.32-4.49 (1H, m) , 5.68 (1H, d, J = 7.6 Hz), 6.93 (2H, d, J = 9.1 Hz), 7.99 (2H, d, J = 9.1 Hz).
[0673]
B) 4-{ [ (2S) -2- (acetylamino) propyl] oxy}benzoic acid
1M Aqueous sodium hydroxide solution (23 mL) was 'added to a solution (7 mL) of methyl 4-{[(2S)-2-
(acetylamino) propyl] oxy}benzoate (3.80 g) in methanol, and the mixture was stirred at 60°C for 40 min. The reaction mixture was neutralized with 6M hydrochloric acid, and extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was washed with diisopropyl ether, and the
precipitated solid was collected by filtration to give the title compound (3.33 g) .
¾ NMR (300 MHz, DMSO-d6) δ 1.15 (3H, d, J = 6.8 Hz), 1.81 (3H, s), 3.78-4.20 (3H, m) , 7.02 (2H, d, J = 9.1 Hz), 7.87 (2H, d, J = 9.1 Hz), 7.95 (1H, d, J = 7.6 Hz), 12.63 (1H, brs) .
[0674]
C) 4-{ [ (2S) -2- (acetylamino) propyl] oxy}-N- (2, 4- dihydroxyphenyl) benzamide
Using 4- {[ (2S) -2- (acetylamino) propyl] oxy}benzoic acid and 4-aminobenzene-l, 3-diol hydrochloride, and in the same manner as in Example 2, step C, the title compound was obtained. XH NMR (300 MHz, DMSO-d6) δ 1.16 (3H, d, J = 6.8 Hz), 1.82 (3H, s), 3.82-3.93 (1H, m) , 3.96-4.05 (1H, m) , 4.06-4.20 (1H, m) ,
6.23 (1H, dd, J = 8.3, 2.7 Hz), 6.35 (1H, d, J = 2.7 Hz), 7.05
(2H, d, J = 9.1 Hz), 7.24 (1H, d, J = 8.3 Hz), 7.82-8.02 (3H, m) , 9.36 (1H, s) .
[0675]
D) N-{ (IS) -2- [4- ( 6-hydroxy-l, 3-benzoxazol-2-yl) phenoxy] -1- methylethyl } acetamide
To a solution of 4-{ [ (2S) -2- (acetylamino) propyl] oxy}-N- (2, 4-dihydroxyphenyl) benzamide (628 mg) and triphenylphosphine (716 mg) in THF (6.0 mL) was added dropwise a toluene solution (2.2 M, 1.24 mL) of diethyl azodicarboxylate, and the mixture was stirred under a nitrogen atmosphere at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (NH, ethyl acetate/methanol) to give the title compound (326 mg) .
XH NMR (300 MHz, DMSO-d6) δ 1.17 (3H, d, J = 6.8 Hz), 1.82 (3H, s), 3.84-4.22 (3H, m) , 6.82 (1H, dd, J = 8.3, 2.3 Hz), 7.06 (1H,, d, J = 2.3 Hz), 7.14 (2H, d, J = 8.7 Hz), 7.52 (1H, d, J = 8.3 Hz), 7.96 (1H, d, J = 7.6 Hz), 8.04 (2H, d, J = 9.1 Hz), 9.79 (1H, s) .
[0676]
E) N- [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] phenoxy} -1-methylethyl] acetamide
Using N- {( IS) -2- [4- ( 6-hydroxy-l, 3-benzoxazol-2- yl) phenoxy] -1-methylethyl} acetamide, and in the same manner as in Example 1, step A, the title compound was obtained.
[0677]
Example 4
N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -5- methylpyridin-3-yl } oxy) -1-methylethyl] acetamide
[0678]
A) tert-butyl { ( IS ) -2- [ ( 6-bromo-5-methylpyridin-3-yl ) oxy] -1- methylethyl } carbamate Under an argon atmosphere, to a solution of 2,5-dibromo- 3-methylpyridine (12.4 g) in THF (100 mL) was added dropwise a hexane solution (1.6 M, 30.9 mL) of n-butyllithium at -78°C, and the obtained mixture was stirred at -78°C for 30 min. To the reaction mixture was added trimethoxyborane (5.52 mL) , and the obtained mixture was stirred at -78°C for 30 min, then at 0°C for 1 hr. To the reaction mixture were added 8 aqueous sodium hydroxide solution (6.18 mL) and aqueous 30% hydrogen peroxide (100 mL) , and the obtained mixture was stirred at 0°C for 30 min, then at room temperature for 30 min. The reaction mixture was acidified with 1M hydrochloric acid, and extracted with ethyl acetate. The combined organic layer was washed with saturated aqueous sodium thiosulfate solution and then
saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) , and the obtained residue was mixed with tert-butyl [ (IS) -2-hydroxy-l-methylethyl] carbamate (4.43 g) , triphenylphosphine (6.63 g) and THF (40 mL) . A toluene solution (1.9 M, 13.3 mL) of diisopropyl azodicarboxylate was added dropwise thereto, and the obtained mixture was stirred at room temperature for 1 hr, then at 70°C overnight. Water was added to the reaction mixture, and the mixture was
extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) and HPLC (C18, mobile phase: water/acetonitrile (containing 5 mM ammonium acetate)) to give the title compound (0.739 g) .
XH NMR (300 MHz, DMSO-d6) δ 1.11 (3H, d, J = 6.8 Hz), 1.37 (9H, s) , 2.30 (3H, s) , 3.72-4.00 (3H, m) , 6.91 (1H, d, J = 7.2 Hz) , 7.36-7.52 (1H, m) , 7.94 (1H, d, J = 3.0 Hz).
[0679]
B) tert-butyl [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -5-methylpyridin-3-yl } oxy) -1- methylethyl] carbamate
Using tert-butyl { (IS) -2- [ ( G-bromo^S-methylpyridin-S- yl) oxy] -1-methylethyl} carbamate, and in the same manner as in Example 1, step C, the title compound was obtained.
MS (ESI+) : [M+H]+ 454.5.
[0680]
C) N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1 , 3-benzoxazol-2-yl] - 5-methylpyridin-3-yl } oxy) -1-methylethyl] acetamide
Using tert-butyl [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -5-methylpyridin-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0681]
Example 5
N- [ (IS) -2- ( { 5-chloro-6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-
2-yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide
[0682]
A) 5-bromo-3-chloro-N- (2, 4-dihydroxyphenyl) pyridine-2- carboxamide
Using 5-bromo-3-chloropyridine-2-carboxylic acid and 4- aminobenzene-1, 3-diol hydrochloride, and in the same manner as in Example 2, step C, the title compound was obtained.
1H NMR (300 MHz, DMSO-d6) δ 6.24 (1H, dd, J = 8.7, 2.6 Hz), 6.40 (1H, d, J = 2.6 Hz), 7.83 (1H, d, J = 8.7 Hz), 8.49 (1H, d, J = 1.9 Hz), 8.78 (1H, d, J = 1.9 Hz), 9.21 (1H, s) , 9.82
(lH, s) , 9.90 (1H, s) .
[0.683]
B) 2- ( 5-bromo-3-chloropyridin-2-yl ) -6- (cyclopropylmethoxy) - 1, 3-benzoxazole
Using 5-bromo-3-chloro-N- (2, 4-dihydroxyphenyl) pyridine-2- carboxamide, and in the same manner as in Example 2, steps D-E, the title compound was obtained.
XH NMR (300 MHz, DMSO-d6) δ 0.25-0.43 (2H, m)„ 0.54-0.70 (2H, m) , 1.16-1.39 (1H, m) , 3.93 (2H, d, J = 6.8 Hz), 7.07 (1H, dd, J = 8.8, 2.3 Hz), 7.44 (1H, d, J = 2.3 Hz), 7.79 (1H, d, J =
8.8 Hz) , 8.62 (1H, d, J = 2.1 Hz) , 8.90 (1H, d, J = 2.1 Hz) .
[0684]
C) N- [ (IS) -2- ( {5-chloro-6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide
Under an argon atmosphere, to a solution of 2- (5-bromo-3- chloropyridin-2-yl) -6- (cyclopropylmethoxy) -1, 3-benzoxazole (300 mg) and trimethoxyborane (0.177 mL) in THF (5 mL) was added dropwise a hexane solution (1.6 M, 1.23 mL) of n- butyllithium at 0°C, and the obtained mixture was -stirred at 0°C for .1 hr. To the reaction mixture was added 1
hydrochloric acid, and, the mixture was extracted with ethyl acetate.. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was mixed with 30% aqueous hydrogen peroxide (1 mL) and THF (5 mL) , and the obtained mixture was stirred at 70°C for 2 hr. To the reaction mixture were added water and saturated aqueous sodium thiosulfate solution, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was mixed with tert-butyl [ ( IS) -2-hydroxy-l- methylethyl] carbamate (138 mg) , triphenylphosphine (207 mg) and THF (5 mL) . A toluene solution (1.9 M, 0.416 mL) of
diisopropyl azodicarboxylate was added dropwise thereto, and the mixture was stirred at room temperature for 1 hr, then at 70°C for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) , and mixed with ethyl acetate (2 mL) and 4 hydrogen chloride/ethyl acetate (2 mL) . The obtained mixture was stirred at room temperature for 3 hr. The solvent was evaporated under reduced pressure, and the residue was mixed with pyridine (2 mL) and acetic
anhydride (2 mL) , and the obtained mixture was stirred at room temperature . for 2 hr. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate/methanol) to give the title compound (22.2 mg) .
[0685]
Example 6
N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -5- fluoropyridin-3-yl } oxy) -1-methylethyl] acetamide
[0686]
A) 6-chloro-5-fluoropyridin-3-ol
Under an argon atmosphere, to a mixture of 5-bromo-2- chloro-3-fluoropyridine (4.45 g) and toluene (50 mL) was added dropwise a hexane solution (1.6 M, 15.8 mL) of n-butyllithium at -78°C, and the obtained mixture was stirred at -78°C for 5 min. To the reaction mixture was added trimethoxyborane (2.84 mL) , and the obtained mixture was stirred at -78°C for 15 min, and then at room temperature overnight. The reaction mixture was cooled to 0°C, 8 aqueous sodium hydroxide solution (3.17 mL) and 30% aqueous hydrogen peroxide (20 mL) were added thereto, and the obtained mixture was stirred at room
temperature for 2 hr. The reaction mixture was cooled to 0°C, and saturated aqueous sodium thiosulfate solution was added thereto. The mixture was neutralized with 1 hydrochloric acid, and extracted with ethyl acetate. The combined organic layer was washed with water and saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (2.20 g) .
XH NMR (300 MHz, DMSO-d6) δ 7.32 (1H, dd, J = 10.2, 2.3 Hz), 7.85 (1H, d, J = 2.3 Hz), 10.77 (1H, s) .
[0687] B) tert-butyl { (IS) -2- [ ( 6-chloro-5-fluoropyridin-3-yl) oxy] -1- methylethyl } carbamate
To a mixture of .6-chloro-5-fluoropyridin-3-ol (2.43 g) , tert-butyl [ (IS) -2-hydroxy-l-methylethyl] carbamate (3.46 g) , triphenylphosphine (6.48 g) and THF (25 mL) was added dropwise a toluene solution (1.9 M, 13.0 mL) of diisopropyl
azodicarboxylate at room temperature, and the obtained mixture was stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound (2.88 g) . ¾ NMR (300 MHz, DMS0-d6) δ 1.11 (3H, d, J = 6.8 Hz) , 1.37 (9H, s), 3.69-4.19 (3H, m) , 6.92 (1H, d, J = 7.5 Hz), 7.72 (1H, dd, J = 10.5, 2.5 Hz) , 8.04 (1H, d, J = 2.5 Hz).
[0688]
C) ethyl 5- ( { (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) -3- fluoropyridine-2-carboxylate
Under a carbon monoxide atmosphere, a mixture of tert- butyl { (IS) -2- [ ( 6-chloro-5-fluoropyridin-3-yl) oxy] -1- methylethyl} carbamate (500 mg) , [1,1'- bis (diphenylphosphino) ferrocene] dichloropalladium ( II )
dichloromethane adduct (135 mg) , triethylamine (0.229 mL) , ethanol (5 mL) and DMF (5 mL) was stirred at 80°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (402 mg) .
MS (ESI+) : [M+H]+ 343.3.
[0689]
D) 5- ( { (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) -3- fluoropyridine-2-carboxylic acid
A mixture of. ethyl 5- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl }oxy) -3-fluoropyridine-2- carboxylate (402 mg) , THF (4 mL) , ethanol (4 mL) and 1M aqueous lithium hydroxide solution (4 mL) was stirred at 0°C for 3 nr.- The reaction mixture was neutralized with 1M hydrochloric acid at 0°C, and extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (357 mg) .
MS (ESI+) : [M+H]+ 315.2.
[0690]
E) tert-butyl [ (IS) -2- ( { 6- [ (2, 4-dihydroxyphenyl) carbamoyl] -5- fluoropyridin-3-yl } oxy) -1-methylethyl] carbamate
A mixture of 5- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) -3-fluoropyridine-2-carboxylic acid (357 mg) , 4-aminobenzene-l , 3-diol hydrochloride (184 mg) , HATU (432 mg) , N, N-diisopropylethylamine (0.391 mL) and DMF (5 mL) was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound (321 mg) . MS (ESI+) : [M+H]+ 422.3.'
[0691]
F) tert-butyl [ (IS) -2- ( { 6- [ 6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate
Triethylamine (0.849 mL) was added to a solution of triphenylphosphine (599 mg) and hexachloroethane (451 mg) in acetonitrile (5 mL) at room temperature, and the obtained mixture was stirred at room temperature for 10 min. To the reaction mixture was further added a mixture of tert-butyl
[ (IS) -2- ( { 6- [ (2, -dihydroxyphenyl) carbamoyl] -5-fluoropyridin- 3-yl }oxy) -1-methylethyl] carbamate (321 mg) and acetonitrile (5 mL) , and the mixture was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) , and the obtained residue (305 mg) was mixed with (bromomethyl) cyclopropane (204 mg) , potassium carbonate (209 mg) and DMF (5 mL) at room
temperature. The obtained mixture was stirred at room
temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (101 mg) .
MS (ESI+) : [M+H]+ 458.2.
[0692]
G) N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] - 5-fluoropyridin-3-yl}oxy) -1-methylethyl] acetamide
A mixture of tert-butyl [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -5-fluoropyridin-3- yl } oxy) -1-methylethyl] carbamate (101 mg) , 4M hydrogen
chloride/ethyl acetate (1 mL) and ethyl acetate (1 mL) was stirred at room temperature for 2 hr. The solvent was
evaporated under reduced pressure, and the residue was mixed with acetic anhydride (1 mL) and pyridine (1 mL) , and the obtained mixture was stirred at room temperature for 1 hr. To the reaction mixture was added 1M hydrochloric acid, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over
anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate/methanol) , and recrystallized (hexane/ethyl acetate) to give the title
compound (53.1 mg) .
1H NMR (300 MHz, DMSO-d6) δ 0.29-0.43 (2H, m) , 0.53-0.68 (2H, m) , 1.11-1.38 (4H, m) , 1.83 (3H, s) , 3.91 (2H, d, J = 7.2 Hz), 3.98-4.24 (3H, m) , 7.03 (1H, dd, J = 8.9, 2.4 Hz), 7.41 (1H, d, J = 2.4 Hz), 7.66-7.81 (2H, m) , 8.02 (1H, d, J = 7.2 Hz),
8.29-8.44 (1H, m) .
mp 158-159 °C
Anal. Calcd for C2iH22 304F: C, 63.15; H, 5.55; N, 10.52. Found: C, 63.13; H, 5.65; N, . 10.31.
[0693]
Example 7
N- [ (IS) -2- ( { 5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl }oxy) -1-methylethyl] acetamide
[0694]
Using 3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) isoxazole-5-carboxylic acid and 4-aminobenzene-l, 3-diol hydrochloride, and in the same manner as in Example 2, steps C-F, the title compound was obtained.
[0695]
Example 8
N- [ (IS) -2- ({5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -1H- pyrazol-3-yl }oxy) -1-methylethyl] acetamide
[0696]
A) methyl 3- ({ (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) - lH-pyrazole-5-carboxylate
Using methyl 3-hydroxy-lH-pyrazole-5-carboxylate, and in the same manner as in Example 2, step A, the title compound was obtained.
MS (ESI+) : [M+H]+ 300.4.
[0697]
B) methyl l-benzyl-3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) -lH-pyrazole-5-carboxylate Using methyl 3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) -lH-pyrazole-5-carboxylate and (bromomethyl) benzene, and in the same manner as in Example 1, step A (reaction temperature was room temperature) , the title compound was obtained.
MS (ESI+) : [M+H]+ 390.4.
[0698]
C) l-benzyl-3- ({ (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) -lH-pyrazole-5-carboxylic acid Using methyl l-benzyl-3- ({ (2S) -2- [ (tert- butoxycarbonyl ) amino] ropyl } oxy) -lH-pyrazole-5-carboxylate, and in the same manner as in Example 2, step B, the title compound was obtained.
MS (ESI+) : [M+H]+ 376.4.
[0699] . ■ '
D) tert-butyl [ ( IS) -2- ( { l-benzyl-5- [ (2 , 4- dihydroxyphenyl) carbamoyl] -lH-pyrazol-3-yl }oxy) -1- methylethyl] carbamate
Using l-benzyl-3- ({ (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) -lH-pyrazole-5-carboxylic acid, and in the same manner as in Example 5, step A, the title compound was obtained.
MS (ESI+) : [M+H]+ 483.4.
[0700]
E) tert-butyl [ (IS) -2-{ [l-benzyl-5- ( 6-hydroxy-l, 3-benzoxazol- 2-yl) -lH-pyrazol-3-yl] oxy} -1-methylethyl] carbamate
Using tert-butyl [ (IS) -2- ({ l-benzyl-5- [ (2, 4- dihydroxyphenyl) carbamoyl] -lH-pyrazol-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 2, step D, the title compound was obtained.
MS (ESI+) : [M+H]+ 465.4..
[0701]
F) tert-butyl [( IS) -2- ({ l-benzyl-5- [ 6- (cyclopropylmethoxy) - 1, 3-benzoxazol-2-yl] -lH-pyrazol-3-yl}oxy) -1- methylethyl] carbamate - Using tert-butyl [ (IS) -2-{ [l-benzyl-5- ( 6-hydroxy-l, 3- benzoxazol-2-yl) -lH-pyrazol-3-yl] oxy} -1-methylethyl] carbamate, and in the same manner as in Example 2, step E, the title compound was obtained.
MS (ESI+) : [M+H]+ 519.4.
[0702]
G) N- [ (IS) -2- ( {l-benzyl-5- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -lH-pyrazol-3-yl } oxy) -1-methylethyl] acetamide Using tert-butyl [ (IS) -2- ({l-benzyl-5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -lH-pyrazol-3- yl} oxy) -1-methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
MS (ESI+) : [M+H]+ 461.5.
[0703]
H) N- [ (IS) -2- ( {5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] - lH-pyrazol-3-yl } oxy) -1-methylethyl] acetamide
Under a hydrogen atmosphere, a mixture of N- [ ( IS) -2- ( { 1- benzyl-5- [ 6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -1H- pyrazol-3-yl}oxy) -1-methylethyl] acetamide (120 mg) , 20% palladium hydroxide/carbon (containing water (50%), 60 mg) , ethanol (5 mL) and THF (3 mL) was stirred at 50°C for 4 hr. The catalyst was removed by filtration, and the obtained filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (23.4 mg) .
[0704]
Example 9
N- [ (IS) -2- ( { 5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -4- fluoro-lH-pyrazol-3-yl}oxy) -1-methylethyl] acetamide
[0705]
Under a hydrogen atmosphere, a mixture of N- [ (IS) -2- ( { 1- benzyl-5- [ 6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -1H- pyrazol-3-yl } oxy) -1-methylethyl] acetamide (200 mg) , 20% palladium hydroxide/carbon (containing water (50%) , 200 mg) , ethanol (7 mL) and THF (4 mL) was stirred at 50°C for 4 hr. The catalyst was removed by filtration, and the obtained - filtrate was concentrated under reduced pressure. The residue was mixed with acetonitrile (10 mL) , THF (10 mL) and 1- (chloromethyl) -4-fluoro-1, 4-diazoniabicyclo [2.2.2] octane ditetrafluoroborate (369 mg) , and the obtained mixture was stirred at 70°C for 3 hr. To the reaction mixture was further added 1- (chloromethyl) -4-fluoro-1, 4- diazoniabicyclo [2.2.2 ] octane ditetrafluoroborate (369 mg) , and the obtained mixture was stirred at 70°C for 2 hr. To the reaction mixture was further added 1- (chloromethyl) -4-fluoro- 1, 4-diazoniabicyclo [2.2.2] octane ditetrafluoroborate (369 mg) , and the obtained mixture was stirred at 70°C for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine,- and dried over anhydrous
magnesium sulfate, and the solvent was evaporated. under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) and HPLC
(Ascentis RP-Amide, mobile phase: water/acetonitrile
(containing 5 mM ammonium acetate) ) to give the title compound (6.2 mg) .
[0706]
Example 10
- [ (IS) -2- ( {'5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -1- methyl-lH-pyrazol-3-yl}oxy) -1-methylethyl] acetamide
[0707]
A) methyl 3- ({ (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) - l-methyl-lH-pyrazole-5-carboxylate
Using methyl 3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) -lH-pyrazole-5-carboxylate and iodomethane, and in the same manner as in Example 8, step B, the title compound was obtained.
MS (ESI+) : [M+H]+ 314.5.
[0708]
B) 3- ({ (2S) -2- [ (tert-butoxycarbonyl) amino] propyl}oxy) -1- methyl-lH-pyrazole-5-carboxylic acid
Using methyl 3- ({ (2S) -2- [ (tert- butoxycarbonyl) amino] propyl} oxy) -l-methyl-lH-pyrazole-5- carboxylate, and in the same manner as in Example 2, step B, the title compound was obtained.
MS (ESI+) : [M+H]+ 300.4.
[0709]
C) tert-butyl [ (IS) -2- ( { 5- [ (2, 4-dihydroxyphenyl) carbamoyl] -1- methyl-lH-pyrazol-3-yl } oxy) -1-methylethyl] carbamate
Using 3- ({ (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) - l-methyl-lH-pyrazole-5-carboxylic acid, and in the same manner as in Example 5, step A, the title compound was obtained.
MS (ESI+) : [M+H]+ 407.3.
[0710]
D) tert-butyl. [ (IS) -2-{ [5- (6-hydroxy-l, 3-benzoxazol-2-yl) -1- methyl-lH-pyrazol-3-yl] oxy} -1-methylethyl] carbamate
Using tert-butyl [ (IS) -2- ( { 5- [ (2, 4- dihydroxyphenyl) carbamoyl] -l-methyl-lH-pyrazol-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 2, step D, the title compound was obtained.
MS (ESI+) : [M+H]+ 389.3. ,
[0711]
E) tert-butyl [ (IS) -2- ( {5- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -l-methyl-lH-pyrazol-3-yl } oxy) -1- methylethyl] carbamate
Using tert-butyl [ (IS) -2-{ [5- (6-hydroxy-l, 3-benzoxazol-2- yl) -l-methyl-lH-pyrazol-3-yl] oxy} -1-methylethyl] carbamate, and in the same manner as in Example 2, step E, the title compound was obtained.
MS (ESI+) : [M+H]+ 443.5.
[0712]
F) N- [ (IS) -2- ( {5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] - l-methyl-lH-pyrazol-3-yl } oxy) -1-methylethyl] acetamide
Using tert-butyl [( IS) -2- ({ 5- [ 6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -l-methyl-lH-pyrazol-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0713]
Example 11
N- [ (IS) -2- ( {5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -4- fluoro-l-methyl-lH-pyrazol-3-yl }oxy) -1-methylethyl] acetamide [0714]
A mixture of N- [ (IS) -2- ({ 5- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -l-methyl-lH-pyrazol-3-yl } oxy) -1- methylethyl] acetamide (193 mg) , 1- (chloromethyl) -4-fluoro-1, 4- diazoniabicyclo [2.2.2] octane ditetrafluoroborate (427 mg) and acetonitrile (10 mL) was stirred at 60°C for 7 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound (11.2 mg) .
[0715]
Example 12
N- [ (IS) -2-{4- [5- (cyclopropylmethoxy) -2H-indazol-2-yl] phenoxy} -
1-methylethyl] acetamide
[0716]
A) 1- [4- (benzyloxy) phenyl] -1- (2-bromo-5- methoxybenzyl) hydrazine
To a solution of [4- (benzyloxy) phenyl] hydrazine
hydrochloride (2.0 g) in THF (25 mL) was added dropwise a THF solution (1.9 M, 8.4 mL) of sodium hexamethyldisilazide under ice-cooling, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was added l-bromo-2-
(bromomethyl) -4-methoxybenzene (2.23 g) under ice-cooling, and the mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the solvent was
evaporated under reduced pressure. To the residue was added water, and the mixture was extracted with ethyl acetate. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (1.56 g) .
XR NMR (300 MHz, CDC13) δ 3.63 (2H, s), 3.73 (3H, s) , 4.52 (2H, s), 5.02 (2H, s), 6.71 (1H, dd, J = 8.7, 3.0 Hz), 6.85-6.97 (3H, m) , 6.97-7.07 (2H, m) , 7.27-7.54 (6H, m) .
[0717]
B) 2- [4- (benzyloxy) phenyl] -5-methoxy-2H-indazole
A mixture of 1- [4- (benzyloxy) phenyl] -1- (2-bromo-5- methoxybenzyl) hydrazine (1.50 g) , palladium ( II ) acetate (41 mg) , 1, 1' -bis (diphenylphosphino) ferrocene (151 mg) , sodium tert-butoxide (436 mg) and toluene (18 mL) was stirred under an argon atmosphere at 90°C overnight. The solvent was
evaporated under reduced pressure, and the obtained mixture was diluted with ethyl acetate and water, and the organic layer was separated. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (163 mg) .
¾ NMR (300 MHz, DMSO-d6) δ 3.80 (3H, s) , 5.19 (2H, s) , 6.97 (1H, dd, J = 9.1, 2.3 Hz), 7.01 (1H, d, J = 1.5 Hz), 7.13-7.26 (2H, m), 7.28-7.55 (5H, m) , 7.61 (1H, d, J = 9.4 Hz), 7.83- 8.03 (2H, m) , 8.79 (1H, d, J = 1.1 Hz).
[0718]
C) 4- (5-methoxy-2H-indazol-2-yl) phenol
Under a hydrogen atmosphere, a mixture of 2- [4- (benzyloxy) phenyl] -5-methoxy-2H-indazole (160 mg) , 10%
palladium/carbon (containing water (50%) , 52 mg) , methanol (10 mL) and THF (5 mL) was stirred at room temperature for 1 hr. The catalyst was removed by filtration, and the obtained filtrate was concentrated under reduced pressure to give the title compound (121 mg) .
XH NMR (300 MHz, DMSO-d6) δ 3.79 (3H, s) , 6.86-6.93. (2H, m) , 6.95 (1H, dd, J = 9.3, 2.5 Hz), 7.01 (1H, d, J = 1.9 Hz), 7.59 (1H, d, J = 9.4 Hz), 7.75-7.85 (2H, m) , 8.71 (1H, d, J = 1.1 Hz) , 9.88 (1H, brs) .
[0719]
D) tert-butyl { (IS) -2- [4- (5-methoxy-2H-indazol-2-yl) phenoxy] - 1-methylethyl } carbamate
Using 4- (5-methoxy-2H-indazol-2-yl) phenol, and in the same manner as in Example 1, step B, the title compound was obtained.
XH NMR (300 MHz, DMSO-d6) δ 1.32 (3H, d, . J = 6.8 Hz),.1.46 (9H, s), 3.86 (3H, s), 3.99 (2H, d, J = 3.8 Hz), 4.02-4.16 (1H, m) , 6.90 (1H, d, J = 2.3 Hz), 6.97-7.07 (3H, m) , 7.67 (1H, d, J = 8.7 Hz) , 7.77 (2H, d, J = 9.1 Hz), 8.18 (1H, s) .
[0720]
E) N-{ (IS) -2- [4- (5-methoxy-2H-indazol-2-yl) phenoxy] -1- methylethyl } acetamide
Using tert-butyl { ( IS ) -2- [4- ( 5-methoxy-2H-indazol-2- yl)phenoxy] -1-methylethyl} carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
XH NMR (300 MHz, DMSO-d6) & 1.17 (3H, d, J = 6.4 Hz), 1.83 (3H, s), 3.80 (3H, s), 3.83-3.93 (1H, m), 3.94-4.05 (1H, m) , 4.05- 4.21 (1H, m) , 6.91-7.05 (2H, m) , 7.07-7.19 (2H, m), '7.60 (1H, d, J = 9.1 Hz), 7.89-8.02 (3H, m) , 8.80 (1H, d, J = 0.8 Hz).
[0721]
F) N-{ (IS) -2- [4- (5-hydroxy-2H-indazol-2-yl) phenoxy] -1- methylethyl} acetamide
To a solution of N-{ (IS) -2- [4- (5-methoxy-2H-indazol-2- yl) phenoxy] -1-methylethyl} acetamide (70 mg) in dichloromethane (3 mL) was added dropwise a dichloromethane solution (1.0 M, 0.83 mL) of tribromoborane under ice-cooling, and the mixture was stirred at room temperature for 3 hr. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution under ice-cooling, and the mixture was extracted with ethyl acetate. The separated organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound (48 mg) .
XH NMR (300 MHz, CDC13) δ 1.17 (3H, d, J = 6.8 Hz), 1.83 (3H, s), 3.82-3.92 (1H, m) , 3.95- 4.05 (1H, m) , 4.05-4.22 (1H, m) , 6.81-6.96 (2H, m) , 7.07-7.19 (2H, m) , 7.54 (1H, d, J = 9.1 Hz), 7.86-7.99 (3H, m) , 8.68 (1H, d, J = 0.8 Hz), 9.25 (1H, s) .
[0722]
G) N- [ (IS) -2-{ 4- [5- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy} -1-methylethyl] acetamide
Using N- { ( IS) -2- [4- (5-hydroxy-2H-indazol-2-yl) phenoxy] -1- methylethyl } acetamide, and in the same manner as in Example 2, step Έ, the title compound was obtained.
[0723]
Example 13
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] phenoxy} - 1-methylethyl] acetamide
[0724]
A) 6- (cyclopropylmethoxy) -lH-indazole
Using 6-hydroxy-lH-indazole, and in the same manner as in Example 1, step A, the title compound was obtained.
XH NMR (300 MHz, CDC13) δ 0.33-0.44 (2H, m) , 0.58-0.74 (2H, m) , 1.19-1.42 (1H, m) , 3.85 (2H, d, J = 7.2 Hz), 6.74-6.93 (2H, m) , 7.60 (1H, dd, J = 8.7, 0.8 Hz), 7.96 (1H, . d, J = 0.8 Hz), 9.92 (1H, brs) .
[0725]
B) 2- [4- (benzyloxy) phenyl] -6- (cyclopropylmethoxy) -2H-indazole
A mixture of 6- (cyclopropylmethoxy) -lH-indazole (376 mg) , 1- (benzyloxy) -4-bromobenzene (632 mg) , copper (I) iodide (38.1 mg) , (.IRS, 2RS) -N, N' -dimethylcyclohexane-1, 2-diamine (114 mg) , tripotassium phosphate (892 mg) and toluene (2 mL) was stirred under an argon atmosphere at 110°C overnight. The reaction mixture was diluted with ethyl acetate and water, and filtered through celite. The organic layer separated from the obtained filtrate was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (741 mg) of the title compound and 1- [4- (benzyloxy) phenyl] -6- (cyclopropylmethoxy) -lH-indazole .
MS (ESI+) : [M+H]+ 371.2.
[0726]
C) 4- [ 6- (cyclopropylmethoxy) -2H-indazol-2-yl] phenol
Using a mixture of 2- [4- (benzyloxy) phenyl] -6- (cyclopropylmethoxy) -2H-indazole and 1- [4- (benzyloxy) phenyl] - 6- (cyclopropylmethoxy) -lH-indazole, and in the same manner as in Example 12, step C, a mixture of the title compound and 4- [ 6- (cyclopropylmethoxy) -lH-indazol-l-yl] phenol was obtained. MS (ESI+) : [M+H]+ 281.2.
[0727]
D) tert-butyl [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy} -l-methylethyl].carbamate
Using a mixture of 4- [6- (cyclopropylmethoxy) -2H-indazol-
2-yl]phenol and 4- [ 6- (cyclopropylmethoxy) -lH-indazol-1- yl] phenol, and in the same manner as in Example 1, step B, the title compound was obtained.
MS (ESI+) : [M+H]+ 438.4.
[0728]
E) N- [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy} -1-methylethyl] acetamide
Using tert-butyl [( IS) -2- { 4- [ 6- (cyclopropylmethoxy) -2H- indazol-2-yl] phenoxy} -1-methylethyl] carbamate (100 mg) , and in the same manner as in Example 1, step D, the title compound was obtained (50.1 mg) .
[0729]
Example 14 N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] pyridin-
3-yl }oxy) -1-methylethyl] acetamide
[0730]
A) 2- [5- (benzyloxy) pyridin-2-yl] -6- (cyclopropylmethoxy) -2H- indazole
Using 6- (cyclopropylmethoxy) -lH-indazole and 5- (benzyloxy) -2-chloropyridine, and in the same manner as in Example 13, step B, the title compound was obtained.
XH NMR (300 MHz, DMS0-d6) δ 0.29-0.44 (2H, m) , 0.53-0.67 (2H, m) , 1.22-1.30 (1H, m) , 3.88 (2H, d, J = 6.8 Hz), 5.27 (2H, s) ,
6.78 (1H, dd, J = 9.1, 2.3 Hz) , 6.9.4 (1H, d, J = 1.9 Hz) ,
7.30-7.47 (3H, m), 7.47-7.54 (2H, m) , 7.65 (1H, d, J = 9.1 Hz), 7.74 (1H, dd, J = 9.1, 3.0 Hz), 8.07 (1H, d, J = 8.7 Hz), 8.32 (1H, d, J = 2.7 Hz) , 8.99 ( 1H, d, J = 0.8 Hz ) .
[0731]
B) 6- [ 6- (cyclopropylmethoxy) -2H-indazol-2-yl] pyridin-3-ol
Using 2- [5- (benzyloxy) pyridin-2-yl] -6- (cyclopropylmethoxy) -2H-indazole, and in the same manner as in Example 12, step C, the title compound was obtained.
Η NMR (300 MHz, DMSO-d6) δ 0.26-0.44 (2H, m) , 0.51-0.68 (2H, m) , 1.21-1.29 (1H, m) , 3.87 (2H, d, J = 7.2 Hz), 6.77 (1H, dd, J = 9.1, 2.3 Hz) , 6.91-6.98 (1H, m) , 7.41 (1H, dd, J = 8.9,
2.8 Hz), 7.64 (1H, d, J = 9.1 Hz), 7.97 (1H, d, J = 8.7 Hz), 8.05 (1H, d, J = 3.0 Hz), 8.94 (1H, d, J = 0.8 Hz), 10.41 (1H, brs) .
[0732]
C) tert-butyl [( IS) -2- ({ 6- [ 6- (cyclopropylmethoxy) -2H-indazol-
2-yl] pyridin-3-yl } oxy) -1-methylethyl] carbamate
Using 6- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] pyridin-
3-ol, . and in the same manner as in Example 1, step B, the title compound was obtained.
MS (ESI+) : [M+H]+ 439.1.
[0733]
D) N- [ (IS) -2- ( {6- [6- (cyclopropylmethoxy) -2H-indazol-2- yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide Using tert-butyl [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -2H- indazol-2-yl] pyridin-3-yl }oxy) -1-methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0734]
Example 15
1- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl} oxy) -1-methylethyl] urea
[0735]
A mixture of tert-butyl [ (IS) -2- ( { 6- [6-
(cyclopropylmethoxy) -1, 3-benzoxazol-2-yl]pyridin-3-yl}oxy) -1- methylethyl] carbamate (84.7 mg) , ethyl acetate (2 mL) and 4 hydrogen chloride/ethyl acetate (2 mL) was stirred at room temperature .for 3 hr. The solvent was evaporated under reduced pressure, and the residue was mixed with triethylamine (1 mL) , THF (5 mL) and trichloroacetyl isocyanate (0.034 mL) at 0°C, and the obtained mixture was stirred at 0°C for 30 min. To the reaction mixture was added 8 ammonia/methanol (5 mL) , and the obtained mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate/methanol) to give the title compound (6.3 mg) .
[0736]
Example 16
1- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) -1-methylethyl] -3-methylurea
[0737]
A mixture of tert-butyl [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] pyridin-3-yl }oxy) -1- methylethyl] carbamate (86.8 mg) , ethyl acetate (2 mL) and 4M hydrogen chloride/ethyl acetate (2 mL) was stirred at room temperature for 3 hr. The solvent was evaporated under reduced pressure, and the residue was mixed with triethylamine (0.5 mL) , THF (2 mL) and methyl isocyanate (0.014 mL) at 0°C, and the obtained mixture was stirred at room temperature for 2 hr.
Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate/methanol) to give the title compound (20 mg) .
[0738]
Example 17
methyl [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) -1-methylethyl] carbamate
[0739]
A mixture of tert-butyl [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] pyridin-3-yl } oxy) -1- methylethyl] carbamate (84.6 mg) , ethyl acetate (2 mL) and 4M hydrogen chloride/ethyl acetate (2 mL) was stirred at room temperature for 3 hr. The solvent was evaporated under reduced pressure, and the residue was mixed with triethylamine (0.5 mL) , THF (2 mL) and methyl chloroformate (0.044 mL) at 0°C, and the obtained mixture was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (17.5 mg) .
[0740]
Example 18
1- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -5- fluoropyridin-3-yl } oxy) -1-methylethyl] urea
[0741]
Using tert-butyl [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 15, step A (using pyridine instead of triethylamine) , the title compound was obtained.
[0742]
Example 19
1- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -5- fluoropyridin-3-yl} oxy) -1-methylethyl] -3-methylurea
[0743]
Using tert-butyl [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 16, step A (using pyridine instead of triethylamine) , the title compound was obtained.
[0744]
Example 20
1- [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl } oxy) -1-methylethyl] -3-methylurea
[0745]
Using tert-butyl [( IS) -2- ({ 5- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] isoxazol-3-yl } oxy) -1-methylethyl] carbamate, and in the same manner as in Example 16, step A, the title compound was obtained.
[0746]
Example 21
methyl [ (IS) -2- ( {5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl } oxy) -1-methylethyl] carbamate
[0747]
Using tert-butyl [ (IS) -2- ({ 5- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] isoxazol-3-yl } oxy) -1-methylethyl] carbamate, and in the same manner as in Example 17, step A, the title compound was obtained.
[0748]
Example 22
1- [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl }oxy) -1-methylethyl] urea [0749]
A mixture of tert-butyl [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] isoxazol-3-yl } oxy) -1- methylethyl] carbamate (430 mg) , ethyl acetate (8 mL) , methanol (1 mL) and 4 hydrogen chloride/ethyl acetate (5 mL) was stirred at room temperature overnight. The precipitated solid was collected by filtration, and washed with hexane. The obtained solid was suspended in THF (10 mL) , triethylamine (4 mL) and (trimethyl) silyl isocyanate (0.271 mL) were added thereto at room temperature, .and the mixture was stirred at room temperature for 4 hr. The precipitated solid was
collected by filtration, and washed with diethyl ether to give the title compound (43.9 mg) .
[0750]
Example 23 "
N- [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -4- methylisoxazol-3-yl } oxy) -1-methylethyl] acetamide
[0751]
A) tert-butyl [ (IS) -2- ( {5- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -4-methylisoxazol-3-yl } oxy) -1- methylethyl] carbamate
Under an argon atmosphere, to a solution of tert-butyl [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl }oxy) -1-methylethyl] carbamate (644 mg) in THF (15 mL) was added dropwise a hexane solution (1.6 M, 2.156 mL) of n-butyllithium at -78°C, and the mixture was stirred at - 78°C for 20 min. To the reaction mixture was added iodomethane (0.140 mL) , and the mixture was stirred at -78°C for 15 min, and then at 0°C for 1 hr. The. reaction mixture was neutralized with 1 hydrochloric acid, and extracted with ethyl acetate. The combined organic layer was washed with water and saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (46.0 mg) . XH N R (300 MHz, DMSO-d6) δ 0.30-0.39 (2H, m) , 0.54-0.63 (2H, m) , 1.12 (3H,■ d, J = 6.4 Hz), 1.22-1.29 (1H, m) , 1.38 (9H, s) ,
2.26 (3H, s), 3.86-4.02 (3H, m) , 4.09-4.26 (2H, m) , 6.90-7.00
(1H, m) , 7.12 (1H, dd, J = 9.1, 2.3 Hz), 7.41 (1H, d, J = 2.3 Hz) , 7.76 (1H, d, J = 9.1 Hz) .
[0752]
B) N- [ (IS) -2- ( {5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] - 4-methylisoxazol-3-yl}oxy) -1-methylethyl] acetamide
Using tert-butyl [ (IS) -2- ({ 5- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -4-methylisoxazol-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0753]
Example 24
N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -2, 3-dihydro-l- benzofuran-2-yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide
[0754]
A) (2-bromo-4-hydroxyphenyl) acetic acid
A dichloromethane solution (1.0 M, 150 mL) of
tribromoborane was added dropwise to a solution of (2-bromo-4- methoxyphenyl) acetic acid (15.0 g) in dichloromethane (160 mL) at room temperature, and the reaction mixture was refluxed for 3 hr, allowed to cool to room temperature, and poured into ice water. The mixture was extracted with ethyl acetate, and the organic layer was separated. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The obtained yellow solid was
collected by filtration and washed with hexane-diethyl ether to give the title compound (10.3 g) .
XH NMR (300 MHz, DMSO-d6) δ 3.58 (2H, s) , 6.73 (1H, dd, J = 8.3, 2.3 Hz), 6.98 (1H, d, J = 2.3 Hz), 7.17 (1H, d, J = 8.3 Hz), 9.76 (1H, s) , 12.31 (1H, brs) .
[0755]
B) cyclopropylmethyl [2-bromo-4- (cyclopropylmethoxy) phenyl] acetate A solution of (bromomethyl) cyclopropane (10.52 g) , (2- bromo-4-hydroxyphenyl) acetic acid (6.0 g) and potassium
carbonate (7.18 g) in DMF (200 mL) was stirred at 80°C for 8 hr. The reaction mixture was allowed to cool to room temperature, and the solvent was evaporated under reduced pressure. The residue was diluted with diethyl ether and water, and the organic layer was separated. The organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound (7.89 g) .
1H NMR (300 MHz, DMSO-d6) δ 0.20-0.28 (2H, m) , 0.28-0.35 (2H, m) , 0.43-0.52 (2H, m) , 0.52-0.63 (2H, m) , 0.97-1.14 (1H, m) , 1.14-1.29 (1H, m) , 3.73 (2H, s) , 3.82 (2H, d, J = 6.8 Hz), 3.89 (2H, d, J = 7.2 Hz), 6.92 (1H, dd, .J = 8.5, 2.7 Hz), 7.16
(1H, d, J = 2.7 Hz) , 7.29 (1H, d, J = 8.5 Hz).
[0756]
C) [2-bromo-4- (cyclopropylmethoxy) phenyl] acetic acid
1M Aqueous sodium hydroxide solution (30 mL) was added to a solution of cyclopropylmethyl [2-bromo-4-
(cyclopropylmethoxy) phenyl] acetate (6 g) in methanol (50 mL) at room temperature, and the mixture was stirred at 50°C for 2 hr. The reaction mixture was allowed to cool to room- temperature, water was added thereto, and the mixture was washed with diisopropyl ether. The aqueous layer was acidified with 1M hydrochloric acid, and extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure to give the title
compound (4.48 g) .
XH NMR (300 MHz, DMSO-d6) δ 0.16-0.44 (2H, m) , 0.44-0.69 (2H, m) , 0.99-1.33 (1H, m) , 3.62 (2H, s) , 3.82 (2H, d, J = 7.2 Hz), 6.91 (1H, dd, J = 8.3, 2.4 Hz), 7.14 (1H, d, J = 2.4 Hz), 7.27 (1H, d, J = 8.3 Hz), 12.37 (1H, brs) .
[0757] D) 2- [2-bromo-4- (cyclopropylmethoxy) phenyl] -N-methoxy-N- methylacetamide
WSC (4.89 g) was added to a solution of N,0- dimethylhydroxyamine hydrochloride (2.49 g) , [2-bromo-4- (cyclopropylmethoxy) phenyl] acetic acid (4.85 g) , HOBt (3.91 g) and triethylamine (3.56 mL) in acetonitrile (100 mL) , and the mixture was stirred at room temperature for 15 hr. The
reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate. The mixture was washed with 1M hydrochloric acid, water, saturated sodium hydrogen carbonate and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, passed through an NH silica gel pad, and the solvent was evaporated under reduced pressure to give the title compound (4.78 g) . MS (ESI+) :
[M+H]+ 328.0.
[0758]
E) 2- [2-bromo-4- (cyclopropylmethoxy) phenyl] -1- (5-{ [tris(l- methylethyl) silyl] oxy}pyridin-2-yl) ethanone
A hexane solution (1.6 M, 11.43 mL) of n-butyllithium was added dropwise to a solution of 2-bromo-5- { [tris ( 1- methylethyl) silyl] oxy}pyridine (4.03 g) in diethyl ether (60 mL) at -78°C. The reaction mixture was stirred at -78°C for 15 min and allowed to warm to 0°C over 1 hr. The reaction mixture was cooled to -78°C, and a solution of 2- [2-bromo-4- (cyclopropylmethoxy) phenyl] -N-methoxy-N-methylacetamide (4.0 g) in diethyl ether (30 mL) was added dropwise thereto. The reaction mixture was allowed to warm to room temperature, and stirred at room temperature for 15 hr.. The reaction mixture was poured into an ice-cooled saturated aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (1.50 g) . XH NMR (300 MHz,■ DMSO-de) δ 0.26-0.37 (2H, m) , 0.49-0.64 (2H, m) , 1.09 (18H, d, J = 7.2 Hz), 1.14-1.28 (4H, m) , 3.81 (2H, dd, J = 4.7, 2.1 Hz), 4.58 (2H, s) , 6.86-6.96 (1H, m), 7.11-7.33
(2H, m) , 7.48 (1H, dd, J = 8.7, 2.6 Hz), 7.95 (1H, d, J = 8.7 Hz), 8.37 (1H, d, J = 2.6 Hz)..
[0759]
F) 2- [2-bromo-4- (cyclopropylmethoxy) phenyl] -1- (5-{ [tris(l- methylethyl) silyl] oxy}pyridin-2-yl) ethanol
Sodium borohydride (0.109 g) was added to a solution of 2- [2-bromo-4- (cyclopropylmethoxy) phenyl] -1- (5-{ [tris (1- methylethyl) silyl] oxy}pyridin-2-yl) ethanone (1.50 g) in
ethanol (10 mL) at room temperature. The reaction mixture was stirred at room temperature for 1 hr, and the solvent was evaporated under reduced pressure. The residue was diluted with ethyl acetate and water, and the organic layer was
separated. The organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (1.210 g) .
1H NMR (300 MHz, DMSO-d6) δ 0.25-0.35 (2H, m) , 0.49-0.61 (2H, m) , 1.06 (18H, d, J = 7.2 Hz), 1.13-1.22 (4H, m) , 2.89 (1H, dd, J = 13.6, 7.9 Hz), 3.11 (1H, dd, J = 13.6, 5.7 Hz), 3.75-3.81 (2H, m) , 4.65-4.85 (1H, m) , 5.38 (1H, d, J = 5.3 Hz), 6.87 (1H, dd, J = 8.3, 2.6 Hz), 6.98-7.14 (2H, m) , 7.15-7.39 (1H, m) , 8.09 (2H, d, J = 2.3 Hz) .
[0760]
G) 6- [6- (cyclopropylmethoxy) -2, 3-dihydro-l-benzofuran-2- yl]'pyridin-3-ol
Sodium hydride (27.7 mg) was added to a suspension of 2-
[2-bromo-4- (cyclopropylmethoxy) phenyl] -1- (5-{ [tris(l- methylethyl) silyl] oxy}pyridin-2-yl) ethanol (600 mg) and.
copper (I) chloride (5.71 mg) in toluene (10 mL) at room
temperature. The reaction mixture was stirred at 120°C for 3 hr, and allowed to cool to room temperature. Water was added to the mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was dissolved in THF . (10 mL) , and a THF solution (1.0 M, 5.76 mL) of tetrabutylammonium fluoride was added thereto. The reaction mixture was stirred at room temperature for 30 min, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (180 mg) .
MS (ESI+) : [M+H]+ 284.1.
[0761]
H) tert-butyl [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -2, 3-dihydro- l-benzofuran-2-yl] pyridin-3-yl }oxy) -1-methylethyl] carbamate A toluene solution (1.9 M, 0.474 mL) of diisopropyl azodicarboxylate was added dropwise to a solution of tert- butyl [ (IS) -2-hydroxy-l-methylethyl] carbamate (158 mg) ,
' triphenylphosphine (236 mg) and 6- [ 6- (cyclopropylmethoxy) -2 , 3- dihydro-l-benzofuran-2-yl]pyridin-3-ol (170 mg) in THF (30 mL) at room temperature. The reaction mixture was stirred at room temperature for 16 hr, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (80 mg) .
MS (ESI+) : [M+H]+ 441.2.
[0762]
I) N- [ (IS) -2- ( {6- [6- (cyclopropylmethoxy) -2 , 3-dihydro-l- benzofuran-2-yl] yridin-3-yl }oxy) -1-methylethyl] acetamide
4M Hydrogen chloride/ethyl acetate (10 mL) was added dropwise to a solution of tert-butyl [ (IS) -2- ( { 6- [6-
(cyclopropylmethoxy) -2, 3-dihydro-l-benzofuran-2-yl] pyridin-3- yl }oxy) -1-methylethyl] carbamate (80 mg) in ethyl acetate (5 mL) at room temperature, and the reaction mixture was stirred at room temperature for 6 hr. The solvent was evaporated under reduced pressure, and the residue was dissolved in pyridine (10 mL), and acetic anhydride (0.026 mL) was added thereto at room temperature. The reaction mixture was stirred at room temperature for 2 hr, and the solvent was evaporated under reduced pressure. The residue was diluted with water, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated sodium hydrogen carbonate and saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(ethyl acetate/methanol) to give the title compound (49.3 mg) .
[0763]
Example 25
N-{ (IS) -2-[4- (6-ethoxy-2H-indazol-2-yl) -3-fluorophenoxy] -1- methylethyl } acetamide monohydrate
[0764]
A) 4-ethoxy-l-methyl-2-nitrobenzene
4- ethyl-3-nitrophenol (10.0 g) was mixed with iodoethane (10.5 mL) , potassium carbonate (13.5 g) and DMF (130 mL) , and the obtained mixture was stirred at 60°C overnight. Water was added to the reaction mixture, and the mixture was extracted twice with diethyl ether. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure to give the title compound as a yellow oil (11.8 g) .
¾ NMR (300 MHz, CDC13) δ 1.43 (3H, t, J = 7.0 Hz), 2.52 (3H, s), 4.06 (2H, q, J = 6,8 Hz), -7.04 (1H, dd, J = 8.5, 2.8 Hz), 7.21-dH, d, J = 8.7 Hz), 7.49 (1H, d, J = 3.0 Hz).
[0765]■
B) 1- (bromomethyl) -4-ethoxy-2-nitrobenzene
A mixture of 4-ethoxy-l-methyl-2-nitrobenzene (11.8 g) , N-bromosuccinimide (17.4 g) , 2, 2' -azobisisobutyronitrile (1.07 g) and ethyl acetate (300 mL) was stirred under an argon atmosphere at -90°C overnight. The solvent was evaporated under reduced pressure, and the residue was diluted with diethyl ether, and the mixture was washed three times with water. The separated organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a yellow oil (11.3 g) .
½ NMR (300 MHz, CDC13) δ 1.45 (3H, t, J = 7.2 Hz), 4.10 (2H, q, J = 6.8 Hz), 4.80 (2H, s) , 7.11 (1H, dd, J = 8.5, 2.8 Hz), 7.44 (1H, d, J = 8.3 Hz), 7.54 (1H, d, J = 2.6 Hz).
[0766]
C) 4-ethoxy-2-nitrobenzaldehyde
A mixture of 1- (bromomethyl) -4-ethoxy-2-nitrobenzene
(11.3 g) , 4-methylmorpholine N-oxide (10.1 g) , molecular sieves 4A (11 g) and acetonitrile (220 mL) was stirred under an argon atmosphere at room temperature for 1 hr. The reaction mixture was filtered through celite, and the solvent of the filtrate was evaporated under reduced pressure. The residue was diluted with ethyl acetate, and the mixture was washed twice with water. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried ov^er anhydrous
magnesium sulfate, and the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a yellow solid (5.65 g) .
¾ NMR (300 MHz, CDC13) δ 1.49 (3H, t, J = 7.0 Hz), 4.19 (2H, q, J = 6.8 Hz), 7.21 (1H, dd, J = 8.5, 2.1 Hz), 7.50 (1H, d, J = 2.3 Hz), 7.97 (1H, d, J = 8.7 Hz), 10.29 (1H, s) .
[0767]
D) tert-butyl [ (IS) -2- (3-fluoro-4-nitrophenoxy) -1- methylethyl] carbamate
To a mixture of 3-fluoro-4-nitrophenol (2.02 g) , tert- butyl [ (IS) -2-hydroxy-l-methylethyl] carbamate (5.62 g) ,
triphenylphosphine (8.41 g) and THF (60 mL) was added dropwise a toluene solution (1.9 M, 16.9 mL) of diisopropyl azodicarboxylate. ' at room temperature, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a pale-yellow solid (4.03 g) .
XH NMR (300 MHz, CDC13) δ 1.30 (3H, d, J = 6.8 Hz), 1.45 (9H, s), 3.94-4.14 (3H, m) , 4.62 (1H, brs) , 6.68-6.87 (2H, m) , 8.02-8.17 (1H, m) .
[0768]
E) tert-butyl [ (IS) -2- (4-amino-3-fluorophenoxy) -1- methylethyl] carbamate
Under a hydrogen atmosphere, a mixture of tert-butyl
[ (IS) -2- (3-fluoro-4-nitrophenoxy) -1-methylethyl] carbamate (10.2 g) , 10% palladium/carbon (containing water (50%), 500 mg) and ethanol (150 mL) was stirred at room temperature for 1 hr. The catalyst was removed by filtration, and the obtained filtrate was concentrated under reduced pressure to give the title compound as a brown solid (8.64 g).
XH NMR (300 MHz, CDC13) 6 1.26 (3H, d, J = 6.8 Hz), 1.45 (9H, s), 3.44 (2H, brs), 3.79-3.89 (2H, m) , 4.00 (1H, brs), 4.74 (1H, brs), 6.50-6.58 (1H, m) , 6.62 (1H, dd, J = 12.5, 2.7 Hz), 6.71 (1H, dd, J = 9.8, 8.7 Hz).
MS (ESI+) : [M+H]+ 185.2.
[0769]
F) tert-butyl { (IS) -2- [4- (6-ethoxy-2H-indazol-2-yl) -3- fluorophenoxy] -1-methylethyl } carbamate
A mixture of 4-ethoxy-2-nitrobenzaldehyde (5.20 g) , tert- butyl [ (IS) -2- (4-amino-3-fluorophenoxy) -1- methylethyl] carbamate (7.58 g) , magnesium sulfate (3.21 g) and ethanol (60 mL) was stirred under reflux overnight. The reaction mixture was concentrated under reduced pressure, triethyl phosphite (13.7 mL) was added to the residue, and the mixture was stirred at 130°C for 3 hr. The reaction mixture was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a yellow solid (6.53 g) . XH NMR (300 MHz, CDC13) δ 1.31 (3H, d, J = 6.8 Hz), 1.44-1.51 (12H, m) , 3.98 (2H, d, J = 3.8 Hz) , 4.03-4.17 (3H, m) , 4.71 (1H, brs), 6.76-6.88 (3H, m) , 6.98 (1H, s) , 7.56 (1H, d, J = 9.1 Hz) , 7.86-7.95 (1H, m) , 8.28 (1H, d, J = 2.3 Hz).
MS (ESI+) : [M+H]+ 430.3. ,
[0770]
G) N-{ (IS) -2- [4- (6-ethoxy-2H-indazol-2-yl) -3-fluorophenoxy] -1- methylethyl } acetamide monohydrate
A mixture of tert-butyl { (IS) -2- [4- (6-ethoxy-2H-indazol-
2-yl) -3-fluorophenoxy] -1-methylethyl } carbamate (6.53 g) , 4M hydrogen chloride/ethyl acetate (20 mL) and ethyl acetate (40 rtiL) was stirred at room temperature for 1 hr. The reaction mixture was concentrated under reduced pressure, and the
obtained residue was mixed with acetic anhydride (20 mL) and pyridine (50 mL) . The obtained mixture was stirred at room temperature for 1 hr. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with THF and ethyl acetate, and the mixture was washed three times with 1M hydrochloric acid. The separated aqueous layer was
extracted again with ethyl acetate. The combined organic layer was washed with saturated aqueous sodium hydrogen carbonate and saturated brine, and dried over anhydrous magnesium
sulfate, and the solvent was evaporated under reduced pressure. The residue was dissolved in ethanol, and the solution was filtered through silica gel. The filtrate was concentrated, and the residue was recrystallized (ethanol/ethyl acetate) to give the title compound as colorless crystals (2.36 g) .
XH NMR (300 MHz, DMSO-d6) δ 1.17 (3H, d, J = 6.8 Hz), 1.38 (3H, t, J = 7.0 Hz), 1.83 (3H, s) , 3.87-3.95 (1H, m) , 3.99-4.20 (4H, m) , 6.76 (1H, dd, J = 9.0, 2.3 Hz), 6.93-7.05 (2H, m) , 7.19 (1H, dd, J = 13.6, 2.6 Hz), 7.64 (1H, d, J = 9.0 Hz), 7.81 (1H, t, J = 9.0 Hz), 7.96 (1H, d, J = 7.5 Hz), 8.59 (1H, d, J = 1.9 Hz) .
Anal. Calcd for C2oH22 303F-H20:C, 61.69;H, 6.21;N, 10.79 FoundiC, 61. 5;H, 6.31;N, 10.65.
[0771]
Example 26
N-{ (IS) -2- [4- (6-ethoxy-2H-indazol-2-yl)phenoxy] -1- methylethyl } acetamide
[0772]
A) tert-butyl [ (IS) -l-methyl-2- (4-nitrophenoxy) ethyl] carbamate
Using 4-nitrophenol (5.29 g) , and in the same manner as in Example 25, step D, the title compound was obtained as a pale-yellow solid (11.23 g) .
λΕ NMR (300 MHz, " CDC13) δ 1.31 (3H, d, J = 6.8 Hz), 1.45 (9H, s), 3.95-4.16 (3H, m) , 4.67 (1H, brs) , 6.93-7.03 (2H, m) , 8.12-8.29 (2H, m) .
[0773]
B) tert-butyl [ (IS) -2- ( 4-aminophenoxy) -1-methylethyl] carbamate
Using tert-butyl [ (IS) -l-methyl-2- (4- nitrophenoxy) ethyl] carbamate (444 mg) , and in the same manner as in Example 25, step E, the title compound was obtained as a pale-yellow solid (399 mg) .
XH NMR (300 MHz, CDC13) δ 1.27 (3H, d, J = 6.8 Hz), 1.45 (9H, s), 3.42 (2H, brs), 3.78-3.90 (2H, m) , 4.00 (1H, brs), 4.79
(1H, brs), 6.59-6.67 (2H, m) , 6.70-6.79 (2H, m) .
MS (ESI+) : [M+H-Boc]+ 167.3.
[0774]
C) tert-butyl { ( IS) -2- [ 4- ( 6-ethoxy-2H-indazol-2-yl ) phenoxy] -1- methylethyl } carbamate
Using 4-ethoxy-2-nitrobenzaldehyde (293 mg) and tert- butyl [ (IS) -2- (4-aminophenoxy) -1-methylethyl] carbamate (399 mg) , and in the same manner as in Example 25, step F, the title compound was obtained as a pale-brown solid (459 mg) . 1H NMR (300 MHz, CDC13) δ 1.32 (3H, d, J = 6.8 Hz), 1.44-1.51 (12H, m) , 3.98 (2H, d, J = 4.1 Hz), 4.03-4.18 (3H, m) , 4.76 (1H, brs), 6.80 (1H, dd, J = 9.0, 2.3 Hz), 6.99-7.06 (3H, m) , 7.55 (1H, d, J = 9.0 Hz), 7.69-7.81 (2H, m) , 8.21 (1H, s) . MS (ESI+) : [M+H]+ 412.3. [0775]
D) N-{ (IS) -2- [4- ( 6-ethoxy-2H-indazol-2-yl) henoxy] -1- methylethyl } acetamide
Using tert-butyl { ( IS ) -2- [4- ( 6-ethoxy-2H-indazol-2- yl) phenoxy] -1-methylethyl } carbamate (459 mg) , and in the same manner as in Example 25, step G, the title compound was
obtained as colorless crystals (139 mg) .
XH N R (300 MHz, DMSO-d6) 6 1.17 (3H, d, J = 6.8 Hz), 1.38 (3H, t, J = 6.8 Hz), 1.83 (3H, s) , 3.82-3.92 (1H, m), 3.96-4.18 (4H, m) , 6.74 (1H, dd, J = 9.1, 2.3 Hz), 6.98 (1H, d, J = 1.5 Hz), 7.07-7.17 (2H, m) , 7.61 (lH, d, J = 9.1 Hz), 7.86-8.01 (3H, m) , 8.86 (1H, d, J = 0.8 Hz) .
Anal. Calcd for
C2oH23N303:C, 67.97;H, 6.56;N, 11.89. Found: C, 67.96; H, 6.57 ; N, 12.17.
[0776]
Example 27
N- [ (IS) -2-{4- [5- (cyclopropylmethoxy) -2H-benzotriazol-2- yl] phenoxy} -1-methylethyl] acetamide
[0777]
A) 4- (cyclopropylmethoxy) -2-nitroaniline
Using 4-amino-3-nitrophenol (1.54 g) , and in the same manner as in Example 2, step E, the title compound was
obtained as a pale-orange solid (1.15 g) .
XH NMR (300 MHz, DMSO-d6) δ 0.25-0.39 (2H, m) , 0.48-0.64 (2H, m) , 1.07-1.28 (1H, m) , 3.76 (2H, d, J = 7.2 Hz), 6.99 (1H, d, J = 9.4 Hz), 7.17 (1H, dd, J = 9.1, 3.0 Hz), 7.25 (2H, s) , 7.33 (1H, d, J = 3.0 Hz) .
[0778]
B) 4-{ [4- (cyclopropylmethoxy) -2-nitrophenyl] diazenyl }phenol
To a mixture of 4- (cyclopropylmethoxy) -2-nitroaniline
(416 mg) and ethanol (2 mL) was added 6M hydrochloric acid
(1.5 mL) , and ethanol was evaporated under reduced pressure. To the obtained suspension was added a mixture of sodium
nitrite (145 mg) and water (1 mL) under ice-cooling, and the mixture was stirred for 30 min. A mixture of phenol (245 mg) and 8M aqueous sodium hydroxide solution (1.2 mL) was added thereto, and the mixture was stirred for 1 hr. To the reaction mixture was added 1M hydrochloric acid, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under, reduced pressure. The residue was purified by silica gel- column chromatography (hexane/ethyl acetate) to give the title compound as a dark red solid- (187 mg) .
¾ NMR (300 MHz, CDC13) δ 0.34-0.44 (2H, m) , 0.64-0.76 (2H, m) , 1.24-1.39 (1H, m) , 3.92 (2H, d, J = 6.8 Hz), 5.25 (1H, s) , 6.87-6.98 (2H, m) , 7.15 (1H, dd, J = 9.1, 2.7 Hz), 7.30 (1H, d, J = 2.7 Hz), 7.76 (1H, d, J = 9.1 Hz), 7.80-7.89 (2H, m) .
MS (ESI+) : [M+H]+ 314.2.
[0779]
C) 4- [5- (cyclopropylmethoxy) -2H-benzotriazol-2-yl] phenol
A mixture of 4-{ [4- (cyclopropylmethoxy) -2- nitrophenyl] diazenyl }phenol and triethyl phosphite (4 mL) was stirred at 140°C overnight. The reaction mixture was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a yellow solid (103 mg) .
■ ¾ NMR (300 MHz, CDC13) δ 0.35-0.45 (2H, m) , 0.62-0.75 (2H, m) , 1.27-1.41 (1H, m) , 3.89 (2H, d, J = 6.8 Hz), 5.14 (1H, brs) , 6.90-7.02 (2H, m) , 7.07 (1H, d, J = 2.3 Hz), 7.13 (1H, dd, J = 9.4, 2.3 Hz), 7.77 (1H, d, J = 9.1 Hz), 8.09-8.21 (2H, m) .
[0780]
D) tert-butyl [( IS) -2- { 4- [5- (cyclopropylmethoxy) -2H- benzotriazol-2-yl] phenoxy} -1-methylethyl] carbamate
Using 4- [5- (cyclopropylmethoxy) -2H-benzotriazol-2- yl]phenol (100 mg) , and in the same manner as in Example 1, step B, the title compound was obtained as a yellow solid (121 mg) .
XH NMR (300 MHz, CDC13) δ 0.35-0.47 (2H, m) , 0.64-0.76 (2H, m) , 1.30-1.39 (4H, m) , 1.46 (9H, s) , 3.89 (2H, d, J = 6.8 Hz), 4.00 (2H, d, J = 4.2 Hz), 4.04-4.16 (1H, m) , 4.76 (1H, brs), 7.00-7.09 (3H, m) , 7.13 (1H, dd, J = 9.1, 2.3 Hz), 7.78 (1H, d,
J = 9.1 Hz), 8.13-8.26 (2H, m) .
MS (ESI+) : [M+H-Boc]+ 339.2.
[0781]
E) N- [ (IS) -2-{ 4- [5- (cyclopropylmethoxy) -2H-benzotriazol-2- yl]phenoxy}-l-methylethyl] acetamide
Using tert-butyl [( IS) -2- { 4- [5- (cyclopropylmethoxy.) -2H- benzotriazol-2-yl] phenoxy} -1-methylethyl] carbamate (119 mg) , and in the same manner as in Example 25, step G, the title compound was obtained as colorless crystals (60.3 mg) .
XH NMR (300 MHz, DMSO-d6) δ 0.31-0.42 (2H, m) , 0.56-0.67 (2H, m) , 1.18 (3H, d, J = 6.8 Hz), 1.22-1.37 (1H, m) , 1.83 (3H, s) , 3.86-3.97 (3H, m), 3.98-4.06 (1H, m) , 4.06-4.20 (1H, m), 7.11- 7.23 (3H, m) , 7.25 (1H, d, J = 1.9 Hz), 7.88 (1H, d, J = 9.0 Hz), 7.96 (1H, d, J = 7.5 Hz), 8.09-8.21 (2H, m) .
Anal . Calcd for "
C2iH24 403:C, 66.30;H, 6.36;N, 14.73. Found:C, 66.21;H, 6.36;N, 14.68.
[0782]
Example 28
N- [ (IS) -2-{ [6- (6-ethoxy-l, 3-benzoxazol-2-yl) pyridin-3-yl] oxy}- 1-methylethyl] acetamide
[0783]
A) tert-butyl . [ (IS) -2-{ [6- ( 6-ethoxy-l, 3-benzoxazol-2- yl) pyridin-3-yl] oxy} -1-methylethyl] carbamate
To a mixture of methyl 5-hydroxypyridine-2-carboxylate
(5.30 g) , tert-butyl [ (IS) -2-hydroxy-l-methylethyl] carbamate (6.67 g) , triphenylphosphine (12.71 g) and THF (50 mL) was added dropwise a toluene solution (1.9 M, 25.5 mL) of
diisopropyl azodicarboxylate at room temperature, and the mixture was stirred at room temperature overnight. The
reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (7.52 g) of methyl 5- ({ (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) pyridine-2- carboxylate and impurity. A mixture of the obtained methyl 5- ( { (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) pyridine-2- carboxylate (7.52 g, mixture with impurity), THF (70 mL) , methanol (70 mL) and 1 sodium hydroxide (70 mL) was stirred at room temperature overnight. The reaction mixture was neutralized with 6M hydrochloric acid at 0°C, and concentrated under reduced pressure, and the residue was extracted with a mixed solvent of ethyl acetate/2-propanol (volume ratio 3/1) . The obtained organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give a mixture (7.17 g) of 5- ({ (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) pyridine-2-carboxylic acid and impurity. A mixture of the obtained 5— ({ (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) pyridine-2-carboxylic acid (7.17 g, mixture with impurity), 4-aminobenzene-l, 3-diol hydrochloride (3.91 g) , HATU (9.20 g) , N,N- diisopropylethylamine (8.34 mL) and D F (70 mL) was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give tert-butyl [ (IS) -2- ( { 6- [ (2,4- dihydroxyphenyl) carbamoyl] pyridin-3-yl }oxy) -1- methylethyl] carbamate as a mixture with impurity (14.1 g) . To a solution of hexachloroethane (13.2 g) and triphenylphosphine (18.3 g) in acetonitrile (100 mL) was added triethylamine (24.4 mL) at room temperature, and the obtained mixture was stirred at room temperature for 10 min. A mixture of tert- butyl [ (IS) -2- ( { 6- [ (2, 4-dihydroxyphenyl) carbamoyl] pyridin-3- yl } oxy) -1-methylethyl] carbamate (14.1 g, mixture with
impurity) obtained by the aforementioned method and
acetonitrile (100 mL) was added thereto. -The obtained mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give tert-butyl [ (IS) -2-{ [6- ( 6-hydroxy-l, 3- benzoxazol-2-yl) pyridin-3-yl] oxy} -1-methylethyl] carbamate as a mixture with impurity ( 17.5 g) . A mixture of the obtained tert-butyl [ (IS) -2-{ [ 6- ( 6-hydroxy-l , 3-benzoxazol-2-yl) pyridin-
3-yl] oxy} -1-methylethyl] carbamate (17.5 g', mixture with impurity), iodoethane (3.99 mL) , potassium carbonate (6.90 g) and DMF (150 mL) was stirred at 60°C for 5 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound as a white powder (5.53 g) .
XH NMR (300 MHz, DMSO-d6) δ 1.15 (3H, d, J = 6.8 Hz), 1.28-1.43 (12H, m) , 3.78-4.19 (5H, m) , 6.89-7.05 (2H, m) , 7.40 (1H, d, J = 2.3 Hz) , 7.61 (1H, dd, J = 8.9, 2.8 Hz) , 7.68 (1H, d, J = 8.7 Hz) , 8.20 (1H, d, J = 8.7 Hz)., 8.45 (1H, d, J = 2.6 Hz) . MS (ESI+) : [M+H]+ 414.2.
[0784]
B) N- [ (IS) -2-{ [6- ( 6-ethoxy-l, 3-benzoxazol-2-yl) pyridin-3- yl] oxy} -1-methylethyl] acetamide
A mixture of tert-butyl [ (IS) -2-{ [6- (6-ethoxy-l, 3- benzoxazol-2-yl) pyridin-3-yl] oxy} -1-methylethyl] carbamate (5.53 g) , 4M hydrogen chloride/ethyl acetate (100 mL) and ethyl acetate (100 mL) was stirred at room temperature for 2 hr. The reaction mixture was concentrated under reduced pressure, and the obtained residue was mixed with acetic anhydride (50 mL) and pyridine (50 mL) . The obtained mixture was stirred at room temperature overnight. To the reaction mixture was added 1M hydrochloric acid, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate/methanol) , and recrystallized (ethanol/hexane) to give the title compound as white crystals (3.48 g) .
XH NMR (300 MHz, DMSO-d6) δ 1.18 (3H, d, J = 6.4 Hz), 1.37 (3H, t, J = 7.0 Hz), 1.82 (3H, s) , 3.94-4.23 (5H, m) , 7.00 (1H, dd, J - 8.7, 2.3 Hz), 7.40 (1H, d, J = 2.3 Hz), 7.63 (1H, dd, J = 8.7, 3.0 Hz), 7.68 (1H, d, J = 8.7 Hz), 7.98 (1H, d, J = 7.5 Hz), 8.21 (1H, d, J = 8.7 Hz), 8.47 (1H, d, J = 2.6 Hz).
Anal. Calcd for
Ci9H2iN304:C, 64.21;H, 5.96; N , 11.82. Found: C, 64.04 ;H, 6.00 ;N, 11.72.
[0785]
Example 29
N-{ (lS)-2-[ (6-{6-[ (3, 3-difluorocyclobutyl) methoxy] -1, 3- benzoxazol-2-yl }pyridin-3-yl) oxy] -1-methylethyl } acetamide
[0786]
A) tert-butyl { (IS) -2- [ (6-{ 6- [ (3, 3- difluorocyclobutyl) methoxy] -1, 3-benzoxazol-2-yl }pyridin-3- yl) oxy] -1-methylethyl } carbamate
Using tert-butyl [ (IS) -2-{ [6- (6-hydroxy-l, 3-benzoxazol-2- yl) pyridin-3-yl] oxy} -1-methylethyl] carbamate and (3,3- difluorocyclobutyl) methyl methanesulfonate, and in the same manner as in Example 2, step E, the title compound was
obtained.
MS (ESI+) : [M+H]+ 490.1.
[0787]
B) N-{ (lS)-2-[ (6-{6-[ (3,3-difluorocyclobutyl)methoxy]-l,3- benzoxazol-2-yl }pyridin-3-yl) oxy] -1-methylethyl } acetamide
Using tert-butyl { (IS) -2- [ (6-{6-[ (3,3- difluorocyclobutyl) methoxy] -1, 3-benzoxazol-2-yl Jpyridin-S- yl) oxy] -1-methylethyl } carbamate, and in the same manner as in Example 1, step D, the title compound was obtained. [0788]
Example 30
N- [ (IS) -2- ( { 6- [6- (2, 2-difluoropropoxy) -1, 3-benzoxazol-2- yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide
[0789]
A) tert-butyl [ (IS) -l-methyl-2- ( { 6- [6- (2-oxopropoxy) -1, 3- benzoxazol-2-yl]pyridin-3-yl}oxy) ethyl] carbamate
Using tert-butyl [ (IS) -2-{ [6- ( 6-hydroxy-l, 3-benzoxazol-2- yl) pyridin-3-yl] oxy} -1-methylethyl] carbamate and 1- bromopropan-2-one, and in the same manner as in Example 2, step E, the title compound was obtained.
MS (ESI+) : [M+H]+ 442.3.
[0790]
B) tert-butyl [ (IS) -2- ({6- [6- (2, 2-difluoropropoxy) -1,3- benzoxazol-2-yl] pyridin-3-yl } oxy) -1-methylethyl] carbamate
A mixture of tert-butyl [ (IS) -l-methyl-2- (.{6- [6- (2- oxopropoxy) -1, 3-benzoxazol-2-yl] pyridin-3- yl} oxy) ethyl] carbamate (1.30 g) , bis (2- methoxyethyl) aminosulfur trifluoride (1.63 mL) and toluene (20 mL) was stirred at room temperature for 1 hr, then at 80°C for 3 hr. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue, was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (180 mg) .
MS (ESI+) : [M+H]+ 464.2.
[0791]
C) N- [ (IS) -2- ( { 6- [6- (2, 2-difluoropropoxy) -1, 3-benzoxazol-2- yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide
Using tert-butyl [ (IS) -2- ( { 6- [6- (2, 2-difluoropropoxy) - 1, 3-benzoxazol-2-yl] pyridin-3-yl } oxy) -1-methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0792]
Example 31 .
N- [ (IS) -2- ( { 6- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide
[0793]
A) tert-butyl [ (IS) -2- ({ 6- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] pyridin-3-yl }oxy) -1-methylethyl] carbamate
Using methyl 5-hydroxypyridine-2-carboxylate, and in the same manner as in Example 2, steps A-E, the title compound was obtained.
MS (ESI+) : [M+H]+ 440.5.
[0794]
B) N- [ (IS) -2- ( { 6- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide
Using tert-butyl [ (IS) -2- ({ 6- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl]pyridin-3-yl}oxy) -1-methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0795]
Example 32
N- [ (IS) -2- ( { 6- [5- (2-cyclopropylethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) -1-methylethyl] acetamide
[0796]
A) tert-butyl [ (IS) -2- ({ 6- [5- (2-cyclopropylethoxy) -1, 3- benzoxazol-2-yl] pyridin-3-yl } oxy) -1-methylethyl] carbamate
Using tert-butyl [ (IS) -2-{ [6- (5-hydroxy-l, 3-benzoxazol-2- yl) pyridin-3-yl] oxy} -1-methylethyl] carbamate and 2- cyclopropylethyl methanesulfonate, and in the same manner as in Example 2, step E, the title compound was obtained.
MS (ESI+) : [M+H]+ 454.1.
[0797]
B) N- [ (IS) -2- ( { 6- [5- (2-cyclopropylethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) -1-methylethyl] acetamide
Using tert-butyl [ (IS) -2- ({ 6- [5- (2-cyclopropylethoxy) - 1, 3-benzoxazol-2-yl]pyridin-3-yl}oxy) -1-methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0798]
Example 33
N- [ (IS) -l-methyl-2- ( {5- [5- ( 1-methylethoxy) -1 , 3-benzoxazol-2- yl] isoxazol-3-yl }oxy) ethyl] acetamide
[0799]
A) tert-butyl [ (IS) -l-methyl-2- ({ 5- [5- (1-methylethoxy) -1, 3- benzoxazol-2-yl] isoxazol-3-yl } oxy) ethyl] carbamate
Using tert-butyl [ (IS) -2-{ ['5- (5-hydroxy-l, 3-benzoxazol-2- yl) isoxazol-3-yl] oxy} -1-methylethyl] carbamate (200 mg) and 2- iodopropane (0.106 mL) , and in the same manner as in Example 2, step E, the' title compound was obtained (246 mg) .
MS (ESI+) : [M+H]+ 418.2.
[0800]
B) N- [ (IS) -l-methyl-2- ( {5- [5- (1-methylethoxy) -1, 3-benzoxazol- 2-yl] isoxazol-3-yl } oxy) ethyl] acetamide
Using tert-butyl [( IS) -l-methyl-2- ({ 5- [5- ( 1- methylethoxy) -1, 3-benzoxazol-2-yl] isoxazol-3- yl } oxy) ethyl] carbamate (240 mg) , and in the same manner as in Example 1, step D, the title compound was obtained (111 mg) .
[0801]
Example 34
N- [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -4- fluoroisoxazol-3-yl } oxy) -1-methylethyl] acetamide
[0802]
A) 2-{ (IS) -2- [ (4-fluoro-5-methylisoxazol-3-yl) oxy] -1- methylethyl } -lH-isoindole-1, 3 (2H) -dione
Using 4-fluoro-5-methylisoxazol-3-ol and 2- [(IS) -2- hydroxy-l-methylethyl] -lH-isoindole-1, 3 (2H) -dione, and in the same manner as in Example 1, step B, the title compound was obtained.
1H NMR (300 MHz, . DMSO-de) δ 1.45 (3H, d, J = 6.8 Hz), 2.30 (3H, d, J = 2.3 Hz), 4.31-4.84 (3H, m) , 7.68-7.99 (4H, m) . [0803]
B) 2- [ (IS) -2-{ [4-fluoro-5- (hydroxymethyl) isoxazol-3-yl] oxy}-l- methylethyl] -lH-isoindole-1, 3 (2H) -dione
A mixture of 2-{ (IS) -2- [ (4-fluoro-5-methylisoxazol-3- yl) oxy] -l-methylethyl}-lH-isoindole-l, 3 (2H) -dione (383 mg) , N- bromosuccinimide (269 mg) , 2, 2 ' -azobis (2-methylpropionitrile) (20.7 mg) and (trifluoromethyl) benzene (5 mL) was stirred at
100°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) . The obtained residue was mixed with l-methylpyrrolidin-2-one (5 mL) and water (10 mL) , and the mixture was stirred at 105°C overnight. The reaction mixture was extracted with ethyl acetate, and the obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a colorless oil (118 mg) .
XH NMR (300 MHz, DMS0-d6) δ 1.46 (3H, d, J = 6.4 Hz), 4.36-4.81 (5H, m) , 5.66 (1H, t, J = 6.0 Hz), .7.66-8.00 (4H, m) .
[0804]
C) tert-butyl [ (IS) -2-{ [4-fluoro-5- (hydroxymethyl) isoxazol-3- yl] oxy} -1-methylethyl] carbamate
A mixture of 2- [ ( IS ) -2- { [ 4-fluoro-5- (hydroxymethyl) isoxazol-3-yl] oxy} -1-methylethyl] -lH-isoindole- 1, 3 (2H) -dione (118 mg) , hydrazine monohydrate (92 mg) and THF (2 mL) was stirred at 60°C for 2 hr. The reaction mixture was concentrated under reduced pressure, and the precipitate was filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was mixed with di-tert-butyl
dicarbonate (201 mg) and ethanol (2 ml) . The obtained mixture was stirred at 50°C overnight, and allowed to cool to room temperature, and 1M sodium hydroxide (2 mL) was added thereto.
The obtained mixture was stirred at room temperature for 3 hr, neutralized with 1 hydrochloric acid at 0°C, and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound as a
colorless oil (60.8 mg) .
ltt NMR (300 MHz, DMSO-d6) δ 1.09 (3H, d, J = 6.8 Hz), 1.37 (9H, s), 3.78-4.21 (3H, m) , 4.49 (2H, dd, J = 6.0, 1.7 Hz), 5.69 (1H, t, J = 6.0 Hz), 6.93 (1H, d, J = 7.9 Hz).
[0805]
D) tert-butyl { (IS) -2- [ (4-fluoro-5-formylisoxazol-3-yl) oxy] -1- methylethyl } carbamate
A mixture of tert-butyl [ ( IS) -2- { [4-fluoro-5- (hydroxymethyl) isoxazol-3-yl] oxy} -1-methylethyl] carbamate (164 mg) , Dess-Martin periodinane (288 mg) and acetonitrile (3 mL) was stirred at 0°C for 1 hr, and then at room temperature for 30 min. To the reaction mixture was further added Dess-Martin periodinane (288 mg) , and the mixture was stirred at room temperature for 30 min. To the reaction mixture were added saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium thiosulfate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a colorless oil (155 mg) .
X 1 NMR (300 MHz, DMSO-d6) δ 1.10 (3H, d, J = 6.8 Hz), 1.37 (9H, s), 3.83-3.98 (1H, m) , 4.12-4.39 (2H, m) , 6.97 (1H, d, J = 8.0 Hz) , 9.83 (1H, s) .
[0806].
E) 3- ( { (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) -4- fluoroisoxazole-5-carboxylic acid
To a mixture of tert-butyl { (IS) -2- [ (4-fluoro-5- formylisoxazol-3-yl) oxy] -1-methylethyl } carbamate (244 mg) , sodium dihydrogen phosphate (305 mg) , 2-methylbut-2-ene (449 mL) , 2-methylpropan-2-ol (5 mL) and water (1 mL) was added sodium chlorite (115 mg) at. room temperature, and the obtained mixture was stirred at room temperature overnight. Water was added to the reaction, mixture, and the mixture was extracted with a mixed solvent of ethyl acetate/2-propanol (volume ratio 3/1) . The obtained organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound as a white powder (256 mg) . XH N R (300 MHz, DMSO-d6) δ 1.08 (3H, d, J = 6.8 Hz), 1.37 (9H, s) , 3.78-4.23 (3H, m) , 6.94 (1H, d, J = 7.9 Hz) .
[0807]
F) tert-butyl [ (IS) -2- ( { 5- [ (2, 5-dihydroxyphenyl) carbamoyl] -4- fluoroisoxazol-3-yl}oxy) -1-methylethyl] carbamate
Using 3- ( { (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) - 4-fluoroisoxazole-5-carboxylic acid, and in the same manner as in Example 2, step C, the title compound was obtained.
MS (ESI-) : [M-H]" 410.3.
[0808]
G) N- [ (IS) -2- ( {5- [5- (cyclopropylmethoxy) -1 , 3-benzoxazol-2-yl] - 4-fluoroisoxazol-3-yl}oxy) -1-methylethyl] acetamide
Using tert-butyl [ (IS) -2- ( { 5- [ (2, 5- dihydroxyphenyl) carbamoyl] -4-fluoroisoxazol-3-yl }oxy) -1- methylethyl] carbamate, and in the same manner as in Example 2, steps D-E and Example 1, step D, the title compound was
obtained.
[0809]
Example 35
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -1, 3-benzothiazol-2- yl] phenoxy} -1-methylethyl] acetamide
[0810]
A) 2-ethylhexyl 3-{ [5- (benzyloxy) -2- nitrophenyl] sulfanyl }propanoate
To a mixture of 4- (benzyloxy) -2-fluoro-l-nitrobenzene (2.00 g) , potassium carbonate (1.23 g) and DMF (11 mL) was added dropwise 2-ethylhexyl 3-sulfanylpropanoate (2.02 mL) , and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate, and washed with saturated brine. The obtained organic layer was dried over anhydrous magnesium sulfate, and the solvent was
evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a yellow liquid (3.60 g) .
XH NMR (300 MHz, DMSO-d6) δ 0.75-0.90 (6H, m) , 1.15-1.35 ( 8H, m) , 1.44-1.57 (1H, m) , 2.68 (2H, t, J = 6.8 Hz), 3.26 (2H, t, J = 6.8 Hz), 3.96 (2H, d, J = 5.7 Hz), 5.32 (2H, s) , 6.93-7.12 (2H, m) , 7.31-7.53 (5H, m), 8.18-8.28 (1H, m) .
[0811]
B) 2-ethylhexyl 3-{ [2-amino-5- (benzyloxy) phenyl] sulfanyl }propanoate
To a solution of 2-ethylhexyl 3- { [5- (benzyloxy) -2- nitrophenyl] sulfanyl }propanoate (3.60 g) and 6M hydrochloric acid (2.69 mL) in ethanol (46 mL) was added reduced iron (4.51 g) , and the mixture was heated under reflux for 3 hr. The insoluble material was removed by filtration, and the solvent of the filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound as a dark red liquid (2.38 g).
¾ NMR (300 MHz, CDC13) δ 0.80-0.95 (6H, m) , 1.18-1.42 (9H, m) , 2.54 (2H, t, J = 7.2 Hz), 2.99 (2H, t, J = 7.2 Hz), 4.00 (2H, dd, J = 5.8, 1.7 Hz), 4.04-4.13 (2H, m) , 4.98 (2H, s) , 6.68
(1H, d, J = 8.7 Hz), 6.79-6.86 (1H, m) , 7.04 (1H, d, J = 3.0 Hz) , 7.28-7.47 (5H, m) .
[0812]
C) 2-ethylhexyl 3-{ [2-{ [ (4-{ [ (2S) -2- (acetylamino) propyl] oxy}phenyl) carbonyl] amino} -5- (benzyloxy) phenyl] sulfanyl}propanoate
Using 2-ethylhexyl 3-{ [2-amino-5- (benzyloxy) phenyl] sulfanyl}propanoate (1.00 g) and 4-{[(2S)-2- (acetylamino) propyl] oxy}benzoic acid (628 mg) , and in the same manner as in Example 2, step C, the title compound (1.02 g) was obtained.
1H N R (300 MHz, CDC13) δ 0.80-0.95 (6H, m) , 1.21-1.40 (11H, m) , 1.48-1.60 (1H, m), 2.01 (3H, s) , 2.52 (2H, t, J = 7.1 Hz), 3.02 (2H, t, J = 7.1 Hz), 3.91-4.13 (4H, m) , 4.37-4.49 (1H, m) , 5.06 (2H, s), 5.70 (1H, d, J = 7.5 Hz), 6.93-7.06 (3H, m) ,
7.16 (1H, d, J = 3.0 Hz), 7.23-7.44 (5H, m) , 7.90 (2H, d, J =
8.7 Hz), 8.44 (1H, d, J = 9.0 Hz), 9.01 (1H, s) .
[0813]
D) N- [ (IS) -2-{ 4- [6- (benzyloxy) -1, 3-benzothiazol-2-yl] phenoxy} - 1-methylethyl] acetamide
To a solution of 2-ethylhexyl 3-{ [2-{ [ (4-{ [ (2S) -2- (acetylamino) propyl] oxyjphenyl) carbonyl] amino}-5- (benzyloxy) phenyl] sulfanyl }propanoate (1.00 g) in THF (7.0 mL) was added sodium methoxide (28% methanol solution, 2.0 mL) , and the mixture was stirred at room temperature for 1 hr under a nitrogen atmosphere. The reaction mixture was cooled to 0°C, trifluoroacetic acid (4.0 mL) was added thereto, and the mixture was stirred at 80°C'for 3 hr. The reaction mixture was diluted with ethyl acetate, and washed with aqueous potassium carbonate solution and saturated brine, and the solvent was evaporated under reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate) , and washed with a 1:1 mixture of ethyl acetate/diisopropyl ether to give the title compound (504 mg) .
1H NMR (300 MHz, CDC13) δ 1.34 (3H, d, J = 6.9 Hz), 2.01 (3H, s), 4.02 (2H, td, J = 8.9, 3.9 Hz), 4.37-4.50 (1H, m) , 5.14 (2H, s), 5.70 (lH, d, J = 7.8 Hz), 6.99 (2H, d, J = 8.7 Hz), 7.14 (1H, dd, J = 9.3, 2.6 Hz), 7.29-7.51 (6H, m) , 7.91 (1H, d, J = 9.0 Hz), 7.97 (2H, d, J = 8.7 Hz).
[0814] E) N- [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) -1, 3-benzothiazol-2- yl] phenoxy} -1-methylethyl] acetamide
A mixture of N- [ ( IS ) -2- { 4- [ 6- (benzyloxy) -1, 3- benzothiazol-2-yl] phenoxy} -1-methylethyl] acetamide (46 mg) , trifluoroacetic acid (1 mL) and thioanisole (0.1 mL) was stirred at 55°C for 16 hr. The reaction mixture was
concentrated under reduced pressure, and the residue was washed with diisopropyl ether to give N-{ (IS) -2- [4- (6-hydroxy- 1, 3-benzothiazol-2-yl) phenoxy] -1-methylethyl } acetamide (38.6 mg) as a powder. Using the obtained powder, and in the same manner as in Example 1, step A, the title compound was
obtained.
XH NMR (300 MHz, CDC13) δ 0.35-0.41 (2H, m) , 0.64-0.71 (2H, m) , 1.30-1.36 (4H, m) , 2.01 (3H, s) , 3.87 (2H,. d, J = 6.9 Hz) , 4.02 (2H, td, J = 9.0, 3.6 Hz), 4.39-4.45 (1H, m) , 5.65-5.75 (1H, m) , 6.99 (2H, d, J = 9.0 Hz), 7.08 (1H, dd, J = 9.0, 2.7 Hz), 7.32 (1H, d, J = 2.4 Hz), 7.89 (1H, d, J = 9.0 Hz), 7.97 (2H, d, J = 9.0 Hz) .
[0815]
Example 36
N- [ (IS) -2- ( { 5- [6- (cyclopropylmethoxy) -1, 3-benzothiazol-2- yl] isoxazol-3-yl}oxy) -1-methylethyl] acetamide
[0816]
A) 4- (cyclopropylmethoxy) -2-fluoro-l-nitrobenzene
Using 3-fluoro-4-nitrophenol, and in the same manner as in Example 1, step A, the title compound was obtained.
XH NMR (300 MHz, DMSO-d6) δ 0.28-0.43 (2H, m) , 0.50-0.66 (2H, m) , 1.19-1.35 (1H, m) , 3.99 (2H, d, J = 7.2 Hz), 6.97 (1H, d, J = 9.4 Hz), 7.16 (1H, dd, J = 13.6, 2.6 Hz), 8.13 (1H, t, J = 9.1 Hz).
[0817]
B) 2-ethylhexyl 3- { [5- (cyclopropylmethoxy) -2- nitrophenyl] sulfanyl Jpropanoate
Using 4- (cyclopropylmethoxy) -2-fluoro-l-nitrobenzene, and in the same manner as in Example 35, step A, the title compound was obtained.
XH NMR_(300 MHz, DMSO-d6) δ 0.32-0.41' (2H, m) , 0.55-0.66 (2H, m) , 0.81-0.91 (6H, m) , 1.20-1.37 (9H, m) , 1.47-1.59 (1H, m) , 2.73 (2H, t, J = 6.8 Hz), 3.29 (2H, t, J = 6.8 Hz), 3.-97 (2H, d, J = 5.7 Hz), 4.01 (2H, d, J = 3.0 Hz), 6.89-6.98 (2H, m) , 8.22 (1H, d, J = 9.8 Hz) .
[0818]
C) 2-ethylhexyl 3-{ [2-amino-5- .
(cyclopropylmethoxy) phenyl] sulfanyl }prbpanoate
Using 2-ethylhexyl 3- { [5- (cyclopropylmethoxy) -2- nitrophenyl] sulfanyl }propanoate, and in the same manner as in Example 35, step B, the title compound was obtained.
XH NMR (300 MHz, DMSO-d6) δ 0.22-0.32 (2H, m) , 0.53 (2H, dd, J = 8.3, 1.9 Hz), 0.80-0.91 (6H, m) , 1.20-1.38 (9H, m) , 1.46- 1.60 (1H, m) , 2.51-2.56 (2H, m) , 2.92 (2H, t, J = 7.0 Hz), 3.67 (2H, d, J = 6.8 Hz), 3.95 (2H, d, J = 5.7 Hz), 4.86 (2H, s), 6.63-6.69 (1H, m) , 6.70 (1H, d, J = 2.6 Hz), 6.80 (1H, d, J = 2.6 Hz) .
[0819]
D) methyl 3- {[ (2S)' -2- (acetylamino) propyl] oxy} isoxazole-5- carboxylate
Using methyl 3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) isoxazole-5-carboxylate, and in the ' same manner as in Example 1, step D, the title compound was obtained.
MS (ESI+) : [M+H]+ 243.1.
[0820]
E) 3-{ [ (2S) -2- (acetylamino) propyl] oxy} isoxazole-5-carboxylic acid
Using methyl 3-{[(2S)-2- (acetylamino) propyl] oxy}isoxazole-5-carboxylate, and in the same manner as in Example 2, step B, the title compound was ■ obtained.
MS (ESI+) : [M+H]+ 229.1.
[0821] F) 2-ethylhexyl 3-{ [2-{ [ (3-{ [ (2S) -2-
(acetylamino) propyl] oxy} isoxazol-5-yl) carbonyl] amino}-5- (cyclopropylmethoxy) phenyl] sulfanyl Jpropanoate
Using 3- { [ (2S) -2- (acetylamino) propyl] oxy} isoxazole-5- carboxylic acid and 2-ethylhexyl 3-{ [2-amino-5-
(cyclopropylmethoxy) phenyl] sulfanyl }propanoate, and in the same manner as in Example 2, step C, the title compound was obtained.
MS (ESI+) : [M+H]+ 590.1. .
[0822]
G) N- [ (IS) -2- ( {5- [6- (cyclopropylmethoxy) -1, 3-benzothiazol-2- yl] isoxazol-3-yl }oxy) -1-methylethyl] acetamide
A mixture of 2-ethylhexyl 3- { [2- { [ ( 3- { [ (2S ) -2- (acetylamino) propyl] oxy} isoxazol-5-yl) carbonyl] amino}-5- (cyclopropylmethoxy) phenyl] sulfanyl }propanoate (935 mg) , sodium ethoxide (20% ethanol solution, 1.08 g) and THF (10 mL) was stirred at room temperature for 30 min. To the reaction mixture was added trifluoroacetic acid (0.611 mL) at 0°C, and the obtained mixture was stirred at 70°C overnight. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) , and recrystallized (ethyl acetate) to give the title compound as white crystals (71.6 mg) .
[0823]
Example 37
N- [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzothiazol-2- yl] ispxazol-3-yl }oxy) -1-methylethyl] acetamide
[0824]
A) 4- (cyclopropylmethoxy) -1-fluoro-2-nitrobenzene
Using 4-fluoro-3-nitrophenol, and in the same manner asin Example 1, step A, the title compound was obtained. XH N R (300 MHz, DMSO-d6) δ 0.29-0.41 (2H, m) , 0.53-0.63 (2H, m) , 1.20-1.30 (1H, m) , 3.91 (2H, d, J = 6.8 Hz), 7.34-7.43 (1H, m) , 7.47-7.56 (1H, m) , 7.57-7.63 (1H, m) .
[0825]
B) 2-ethylhexyl 3- { [4- (cyclopropylmethoxy) -2- nitrophenyl] sulfanyl}propanoate
Using 4- (cyclopropylmethoxy) -1-fluoro-2-nitrobenzene, and in the same manner. as in Example 35, step A, the title
compound was obtained.
¾ NMR (300 MHz, DMSO-d6) δ 0.29-0.42 (2H, m) , 0.52-0.65 (2H, m) , 0.75-0.93 (6H, m) , 1.08-1.39 (9H, m) , 1.43-1.60 (1H, m) , ' 2.57-2.70 (2H, m) , 3.21 (2H, t, J = 7.0 Hz), 3.86-4.00 (4H, m) , 7.33 (1H, dd, J = 8.9, 2.8 Hz), 7.52-7.67 (2H, m) .
[0826]
C) 2-ethylhexyl 3-{ [2-amino-4-
(cyclopropylmethoxy) phenyl] sulfanyl }propanoate
Using 2-ethylhexyl 3- { [4- (cyclopropylmethoxy) -2- nitrophenyl] sulfanyl }propanoate, and in the same manner as in Example 35, step B, the title compound was obtained.
XH NMR (300 MHz, DMSO-d6) δ 0.23-0.34 (2H, m) , 0.48-0.61 (2H, iti) , 0.76-0.92 (6H, m) , 1.21-1.38 (9H, m) , 1.45-1.60 (1H, m) , 2.41-2.49 (2H, m) , 2.73-2.80 (2H, m) , 3.71 (2H, d, J = 7.2 Hz), 3.93 (2H, d, J = 5.7 Hz), 5.37 (2H, s) , 6.09 (1H, dd, J = 8.7, 2.6 Hz), 6.29 (1H, d, J = 2.6 Hz), 7.09 (1H, d, J = 8.7 Hz).
[0827]
D) 2-ethylhexyl 3-{ [2-{ [ (3-{ [ (2S) -2-
(acetylamino) propyl] oxy}isoxazol-5-yl) carbonyl] amino}-4- (cyclopropylmethoxy) phenyl] sulfanyl }propanoate
Using 3- { [ (2S) -2- (acetylamino) propyl] oxy} isoxazole-5- carboxylic acid and 2-ethylhexyl 3-{ [2-amino-4-
(cyclopropylmethoxy) phenyl] sulfanyl }propanoate, and in the same manner as in Example 2, step C, the title compound was obtained.
MS (ESI+) : [M+H]+ 590.1.
[0828] E) N-[(lS)-2-({5-[5- (cyclopropylmethoxy) -1, 3-benzothiazol-2- yl] isoxazol-3-yl }oxy) -1-methylethyl] acetamide
Using 2-ethylhexyl 3-{ [2-{ [ (3-{ [ (2S) -2- (acetylamino) propyl] oxy} isoxazol-5—yl) carbonyl] mino }—4—
(cyclopropylmethoxy) phenyl] sulfanyl }propanoate, and in the same manner as in Example 36, step G, the title compound was obtained.
[0829]
Example 38
N- [ (IS) -2- ( { 5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -4- methyl-lH-pyrazol-3-yl}oxy) -1-methylethyl] acetamide
[0830]
A) methyl 4-bromo-3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) -lH-pyrazole-5-carboxylate
A mixture of methyl.3- ( { (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) -lH-pyrazole-5-carboxylate
(2.00 g) , N-bromosuccinimide (1.43 g) and acetonitrile (50 mL) was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a white powder (2.20 g) . XH NMR (300 MHz, DMSO-d6) δ 1.08 (3H, d, J = 6.8 Hz), 1.37 (9H, s), 3.68-4.20 (6H, m) , 6.84 (1H, d, J = 8.3 Hz), 13.53 (1H, s) .
[0831]
B) methyl l-benzyl-4-bromo-3- ( { (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) -lH-pyrazole-5-carboxylate
Using methyl 4-bromo-3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) -lH-pyrazole-5-carboxylate and benzyl bromide, and in the same manner as in Example 1, step A, the title compound was obtained.
1H NMR (300 MHz, DMSO-d6) δ 1.08 (3H, d, J = 6.8 Hz), 1.37 (9H, s), 3.73-4.15 (6H, m) , 5.54 (2H, s) , 6.86 (1H, d, J = 7.9 Hz), 7.07-7.40 (5H, m) .
[0832]
C) methyl l-benzyl-3- (.{ (2S) -2- [ (tert- butoxycarbonyl) amino] propyl} oxy) -4-methyl-lH-pyrazole-5- carboxylate
Under an argon atmosphere, a mixture of methyl 1-benzyl- 4-bromo-3- ( { (2S) -2- [ (tert-butoxycarbonyl) amino] propyl }oxy) -1H- pyrazole-5-carboxylate (1.03 g) , trimethylboroxin (552 mg) , [1,1' -bis (diphenylphosphino) ferrocene] dichloropalladium(II) dichloromethane adduct (181 mg) , potassium carbonate (912 mg) and DMF (20 mL) was stirred at 155°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained. organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound as a white powder (330 mg).
MS (ESI+) : [M+H]+ 404.2.
[0833]
D) l-benzyl-3- ({ (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) -4-methyl-lH-pyrazole-5- carboxylic acid
Using methyl l-benzyl-3- ({ (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) -4-methyl-lH-pyrazole-5- carboxylate, and in the same manner as in Example 2, step B, the title compound was obtained.
MS (ESI+) : [M+H]+ 390.2.
[0834]
E) tert-butyl [ (IS) -2- ( { l-benzyl-5- [ (2, 4- dihydroxyphenyl) carbamoyl] -4-methyl-lH-pyrazol-3-yl } oxy) -1- methylethyl] carbamate
Using l-benzyl-3- ({ (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) -4-methyl-lH-pyrazole-5- carboxylic acid and 4-aminobenzene-l, 3-diol hydrochloride, and in the same manner as in Example 2, step C, the title compound was obtained.
MS (ESI+) : [M+H]+ 497.2.
[0835]
F) tert-butyl [ (IS) -2-{ [l-benzyl-5- ( 6-hydroxy-l, 3-benzoxazol-
2-yl) -4-methyl-lH-pyrazol-3-yl] oxy} -1-methylethyl] carbamate
Using tert-butyl [ (IS) -2- ({ l-benzyl-5- [ (2, 4- dihydroxyphenyl) carbamoyl] -4-methyl-lH-pyrazol-3-yl } oxy) -1- methyiethyl] carbamate, and in the same manner as in Example 2, step D, the title compound was obtained.
MS (ESI+) : [M+H]+ 479.2..
[0836]
G) tert-butyl [( IS) -2- ({ l-benzyl-5- [ 6- (cyclopropylmethoxy) - 1, 3-benzoxazol-2-yl] -4-methyl-lH-pyrazol-3-yl } oxy) -1- methylethyl] carbamate
Using tert-butyl [ (IS) -2-{ [l-benzyl-5- (6-hydroxy-l, 3- benzoxazol-2-yl) -4-methyl-lH-pyrazol-3-yl] oxy} -1- methylethyl] carbamate, and in the same manner as in Example 1, step A, the title compound was obtained.
XH NMR (300 MHz, DMSO-d6) δ 0.28-0.38 (2H, m) , 0.51-0.65 (2H, m) , 1.10 (3H, d, J = 6.8 Hz), 1.24-1.31 (1H, m) , 1.38 (9H, s) , 2.22 (3H, s), 3.76-4.13 (5H, m) , 5.75 (2H, s), 6.85 (1H, d, J = 8.3 Hz), 6.96-7.06 (1H, m) , 7.09-7.35 (5H, m) , 7.40 (1H, d, J = 2.3 Hz), 7.68 (1H, d, J = 8.7 Hz).
[0837]
H) N- [ (IS) -2- ( {l-benzyl-5- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -4-methyl-lH-pyrazol-3-yl } oxy) -1- methylethyl] acetamide
Using tert-butyl [( IS ) -2- ({ l-benzyl-5- [ 6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -4-methyl-lH-pyrazol-
3-yl}oxy) -1-methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
MS (ESI+) : [M+H]+ 475.3.
[0838]
I) N- [ (IS) -2- ( {5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] - 4-methyl-lH-pyrazol-3-yl}oxy) -1-methylethyl] acetamide
Using N- [ ( IS) -2- ( { 1-benzyl-5- [ 6- (cyclopropylmethoxy) -1,3- benzoxazol-2-yl] -4-methyl-lH-pyrazol-3-yl } oxy) -1- methylethyl] acetamide, and in the same manner as in Example 8, step H, the title compound was obtained.
[0839]
Example 39
N- [ (IS) -2- ( { l-benzyl-5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol- 2-yl] -lH-pyrazol-3-yl}oxy) -1-methylethyl] acetamide
[0840]
A) tert-butyl [ ( IS ) -2- ( { l-benzyl-5- [ (2 , 5- dihydroxyphenyl) carbamoyl] -lH-pyrazol-3-yl } oxy) -1- methylethyl] carbamate
Using l-benzyl-3- ( { (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) -lH-pyrazole-5-carboxylic acid, and in the same manner as in Example 2, step C, the title compound was obtained.
MS (ESI+) : [M+H]+ 483.4..
[0841]
B) tert-butyl [ (IS) -2-{ [l-benzyl-5- (5-hydroxy-l, 3-benzoxazol- 2-yl) -lH-pyrazol-3-yl] oxy} -1-methylethyl] carbamate
Using tert-butyl [ (IS) -2- ({l-benzyl-5- [ (2, 5- dihydroxyphenyl) carbamoyl] -lH-pyrazol-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 2, step D, the title compound was obtained.
MS (ESI+) : [M+H]+ 465.4.
[0842]
C) tert-butyl [ (IS) -2- ({ l-benzyl-5- [5- (cyclopropylmethoxy) -
1, 3-benzoxazol-2-yl] -lH-pyrazol-3-yl } oxy) -1- methylethyl] carbamate
Using tert-butyl [ (IS) -2-{ [l-benzyl-5- (5-hydroxy-l, 3- benzoxazol-2-yl) -lH-pyrazol-3-yl] oxy} -1-methylethyl] carbamate, and in the same manner as in Example 1, step A, the title compound was obtained.
MS (ESI+) : [M+H]+ 519.4. [0843]
D) N- [ (IS) -2- ( { l-benzyl-5- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -lH-pyrazol-3-yl}oxy) -1-methylethyl] acetamide Using tert-butyl [ (IS) -2- ({l-benzyl-5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -lH-pyrazol-3- yl }oxy) -1-methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0844]
Example 40
N- [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -1H- pyrazol-3-yl}oxy) -1-methylethyl] acetamide
[0845]
Using N- [ (IS) -2- ({ l-benzyl-5- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -lH-pyrazol-3-yl } oxy) -1-methylethyl] acetamide, and in the same manner as in Example 8, step H, the title compound was obtained.
[0846]
Example 41
N- [ (IS) -2- ( { 5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -4- methylisoxazol-3-yl}oxy) -1-methylethyl] acetamide
[0847]
A) tert-butyl [ (IS) -2- ( {5- [ (2, 4- dihydroxyphenyl) carbamoyl] isoxazol-3-yl } oxy) -1- methylethyl] carbamate
Using 3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) isoxazole-5-carboxylic acid and 4-aminobenzene-l, 3-diol hydrochloride, and in the same manner as in Example 2, step C, the title compound was
obtained.
MS (ESI-) : [M-H] ~ 392.3.
[0848]
B) tert-butyl [ (IS) -2- ( {5- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] isoxazol-3-yl } oxy) -1-methylethyl] carbamate
Using tert-butyl [ (IS) -2- ( { 5- [ (2, 4- dihydroxyphenyl) carbamoyl] isoxazol-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 2, step D and Example 1, step A, the title compound was obtained. MS (ESI+) : [M+H] + 430.1.
[0849]
C) tert-butyl [ (IS) -2- ( {5- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -4-methylisoxazol-3-yl } oxy) -1- methylethyl] carbamate
Using tert-butyl [ (IS) -2- ({ 5- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] isoxazol-3-yl } oxy) -1-methylethyl] carbamate, and in the same manner as in Example 23, step A, the title compound was obtained.
1H. NMR (300 MHz, DMSO-d6) δ 0.27-0.43 (2H, m) , 0.52-0.70 (2H, m) , 1.12 (3H, d, J = 6.8 Hz), 1.19-1.32 (1H, m) , 1.38 (9H, s) , 2.25 (3H, s), 3.79-4.02 (3H, m) , .4.05-4.25 (2H, m) , 6.86-7.01 (1H, m) , 7.08 (1H, dd, J = 8.8, 2.4 Hz), 7.47 (lH, d, J = 2.4 Hz) , 7.77 (1H, d, J = 8.8 Hz) .
[0850]
D) N- [ (IS) -2- ( { 5- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] - 4-methylisoxazol-3-yl } oxy) -1-methylethyl] acetamide
Using tert-butyl [( IS) -2- ({ 5- [ 6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -4-methylisoxazol-3-yl}oxy) -1- methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0851]
Example 42
N- [2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] isoxazol-
3-yl } oxy) -1- (fluoromethyl) ethyl] acetamide
[0852]
A) methyl 3- ( 3-fluoro-2-hydroxypropoxy) isoxazole-5-carboxylate A mixture of methyl 3-hydroxyisoxazole-5-carboxylate
(1.88 g) , 2- (fluoromethyl) oxirane (1.00 g) , potassium
carbonate (1.82 g) and DMF (2 mL) was stirred at room
temperature for 2 hr, and then at 70°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound as a white powder (585 mg) .
MS (ESI+) : [M+H]+ 220.1.
[0853]
B) 3- (3-fluoro-2-hydroxypropoxy) isoxazole-5-carboxylic acid
Using methyl 3- (3-fluoro-2-hydroxypropoxy) isoxazole-5- carboxylate, and in the same manner as in Example 6, step D, the title compound was obtained.
MS (ESI-) : [M-H] " 204.1.
[0854]
C) 2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] isoxazol- 3-yl }oxy) -1- (fluoromethyl) ethyl methanesulfonate
A mixture of 3- ( 3-fluoro-2-hydroxypropoxy) isoxazole-5- carboxylic acid (457 mg) , methanesulfonyl chloride (0.517 mL) , . triethylamine (0.668 mL) and THF (20 mL) was stirred at 0°C for 1 hr, and then at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was mixed with 2-aminobenzene-l, 4-diol hydrochloride (360 mg) , HATU (848 mg) , N, N-diisopropylethylamine (0.769 mL) and DMF (10 mL) , and the obtained mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (318 mg) of 2- ( { 5- [ (2, 5-dihydroxyphenyl) carbamoyl] isoxazol-3- yl }oxy) -1- (fluoromethyl) ethyl methanesulfonate and impurity.
To a solution of hexachloroethane (482 mg) and triphenylphosphine (641 mg) in acetonitrile (5 mL) was added triethylamine (0.908 mL) at room temperature, and the obtained mixture was stirred at room temperature, for 10 min. A mixture of 2- ( {5- [ (2, 5-dihydroxyphenyl) carbamoyl] isoxazol-3-yl } oxy) -1- (fluoromethyl) ethyl methanesulfonate (318 mg, mixture with impurity) obtained by the aforementioned method, acetonitrile (5 mL) and THF (2 mL) was added thereto, and the obtained mixture was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give a mixture (321 mg) of 2-fluoro- l-({ [5- (5-hydroxy-l, 3-benzoxazol-2-yl) isoxazol-3- yl] oxy}methyl) ethyl methanesulfonate and impurity. A mixture of the obtained 2-fluoro-l- ({ [5- (5-hydroxy-l, 3-benzoxazol-2- yl) isoxazol-3-yl] oxy}methyl) ethyl methanesulfonate (321 mg, mixture with impurity), (bromomethyl) cyclopropane (128 mg) , potassium carbonate (131 mg) and DMF (5 mL) was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a white powder (97.3 mg) .
MS (ESI+) : [M+H]+ 427.0.
[0855]
D) N- [2- ({ 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl}oxy) -1- (fluoromethyl) ethyl] acetamide
A mixture of 2- ({ 5- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] isoxazol-3-yl}oxy) -1- (fluoromethyl) ethyl methanesulfonate (97.3 mg) , sodium azide (29.7 mg) and
dimethyl sulfoxide (2 mL) was stirred at 100°C for 4 hr. Water was added to the reaction mixture, and the mixture was
extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was mixed with
triphenylphosphine (71.8 mg) , THF (3 mL) and water (1 mL) , and the obtained mixture was stirred at 90°C for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was mixed with acetic anhydride (1 mL) , triethylamine (.1 mL) and ethyl acetate (3 mL) , and the obtained mixture was stirred at 60°C overnight. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) . The obtained residue was separated by HPLC (C18, mobile phase:
water/acetonitrile (containing 0.1% TFA) ) . A saturated aqueous sodium hydrogen carbonate solution was added to the obtained fraction, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure to give the title compound as white crystals (52.3 mg) .
[0856]
Example 43
N-{ 1- [ ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl }oxy) methyl] -2, 2-difluoroethyl } acetamide
[0857]
A) methyl 3- [ (2-hydroxybut-3-en-l-yl) oxy] isoxazole-5- carboxylate
Using 2-ethenyloxirane, and in the same manner as in Example 42, step A, the title compound was obtained.
MS (ESI+) : [M+H]+ 214.0.
[0858] B) methyl 3- ( 3 , 3-difluoro-2-hydroxypropoxy) isoxazole-5- carboxylate
A mixture of methyl 3- [ (2-hydroxybut-3-en-l- yl ) oxy] isoxazole-5-carboxylate (2.71 g) , t-butyldimethylsilyl trifluoromethanesulfonate (4.03 g) , 2 , 6-dimethylpyridine (1.64 g) and THF (30 mL) was stirred at room temperature for 2 hr. To the reaction mixture was added IM hydrochloric acid, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated aqueous sodium
hydrogen carbonate solution, and then saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was mixed with tetraoxide osmium (7% immobilized catalyst, 2.31 g) , sodium periodate (13.6 g) , acetonitrile (30 mL) , acetone (30 mL) and water (20 mL) , and the obtained mixture was stirred at room temperature for 3 days. The precipitate was removed by filtration, and the filtrate was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was mixed with toluene (20 mL) , diethylaminosulfur trifluoride (5.04 mL) was slowly added dropwise thereto at room temperature, and the obtained mixture was stirred at room temperature for 2 hr. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was mixed with THF (20 mL) , tetrabutylammonium
fluoride (1.0M THF solution, 25.4 mL) was slowly added
dropwise thereto at 0°C, and the obtained mixture was stirred at 0°C for 30 min. To the reaction mixture was added IM hydrochloric acid, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a white powder (370 mg) . MS (ESI+) : [M+H]+ 238.1.
[0859]
C) methyl 3- { 3, 3-difluoro-2-
[ (methylsulfonyl) oxy] propoxy} isoxazole-5-carboxylate
A mixture of methyl 3- (3, 3-difluoro-2- hydroxypropoxy) isoxazole-5-carboxylate (370 mg) ,
methanesulfonyl chloride (0.362 mL) , triethylamine (0.652 mL) and THF (10 mL) was stirred at 0°C for 1 hr, and then at room temperature overnight. .Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a colorless oil (432 mg) .
1H NMR (300 MHz, DMSO-d6) δ 3.33 (3H, s) , 3.89 (3H, s) , 4.37- 4.78 (2H, m) , 5.14-5.45 (1H, m) , 6.13-6.66 (1H, m) , 7.20 (1H, s).
[0860]
D) 1- [({ 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl}oxy)methyl] -2, 2-difluoroethyl
methanesulfonate
Using methyl 3-{ 3, 3-difluoro-2-
[ (methylsulfonyl) oxy] propoxy} isoxazole-5-carboxylate, and in the same manner as in Example 6, step D and Example 2, steps
C-E, the title compound was obtained.
MS (ESI+) : [M+H]+ 445.0.
[0861]
E) N-{ 1- [ ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl}oxy)methyl] -2, 2-difluoroethyl } acetamide
Using 1- [({ 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] isoxazol-3-yl}oxy)methyl] -2, 2-difluoroethyl methanesulfonate, and in the same manner as in Example 42, step D, the title compound was obtained.
[0862]
Example 44
1- [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -4- methylisoxazol-3-yl}oxy) -1-methylethyl] -3-methylurea
[0863]
Using tert-butyl [ (IS) -2- ({ 5- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -4-methylisoxazol-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 16 (using pyridine instead of triethylamine) , the title compound was obtained.
[0864]
Example 45
1- [ (IS) -2- ( { 5- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -4- methylisoxazol-3-yl }oxy) -1-methylethyl] urea
[0865]
Using tert-butyl [ (IS) -2- ({ 5- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -4-methylisoxazol-3-yl } oxy) -1- methylethyl] carbamate, and in the ' same manner as in Example 22 (using pyridine instead of triethylamine) , the title compound was obtained.
[0866]
Example 46
N- [ (IS) -2-{ [5- (5-ethoxy-l, 3-benzoxazol-2-yl) isoxazol-3- yl] oxy} -1-methylethyl] acetamide
[0867]
A) tert-butyl [ (IS) -2-{ [5- (5-ethoxy-l, 3-benzoxazol-2- yl) isoxazol-3-yl] oxy} -1-methylethyl] carbamate
Using tert-butyl [ (IS) -2-{ [5- (5-hydroxy-l, 3-benzoxazol-2- yl) isoxazol-3-yl] oxy} -1-methylethyl] carbamate and ethyl iodide, and in the same manner as in Example 2, step E, the title compound was obtained.
MS (ESI+) : [M+H]+ 404.3.
[0868] B) N- [ (IS) -2-{ [5- (5-ethoxy-l, 3-benzoxazol-2-yl) isoxazol-3- yl] oxy}-l-methylethyl] acetamide
Using tert-butyl [ (IS) -2-{ [5- (5-ethoxy-l, 3-benzoxazol-2- yl) isoxazol-3-yl] oxy} -1-methylethyl] carbamate, and in the same manner as in Example- 2, step F, the title compound was
obtained.
[0869]
Example 47
N- (3-{ 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] pyridin-3- yl}-l-methyl-3-oxopropyl) acetamide
[0870]
A) tert-butyl { 3- [methoxy (methyl) amino] -l-methyl-3- oxopropyl } carbamate
Using 3- [ (tert-butoxycarbonyl) amino] butanoic acid, and in the same manner as in Example 24, step D, the title compound was obtained..
XH NMR (300 MHz, DMSO-d6) δ 1.03 (3H, d, J = 6.8 Hz), 1.37 (9H, s), 2.34-2.47 (1H, m) ,' 2.52-2.61 (1H, m) , 3.07 (3H, s), 3.64 (3H, s), 3.74-3.94 (1H, m) , 6.71 (1H, d, J = 8.3 Hz).
[0871]
B) tert-butyl [3- ( 6-chloropyridin-3-yl) -l-methyl-3- oxopropyl] carbamate
Using tert-butyl { 3- [methoxy (methyl) amino] -l-methyl-3- oxopropyl } carbamate and 5-bromo-2-chloropyridine, and in the same manner as in Example 24, step E, the title compound was obtained.
XH NMR (300 MHz, DMSO-d6) δ 1.11 (3H, d, J = 6.8 Hz), 1.31 (9H, s), 2.90-3.09 (1H, m) , 3.10-3.25 (1H, m) , 3.85-4.08 (1H, m) , 6.85 (1H, d, J = 7.6 Hz), 7.69 (1H, d, J = 8.3 Hz), 8.29 (1H, dd, J = 8.3, 2.3 Hz), 8.94 (1H, d, J = 2.3 Hz).
[0872]
C) tert-butyl (3-{ 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl }-l-methyl-3-oxopropyl) carbamate
Using tert-butyl [3- ( 6-chloropyridin-3-yl) -l-methyl-3- oxopropyl] carbamate, and in the same manner as in Example 1, step C, the title compound was obtained.
MS (ESI+) : [M+H]+ 452.0.
[0873]
D) N- (3-{ 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } -l-methyl-3-oxopropyl) acetamide
Using tert-butyl ( 3- { 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] pyridin-3-yl } -l-methyl-3-oxopropyl ) carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0874]
Example 48
methyl [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] -5-fluoropyridin-3-yl } oxy) -1-methylethyl] carbamate
[0875]
Using tert-butyl [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate, and in. the same manner as in Example 17, step A, the title compound was obtained.
[0876]
Example 49
N- [ (IS) -3-{ 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } -1-methylpropyl] acetamide
[0877]
A) 2- (5-bromopyridin-2-yl) -6- (cyclopropylmethoxy) -1, 3- benzoxazole
Using 5-bromopyridine-2-carboxylic acid and 4- aminobenzene-1, 3-diol hydrochloride, and in the same manner as in Example 2, steps C-D and Example 1, step A, the title compound was obtained.
H NMR (300 MHz, DMSO-d6) δ 0.21-0.45 (2H, m) , 0.53-0.76 (2H, m) , 1.09-1.44 (1H, m) , 3.92 (2H, d, J = 6.8 Hz), 7.06 (1H, dd, J = 8.7, 2.3 Hz), 7.43 (1H, d, J = 2.3 Hz), 7.74 (1H, d, J = 8.7 Hz), 8.11-8.21 (1H, m) , 8.24-8.44 (1H, m) , 8.91 (1H, d, J = 2.3 Hz) .
[0878] B) tert-butyl [ (IS) -3-{ 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] pyridin-3-yl } -l-methylprop-2-yn-l-yl] carbamate
Under an argon atmosphere, a mixture of 2- (5- bromopyridin-2-yl) -6- (cyclopropylmethoxy) -1, 3-benzoxazole (200 mg) , tert-butyl [( IS) -l-methylprop-2-yn-l-yl] carbamate (196 mg) , dichlorobis (triphenylphosphine) palladium (II) (20.3 mg) , copper (I) iodide (11.0 mg),. triethylamine (0.081 mL) and DMF (5 ml,) was stirred at 80°C for 8 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a yellow powder (150 mg) .
MS (ESI+) : [M+H]+ 434.5.
[0879]
C) N- [ (IS) -3-{ 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } -l-methylprop-2-yn-l-yl] acetamide
Using tert-butyl [ (IS) -3-{ 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] pyridin-3-yl} -l-methylprop-2-yn-l-yl] carbamate, and in the same manner as in Example 1, step. D, the title compound was obtained.
MS (ESI+) : [M+H]+ 376.1.
[0880]
D) N- [ (IS) -3-{ 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl} -1-methylpropyl] acetamide
Under a hydrogen atmosphere, a mixture of N- [ (IS) -3-{ 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] pyridin-3-yl } -1- methylprop-2-yn-l-yl] acetamide (98.0 mg) , 10% palladium/carbon (containing water (50%), 19.6 mg) , methanol (5 mL) and THF (1 mL) was stirred at 50°C for 4 hr. The catalyst was removed by filtration, and the obtained filtrate was concentrated under reduced pressure. The residue was purified by silica gel.
column chromatography (hexane/ethyl acetate/methanol) to give - the title compound as yellow crystals (37.0 mg) .
[0881]
Example 50
N- [ (IS) -2- ( { 6- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -5- fluoropyridin-3-yl } oxy) -1-methylethyl] acetamide
[0882]
A) tert-butyl [ (IS) -2- ( { 6- [ (2, 5-dihydroxyphenyl) carbamoyl] -5- fluoropyridin-3-yl } oxy) -1-methylethyl] carbamate
Using 5- ( { (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) - 3-fluoropyridine-2-carboxylic acid, and in the same manner as in Example 2, step C, the title compound was obtained.
MS (ESI+) : [M+H]+ 422.3.
[0883]
B) tert-butyl [ (IS) -2- ({ 6- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate
Using tert-butyl [ (IS) -2- ( { 6- [ (2, 5- dihydroxyphenyl) carbamoyl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 2, steps D-E, the title compound was obtained.
MS (ESI+) : [M+H]+ 458.2.
[0884] '
C) N- [ (IS) -2- ( { 6- [5- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] - 5-fluoropyridin-3-yl } oxy) -1-methylethyl] acetamide
Using tert-butyl [ (IS) -2- ({ 6- [5- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0885]
Example 51
N- [ (IS) -2-{ [6- (6-ethoxy-l, 3-benzoxazol-2-yl) -5-fluoropyridin-
3-yl] oxy} -1-methylethyl] acetamide
[0886]
A) tert-butyl [ (IS) -2-{ [6- (6-ethoxy-l, 3-benzoxazol-2-yl) -5- fluoropyridin-3-yl] oxy} -1-methylethyl] carbamate Using tert-butyl [ (IS) -2- ( { 6- [ (2, 4- dihydroxyphenyl) carbamoyl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate and ethyl iodide, and in the same manner as in Example 2, steps D-E, the title compound was obtained. MS (ESI+) : [M+H]+ 432.1.
[0887]
B) N- [ (IS) -2— { [ 6- ( 6-ethoxy-l, 3-benzoxazol-2-yl) -5- fluoropyridin-3-yl] oxy} -1-meth'ylethyl] acetamide
Using tert-butyl [ (IS) -2-{ [6- (6-ethoxy-l, 3-benzoxazol-2- yl) -5-fluoropyridin-3-yl] oxy} -1-methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
[0888]
Example 52
N- [ (IS) -2- ( { 6- [6- (2-fluoropropoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) -1-methylethyl] acetamide
[0889]
A mixture of tert-butyl [ (IS) -2- ( { 6- [6- (2- hydroxypropoxy) -1, 3-benzoxazol-2-yl] pyridin-3-yl } oxy) -1- methylethyl] carbamate (1.02 g) (obtained using tert-butyl
[ (IS) -2-{ [6- (6-hydroxy-l, 3-benzoxazol-2-yl) pyridin-3-yl] oxy}- 1-methylethyl] carbamate (4.00 g) and l-bromopropan-2-one (1.56 g) and in the same manner as in Example 2, step E and Example 24, step F) , bis (2-methoxyethyl) aminosulfur trifluoride (0.848 mL) and toluene (10 mL) was stirred at room temperature for 1 hr. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give tert-butyl [ (IS) -2- ( { 6- [6- (2- fluoropropoxy) -1, 3-benzoxazol-2-yl] pyridin-3-yl } oxy) -1- methylethyl] carbamate . Using the obtained compound, and in the same manner as in Example 1, step D, the title compound was obtained (61.3 mg) .
[0890]
Example 53
N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -2- methoxypyridin-3-yl } oxy) -1-methylethyl] acetamide
[0891]
A) 3- ( { (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) -6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] pyridin-2-yl acetate A mixture of tert-butyl [ ( IS) -2- ( { 6- [ 6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] pyridin-3-yl } oxy) -1- methylethyl] carbamate (2.34 g) , m-chloroperbenzoic acid (2.66 g) and acetonitrile (30 mL). was stirred at 50°C overnight. To the reaction mixture were added saturated sodium hydrogen carbonate and aqueous sodium thiosulfate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over
anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (200 mg) of tert-butyl [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) - 1, 3-benzoxazol-2-yl] -l-oxidepyridin-3-yl }oxy) -1- methylethyl] carbamate and impurity. A mixture of the
aforementioned tert-butyl [ (IS) -2- ({ 6- [ 6- (cyclopropylmethoxy) - 1, 3-benzoxazol-2-yl] -l-oxidepyridin-3-yl }oxy) -1- methylethyl] carbamate (200 mg, mixture with impurity), acetic anhydride (224 mg) and toluene (5 mL) was stirred at 110°C overnight. The reaction mixture was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a' colorless oil (111 mg) .
H NMR (300 MHz, DMSO-d6) δ 0.26-0.42 (2H, m) , 0.53-0.68 (2H, m) , 1.11 (3H, d, J = 6.8 Hz), 1.21-1.33 (1H, m) , 1.39 (9H, s) , 2.37 (3H, s), 3.78-4.03 (5H, m) , 6.92 (1H, d, J = 7.9 Hz), 7.02 (1H, dd, J = 8.7, 2.3 Hz), 7.39 (1H, d, J = 2.3 Hz), 7.68 (1H, d, J = 9.0 Hz), 7.81 (1H, d, J = 8.7 Hz), 8.19 (1H, d, J = 8.3 Hz) . [0892]
B) tert-butyl [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -2-methoxypyridin-3-yl }oxy) -1- methylethyl] carbamate
A mixture of 3- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) -6- [6- (cyclopropylmethoxy) - 1, 3-benzoxazol-2-yl] pyridin-2-yl acetate (111 mg) , THF (1 mL) , methanol (1 mL) and 1 lithium hydroxide aqueous solution (1 mL) was stirred at 0°C for 2 hr. The reaction mixture was neutralized with 1M hydrochloric acid at 0°C, and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the. solvent was evaporated under reduced pressure. The residue was mixed with toluene (2 mL) , methyl iodide (0.021 mL) and silver (I) carbonate (92 mg) , and the obtained mixture was stirred at 85°C for 3 days. To the reaction mixture were further added methyl iodide (0.021 mL) and silver (I) carbonate (92 mg) , and the mixture was stirred at 85°C for 4 hr. Water was added to the reaction mixture, and the mixture was
extracted with ethyl acetate. The obtained organic layer was washed with. saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a white powder (70.0 mg) .
MS (ESI+) : [M+H]+ 470.3.
[0893]
C) N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] - 2-methoxypyridin-3-yl } oxy) -1-methylethyl] acetamide
Using tert-butyl [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -2-methoxypyridin-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained.
MS (ESI+) : [M+H]+ 376.1.
[0894] Example 54
N- [ (IS) -2-{ [6- (6-ethoxy-l, 3-benzoxazol-2-yl) pyridin-3-yl] oxy}-
1-methylethyl] -2, 2, 2-trifluoroacetamide
[0895]
A mixture of tert-butyl [( IS) -2- {[ 6- ( 6-ethoxy-l, 3- benzoxazol-2-yl) pyridin-3-yl] oxy} -1-methylethyl] carbamate (300 mg) , ethyl acetate (10 mL) and 4M hydrogen chloride/ethyl acetate (10 mL) was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was dissolved in pyridine (3 mL) , and trifluoroacetic
anhydride (0.150 mL) was added thereto. The mixture was stirred at room temperature for 2 hr. To the reaction mixture was further added trifluoroacetic anhydride (0.301 mL) , and the mixture was stirred at room temperature for 2 hr. To the reaction mixture were added water and 1M hydrochloric acid, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) , and
recrystallized (ethyl acetate) to give the title compound as white crystals (205 mg) .
[0896]
Example 55
N- [ (IS) -2-{ [6- (6-ethoxy-l, 3-benzoxazol-2-yl) pyridin-3-yl] oxy}- 1-methylethyl] -2 , 2-difluoroacetamide
[0897]
A mixture of tert-butyl [ (IS) -2-{ [6- (6-ethoxy-l, 3- benzoxazol-2-yl) pyridin-3-yl] oxy} -1-methylethyl] carbamate (300 mg) , ethyl acetate (5 mL) and 4M hydrogen chloride/ethyl acetate (5 mL) was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was mixed with difluoroacetic acid (105 mg) , WSC (209 mg) , HOBt (167 mg), triethylamine (0.506 mL) and DMF (3 mL) . The mixture was stirred at room temperature for 3 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) , and recrystallized (ethyl acetate) to give the title compound as white crystals (164 mg) .
[0898]
Example 56
N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] -1- oxidepyridin-3-yl } oxy) -1-methylethyl] acetamide
[0899]
A) tert-butyl [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -l-oxidepyridin-3-yl }oxy) -1- methylethyl] carbamate
A mixture of tert-butyl [ ( IS ) -2- ( { 6- [ 6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] pyridin-3-yl } oxy) -1- methylethyl] carbamate (529 mg) , m-chloroperbenzoic acid (602 mg) and acetonitrile (10 mL) was stirred at room temperature for 8 hr. To the reaction mixture were added saturated sodium hydrogen carbonate and aqueous sodium thiosulfate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a pale-yellow solid (134 mg) .
MS (ESI+) : [M+H]+ 456.4.
[0900]
B) N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-yl] - l-oxidepyridin-3-yl }oxy) -1-methylethyl] acetamide
Using tert-butyl [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -1, 3- benzoxazol-2-yl] -l-oxidepyridin-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 1, step D, the title compound was obtained. [0901]
Example 57
N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -2-methyl-2 , 3-dihydro-l- benzofuran-2-yl] pyridin-3-yl}oxy) -1-methylethyl] acetamide
[0902]
A) 1- [2-bromo-4- (cyclopropylmethoxy) phenyl] propan-2-one
To a solution (50 mL) of 2- [2-bromo-4- (cyclopropylmethoxy) phenyl] -N-methoxy-N-methylacetamide (3.00 g) in THF was added dropwise methylmagnesium bromide (19.6 mL, 1.4 M, a mixed solution of toluene-diethyl ether (3/1)) under ice-cooling. The mixture was stirred at room temperature for 3 hr, poured into saturated aqueous ammonium chloride solution, and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a colorless oil (1.29 g) .
XH NMR (300 MHz, DMSO-d6) δ 0.20-0.40 (2H, m) , 0.46-0.69 (2H, m) , 0.99-1.39 (1H, m) , 2.14 (3H, s) , 3.77-3.87 (4H, m) , 6.91 (1H, dd, J = 8.5, 2.5 Hz), 7.14 (1H, d, J = 2.6 Hz), 7.20 (1H, d, J = 8.7 Hz).
[0903]
B) N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -2-methyl-2 , 3-dihydro- l-benzofuran-2-yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide
Using 1- [2-bromo-4- (cyclopropylmethoxy) phenyl] propan-2- one, and in the same manner as in Example 24, steps E and G-I, the title compound was obtained.
[0904]
Example 58
N- [ (IS) -2- ( {2- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl]pyrimidin-5-yl}oxy) -1-methylethyl] acetamide
[0905]
A) 2- ( 5-bromopyrimidin-2-yl ) -6- (cyclopropylmethoxy) -1, 3- benzoxazole Using 5-bromopyrimidine-2-carboxylic acid and 4- aminobenzene-1, 3-diol hydrochloride, and in the same manner as in Example 2, steps C-E, the title compound was obtained. - XH NMR (300 MHz, DMSO-d6) δ 0.29-0.43 (2H, m) , 0.51-0.72 (2H, m) , 1.15-1.40 (1H, m) , 3.93 (2H, d, J = 7.2 Hz), 7.09 (1H, dd, J = 8.8, 2.4 Hz), 7.45 (1H, d, J = 2.4 Hz), 7.79 (1H, d, J = 8.8 Hz) , 9.23 (2H, s) .
[0906]
B) 2- [5- (benzyloxy) pyrimidin-2-yl] -6- (cyclopropylmethoxy) -1, 3- benzoxazole
Under an argon atmosphere, a mixture of 2- (5- bromopyrimidin-2-yl ) -6- (cyclopropylmethoxy) -1, 3-benzoxazole (260 mg) , benzyl alcohol (812 mg) , cesium carbonate (368 mg) , copper (I) iodide (14.3 mg) , 1, 10-phenanthroline (27.0 mg) and toluene (5 mL) was stirred at 110°C for 3 days. The
precipitate was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a pale-yellow solid (205 mg) .
XH NMR (300 MHz, DMSO-d6) δ 0.31-0.43 (2H, m) , 0.52-0.68 (2H, m) , 1.16-1.34 (1H, m) , 3.92 (2H, d, J = 7.2 Hz), 5.40 (2H, s) , 7.05 (1H, dd, J = 8.9, 2.4. Hz) , 7.32-7.59 (6H, m) , 7.74 (lH, d, J = 8.9 Hz) , 8.83 (2H, s) .
[0907]
C) N- [ (IS) -2- ( {2- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl]pyrimidin-5-yl}oxy) -1-methylethyl] acetamide
Using 2- [5- (benzyloxy) pyrimidin-2-yl] -6- (cyclopropylmethoxy) -1, 3-benzoxazole, and in the same manner as in Example 8, step H, Example 2, step A and Example 1, step D, the title compound was obtained.
[0908]
Example 59
N-{ (IS) -2- [4-(5-methoxy-2H-indazol-2-yl)phenoxy] -1- methylethyl } acetamide ,
[0909] N-{ (IS) -2- [4- (5-methoxy-2H-indazol-2-yl)phenoxy] -1- methylethyl } acetamide
Using [4- (benzyloxy) phenyl] hydrazine hydrochloride (2.0 g) and l-bromo-2- (bromomethyl) -4-methoxybenzene (2.23 g) , and in the same manner as in Example 12, steps A-E, the title compound was obtained as colorless crystals (75.6 mg) .
[0910]
Example 60
N- [ (IS) -2- ( { 6- [6- (3, 3-difluorobutoxy) -1, 3-benzoxazol-2-yl] -5- fluoropyridin-3-yl} oxy) -1-methylethyl] acetamide
[0911]
A) 3, 3-difluorobutyl methanesulfonate
To a solution of 3 , 3-difluorobutan-l-ol (2.60 g) and triethylamine (6.58 mL) in THF (50 mL) was added dropwise methanesulfonyl chloride (2.74 mL) at 0°C, and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a pale-yellow oil (2.69 g) ·
XH NMR (300 MHz, DMSO-d6) δ 1.66 (3H, t, J = 19.3 Hz), 2.38 (2H, tt, J = 15.8, 6.4 Hz), 3.21 (3H, s) , 4.34 (2H, t, J = 6.4 Hz).
[0912]
B) tert-butyl [ (IS) -2- ( { 6- [6- (3, 3-difluorobutoxy) -1, 3- benzoxazol-2-yl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate
Using tert-butyl [ (IS) -2- ( { 6- [ (2, 4- dihydroxyphenyl) carbamoyl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate and 3, 3-difluorobutyl methanesulfonate, and in the same manner as in Example 2, steps C-D, the title compound was obtained.
MS (ESI+) : [M+H]+ 496.1. [0913] .
C) N- [ (IS) -2- ( { 6- [6- (3, 3-difluorobutoxy) -1 , 3-benzoxazol-2-yl] - 5-fluoropyridin-3-yl}oxy) -1-methylethyl] acetamide
Using tert-butyl [ (IS) -2- ( { 6- [6- (3, 3-difluorobutoxy) -1, 3- benzoxazol-2-yl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 1,- step D, the title compound was obtained.
[0914]
Example 61
1- [ ( IS) -2- { - [ 6- (cyclopropylmethoxy) -2H-indazol-2-yl] phenoxy} - 1-methylethyl] urea
[0915]
A mixture of tert-butyl [ ( IS ) -2- { 4- [ 6- (cyclopropylmethoxy) -2H-indazol-2-yl] phenoxy} -1- methylethyl] carbamate (310 mg) and 4M hydrogen chloride/ethyl acetate (5 mL) was stirred at room temperature for 1 hr. To the reaction, mixture was added diethyl ether, the resultant precipitate was collected by filtration, and washed with ethyl acetate to give (2S) -l-{ 4- [ 6- (cyclopropylmethoxy) -2H-indazol- 2-yl] phenoxy}propan-2-amine hydrochloride (255 mg) . A mixture of (2S) -l-{4- [6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy}propan-2-amine hydrochloride (84 mg) ,
(trimethyl) silyl isocyanate (78 mg) , triethylamine (68 mg) and THF (1 mL) was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was diluted with ethyl acetate and THF, and the mixture was washed with water. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as colorless crystals (39.5 mg) .
[0916]
Example 62 1- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] phenoxy} -
1-methylethyl] -3-methylurea
[0917]
A mixture of tert-butyl [ (IS) -2-{ 4— [ 6—
(cyclopropylmethoxy) -2H-indazol-2-yl] phenoxy} -1- methylethyl] carbamate (310 mg) and 4M hydrogen chloride/ethyl acetate (5 mL) was stirred at room temperature for 1 hr. To the reaction mixture was added diethyl ether, and the
resultant precipitate was collected by filtration, and washed with ethyl acetate to give (2S) -l-{ 4- [6- (cyclopropylmethoxy) - 2H-indazol-2-yl] phenoxy}propan-2-amine hydrochloride (255 mg) . A mixture of (2S) -l-{ 4- [6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy}propan-2-amine hydrochloride (84 mg) , methyl
isocyanate (38.5 mg) , triethylamine (68 mg) and THF (1 mL) was stirred at room temperature overnight. The solvent was
evaporated under reduced pressure, and the residue was diluted with ethyl acetate, and the mixture was washed with water. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as colorless crystals
(51.9 mg) .
[0918]
Example 63
3-[(lS)-2-{4-[6- (cyclopropylmethoxy) -2H-indazol-2-yl] phenoxy} -
1-methylethyl] -1, 1-dimethylurea
[0919]
A mixture of tert-butyl [ (IS) -2-{ 4- [ 6-
(cyclopropylmethoxy) -2H-indazol-2-yl] phenoxy}-l- methylethyl] carbamate (310 mg) and 4M hydrogen chloride/ethyl acetate (5 mL) was stirred at room temperature for 1 hr. To the reaction mixture was added diethyl ether, and the
resultant precipitate was collected by filtration, and washed with ethyl acetate to give (2S) -1- {4- [ 6- (cyclopropylmethoxy) -
2H-indazol-2-yl] phenoxy}propan-2-amine hydrochloride (255 mg) . A mixture of (2S) -l-{ 4- [6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy}propan-2-amine hydrochloride (84 mg) ,
dimethylcarbamoyl chloride (72.5 mg) , triethylamine (68 mg) and THF (1 mL) was stirred at 50°C overnight. The solvent was evaporated under reduced pressure, and the residue was diluted with ethyl acetate, and the mixture was washed with water. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a pale-yellow powder (42.8 mg) .
[0920]
Example 64
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -7-fluoro-2H-indazol-2- yl] henoxy} -1-methylethyl] acetamide
[0921] .
A) 4- (cyclopropylmethoxy) -2, 3-difluorobenzaldehyde
Using 2 , 3-difluoro-4-hydroxybenzaldehyde (316 mg) , and in the same manner as in Example 2, step E, the title compound was obtained as a brown oil (397 mg) .
XH NMR (300 MHz, CDC13) δ 0.40 (2H, q) , 0.66-0.75 (2H, m) ,
1.25-1.41 (1H, m) , 3.98 (2H, d, J = 6.8 Hz), 6.82 (1H, ddd, J = 8.8, 6.9, 1.7 Hz), 7.54-7.65 (1H, m) , 10.19 (1H, s) .
[0922]
B) tert-butyl [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) -7-fluoro-2H- indazol-2-yl] phenoxy} -1-methylethyl] carbamate
A mixture of 4- (cyclopropylmethoxy) -2, 3- difluorobenzaldehyde (397 mg) , tert-butyl [(lS)-2-(4- aminophenoxy) -1-methylethyl] carbamate (498 mg) and ethanol (12 mL) was stirred under reflux overnight. The reaction mixture was concentrated under reduced pressure, sodium azide (507 mg) and DMF (8 mL) were added to the residue, and the mixture was stirred at 140°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The. separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with . saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a yellow solid (74.5 mg) .
MS (ESI+) : [M+H]+ 456.0.
[0923],
C) N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -7-fluoro-2H-indazol-2- yl] phenoxy} -l-methylethyl] acetamide
Using tert-butyl [ (IS) -2- {4- [6- (cyclopropylmethoxy) -7- fluoro-2H-indazol-2-yl] phenoxy} -l-methylethyl] carbamate (75.3 mg) , and in the same manner as in Example 25, step G, the title compound was obtained as colorless crystals (49 mg) .
[0924]
Example 65
N- [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) -4-fluoro-2H-indazol-2- yl] phenoxy} -l-methylethyl] acetamide
[0925]
Using 2 , 6-difluoro-4-hydroxybenzaldehyde (316 mg) , and in the same manner as in Example 2, step E, Example 64, step B and Example 25, step G, the title compound was obtained as colorless crystals (167 mg) .
[0926]
Example 66
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -5-fluoro-2H-indazol-2- yl] phenoxy} -l-methylethyl] acetamide
[0927]
Using 2 , 5-difluoro-4-hydroxybenzaldehyde (316 mg) , and in the same manner as in Example 2, step E, Example 64, step B and Example 25, step G, the title compound was obtained as colorless crystals (33.6 mg) .
[0928]
Example 67
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] -3- fluorophenoxy} -1-methylethyl] acetamide
A) 4- (cyclopropylmethoxy) -2-nitrobenzaldehyde
Using 4-methyl-3-nitrophenol (49.1 g) and
(bromomethyl) cyclopropane (47.6 g) , and in the same manner as in Example 25, steps A-C, the title compound was obtained as yellow crystals (20.89 g) .
XH NMR (300 MHz, CDC13) δ 0.37-0.45 (2H, m) , 0.66-0.77 (2Η,' m) , 1.22-1.39 (1H, m) , 3.95 (2H, d, J = 7.2 Hz), 7.22 (1H, dd, J = 8.7, 2.7 Hz), 7.50 (1H, d, J = 2.3 Hz), 7.97 (1H, d, J = 8.7 Hz) , 10.29 (1H, s) .
[092.9]
B) tert-butyl [( IS) -2- { 4- [ 6- (cyclopropylmethoxy) -2H-indazol-2- yl] -3-fluorophenoxy} -1-methylethyl] carbamate
Using 4- (cyclopropylmethoxy) -2-nitrobenzaldehyde (547 mg) and tert-butyl [ (IS) -2- (4-amino-3-fluorophenoxy) -1- methylethyl] carbamate (703 mg) , and in the same manner as in Example 25, step F, the title compound was obtained as yellow solid (835 mg) .
MS (ESI+) : [M+H]+ 456.4.
[0930]
C) (2S) -l-{ 4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] -3- fluorophenoxy}propan-2-amine
A mixture of tert-butyl [ ( IS) -2- { 4- [ 6- (cyclopropylmethoxy) -2H-indazol-2-yl] -3-fluorophenoxy} -1- methylethyl] carbamate (544 mg) and 4M hydrogen chloride/ethyl acetate (5 mL) was stirred at room temperature for 1 hr. The reaction mixture was concentrated under reduced pressure, to the obtained residue was added saturated aqueous sodium
hydrogen carbonate solution, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under
reduced pressure to give the title compound as an orange oil (424 mg) .
MS (ESI+) : [M+H]+ 356.2.
[0931]
D) N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] -3- fluorophenoxy} -1-methylethyl] acetamide
A mixture of (2S) -1- { 4- [ 6- (cyclopropylmethoxy) -2H- indazol-2-yl] -3-fluorophenoxy}propan-2-amine (211 mg) , acetyl chloride (70 mg) , triethylamine (90 mg) and THF (4 mL) was stirred at room temperature for 1 hr. The solvent was
evaporated under reduced pressure, and the residue was diluted with ethyl acetate, and the mixture was washed with water. The separated, aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/ethyl acetate) , and recrystallized (hexane/ethyl acetate) to give the title compound as colorless crystals (94 mg) .
[0932]
Example 68
1- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] -3- fluorophenoxy} -1-methylethyl] urea
[0933]
A mixture of (2S) -1- { 4- [ 6- (cyclopropylmethoxy) -2H- indazol-2-yl] -3-fluorophenoxy}propan-2-amine (211 mg) ,
(trimethyl) silyl isocyanate (137 mg) and THF (4 mL) was
stirred at room temperature overnight. The solvent was
evaporated under reduced pressure, and the residue was diluted with ethyl acetate, and the mixture was washed with water. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) , and recrystallized (ethanol/ethyl acetate) to give the title compound as colorless crystals (117 mg) .
[0934]
Example 69
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] -2- fluorophenoxy} -1-methylethyl] acetamide
[0935]
Using 2-fluoro-4-nitrophenol (471 mg) and 4- (cyclopropylmethoxy) -2-nitrobenzaldehyde (623 mg) , and in the same manner as in Example 25, steps D-G, the title compound was obtained as colorless crystals (57 mg) .
[0936]
Example 70
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] -2,5- difluorophenoxy} -1-methylethyl] acetamide
[0937]
Using 2, 5-difluoro-4-nitrophenol (525 mg) and 4- (cyclopropylmethoxy) -2-nitrobenzaldehyde (231 mg) , and in the same manner as in Example 25, steps D-G, the title compound was obtained as. colorless crystals (59.6 mg) .
[0938]
Example 71
N- [ (IS) -2-{4- [7-chloro-6- (cyclopropylmethoxy) -2H-indazol-2- yl]phenoxy}-l-methylethyl] acetamide
[0939]
A) 6- (cyclopropylmethoxy) -2- (4-{ [tris (1- methylethyl) silyl] oxyjphenyl) -2H-indazole
Under a hydrogen atmosphere, a mixture of tris (1- methylethyl) (4-nitrophenoxy) silane (1.50 g) , 10%
palladium/carbon (containing water (50%), 150 mg) and ethyl acetate (20 mL) was stirred at room temperature for 1 hr. The catalyst was removed by filtration, and the obtained filtrate was concentrated under reduced pressure. A solution of the obtained brown oil and 4- (cyclopropylmethoxy) -2- nitrobenzaldehyde (1.12 g) in ethanol (20 mL) was stirred at 70°C overnight. The reaction mixture was concentrated under reduced pressure, triethyl phosphite (5 mL) was added thereto, and the mixture was stirred at 130°C for 4 hr. "The reaction mixture was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound as a yellow solid (6.53 g) .
XH NMR (300 MHz, CDC13) 6 0.36-0.44 (2H, m) , 0.61-0.73 (2H, m) ,
1.09-1,16 (18H, m) , 1.24-1.39 (4H, m) , 3.87 (2H, d, J = 6.8 Hz), 6.84 (1H, dd, J = 9.0, 2.3 Hz), 6.93-7.02 (3H, m) , 7.56
(1H, d, J = 9.0 Hz), 7.64-7.72 (2H, m) , 8.20 (1H, s) .
[0940]
B) 7-chloro-6- (cyclopropylmethoxy) -2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole
A mixture of 6- (cyclopropylmethoxy) -2- (4-{ [tris (1— methylethyl) silyl] oxy}phenyl) -2H-indazole (1.23 g), N- chlorosuccinimide (389 mg) and acetic acid (10 mL) was stirred at 100°C overnight. The reaction mixture was neutralized with saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate. The separated organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a pale-yellow oil (1.20 g) .
XH NMR (300 MHz, CDC13) δ 0.35-0.43 (2H, m) , 0.58-0.69 (2H, m) ,
1.10-1.14 (18H, m) , 1.25-1.39 (4H, m) , 4.01 (2H, d, J = 7.2 Hz), 6.93-7.03 (3H, m) , 7.56 (1H, d, J = 9.1 Hz), 7.68-7.77 (2H, m) , 8.29 (1H, s) .
[0941]
C) 4- [7-chloro-6- (cyclopropylmethoxy) -2H-indazol-2-yl] phenol
To a solution of 7-chloro-6- (cyclopropylmethoxy) -2- (4- { [tris (1-methylethyl) silyl] oxy}phenyl) -2H-indazole (112 mg) in THF (1 mL) was added a THF solution (1.0 M, 0.71 mL) of tetrabutylammonium fluoride at room temperature, and the mixture was stirred for 1 nr. The solvent was evaporated under reduced pressure, water was added to the residue, and the mixture was extracted with ethyl acetate. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as colorless crystals (44.6 mg) .
MS (ESI+) : [M+H]+ 315.1.
[0942]
D) N- [ (IS) -2-{4- [7-chloro-6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy} -1-methylethyl] acetamide
Using 4- [7-chloro-6- (cyclopropylmethoxy) -2H-indazol-2- yl]phenol (43 mg) , and in the same manner as in Example 25, steps D and G, the title compound was obtained as colorless crystals (.20.4 mg) .
[0943]
Example 72
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -3-methyl-2H-indazol-2- yl] phenoxy} -1-methylethyl] acetamide
[0944]
A) 6- (cyclopropylmethoxy) -3-methyl-2- (4-{ [tris (1- methylethyl) silyl] dxylphenyl) -2H-indazole
To a solution of 6- (cyclopropylmethoxy) -2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole (218 mg) in THF (5 mL) was added dropwise a THF solution (1.11 M, 0.5'9 mL) of lithium diisopropylamide at -78°C under an argon atmosphere, and the mixture was stirred for 30 min. To the reaction mixture was added methyl iodide (142 mg) at -78°C, and the mixture was stirred for 1.5 hr. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column- chromatography
(hexane/ethyl acetate) to give the title compound as a
colorless oil (159 mg) .
MS (ESI+) : [M+H]+ 451.3.
[0945]
B) N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -3-methyl-2H-indazol-2- yl] phenoxy} -l-methylethyl] acetamide
Using 6- (cyclopropylmethoxy) -3-methyl-2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole (271 mg) , and in the same manner as in Example 71, step C, Example 25, step D and step G, the title compound was obtained as colorless crystals (156 mg) .
[0946]
Example 73
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -3-fluoro-2H-indazol-2- yl] phenoxy} -l-methylethyl] acetamide
[0947]
A) 6- (cyclopropylmethoxy) -3-fluoro-2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole
[0948]
-To a solution of 6- (cyclopropylmethoxy) -2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole (218 mg) in THF (2.5 mL) was added dropwise a THF solution (1.11 M, 0.59 mL) of lithiumdiisopropylamide at -78°C under an argon atmosphere, and the mixture was stirred for 30 min. To the reaction mixture was added N-fluorobenzenesulfonimide (236 mg) at -78°C, and the mixture was stirred at 0°C for 1.5 hr. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound as colorless crystals (110 mg) .
MS (ESI+) : [M+H]+ 455.2. [0949]
B) N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -3-fluoro-2H-indazol-2- yl] phenoxy} -1-methylethyl] acetamide
Using 6- (cyclopropylmethoxy) -3-fluoro-2- (4- { [tris (1- . methylethyl) silyl] oxy}phenyl) -2H-indazole (165 mg) , and in the same manner as in Example 71, step C and Example 25, steps D and G, the title compound was obtained as colorless crystals (97 mg) .
[0950]
Example 74
N- [ (IS) -2-{4- [7-bromo-6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy} -1-methylethyl] acetamide
[0951]
A) 7-bromo-6- (cyclopropylmethoxy) -2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole
To a solution of 6- (cyclopropylmethoxy) -2- (4- {[tris ( 1- methylethyl) silyl] oxy}phenyl) -2H-indazole (1.31 g) in ethyl acetate (15 mL) were added N-bromosuccinimide (0.56 g) and azobisisobutyronitrile (99 mg) , and the mixture was stirred at 80°C for 3 hr. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as an orange oil (1.41 g) .
XH N R (300 MHz, CDC13) δ 0.35-0.45 (2H, m) , 0.59-0.69 (2H, m) , 1.09-1.16 (18H, m) , 1.21-1.41 (4H, m) , 4.01 (2H, d, J = 6.8 Hz), 6.94 (1H, d, J = 9.1 Hz), 6.96-7.03 (2H, m) , 7.59 (1H, d, J = 9.1 Hz), 7.70-7.78 (2H, m) , 8.33 (1H, s) .
[0952]
B) N- [ (IS) -2-{ 4- [7-bromo-6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy} -1-methylethyl] acetamide
Using 7-bromo-6- (cyclopropylmethoxy) -2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole (920 mg) , and in the same manner as in Example 71, step C and Example 25, steps D and G, the title compound was obtained as colorless crystals (585 mg) .
[0953]
Example 75
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -3- (trifluoromethyl) -2H- indazol-2-yl] phenoxy} -1-methylethyl] acetamide
[0954]
A) 6- (cyclopropylmethoxy) -3-iodo-2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole
To a solution of 6- (cyclopropylmethoxy) -2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole (803 mg) in THF (6 mL) was added dropwise a THF. solution (1.11 M, 3.3 mL) of lithiumdiisopropylamide at -78°C under an argon atmosphere, and the mixture was stirred at 0°C for 2 hr. To the reaction mixture was added a solution of iodine (933 mg) in THF (3 mL) , and the mixture was stirred at 0°C for 1 hr. To the reaction mixture was added saturated aqueous sodium thiosulfate
solution, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The obtained crystals were recrystallized from methanol to give the title compound as colorless crystals (782 mg) .
MS (ESI+) : [M+H]+ 563.3.
[0955]
B) methyl ({ 4- [6- (cyclopropylmethoxy) -3- (trifluoromethyl) -2H- indazol-2-yl] phenoxy} sulfonyl) (difluoro) acetate
A mixture of■ 6- (cyclopropylmethoxy) -3-iodo-2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole (500 mg) , copper (I) iodide (169 mg) , methyl difluoro (fluorosulfonyl) acetate (1.71 g) and DMF (4 mL) was stirred at 80°C for 1 hr under an argon atmosphere. The reaction- mixture was filtered through celite, and the filtrate was concentrated under reduced pressure.
Saturated aqueous ammonium chloride solution was added to the residue, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as colorless crystals (365 mg) .
MS (ESI+) : [M+H]. + 521.0.
[0956]
C) 4- [6- (cyclopropylmethoxy) -3- (trifluoromethyl) -2H-indazol-2- yl] phenol
To a solution of methyl ({ 4- [ 6- (cyclopropylmethoxy) -3- (trifluoromethyl) -2H-indazol-2- yl] phenoxy} sulfonyl) (difluoro) acetate (365 mg) in methanol (4 mL) was added dropwise 27% sodium methoxide methanol solution (1 mL) at room temperature, and the mixture was stirred for 3 hr. The reaction mixture was neutralized with saturated aqueous ammonium. chloride solution, and extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound as a
colorless powder (179 mg) .
MS (ESI+) : [M+H]+ 349.3.
[0957]
D) N- [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) -3- (trifluoromethyl) - 2H-indazol-2-yl] phenoxy} -1-methylethyl] acetamide
Using 4- [6- (cyclopropylmethoxy) -3- (trifluoromethyl ) -2H- indazol-2-yl] phenol (179 mg) , and in the same manner as in Example 25, steps D and G, the title compound was obtained as colorless crystals (117 mg) .
[0958]
Example 76
N- [ (IS) -2-{4- [3-cyano-6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy} -1-methylethyl ] acetamide
[0959]
A) 6- (cyclopropylmethoxy) -2- (4- { [tris ( 1- methylethyl) silyl] oxy}phenyl) -2H-indazole-3-carbonitrile
A mixture of 6- (cyclopropylmethoxy) -3-iodo-2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole (281 mg) ,
tris (dibenzylideneacetone) dipalladium ( 0) (92 mg) , 1> 1'- bis (diphenylphosphino) ferrocene (111 mg) , zinc cyanide (88 mg) , zinc powder (33 mg) and N, N-dimethylacetamide (3 mL) was stirred at 120°C for 1.5 hr under an argon atmosphere. The reaction mixture was filtered through silica gel, and the filtrate was concentrated under reduced pressure. To the residue was added water, and the mixture was extracted with ethyl acetate. The combined organic layer was washed three times with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as colorless crystals (189 mg) .
XH N R (300 MHz, CDCI3) δ 0.36-0.45 (2H, m) , 0.64-0.75 (2H, m) , 1.10-1.16 (18H, m) , 1.23-1.38 (4H, m) , 3.88 (2H, d, J = 6.8 Hz), 6.99-7.07 (3H, m) , 7.07-7.12 (1H, m) , 7.63-7.73 (3H, m) .
[0960]
B) N- [ (IS) -2-{ - [3-cyano-6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy} -l-methylethyl] acetamide
Using 6- (cyclopropylmethoxy) -2- (4-{ [tris (1- methylethyl) silyl] oxy}phenyl) -2H-indazole-3-carbonitrile (187 mg) , and in the same manner as in Example 71, step C and
Example 25, steps D and G, the title compound was obtained as colorless crystals (76.7 mg) .
[0961]
Example 77
N- [ (IS) -2-{4- [7-cyano-6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy} -1-methylethyl] acetamide
[0962] A mixture of - [ (IS) -2-{ 4- [7-bromo-6-
(cyclopropylmethoxy) -2H-indazol-2-yl] phenoxy} -1- methylethyl] acetamide (150 mg) ,
tris (dibenzylideneacetone) dipalladium ( 0 ) (45 mg) , 1,1'- bis (diphenylphosphino) ferrocene (54.4 mg) , zinc cyanide (57.7 mg) , zinc powder (10.7 mg) and N, -dimethylacetamide (3 mL) was stirred at 120°C.for 1.5 hr under an argon atmosphere. The reaction mixture was filtered through silica gel, and the filtrate was concentrated under reduced pressure. To the residue was added water, and the mixture was extracted with ethyl acetate. The combined organic layer was washed three times with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as colorless crystals (54.5 mg) .
[0963]
Example 78
N- [ (IS) -2- {4- [6- (cyclopropylmethoxy) -7-methyl-2H-indazol-2- yl] phenoxy} -1-methylethyl] acetamide
[0964]
A mixture of N- [ ( IS) -2- { 4- [ 7-bromo-6- (cyclopropylmethoxy) -2H-indazol-2-yl] phenoxy} -1- methylethyl] acetamide (200 mg) ,
tetrakis (triphenylphosphine) palladium(O) (101 mg) ,
methylboronic acid (131 mg) , aqueous sodium carbonate solution (2 , 0.66 mL) and toluene (1 mL) was stirred at 120°C for 1 hr under an argon atmosphere. The reaction mixture was purified by silica gel column chromatography (hexane/ethyl acetate) , and separated by HPLC (C18, mobile phase: water/acetonitrile (containing 0.1% TFA) ) . To the obtained fraction was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was dried over anhydrous magnesium sulfate, and
concentrated under reduced pressure to give the title compound as colorless crystals (22.5 mg) .
[0965]
Example 79
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] -2- methylphenoxy} -1-methylethyl] acetamide
Using 2-methyl-4-nitrophenol (306 mg) , and in the same manner as in Example 25, steps D-G, the title compound was obtained as colorless crystals (115 mg) .
[0966]
Example 80
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] -3- methylphenoxy} -1-methylethyl] acetamide
Using 3-methyl-4-nitrophenol (306 mg) , and in the same manner as in Example 25, steps D-G, the title compound was obtained as colorless crystals (137 mg) .
[0967]
Example 81
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] -3, 5- difluorophenoxy} -1-methylethyl] acetamide
[0968]
A) 2, 6-difluoro-4- { [tris (1-methylethyl) silyl] oxy}aniline
A mixture of 4-amino-3, 5-difluorophenol (580 mg) ,
imidazole (354 mg) , triisopropylsilane chloride (848 mg) and DMF (12 mL) was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, water was added to the residue, and the mixture was extracted with ethyl acetate. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound as a pale- brown oil (1.0 g) .
XH NMR (300 MHz, CDC13) δ 1.06-1.11 (18H, m) , 1.14-1.32 (3H, m) , 3.38 (2H, brs), 6.28-6.53 (2H, m) . [0969]
B) N- [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) -2H-indazol-2-yl] -3,5- . difluorophenoxy} -1-methylethyl] acetamide
Using 2, 6-difluoro-4- { [tris (1- methylethyl) silyl] oxy}aniline (1.0 g) and 4-
(cyclopropylmethoxy) -2-nitrobenzaldehyde (734- mg), and in the same manner as in Example 25, step F, Example 71, step C and Example 25, steps D and G, the title compound was obtained as colorless crystals (27.6 mg) .
[0970]
Example 82
N- [ (IS) -2-{3-chloro-4- [6- (cyclopropylmethoxy) -2H-indazol-2- yl] phenoxy} -1-methylethyl] acetamide
[0971]
Using 4-amino-3-chlorophenol hydrochloride (580 mg) and
4- (cyclopropylmethoxy) -2-nitrobenzaldehyde (353 mg) , and in the same manner as in Example 81, step A, Example 25, step F, Example 71, step C and Example 25, steps D and G, the title compound was obtained as colorless crystals (263 mg) .
[0972]
Example 83
N- [ (IS) -2-{ 4- [ 6- (cyclopropylmethoxy) imidazo [1, 2-a] pyridin-2- yl] phenoxy}-l-methylethyl] acetamide
[0973]
A) 2-bromo-5- (cyclopropylmethoxy) pyridine
Using 6-bromopyridin-3-ol (5.22 g) , and in the same manner as in Example 2, step E, the title compound was
obtained as a colorless oil (6.82 g) .
MS (ESI+) : [M+H]+ 228.1.
[0974]
B) 5- (cyclopropylmethoxy) pyridin-2-amine
A mixture of 2-bromo-5- (cyclopropylmethoxy) pyridine (5.65 g) , tris (dibenzylideneacetone) dipalladium(O) (454 mg) , 1,1'- binaphthalene-2, 2' -diylbis (diphenylphosphine) (925 mg) , 1,1- diphenylmethanimine (5.42 g) , .sodium t-butoxide (3.33 g) and toluene (50 mL) was stirred at 80°C for 3 hr under an argon atmosphere. The reaction mixture was concentrated under
reduced pressure, and the residue was diluted with THF (15 mL) . 1 Hydrochloric acid (15 mL) was added thereto, and the
mixture was stirred at room temperature for 30 min. 6M
Hydrochloric acid (6 mL) was added thereto, and the organic layer was separated from the aqueous layer. The separated organic layer was extracted with 1M hydrochloric acid. The combined aqueous layer was neutralized with 8M aqueous sodium hydroxide solution, and extracted twice with ethyl acetate.
The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/ethyl acetate) , and recrystallized (hexane/diethyl ether) to give the title compound as colorless crystals (3.67 g) .
MS (ESI+) : [M+H]+ 165.1.
[0975]
C) 4- [ 6- (cyclopropylmethoxy) imidazo [1, 2-a] pyridin-2-yl] phenol A mixture of 5- (cyclopropylmethoxy) pyridin-2-amine (328 mg) , 2-bromo-l- ( 4-hydroxyphenyl ) ethanone (430 mg) and ethanol (10 mL) was stirred at 80°C for 4 hr. The reaction mixture was allowed to cool to room temperature, and the resulting
crystals were collected by filtration. The obtained crystals were dissolved in saturated aqueous sodium hydrogen carbonate solution and THF, and the solution was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure to give the title compound as a. brown solid (561 mg) .
MS (ESI+) : [M+H]+ 281.2.
[0976]
D) N- [ (IS) -2-{ 4- [ 6- (cyclopropylmethoxy) imidazo [1, 2-a] pyridin- 2-yl] phenoxy} -1-methylethyl] acetamide
Using 4- [6- (cyclopropylmethoxy) imidazo [1, 2-a] pyridin-2- yl]phenol (561 mg) , and in the same manner as in Example 25, steps D and G, the title compound was obtained as colorless crystals (39.8 mg) .
[0977]
Example 84
N- [ (IS) -2- { 4- [ 6- (cyclopropylmethoxy) pyrazolo [1, 5-a] pyridin-2- yl] phenoxy} -1-methylethyl] acetamide
[0978]
A) tert-butyl [( IS ) -2- ( 4-iodophenoxy) -1-methylethyl] carbamate Using 4-iodophenol (5.50 g) , and in the same manner as in
Example 1, step B, the title compound was obtained as
colorless crystals (4.71 g) .
MS (ESI+) : [M+H-Boc]+ 278.0.
[0979]
B) 5- (cyclopropylmethoxy) -2- [ (trimethylsilyl) ethynyl] pyridine A mixture of 2-bromo-5- (cyclopropylmethoxy) pyridine (1.145 g) , bis (triphenylphosphine) palladium ( II ) dichloride (175 mg) , copper (I) iodide (48 mg) , trimethylsilylacetylene (737 mg) , t-riethylamine (759 mg) and DMF (15 mL) was stirred at room temperature overnight under an argon atmosphere. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate and water, and the mixture was filtered -through celite. The aqueous layer was separated from the organic layer. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over
anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a yellow oil (774 mg) .
MS (ESI+) : [M+H]+ 246.1.
[0980]
C) 5- (cyclopropylmethoxy) -2-ethynylpyridine
To a solution of 5- (cyclopropylmethoxy) -2- [ (trimethylsilyl) ethynyl] yridine (773 mg) in THF (15 mL) was added a THF solution (1.0 , 4.1 mL) of tetrabutylammonium fluoride at ro.om temperature, and the reaction mixture was concentrated under reduced pressure. The residue was diluted with ethyl acetate and water,, and the aqueous layer was
separated from the organic layer. The separated aqueous layer was extracted again with ethyl acetate." The combined organic ' layer was washed with saturated brine, and dried over
anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a colorless oil (591 mg) .
MS (ESI+) : [M+H]+ 174.2.
[0981]
D) tert-butyl [ (IS) -2- ( 4- { [5- (cyclopropylmethoxy) pyridin-2- yl] ethynyl }phenoxy) -1-methylethyl] carbamate
A mixture of 5- (cyclopropylmethoxy) -2-ethynylpyridine (591 mg), tert-butyl [ (IS) -2- (4-iodophenoxy) -1- methylethyl] carbamate (1.67 g) ,
bis (triphenylphosphine) palladium (II) dichloride (120 mg) , copper (I) iodide (32.5 mg) , triethylamine (518 mg) and DMF (10 mL) was stirred at 60°C overnight under an argon atmosphere. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate and water, filtered through celite, and the aqueous layer was separated from the organic layer. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a yellow solid (1.40 g) .
MS (ESI+) : [M+H]+ 423.2.
[0982]
E) tert-butyl [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) pyrazolo [1, 5- a] pyridin-2-yl] phenoxy} -1-methylethyl] carbamate (Aminooxy) (hydroxy) sulfane dioxide (679 mg) was dissolved in water (3 mL) , and saturated aqueous sodium hydrogen
carbonate solution was added dropwise thereto at 0°C to
neutralize the solution. To the obtained mixture was added a solution of tert-butyl [ (IS) -2- (4-{ [5-
(cyclopropylmethoxy) pyridin-2-yl] ethynyl }phenoxy) -1- methylethyl] carbamate (845 mg) in methanol (5 mL) at room temperature, and the mixture was stirred at 60°C overnight, and concentrated under reduced pressure. To the residue were added DMF (8 mL) and potassium carbonate (829 mg) , and the mixture was stirred at room temperature for 4 hr. The reaction mixture was concentrated under reduced pressure, the residue was diluted with ethyl acetate and water, and the aqueous layer was separated from the organic layer. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a colorless solid (134 mg) .
MS (ESI+) : [M+H]+ 438.2.
[0983]
F) N- [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) pyrazolo [1, 5-a] pyridin-
2-yl] phenoxy} -1-methylethyl] acetamide
Using tert-butyl [ ( IS) -2- { 4- [ 6-
(cyclopropylmethoxy) pyrazolo [ 1, 5-a] pyridin-2-yl] phenoxy} -1- methylethyl] carbamate (134 mg) , and in the same manner as in
Example 25, step G, the title compound was obtained as
colorless crystals (89.8 mg) .
[0984]
Example 85
N- { ( IS) -2- [4- ( 6-ethoxypyrazolo [1, 5-a] pyridin-2-yl) phenoxy] -1- methylethyl } acetamide
[0985]
A) 5-ethoxy-2- [ (trimethylsilyl) ethynyl] pyridine Using 6-bromopyridin-3-ol (3.48 g) , and in the same manner as in Example 25, step A and Example 84, step B, the title compound was obtained as a yellow oil (2.74 g) .
MS (ESI+) : [M+H]+ 220.1.
[0986]
B) 5-ethoxy-2-ethynylpyridine
To a. solution of 5-ethoxy-2- [ (trimethylsilyl) ethynyl] pyridine (2.74 g) in methanol (40 mL) was added 8M aqueous sodium hydroxide solution (3.73 mL) at room temperature, and the reaction mixture was concentrated under reduced pressure. The residue was diluted with ethyl acetate and water, and the aqueous layer was separated from the organic layer. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a pale-brown powder (1.72 g) .
MS (ESI+) : [M+H]+ 148.3.
[0987]
C) tert-butyl [ (IS) -2-{ 4- [ (5-ethoxypyridin-2- yl) ethynyl] phenoxy} -1-methylethyl] carbamate
Using 5-ethoxy-2-ethynylpyridine (1.63 g) , and in the same manner- as in Example 84, step D, the title compound was obtained as a yellow powder (2.22 g) .
MS (ESI+) : [M+H]+ 397.3.
[0988]
D) tert-butyl { (IS) -2- [4- ( 6-ethoxypyrazolo [1, 5-a] pyridin-2- yl) phenoxy] -1-methylethyl } carbamate
To a solution of tert-butyl [ ( IS) -2- { 4- [ ( 5-ethoxypyridin- 2-yl) ethynyl] phenoxy} -1-methylethyl] carbamate (2.25 g) in THF (30 mL) was added 2- [ (aminooxy) sulfonyl] -1, 3, 5- trimethylbenzene (1.75 g, containing water) at room
temperature, and the mixture was stirred for 1 hr, and concentrated under reduced pressure. To the residue were added DMF (20 iriL) and potassium carbonate (1.18 g) , and the mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate and water, and the aqueous layer was separated from the organic layer. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as colorless crystals (1.18 g) .
MS (ESI+) : [M+H]+ 412.3.
[0989]
E) N-{ (IS) -2- [4- (6-ethoxypyrazolo [1, 5-a] pyridin-2-yl) phenoxy] -
1-methylethyl } acetamide
Using tert-butyl { (IS) -2- [4- (6-ethoxypyrazolo [1, 5- a] pyridin-2-yl) phenoxy] -1-methylethyl} carbamate (200 mg) , and in the same manner as in Example 25, step G, the title
compound was obtained as colorless crystals (75 mg) .
[0990]
Example 86
N-{ (IS) -2- [4- (6-ethoxy-3-fluoropyrazolo [1, 5-a] pyridin-2- yl) phenoxy] -1-methylethyl }acetamide
[0991]
A) tert-butyl { (IS) -2- [4- ( 6-ethoxy-3-fluoropyrazolo [1, 5- a] pyridin-2-yl) phenoxy] -1-methylethyl } carbamate
A mixture of tert-butyl { (IS) -2- [4- (6-ethoxypyrazolo [1, 5- a] pyridin-2-yl) phenoxy] -1-methylethyl } carbamate (400 mg) , 1, 1' -difluoro-2, 2 ' -bipyridinium bis (tetrafluoroborate) (358 mg) and acetonitrile (3 mL) was stirred at room temperature for 3 hr. The reaction mixture was neutralized with saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate. The separated organic layer was washed with water and saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as colorless crystals (129 mg) .
ΛΗ NMR (300 MHz, CDC13) δ 1.31 (3H, d, J = 6.8 Hz), 1.41-1.51 (12H, m), 3.92-4.14 (5H, m) , 4.78 (1H, brs) , 6.88 (1H, dd, J = 9.6, 2.1 Hz), 6.95-7.03 (2H, m) , 7.36 (1H, d, J = 9.4 Hz), 7.87 (1H, s), 7.88-7.95 (2H, m) .
[0992]
B) N- { ( IS) -2- [4- ( 6-ethoxy-3-fluoropyrazolo [ 1, 5-a] pyridin-2- yl ) phenoxy] -1-methylethyl } acetamide
Using tert-butyl { (IS) -2- [4- (6-ethoxy-3- fluoropyrazolo [1, 5-a] pyridin-2-yl) phenoxy] -1- methylethyl } carbamate (128 mg) , and in the same manner as in Example 25, step G, the title compound was obtained as
colorless crystals (66 mg) .
[0993]
Example 87
1- [ (IS) -2- ( { 6- [6- (3, 3-difluorobutoxy) -1, 3-benzoxazol-2-yl] -5- fluoropyridin-3-yl } oxy) -1-methylethyl] urea
[0994]
Using tert-butyl [ (IS) -2- ( { 6- [6- (3, 3-difluorobutoxy) -1, 3- benzoxazol-2-yl] -5-fluoropyridin-3-yl } oxy) -1- methylethyl] carbamate, and in the same manner as in Example 22, the title compound was obtained.
[0995]
Example 88
N-{ (IS) -2- [4- (6-ethoxy-7-fluoropyrazolo [1, 5-a] pyridin-2- yl) phenoxy] -1-methylethyl } acetamide
[0996]
A) tert-butyl { (IS) -2- [4- ( 6-ethoxy-7-fluoropyrazolo [1,5- a] pyridin-2-yl ) phenoxy] -1-methylethyl } carbamate
To a solution of tert-butyl { (IS) -2- [4- (6- ethoxypyrazolo [1, 5-a] pyridin-2-yl) phenoxy] -1- methylethyl } carbamate (580 mg) in THF (10 mL) was added dropwise a hexane solution (1.6 M, 2.2 mL) of n-butyllithium at -78°C under an argon atmosphere, and the mixture was stirred for 1.5 hr. To the reaction mixture was added N- fluorobenzenesulfonimide (578 mg) at -78°C, and the mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound as a pale- yellow solid (187 mg) .
MS (ESI+) : [M+H]+ 430.3.
[0997]
B) N-{ (IS) -2- [4- (6-ethoxy-7-fluoropyrazolo [1, 5-a] pyridin-2- yl ) phenoxy] -1-methylethyl } acetamide
Using tert-butyl { ( IS) -2- [4- ( 6-ethoxy-7- fluoropyrazolo [1, 5-a] pyridin-2-yl ) phenoxy] -1- methylethyl } carbamate (187 mg) , and in the same manner as in Example 25, step G, the title compound was obtained as
colorless crystals (108 mg) .
[0998]
Example 89
N- [ (IS) -2- {4- [6- (cyclopropylmethoxy) [1,2, 4] triazolo [1, 5- a] pyridin-2-yl] phenoxy} -1-methylethyl] acetamide
[0999]
A) 2- [4- (benzyloxy) phenyl] -6-
(cyclopropylmethoxy) [1,2,4] triazolo [1, 5-a] pyridine
(Aminooxy) (hydroxy) sulfane dioxide (3.39 g) was dissolved in water (10 mL) , and saturated aqueous sodium hydrogen carbonate solution was added dropwise thereto at 0°C to
neutralize the solution. To the obtained mixture was added a solution of 5- (cyclopropylmethoxy) pyridin-2-amine (1.64 g) in ethanol (25 mL) at 0°C, and the mixture was stirred at 70°C for 3 days. To the reaction mixture were added 4- (benzyloxy) benzaldehyde (2.12 g) and potassium carbonate (4.15 g) , and the mixture was stirred at 70°C for 2 hr. The reaction mixture was concentrated under reduced pressure, and the
residue. was diluted with ethyl acetate and water, and the aqueous layer was separated from the organic layer. The
separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a yellow solid (134 mg) . MS (ESI+) : [M+H]+ 372.2.
[1000]
B) N-[ (IS) -2-{ 4- [6- (cyclopropylmethoxy) [1, 2, ] triazolo [1, 5- . a] pyridin-2-yl] phenoxy} -1-methylethyl] acetamide
Using 2- [4- (benzyloxy) phenyl] -6- (cyclopropylmethoxy) [1, 2, 4] triazolo [1, 5-a] pyridine (453 mg) , and in the same manner as in Example 12, step C and Example 25, steps D and G, the title compound was obtained as colorless crystals (124 mg) .
[1001]
Example 90
N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) [1, 2, 4] triazolo [1, 5- a] pyridin-2-yl] pyridin-3-yl }oxy) -1-methylethyl] acetamide
[1002]
A) methyl 5- ( { (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) pyridine-2-carboxylate
Using methyl 5-hydroxypyridine-2-carboxylate (2.60 g) , and in the same manner as in Example 1, step B, the title compound was obtained as a white solid (4.78 g) .
MS (ESI+) : [M+H]+ 311.2.
[1003]
B) tert-butyl { (IS) -2- [ ( 6-formylpyridin-3-yl ) oxy] -1- methylethyl } carbamate
To a solution of methyl 5- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] ropyl }oxy) pyridine-2-carboxylate (4.78 g) in THF (75 mL) was added a toluene . solution (1.0 M, 30.8 mL) of diisobutylaluminum hydride at -78°C, and the mixture was stirred at -20°C for 2 hr under an argon atmosphere. Sodium sulfate decahydrate (22.7 g).was added thereto at -78°C, and the mixture was stirred at room temperature overnight. The reaction mixture was filtered through celite, and the solvent of the filtrate was evaporated under reduced pressure to give the title compound as a pale-yellow solid (4.30 g) .
MS (ESI+) : [M+H]+ 281.2.
[1004]
C) tert-butyl [ (IS) -2- ( { 6- [6-
(cyclopropylmethoxy) [1,2, 4] triazolo [1, 5-a] pyridin-2- yl] pyridin-3-yl}oxy) -l-methylethyl] carbamate
To a solution of 5- (cyclopropylmethoxy) pyridin-2-amine
(821 mg) in THF (30 mL) was added 2- [ (aminooxy) sulfonyl] - 1, 3, 5-trimethylbenzene (800 mg, containing water) at room temperature, and the mixture was stirred overnight and
concentrated under reduced pressure. To the residue were added DMF (20 mL), tert-butyl { (IS) -2- [ ( 6-formylpyridin-3-yl) oxy] -1- methylethyl} carbamate (1.40 g) and potassium carbonate (1.04 g) , and the mixture was stirred at 60°C for 3 days. The
reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate and water, and the aqueous layer was separated from the organic layer. The
separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a colorless solid (700 mg) .
MS .(ESI+) : [M+H]+ 440.2.
[1005]
D) (2S) -1- ({ 6- [6- (cyclopropylmethoxy) [1, 2, 4] triazolo [1, 5- a] pyridin-2-yl] pyridin-3-yl }oxy) propan-2-amine
Using tert-butyl [ ( IS) -2- ( { 6- [ 6- (cyclopropylmethoxy) [1, 2, 4 ] triazolo [1, 5-a] pyridin-2- yl]pyridin-3-yl}oxy) -1-methylethyl] carbamate (700 mg) , and in the same manner as in Example 67, step C, the title compound was obtained as a yellow gum (491 mg) .
MS (ESI+) : [M+H]+ 340.1.
[1006]
E) N- [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) [1, 2, 4] triazolo [1, 5- a] pyridin-2-yl] pyridin-3-yl }oxy) -1-methylethyl] acetamide
Using (2S) -1- ( { 6- [6- (cyclopropylmethoxy) [1,2,4] triazolo [1, 5-a] pyridin-2- yl] pyridin-3-yl } oxy) propan-2-amine (245 mg) , and in the same manner as in Example 67, step D, the title compound was obtained as colorless crystals (224 mg) .
[1007]
Example 91
1- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) [1, 2, 4] triazolo [1, 5- a] pyridin-2-yl] pyridin-3-yl }oxy) -1-methylethyl] urea
[1008]
Using (2S) -1- ( { 6- [ 6- (cyclopropylmethoxy) [1, 2, 4] triazolo [1, 5-a] pyridin-2- yl] pyridin-3-yl}oxy) propan-2-amine (245 mg) , and in the same manner as in Example 68, the title compound was obtained as colorless crystals (157 mg) .
[1009]
Example 92
N- [ (IS) -2- {4- [6- (cyclopropylmethoxy) -3-fluoroimidazo [1, 2- a] pyridin-2-yl] phenoxy} -1-methylethyl] acetamide
[1010]
A) 4- [ 6- (cyclopropylmethoxy) imidazo [1, 2-a] pyridin-2-yl] phenyl acetate
Using 4- [6- (cyclopropylmethoxy) imidazo [1, 2-a] pyridin-2- yl]phenol (487 mg) , and in the same manner as in Example 67, step D, the title compound was obtained as a pale-brown powder (494 mg) .
MS (ESI+) : [M+H]+ 323.2.
[1011]
B) 4- [6- (cyclopropylmethoxy.) -3-fluoroimidazo [1, 2-a] pyridin-2- yl] phenol
A mixture of 4- [ 6- (cyclopropylmethoxy) imidazo [1, 2- a] pyridin-2-yl] phenyl acetate (425 mg) , 2 , 6-dichloro-l- fluoropyridinium trifluoromethanesulfonate (1.25 g) and acetonitrile (6 mL) was stirred at room temperature for 4 hr. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted twice with ethyl acetate. The combined organic layer was washed, with saturated brine,' and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) , and the. obtained compound was dissolved in methanol (6 mL) . 1M Aqueous sodium hydroxide solution (0.66 mL) was added at room temperature, and the mixture was stirred for 1 hr, and concentrated under. reduced pressure. The residue was diluted with ethyl acetate and water, and the mixture was neutralized with 1M
hydrochloric acid, and the aqueous layer was separated from the organic layer. The separated aqueous layer was extracted again with ethyl acetate. The combined organic layer was washed with saturated brine, and dried over anhydrous
magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by basic silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a pale-brown powder (54 mg) .
MS (ESI+) : [M+H]+ 299.2.
[1012]
C) N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -3-fluoroimidazo [ 1 , 2- a] pyridin-2-yl] phenoxy} -1-methylethyl] acetamide
Using 4- [6- (cyclopropylmethoxy) -3-fluoroimidazo [1, 2- a] pyridin-2-yl] phenol (53.6 mg) , and in the same manner as in Example 25, steps D and G, the title compound was obtained as a dark-yellow solid (9.4 mg) .
[1013]
Example 93
N- { ( IS) -2- [4- ( 6-ethoxypyrazolo [1, 5-a] pyridin-2-yl) -3- fluorophenoxy] -1-methylethyl } acetamide
[1014]
Using 4-bromo-3-fluorophenol (5.0 g) and 2-bromo-5- ethoxypyridine (2.74 g) , and in the same manner as in Example 1, step B, Example 84, step B, Example 85, step B, Example 84, step D, Example 85, step D and Example 25, step G, the title compound was obtained as pale-pink crystals (91.4 mg) .
[1015]
Example 94
N- [ (IS) -2- ( { 6- [7- (cyclopropylmethoxy) [1, 2, 4] triazolo [1, 5- a] pyridin-2-yl] pyridin-3-yl }oxy) -1-methylethyl] acetamide
[1016]
Using 4- (benzyloxy) pyridin-2-amine (360 mg) , and in the same manner as in Example 90, step C, Example 12, step C, Example 2, step E and Example 25, step G, the title compound was obtained as colorless crystals (42.9 mg) .
[1017]
Example 95
N- [ (IS) -2- {4- [7- (cyclopropylmethoxy) [1, 2, 4] triazolo [1, 5- a] pyridin-2-yl] phenoxy} -1-methylethyl] acetamide
[1018]
A) methyl 4- ( { (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) benzoate
Using methyl 4-hydroxybenzoate (1.52 g) , and in the same manner as in Example 1, step B, the title compound was obtained as a colorless solid (2.36 g).
λη NMR (300 MHz, CDC13) δ 1.30 (3H, d, J = 6.4 Hz), 1.45 (9H, s), 3.89 (3H, s), 3.98 (2H, d, J = 4.2 Hz), .4.07 (1H, brs) , 4.71 (1H, brs), 6.78-7.01 (2H, m) , 7.84-8.14 (2H, m) .
[1019] B) tert-butyl [ ( IS) -2- ( 4-formylphenoxy) -1- methylethyl] carbamate
To a solution of methyl 4- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl }oxy) benzoate (816 mg) in THF (10 mL) was added a toluene solution (1.0 M, 5.28 mL) of
diisobutylaluminum hydride at -78°C, and the mixture was
stirred at room temperature for 30 min under an argon
atmosphere. Sodium sulfate decahydrate (22.7 g) was added thereto at -78°C, and the mixture was stirred at room
temperature for 3 hr. The reaction mixture was filtered
through celite, and the solvent of the filtrate was evaporated under reduced pressure to give a mixture of tert-butyl {(1S)- 2- [4- (hydroxymethyl) henoxy] -1-methylethyl }carbamate and
methyl 4- ( { (2S) -2- [ (tert- ·
butoxycarbonyl) amino] propyl }oxy) benzoate as a pale-yellow oil (813 mg) . A mixture of the aforementioned mixture (813 mg) of tert-butyl { (IS) -2- [4- (hydroxymethyl) phenoxy] -1- methylethyl } carbamate and methyl 4- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) benzoate, sulfur trioxide pyridine complex (657 mg) , DMSO (7 mL) and triethylamine (3 mL) was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted, twice with ethyl acetate. The combined organic layer was washed with water and saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound as a
colorless oil (504 mg) .
XH N R (300 MHz, CDC13) δ 1.31 (3H, d, J = 6.8 Hz), 1.45 (9H, s), 3.95-4.13 (3H, m) , 4.70 (1H, brs) , 6.97-7.08 (2H, m) ,
7.79-7.88 (2H, m) , 9.89 (1H, s) .
[1020]
C) N- [ (IS) -2-{ 4- [7- (cyclopropylmethoxy) [1, 2, ] triazolo [1, 5- a] pyridin-2-yl] phenoxy} -1-methylethyl] acetamide
Using tert-butyl [( IS) -2- (4-formylphenoxy) -1- methylethyl] carbamate (502 mg) and 4- (benzyloxy) pyridin-2- amine (360 mg) , and in the same manner as in Example 90, step C, Example 12, step C, Example 2, step E and Example 25, step G, the title compound was obtained as colorless crystals (53.6 mg) .
[1021]
Example 96
N-{ (lS)-2-[ (6-{6-[ (2,2-difluorocyclopropyl)methoxy]-l,3- benzoxazol-2-yl}-5-fluoropyridin-3-yl) oxy] -1- methylethyl }acetamide
[1022]
A) (2, 2-difluorocyclopropyl) methyl methanesulfonate
Methanesulfonyl chloride (1.43 mL) was added to a solution of (2 , 2-difluorocyclopropyl ) methanol (1.00 g) and triethylamine (2.58 mL) in THF (10 mL) dropwise at 0 °C. The mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (1.47 g) as a colorless oil.
Η NMR (300 MHz, CDC13) δ 1.24-1.43 (1H, m) , 1.57-1.79 (1H, m) , 1.96-2.24 (1H, m) , 3.05 (3H, s) , 4.16-4.45 (2H, m) .
[1023]
B) tert-butyl { (IS) -2-[ (6-{6- [ (2,2- difluorocyclopropyl) methoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl ) oxy] -1-methylethyl } carbamate
Triethylamine (14.1 mL) was added to a solution of hexachlorbethane (7.46 g) and triphenylphosphine (9.91 g) in acetonitrile (50 mL) at room temperature, and the mixture was stirred at room temperature for 10 min. Then a mixture of tert-butyl [ (lS)-2-({6-[ (2, 4-dihydroxyphenyl) carbamoyl] -5- fluoropyridin-3-yl } oxy) -1-methylethyl] carbamate (5.31 g) and acetonitrile (50 mL) was added, and the mixture was stirred at room temperature for 2 hr. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and
concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to' give tert-butyl [ (IS) -2-{ [5-fluoro-6- (6-hydroxy-l, 3- benzoxazol-2-yl) pyridin-3-yl] oxy}—1-methylethyl] carbamate (10.7 g) as a mixture with impurities. A mixture of ,[(lS)-2- { [5-fluoro-6- ( 6-hydroxy-l, 3-benzoxazol-2-yl) pyridin-3-yl] oxy} - 1-methylethyl] carbamate (4.28 g, a mixture with impurities) , (2 , 2-difluorocyclopropyl) methyl methanesulfonate (0.494 g) , potassium carbonate (0.367 g) , and DMF (30 mL) was stirred at 60 °C for 1 hr. Then additional (2,2- difluorocyclopropyl) methyl methanesulfonate (0.494 g) and potassium carbonate (0.367 g) were added, and the mixture was stirred at 60 °C for 1 hr. Then additional (2,2- difluorocyclopropyl) methyl methanesulfonate (0.494 g) and potassium carbonate (0.367 g) were added, and the mixture was stirred at 60 °C for 1 hr. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (1.39 g) as a pale yellow solid.
MS (ESI+) : [M+H]+ 494.2.
[1024]
C) N-{ (lS)-2-[ (6-{6-[ (2,2-difluorocyclopropyl)methoxy]-l,3- benzoxazol-2-yl } -5-fluoropyridin-3-yl) oxy] -1- methylethyl}acetamide
A mixture of tert-butyl { ( IS) -2- [ ( 6- { 6- [ (2 , 2- difluorocyclopropyl)methoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl} carbamate (690 mg) , 4 M hydrogen chloride/ethyl acetate (10 mL) , and ethyl acetate (10 mL) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure. The residue was mixed with pyridine (10 mL) and acetic anhydride (5 mL) . The mixture was stirred at room temperature overnight. 1 M hydrochloric, acid was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column
chromatography (hexane/ethyl acetate) and recrystallization (ethyl acetate) to give the title compound (496 mg) as white crystals . ~ ·
½ NMR (300 MHz, DMSO-d6) δ 1.18 (3H, d, J = 6.3 Hz) , 1.40-1.60 (1H, m) , 1.66-1.81 (1H, m) , 1.82 (3H, s) , 2.18-2.41 (1H, m) , 3.95-4.33 (5H, m) , 7.07 (1H, dd, J = 8.8, 2.4 Hz), 7.49 (1H, d, J = 2.4 Hz), 7.69-7.82 (2H, m) , 8.00 (1H, d, J = 6.8 Hz),
8.34-8.43 (1H, m) .
mp 163 - 164 °C
[1025]
Example 97
l-{ (lS)-2-[ (6-{6-[ (2,2-difluorocyclopropyl)methoxy]-l,3- benzoxazol-2-yl } -5-fluoropyridin-3-yl) oxy] -1-methylethyl }urea [1026]
A mixture of tert-butyl { (IS) -2- [ (6-{ 6- [ (2, 2- difluorocyclopropyl) methoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl } carbamate (690 mg) , 4 M hydrogen chloride/ethyl acetate (10 mL) , and ethyl acetate (10 mL) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure. The residue was mixed with THF (10 mL) and triethylamine (1.559 mL) , and then
trimethylsilyl isocyanate (193 mg) was added. The mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate/methanol) and recrystallization (ethyl acetate) to give the title compound (315 mg) as pale yellow crystals.
XH NMR (300 MHz, DMSO-d6) δ 1.Ί0-1.19 (3H, m) , 1.43-1.61 (1H, m) , 1.65-1.87 (1H, m) , 2.15-2.38 (1Ή, m) , 3.76-4.43 (5H, m) , 5.50 (2H, s) , 6.12 (ΙΗ,' d, J — 7.4 Hz) , 7.07 (1H, dd, J = 8.7, 2.4 Hz), 7.49 (1H, d, J = 2.4 Hz), 7.67-7.87 (2H, m) , 8.32- 8.46 (1H, m) .
[1027]
Example 98
N-{ (lS)-2-[ (6-{6-[2-(2,2-difluorocyclopropyl)ethoxy]-l,3- benzoxazol-2-yl } -5-fluoropyridin-3-yl) oxy] -1- methylethyl } acetamide
[1028] ■
A) 2- (2, 2-difluorocyclopropyl) ethyl methanesulfonate
Methanesulfonyl chloride (1.35 mL) was added to a solution of 2- (2 , 2-difluorocyclopropyl) ethanol (1.42 g) and triethylamine (3.24 mL) in THF (20 mL) dropwise at 0 °C. The mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound (1.31 g) as a pale yellow oil.
XH NMR (300 MHz, DMSO-d6) δ 1.17-1.30 (1H, m) , 1.44-1.98 (4H, m) , 3.19 (3H,. s) , 4.16-4.36 (2H, m) .
[1029]
B) tert-butyl { (IS) -2- [ (6-{ 6- [2- (2, 2- difluorocyclopropyl) ethoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl } carbamate
Triethylamine (14.1 mL) was added to a solution of hexachloroethane (7.46 g) and triphenylphosphine (9.91 g) in acetonitrile (50 mL) at room temperature, and the mixture was stirred at room temperature for 10 min. Then a mixture of tert-butyl [ (IS) -2- ( { 6- [ (2, 4-dihydroxyphenyl) carbamoyl] -5- fluoropyridin-3-yl } oxy) -1-methylethyl] carbamate (5.31 g) and acetonitrile (50 mL) was added, and the mixture was stirred at room temperature for 2 hr. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give tert-butyl [ (IS) -2-{ [5-fluoro-6- ( 6-hydroxy-l, 3- benzoxazol-2-yl) pyridin-3-yl] oxy } -1-methylethyl] carbamate' (10.7 g) as a mixture with impurities. A mixture of tert-butyl [ (IS) -2-{ [5-fluoro-6- (6-hydroxy-l, 3-benzoxazol-2-yl) pyridin-3- yl] oxy} -1-methylethyl] carbamate (4.28 g, a mixture with impurities), 2- (2, 2-difluorocyclopropyl) ethyl methanesulfonate (0.531 g) , potassium carbonate (0.367 g) , and D F (30 mL) was stirred at 60 °C for 1 nr.. Then additional 2-(2,2- difluorocyclopropyl) ethyl methanesulfonate (0.531 g) and potassium carbonate (0.367 g) were added, and the mixture was stirred at 60 °C for 1 hr. Then additional 2- (2, 2- difluorocyclopropyl) ethyl methanesulfonate (1.06 g) and potassium carbonate (0.733 g) were added, and the mixture was stirred at 60 °C for 1 hr. Water was added, and the mixture was extracted with ethyl acetate. The organic layer, was separated, washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (1.83 g) as a colorless oil.
MS (ESI+) : [M+H]+ 508.1.
[1030]
C ) N- { (lS)-2-[ (6-{ 6- [2- (2, 2-difluorocyclopropyl) ethoxy] -1,3- benzoxazol-2-yl}-5-fluoropyridin-3-yl) oxy] -1- methylethyl } acetamide
A mixture of tert-butyl { (IS) -2- [ (6-{ 6- [2- (2, 2- difluorocyclopropyl) ethoxy] -1, 3-benzoxazol-2-yl}-5- fluoropyridin-3-yl) oxy] -1-methylethyl} carbamate (910 mg) , 4 M hydrogen chloride/ethyl acetate (10 mL) , and ethyl acetate (10 mL) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure. The residue was mixed with pyridine (10 mL) and acetic anhydride (5 mL) . The mixture was stirred at room temperature overnight. 1 M hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) and recrystallization (ethyl acetate/hexane) to give the title' compound (475 mg) as white crystals.
XH NMR (300 MHz, DMSO-d6) δ 1.13-1.39 (4H, m) , 1.48-1.69 (1H, m) , 1.73-2.10 (6H, m) , 3.94-4.27 (5H, m) , 7.05 (1H, dd, J = 8.8, 2.4 Hz), 7.46 (1H, d, J = 2.3 Hz), 7.67-7.86 (2H, m) , 7.99 (1H, d, J = 6.9 Hz), 8.33-8.44 (1H, m) . .
[1031]
Example 99
l-{ (lS)-2-[ (6-{6-[2-(2,2-difluorocyclopropyl)ethoxy]-l,3- benzoxazol-2-yl } -5-fluoropyridin-3-yl) oxy] -1-methylethyl } urea [1032]
A mixture of tert-butyl { (IS) -2- [ (6-{ 6- [2- (2, 2- difluorocyclopropyl) ethoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl} carbamate (910 mg) , 4 M hydrogen chloride/ethyl acetate (10 mL) , and EtOAc (10 mL) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure. The residue was mixed with THF (10 mL) and triethylamine (1.999 mL) , and then trimethylsilyl isocyanate (248 mg) was added. The mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate/methanol) and recrystallization (ethyl acetate) to give the title compound (145 mg) as pale yellow crystals. XH NMR (300 MHz, DMSO-d6) δ 1.07-2.01 (8H, m) , 3.86-4.26 (5H, m) , 5.51 (2H, s) , 6.14 (1H, d, J = 7.4 Hz), 7.05 (1H, dd, J =
8.8, 2.4 Hz), 7.46 (1H, d, J = 2.3 Hz), 7.69-7.86 (2H, m) ,
8.30-8.48 (1H, m) .
. [1033]
Example 100
N-{ (IS) -2- [4- (6-ethoxy-3-fluoropyrazolo [1, 5-a] pyridin-2-yl) -3- fluorophenoxy] -1-methylethyl } acetamide
[1034]
A) tert-butyl [( IS ) -2- ( 4-bromo-3-fluorophenoxy) -1- methylethyl] carbamate
Diisopropyl azodicarboxylate (1.9 solution in toluene, 83 mL) was added to a mixture of 4-bromo-3-fluorophenol (25.0 g) , tert-butyl .[ (IS) -2-hydroxy-l-methylethyl] carbamate (25.2 g) , triphenylphosphine (41.2 g) , and THF (250 mL) dropwise at 0 °C. The mixture was stirred at 0 °C for 30 min, and then at room temperature for 3 hr. The mixture was concentrated under reduced pressure. The residue was purified by silica gel.
column chromatography (hexane/ethyl acetate) to give the title compound (33.7 g) as a pale yellow solid.
- XH NMR (300 MHz, DMSO-d6) δ 1.10 (3H, d, J = 6.3 Hz), 1.37 (9H, s), 3.64-3.99 (3H, m) , 6.78 (1H, ddd, J = 8.9, 2.8, 0.9 Hz), 6.89 (1H, d, J = 7.0 Hz), Ί.03 (1H, dd, J = 11.1, 2.8 Hz), ■ 7.50-7.69 (1H, m) .
[1035]
B) 2-bromo-5-ethoxypyridine
A mixture of 6-bromopyridin-3-ol (7.58 g) , iodoethane (5.23 mL)., potassium carbonate (9.03 g) , and DMF (80 mL) was stirred at 60 °C for 3 hr. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and
concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (7.58 g) as a pale yellow solid.
XH NMR (300 MHz, DMSO-d6) δ 1.33 (3H, t, J = 6.9 Hz), 4.10 (2H, q, J = 7.0 Hz), 7.37 (1H, dd, J = 8.7, 3.2 Hz), 7.47-7.62 (1H, m) , 8.10 (1H, d, J = 2.9 Hz) .
[1036]
C) tert-butyl [ (IS) -2- ( 4-ethynyl-3-fluorophenoxy) -1- methylethyl] carbamate ,
Under nitrogen,, a mixture of tert-butyl [ (IS) -2- (4-bromo- 3-fluorophenoxy) -1-methylethyl] carbamate (23.3 g) ,
ethynyl (trimethyl) silane (13.1 g) ,
bis (triphenylphosphine) palladium (II) dichloride (4.70 g) , cuprous iodide (1.27 g) , triethylamine (14.0 mL) , and toluene (20 ml) was stirred at 100 °C overnight. The precipitate was filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved in THF (200 mL) , and tetrabutylammonium fluoride (1.0 solution in THF, 201 mL) was added dropwise at room temperature. The mixture was stirred at room temperature for 2 hr. 1 M hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) and washed with hexane to give the title compound (12.2 g) as a light brown solid.
XH NMR (300 MHz, DMSO-d6) δ 1.10 (3H, d, J = 6.4 Hz), 1.37 (9H, s), 3.72-4.00 (3H, m) , 4.30 (1H, s) , 6.79 (1H, dd, J = 8.6, 2.4 Hz), 6.83-7.00 (2H, m) , 7.39-7.54 (1H, m) .
[1037]
D) tert-butyl [ (IS) -2-{ 4- [ (5-ethoxypyridin-2-yl) ethynyl] -3- fluorophenoxy} -1-methylethyl] carbamate
Under nitrogen, a mixture of tert-butyl [(IS) -2- (4- ethynyl-3-fluorophenoxy) -1-methylethyl] carbamate (9.36 g) , 2- bromo-5-ethoxypyridine (5.86 g) ,
bis (triphenylphosphine) alladium (II) dichloride (2.04 g), cuprous iodide (0.552 g) , triethylamine (6.06 mL) , and. toluene (20 mL) was stirred at 100 °C overnight. The precipitate was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (7.00 g) as a yellow solid.
MS (ESI+) : [M+H]+ 415.1. .
[-1038] .
E) tert-butyl {( IS) -2- [4- ( 6-ethoxypyrazolo [ 1, 5-a] pyridin-2- yl) -3-fluorophenoxy] -1-methylethyl } carbamate
Perchloric acid (6.39 mL) was added to a solution of ethyl N-{ [ (2 , 4 , 6-trimethylphenyl) sulfonyl] oxy} ethanimidoate (10.60 g) in THF (10 mL) dropwise at 0 °C. The mixture was stirred at 0 °C for 20 min. The mixture was poured into iced- water. The precipitate was filtered and washed with water. The residue was added to a solution of tert-butyl [ (IS) -2-{ 4- [ (5- ethoxypyridin-2-yl ) ethynyl] -3-fluorophenoxy} -1- methylethyl] carbamate (7.00 g) in THF (70 mL) at room
temperature. The mixture was stirred at room temperature for 30 min. The solvent was removed under reduced pressure, and the residue was dissolved in DMF (70 mL) . Potassium carbonate (4.67 g) was added at room temperature, and the mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (4.12 g) as a light brown oil.
MS (ESI+) : [M+H]+ 430.1.
[1039]
F) tert-butyl { (IS) -2- [4- ( 6-ethoxy-3-fluoropyrazolo [1,5- a] pyridin-2-yl) -3-fluorophenoxy] -1-methylethyl } carbamate
l-Fluoro-4-hydroxy-l, -diazabicyclo [2.2.2] octane bis (tetrafluoroborate) (0.975 g) was added to a solution of tert-butyl { (IS) -2- [4- ( 6-ethoxypyrazolo [1, 5-a] pyridin-2-yl) -3- fluorophenoxy] -1-methylethyl } carbamate (1.37 g) in
acetonitrile (20 mL) at room temperature. The mixture was stirred at room temperature for 30 min. Then additional 1- fluoro-4-hydroxy-l , 4-diazabicyclo [2.2.2] octane
bis (tetrafluoroborate) . (0.975 g) was added, and the mixture was stirred at room temperature for 30 min. saturated sodium hydrogen carbonate solution was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and
concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (0.105 g) as a colorless oil.
MS (ESI+) : [M+H]+ 448.1.
[1040]
G) N-{ (IS) -2- [4- ( 6-ethoxy-3-fluoropyrazolo [1, 5-a] pyridin-2- yl) -3-fluorophenoxy] -l-methylethyl}acetamide
A mixture of tert-butyl { (IS) -2- [4- ( 6-ethoxy-3- fluoropyrazolo [1, 5-a] pyridin-2-yl ) -3-fluorophenoxy] -1- methylethyl } carbamate (52 mg) , 4 M hydrogen chloride/ethyl acetate (2 mL) , and ethyl acetate (1 mL) was stirred at room temperature for 6 hr. The mixture was concentrated under reduced pressure. The residue was mixed with pyridine (1 mL) and acetic anhydride (1 mL) . The mixture was stirred at room temperature overnight. 1 M hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (18.7 mg) as white
crystals.
XH NMR (300 MHz, DMSO-d6) δ 1.16 (3H, d, J = 6.7 Hz), 1.36 (3H, t, J = 6.9 Hz)', 1.82 (3H, s) , 3.74-4.22 (5H, m) , 6.88-7.16 (3H, m) , 7.53-7.74 (2H, m) , 7.96 (1H, d, J = 7.6 Hz), 8.34 (1H, s) .
[1041]
Example 101
l-{ (IS) -2- [4- (6-ethoxy-3-fluoropyrazolo [1, 5-a] pyridin-2-yl) -3- fluorophenoxy] -1-methylethyl }urea [1042]
A mixture of tert-butyl { (IS) -2- [4- (6-ethoxy-3- fluoropyrazolo [1, 5-a] pyridin-2-yl) -3-fluorophenoxy] -1- methylethyl} carbamate (52 mg) , 4 M hydrogen chloride/ethyl acetate (2 mL) , and ethyl acetate (1 mL) was stirred at room temperature for 6 hr. The mixture was concentrated under reduced pressure. The residue was mixed with THF (1 mL) and triethyamine (0.130 mL) , and then trimethylsilyl isocyanate (16.1 mg) was added. The mixture was stirred at room
temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium- sulfate and
concentrated under reduced pressure. The residue was purified by silica gel column chromatography (NH, hexane/ethyl
acetate/methanol ) and by preparative HPLC (C18,
water/acetonitrile (containing 0.1% trifluoroacetic acid)).
The desired fraction was neutralized with saturated sodium hydrogen carbonate solution and extracted with ethyl acetate. The organic layer was. separated, dried over washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the title compound (4.00 mg) as white crystals.
XH NMR~(300 MHz, DMSO-d6) δ 1.15 (3H, d, J = 6.4 Hz), 1.36 (3H, t, J = 6.9 Hz), 3.76-4.17 (5H, m) , 5.49 (2H, s) , 5.93-6.17 (1H, m) , 6.88-7.18 (3H, m) , 7.56-7.70 (2H, m) , 8.34 (1H, s) .
[1043]
Example 102
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -3-fluoropyrazolo [1, 5- a] pyridin-2-yl] -3-fluorophenoxy} -1-methylethyl] acetamide
[1044]
A) 2-bromo-5- (cyclopropylmethoxy) pyridine
A mixture of 6-bromopyridin-3-ol (10.0 g) ,
(bromomethyl) cyclopropane (7.76 g) , potassium carbonate (11.9 g) , and DMF (100 mL) was stirred at 60 °C overnight. Water was added, and the mixture was extracted with ethyl acetate . The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound (12.0 g) as a colorless oil. -
XH N R (300 MHz, DMSO-d6) δ 0.25-0.40 (2H, m) , 0.52-0.68 (2H, m) , 1.02-1.40 (1H, m) , 3.89 (2H, d, J = 7.1 Hz), 7.37 (1H, dd, J = 8.7, 3.2 Hz), 7.52 (1H, d, J = 8.7 Hz), 8.10 (1H, d, J = 3.0 Hz) .
[1045]
B) tert-butyl [( IS) -2- ( 4- {[ 5- (cyclopropylmethoxy) pyridin-2- yl] ethynyl } -3-fluorophenoxy) -1-methylethyl] carbamate
Under nitrogen, a mixture of 2-bromo-5- (cyclopropylmethoxy) pyridine (3.11 g) , tert-butyl [(lS)-2-(4- ethynyl-3-fluorophenoxy) -1-methylethyl] carbamate (4.00 g) , bis (triphenylphosphine) palladium (II) dichloride (0.957 g) , cuprous iodide (0.260 g) , triethylamine (2.85 mL) , and toluene (10 mL) was stirred at 100 °C overnight. The precipitate was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (5.1.3 g) as a light brown oil.
MS (ESI+) : [M+H]+ 441.2.
[1046]
C) tert-butyl [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) pyrazolo [1, 5- a] pyridin-2-yl] -3-fluorophenoxy} -1-methylethyl] carbamate
Perchloric acid (4.40 mL) was added to a solution of ethyl N-{ [ (2, 4, 6-trimethylphenyl) sulfonyl] oxy} ethanimidoate (7.31 g) in THF (7 mL) dropwise at 0 °C. The mixture was stirred at 0 °C for 20 min. The mixture was poured into iced- water. The precipitate was filtered and washed with water. The residue was added to a solution of tert-butyl [ (IS) -2- (4-{ [5- (cyclopropylmethoxy) pyridin-2-yl] ethynyl } -3-fluorophenoxy) -1- methylethyl] carbamate (5.13 g) in THF (50 mL) at room
temperature. The mixture was stirred at room temperature for 30 min. The solvent was removed under reduced. pressure, and the residue was dissolved in DMF (50 mL) . Potassium carbonate (3.22 g) was added at room temperature, and the mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated . under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (2.05 g) as a light brown solid.
MS (ESI+) : [M+H]+ 456.2.
[1047]
D) tert-butyl [ (IS) -2-{4- [6- (cyclopropylmethoxy) -3- fluoropyrazolo [1 , 5-a] pyridin-2-yl] -3-fluorophenoxy} -1- methylethyl] carbamate
l-Fluoro-4-hydroxy-l, 4-diazabicyclo [2.2.2] octane bis (tetrafluoroborate) (0.919 g) was added to a solution of tert-butyl [ (IS) -2-{4- [6- (cyclopropylmethoxy) pyrazolo [1, 5- a] pyridin-2-yl] -3-fluorophenoxy} -1-methylethyl] carbamate (1.37 g) in acetonitrile (20 mL) at room temperature. The mixture was stirred at room temperature for 30 min. Then additional 1- fluoro-4-hydroxy-l, 4-diazabicyclo [2.2.2] octane
bis (tetrafluoroborate) (0.919 g) was added, and the mixture was stirred at room temperature for 30 min. Saturated sodium hydrogen carbonate solution was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (0.134 g) as a colorless oil.
MS (ESI+) : [M+H]+ 474.2.
[1048]
E) N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) -3-fluoropyrazolo [1, 5- a] pyridin-2-yl] -3-fluorophenoxy} -1-methylethyl] acetamide
A mixture of tert-butyl [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) -3-fluoropyrazolo [1, 5-a] pyridin-2-yl] -3- fluorophenoxy} -1-methylethyl] carbamate (67 mg) , 4 M hydrogen chloride/ethyl acetate (2 mL) , and ethyl acetate (1 mL) was stirred at room temperature for 6 hr. The mixture was
concentrated under reduced pressure. The residue was mixed with pyridine (1 mL) and acetic anhydride (1 mL) . The mixture was stirred at room temperature overnight. 1 M hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (33.4 mg) as white crystals.
1H NMR (300 MHz, DMSO-d6) δ 0.25-0.41 (2H, m) , 0.52-0.70 (2H, m) , 1.16 (3H, d, J = 6.7 Hz ) , 1.21-1.32 (1H, m) , 1.82 (3H, s) , 3.76-4.33 (5H, m) , 6.89-7.15 (3H, m) , 7.57-7.70 (2H, m) , 7.96 (1H, d, J = 7.9 Hz), 8.29 (1H, s) .
[1049]
Example 103
1- [ ( IS) -2-{ 4- [ 6- (cyclopropylmethoxy) -3-fluoropyrazolo [1,5- a] pyridin-2-yl] -3-fluorophenoxy} -1-methylethyl] urea
[1050]
A mixture of tert-butyl [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) -3-fluoropyrazolo [1, 5-a] pyridin-2-yl] -3- fluorophenoxy} -1-methylethyl] carbamate (67 mg) , 4 M hydrogen chloride/ethyl acetate (2 mL) , and ethyl acetate (1 mL) was stirred at room temperature for 6 hr. The mixture was
concentrated under reduced pressure. The residue was mixed with THF (1 mL) and triethylamine (0.158 mL) , and then
trimethylsilyl isocyanate (19.6 mg) was added. The mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (NH, hexane/ethyl acetate/methanol) to give the title compound
(4.40 mg) as white crystals.
XH NMR (300 MHz, DMSO-d6) δ' 0.28-0.39. (2H, m) , 0.60 (2H, · d, J = 7.9 Hz), 1.10-1.32 (4H, m) , 3.77-4.09 (5H, m) , 5.49 (2H, s) , 6.00-6.16 (1H, m) , 6.92-7.16 (3H, m) , 7.56-7.72 (2H, m), 8.30
(1H, s) .
[1051]
Example 104
N- [ (IS) -2- { 4- [ 6- (cyclopropylmethoxy) pyrazolo [1, 5-a] pyridin-2- yl] -3-fluorophenoxy} -1-methylethyl] acetamide
[1052]
A mixture of tert-butyl [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) pyrazolo [1, 5-a] pyridin-2-yl] -3- fluorophenoxy} -1-methylethyl] carbamate (200 mg) , 4 M hydrogen chloride/ethyl acetate (2 mL) , and ethyl acetate (2 mL) was stirred at room temperature for 2 hr. The mixture was
concentrated under reduced pressure. The residue was mixed with pyridine (2 mL) and acetic anhydride (2 mL) . The mixture was stirred at room temperature overnight. 1 M hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column
chromatography (hexane/ethyl acetate) and by preparative "HPLC (C18, water/acetonitrile (containing 0.1% trifluoroacetic acid) ) . The desired fraction was neutralized with saturated sodium hydrogen carbonate solution and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the title compound (60.6 mg) as off-white crystals.
XH NMR (300 MHz, DMSO-d6) δ 0.24-0.40 (2H, m) , 0.54-0.68 (2H, m) , 1.16 (3H, d, J = 6.7 Hz), 1.19-1.35 (1H, m) , 1.82 (3H, s) , 3.79-4.22 (5H, m), 6.83 (1H, d, J = 3.8 Hz), 6.87-7.11 (3H, m) , 7.62 (1H, d, J = 9.6 Hz), 7.87-8.03 (2H, m) , 8.36 (1H, s) .
[1053] Example 105
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) pyrazolo [1, 5-a] pyridin-2- yl] -3-fluorophenoxy} -1-methylethyl] urea
[1054]
A mixture of tert-butyl [ (IS) -2-{ 4- [6-
(cyclopropylmethoxy) pyrazolo [1, 5-a] pyridin-2-yl] -3- fluorophenoxy} -1-methylethyl] carbamate (200 mg) , 4 hydrogen chloride/ethyl acetate (2 mL) , and ethyl acetate (2 mL) was stirred at room temperature for 2 hr. The mixture was
concentrated under reduced pressure. The residue was mixed with THF (2 mL) and triethylamine (0.490 mL) , and then
trimethylsilyl isocyanate (76 mg) was added. The mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (NH,
hexane/ethyl acetate/methanol) and by preparative HPLC (C18, water/acetonitrile (containing 0.1% trifluoroacetic acid)).
The desired fraction was neutralized with saturated sodium hydrogen carbonate solution and extracted with ethyl acetate. The organic layer was separated, dried over washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was recrystallized (ethyl
acetate) to give the title compound (56.9 mg) as off-white crystals.
XH NMR (300 MHz, DMSO-d6) δ 0.27-0.41 (2H, m) , 0.52-0.66 (2H, m) , 1.15 (3H, d, J = 6.4 Hz), 1.19-1.33 (1H, m) , 3.72-4.11 (5H, m) , 5.48 (2H, s) , 6.05 (1H, d, J = 7.3 Hz), 6.8.3 (1H, d, J = 3.6 Hz), 6.86-7.16 (3H, m) , 7.62 (1H, d, J = 9.4 Hz), 7.85- 8.03 (1H, m) , 8.36 (1H, s) .
[1055]
Example 106
1- [ (IS) -2- ( { 6- [6- (2, 2-difluoropropoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) -1-methylethyl] urea [1056]
A) tert-butyl [ (IS) -2- ( { 6- [ (2, 4- dihydroxyphenyl) carbamoyl] pyridin-3-yl } oxy) -1- methylethyl] carbamate
Diisopropyl azodicarboxylate (1.9 M solution in toluene,
9.52 mL) was added to a mixture of methyl 5-hydroxypyridine-2- carboxylate (5.00 g) , tert-butyl [ ( IS) -2-hydroxy-l- methylethyl] carbamate (8.58 g) , triphenylphosphine (12.9 g) , and THF (50 mL) at 0 °C dropwise. The mixture was stirred at room temperature for 3 days . The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give methyl 5- ( { (2S) -2- [ (tert-butoxycarbonyl) amino] propyl } oxy) pyridine-2- carboxylate (810 mg) as a mixture with impurities. A mixture of methyl 5- ({ (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) pyridine-2-carboxylate (810 mg, a mixture with impurities), THF (8 mL) , methanol (8 mL) , and 1 sodium hydroxide (8 mL) was stirred at room temperature for 4 hr. The mixture was neutralized with 1 M hydrochloric acid at 0 °C, and brine was added. The mixture was extracted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give 5- ({ (2S) -2- [ (tert- butoxycarbonyl ) amino] propyl } oxy) pyridine-2-carboxylic acid
(765 mg) as a mixture with impurities. A mixture of 5-({(2S)- 2- [ (tert-butoxycarbonyl) amino] propyl } oxy) pyridine-2-carboxylic acid (765 mg, a mixture with impurities), 4-aminobenzene-l, 3- diol hydrochloride (417 mg) , HATU (982 mg) , N,N- diisopropylethylamine. (0.902 mL) , and DMF (7 mL) was stirred at room temperature overnight. Water was added, and the
mixture was extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous
magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to give the title compound (442 mg) as a pale yellow oil .
MS (ESI+) : [M+H]+ 404.2.
[1057] - B) tert-butyl [ (IS) -2- ( { 6- [6- (2, 2-difluoropropoxy) -1, 3- benzoxazol-2-.yl]pyridin-3-yl}oxy) -1-methylethyl] carbamate
Triethylamine (1.22 mL) was added to a solution of hexachloroethane (648 mg) and triphenylphosphine (862 mg) in acetonitrile (5 mL) at room temperature. The mixture was stirred at room temperature for 10 min. Then a mixture of tert-butyl [ (IS) -2- ( { 6- [ (2, 4- dihydroxyphenyl) carbamoyl] pyridin-3-yl } oxy) -1- methylethyl] carbamate (442 mg) and acetonitrile (5 mL) was added, and the mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was separated? washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture of tert-butyl [ (IS) -2-{ [6- (6-hydroxy-l, 3-benzoxazol-2- yl ) pyridin-3-yl] oxy} -1-methylethyl] carbamate and tert-butyl
[ (IS) -2- ( { 6- [ (2, 4-dihydroxyphenyl ) carbamoyl] pyridin-3-yl } oxy) - 1-methylethyl] carbamate . Triethylamine (1.22 ml) was added to a solution of hexachloroethane (648 mg) and triphenylphosphine (862 mg) in acetonitrile (5 mL) at room temperature. The mixture was stirred at room temperature for 10 min. Then a mixture of tert-butyl [ (IS) -2-{ [6- (6-hydroxy-l, 3-benzoxazol-2- yl) yridin-3-yl] oxy} -1-methylethyl] carbamate and tert-butyl [ (IS) -2- ( { 6- [ (2, -dihydroxyphenyl) carbamoyl] pyridin-3-yl } oxy) - 1-methylethyl] carbamate, and acetonitrile (5 mL) were added, and the mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give tert- butyl [ (IS) -2-{ [6- ( 6-hydroxy-l, 3-benzoxazol-2-yl) pyridin-3- yl] oxy} -1-methylethyl] carbamate (640 mg) as a mixture with impurities. A mixture of tert-butyl [ (IS) -2-{ [6- (6-hydroxy-
1, 3-benzoxazol-2-yl) pyridin-3-yl] oxy} -1-methylethyl] carbamate (640 mg, a mixture with impurities), l-bromopropan-2-one (455 mg) , potassium carbonate (459 mg) , and D F (10 mL) was stirred at 60 °C for 1 hr. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give tert-butyl [ (IS) -l-methyl-2- ({ 6- [6- (2-oxopropoxy) -1, 3- benzoxazol-2-yl]pyridin-3-yl}oxy) ethyl] carbamate (630 mg) as a mixture with impurities. Bis (2-methoxyethyl) aminosulfur trifluoride (0.789 mL) was "added to a mixture of tert-butyl [ (IS) -l-methyl-2- ( { 6- [6- (2-oxopropoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) ethyl] carbamate (630 mg, a mixture with impurities) and toluene (10 mL) at room temperature. The mixture. was stirred at 80 °C for 2 hr. Saturated sodium hydrogen carbonate solution was added, and the mixture was extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (111 mg) as a white solid.
MS (ESI+) : [M+H]+ 464.2.
[1058]
C) 1- [ (IS) -2- ( { 6- [6- (2, 2-difluoropropoxy) -1, 3-benzoxazol-2- yl] pyridin-3-yl } oxy) -1-methylethyl] urea
A mixture of tert-butyl [ (IS) -2- ( { 6- [6- (2, 2- difluoropropoxy) -1, 3-benzoxazol-2-yl]pyridin-3-yl}oxy) -1- methylethyl] carbamate (111 mg) , 4 M hydrogen chloride/ethyl acetate (1 mL) , and ethyl acetate (2 mL) was stirred at room temperature for 4 hr. The mixture was concentrated under reduced pressure. The residue was mixed with THF (2 mL) and triethylamine (0.267 mL) , and then trimethylsilyl isocyanate
(27.6 mg) was added. The mixture was stirred at room
temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and
concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl
acetate/methanol) and recrystallization (ethyl acetate) to give the title compound (38.8 mg) as white crystals.
λΕ NMR (300 MHz, DMSO-d6) δ 1.17 (3H, d, J = 6.5 Hz), 1.78 (3H, t, J = 19.3 Hz), 3.86-4.23 (3H, m) , 4.40 (2H, t, J = 12.7 Hz), 5.49 (2H, s), 6.10 (1H, d, J = 7.3 Hz), 7.11 (1H, dd,' J = 8.8, 2.5 Hz), 7.54 (1H, d, J = 2.4 Hz)., 7.65 (1H, dd, J = 8.8, 2.9 Hz), 7.73 (1H, d, J = 8.9 Hz), 8.22 (1H, d, J = 8.9 Hz), 8.49 (1H, d, J = 2.7 Hz) .
[1059]
Example 107
N-{ (IS) -2- [ (6-{6- [ (3, 3-difluorocyclobutyl)methoxy] -1, 3- benzoxazol-2-yl } -5-fluoropyridin-3-yl) oxy] -1- '.
methylethyl } acetamide
[1060]
A) tert-butyl [ ( IS) -2- { [5-fluoro-6- ( 6-hydroxy-l, 3-benzoxazol- 2-yl) pyridin-3-yl] oxy } -1-methylethyl] carbamate
A mixture of 5- ( { (2S) -2- [ (tert- butoxycarbonyl) amino] propyl } oxy) -3-fluoropyridine-2-carboxylic acid (5.00 g) , 4-aminobenzene-l , 3-diol hydrochloride (2.57 g) , HATU (6.05 g) , N, N-diisopropylethylamine (5.56 mL) , and DMF (50 mL) was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give tert-butyl
[ (IS) -2- ( { 6- [ (2, 4-dihydroxyphenyl) carbamoyl] -5-fluoropyridin- 3-yl } oxy) -1-methylethyl] carbamate (2.5.1 g) as a mixture with impurities. Triethylamine (6.64 mL) was added to a solution of hexachloroethane (3.53 g) and triphenylphosphine (4.69 g) in acetonitrile (25 mL) at room temperature. The mixture was stirred at room temperature for 10 min. Then a mixture of tert-butyl [ (IS) -2- ( { 6- [ (2, 4-dihydroxyphenyl) carbamoyl] -5- fluoropyridin-3-yl } oxy) -l-methylethyl] carbamate (2.51 g, a mixture with impurities) and acetonitrile (25 mL) was added, and the mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (0.770 g) as a pale, yellow solid.
MS (ESI+) : [M+H]+ 404.2.
[1061]
B) tert-butyl { (IS) -2- [ (6-{ 6- [ (3, 3- difluorocyclobutyl ) methoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -l-methylethyl} carbamate
A mixture of tert-butyl [ (IS) -2-{ [5-fluoro-6- (6-hydroxy-
1, 3-benzoxazol-2-yl) pyridin-3-yl] oxy} -l-methylethyl] carbamate (770 mg) , (3, 3-difluorocyclobutyl) methyl methanesulfonate (459 mg) , potassium carbonate (317 mg) , and DMF (10 mL) was stirred at 60 °C for 2 hr. Then additional (3,3- difluorocyclobutyl) methyl methanesulfonate (459 mg) and potassium carbonate (317 mg) were added, and the mixture was stirred at 60 °C overnight. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and
concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (780 mg) as a white solid.
MS (ESI+) : [M+H] + 508.1.
[1062]
C) N-{ (lS)-2-[ (6-{6-[ (3, 3-difluorocyclobutyl) methoxy] -1,3- benzoxazol-2-yl } -5-fluoropyridin-3-yl) oxy] -1- methylethyl } acetamide
A mixture of tert-butyl { (IS) -2- [ (6-{ 6- [ (3, 3- difluorocyclobutyl) methoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl } carbamate (390 mg) , 4 M hydrogen chloride/ethyl acetate (3 mL) , and ethyl acetate (3 mL) was stirred at room temperature for 4 hr. The mixture was concentrated under reduced pressure. The residue was mixed with pyridine (3 mL) and acetic anhydride (1 mL) . The mixture was stirred at room temperature for 3 days. 1 M hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate/methanol) and
recrystallization (ethyl acetate) to give the title compound (218 mg) as white crystals.
¾ NMR (300 MHz, DMSO-d6) δ 1.18 (3H, d, J = 6.3 Hz), 1.82 (3H, s), 2.35-2.86 (5H, m) , 3.94-4.24 (5H, m) , 7.05 (1H, dd, J = 8.8, 2.4 Hz), 7.46 (1H, d, J = 2.4 Hz), 7.65-7.81 (2H, m) , 8.01 (1H, d, J = 7.4 Hz), 8.34-8.44 (1H, m) .
[1063]
Example 108
l-{ (IS) -2- [ (6-{ 6- [ (3, 3-difluorocyclobutyl) methoxy] -1,3- benzoxazol-2-yl } -5-fluoropyridin-3-yl) oxy] -1-methylethyl }urea [1064]
A mixture of tert-butyl { (IS) -2- [ (6-{6- [ (3,3- difluorocyclobutyl) methoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl} carbamate (390 mg) , 4 M hydrogen chloride/ethyl acetate (3 mL) , and ethyl acetate (3 mL) was stirred at room temperature for 4 hr. The mixture was concentrated under reduced pressure. The residue was mixed with THF (3 mL) and triethylamine (0.857 mL) , and then
trimethylsilyl isocyanate (89 mg) was added. The mixture was stirred at room temperature for 3 days. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate/methanol) and recrystallization (ethyl acetate) to give the title compound (227 mg) as white crystals.
XH NMR (300 MHz, DMSO-d6) δ 1.13-1.20 (3H, m) , 2.40-2.90 (5H, m) , 3.80-4.23 (5H, m) , 5.51 (2H, s) , 6.13 (1H, d, J = 7.1 Hz), 7.05 (1H, dd, J = 8.8, 2.4 Hz) , 7.46 (1H, d,' J = 2.4 Hz),
7.69-7.86 (2H, m) , 8.36-8.45 (1H, m) .
[1065]
Example 109
Diastereomer of N-{ (IS) -2- [ (6-{6- [ (2,2- difluorocyclopropyl) methoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl } acetamide (retention time: short)
[1066]
The diastereomeric mixture (186 mg) of the title compound obtained in Example 96 was resolved by preparative HPLC
(CHIRALPAK AD, 50 mmID χ 500 mmL, manufactured by Daicel
Corporation, mobile phase: methanol = 100%) . The residue was recrystallized (ethyl acetate) to give the title compound
(47.4 mg, >99.9% de, retention time: short) as white crystals. ΧΗ NMR (300 MHz, DMSO-d6) δ 1.18 (3H, d, J = 6.3 Hz), 1.42-1.59 (1H, m) , 1.65-1.89 (4H, m) , 2.16-2.39 (1H, m) , 3.96-4.33 (5H, m) , 7.07 (1H, dd, J = 8.8, 2.4 Hz), 7.49 (1H, d, J = 2.3 Hz), 7.69-7.81 (2H, m) , 8.01 (1H, d, J = 6.8 Hz), 8.34-8.42 (1H, m) .
[1067]
Example 110
Diastereomer of N-{ (IS) -2- [ (6-{ 6- [ (2,2- difluorocyclopropyl ) methoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl } acetamide (retention time: long)
[1068]
The diastereomeric mixture (186 mg) of the title compound obtained in Example 96 was resolved by preparative HPLC
(CHIRALPAK AD, 50 mmID * 500 mmL, manufactured by Daicel
Corporation, mobile phase: methanol = 100%) . The residue was recrystallized (ethyl acetate) to give the title compound
(45.8 mg, 99.7% de, retention time: long) as white crystals. XH NMR (300 MHz, DMSO-d6) δ 1.18 (3H, d, J = 6.4 Hz), 1.42-1.59 (1H, m) , 1.67-1.88 (4H, m) , 2.16-2.39 (1H, m) , 4.00-4.33 (5H, m) , 7.07 (1H, dd, J = 8.8, 2.4 Hz), 7.49 (1H, d, J = 2.4 Hz), 7.70-7.82 (2H, m) , 8.01 (1H, d, J = 7.0 Hz) , 8.35-8.41 (1H, m) .
[1069]
Example 111
Diastereomer of l-{ (IS) -2-[ (6-{6- [ (2,2- difluorocyclopropyl) methoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -l-methylethyl}urea (retention time:
short)
[1070]
The diastereomeric mixture (200 mg) of the title compound obtained in Example 97 was resolved by preparative HPLC
(CHIRALPAK AD, 50 mmID * 500 mmL, manufactured by Daicel
Corporation, mobile phase: ethanol/2-propanol = 500/500) . The residue was recrystallized (ethyl acetate) to give the title compound (81^.4 mg, >99.9% de, retention time: short) as yellow crystals.
XH NMR (300 MHz, DMSO-d6) δ 1.17 (3H, d, J = 6.5 Hz), 1.38-1.61 (1H, m) , 1.67-1.85 (1H, m) , 2.11-2.40 (1H, m) , 3.83-4.41 (5H, m) , 5.50 (2H, s) , 6.11 (1H, d, J = 7.1 Hz), 7.07 (1H, dd, J = 8.7, 2.4 Hz), 7.49 (1H, d, J = 2.3 Hz), 7.66-7.89 (2H, m) ,
8.32-8.47 (1H, m) .
[1071]
Example 112
Diastereomer of l-{ (IS) -2-[ (6-{6- [ (2,2- difluorocyclopropyl ) methoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl } urea (retention time:
long)
[1072] The diastereomeric mixture (200 mg) of the title compound obtained in Example 97 was resolved by preparative HPLC .
(CHIRALPAK AD, 50 mmID χ 500 mmL, manufactured by Daicel
Corporation, mobile phase: ethanol/2-propanol = 500/500) . The residue was recrystallized (ethyl acetate) to give the title compound (66.1 mg,. >99.9% de, retention time: long) as white crystals .
XH NMR (300 MHz, DMSO-d6) δ 1.17 (3H, d, J = 6.5 Hz), 1.40-1.58 (1H, m) , 1.66-1.85 (1H, m) , 2.15-2.42 (1H, m) , 3.74-4.36 (5H, m) , 5.50 (2H, s) , 6.11 (1H, d, J = 7.3 Hz), 7.07 (1H, dd, J = 8.8, 2.4 Hz), 7.49 (1H, d, J = 2.3 Hz), 7.67-7.86 (2H, m) , 8.34-8.46 (1H, m) .
[1073]
Example 113
Diastereomer of N-{ (IS) -2- [ (6-{ 6- [2- (2, 2- difluorocyclopropyl ) ethoxy] -1 , 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl ) oxy] -1-methylethyl } acetamide (retention time: short)
[1074]
The diastereomeric mixture (200 mg) of the title compound obtained in Example 98 was resolved by preparative HPLC
(CHIRALPAK AD, 50 mmID χ 500 mmL, manufactured by Daicel
Corporation, mobile phase: methanol = 100%). The residue was recrystallized (ethyl acetate) to give the title compound (57.2 mg, >99.9% de, retention time: short) as white crystals. ½ NMR (300 MHz, DMS0-d6) δ 1.11-1.35 (4H, m) , 1.45-2.11 (7H, m) , 3.94-4.23 (5H, m) , 7.05 (1H, dd, J = 8.8, 2.4 Hz), 7.46 (1H, d, J = 2.3 Hz), 7.67-7.82 (2H, m) , 8.01 (1H, d, J = 6.9 Hz) , 8.33-8.45 (1H, m) .
[1075]
Example 114
Diastereomer of N-{ (IS) -2- [ (6-{ 6- [2- (2, 2- difluorocyclopropyl) ethoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl } acetamide (retention time: long) [1076] -
The diastereomeric mixture (200 mg) of the title compound obtained in Example 98 was resolved by preparative HPLC
(CHIRALPAK AD, 50 mmID * 500 mmL, manufactured by Daicel
Corporation, mobile phase: methanol = 100%). The residue was recrystallized (ethyl acetate) to give the title compound
(57.4 mg, >99.9% de, retention time: long) as white crystals.
!H NMR (300 MHz, DMSO-d6) δ 1.11-1.35 (4H, m) , 1.47-2.14 (7H, m) , 3.96-4.27 (5H, m) , 7.05 (1H, dd, J = 8.8, 2.4 Hz), 7.46 (1H, d, J = 2.3 Hz), 7.69-7.87 (2H, m) , 8.01 (1H, d, J = 6.9 Hz) , 8.31-8.45 (1H, m) .
[1077]
Example 115
Diastereomer of l-{ (IS) -2- [ (6-{ 6- [2- (2, 2- difluorocyclopropyl) ethoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl } urea (retention time:
short)
[1078].
The diastereomeric mixture (100 mg) of the title compound obtained in Example 99 was resolved by -preparative HPLC
(CHIRALPAK AD, 50 mmID * 500 mmL, manufactured by Daicel
Corporation, mobile phase: ethanol = 100%). The residue was recrystallized (ethyl acetate) to give the title compound
(44.0 mg, >99.9% de, retention time: short) as white crystals. XH NMR (300 MHz, DMSO-d6) δ 1.10-2.03 (8H, m) , 3.81-4.27 (5H, m),' 5.52 (2H, s), 6.13 (1H, d, J = 7.2 Hz), 6.97-7.12 (1H, m) , 7.46 (1H, d, J = 2.3 Hz), 7.63-7.84 (2H, m) , 8.36-8.45 (1H, m) .
[1079]
Example 116
Diastereomer of l-{ (IS) -2- [ (6-{ 6- [2- (2, 2- difluorocyclopropyl) ethoxy] -1, 3-benzoxazol-2-yl } -5- fluoropyridin-3-yl) oxy] -1-methylethyl }urea (retention time:
long)
[1080]
The diastereomeric mixture (100 mg) of the title compound obtained in Example 99 was resolved by preparative HPLC
(CHIRALPAK AD, 50 mmID χ 500 mmL, manufactured by Daicel
Corporation, mobile phase: ethanol = 100%). The residue was recrystallized (ethyl acetate) to give the title compound (24.5 mg, >99.9% de, retention time: long) as white, crystals . XH NMR (300 MHz, DMSO-d6) δ 1.05-2.15 (8H, m) , 3.87-4.23 (5H, m) , 5.51 (2H, s) , 6.13 (1H, d, J = 7.6 Hz), 7.05 (1H, dd, J = 8.8, 2.5 Hz), 7.46 (1H, d, J = 2.3 Hz), 7.66-7.83 (2H, m) , 8.35-8.44 (1H, m) .
[1081]
Example 117
Diastereomer of N- [ (IS) -2- ( { 6- [ 6- (cyclopropylmethoxy) -2- methyl-2, 3-dihydro-l-benzofuran-2-yl] pyridin-3-yl } oxy) -1- methylethyl] acetamide
[1082]
A) 2- (2-Bromo-4-hydroxyphenyl) acetic acid
To a solution of (2-bromo-4-methoxyphenyl) acetic acid (0.49 g) in dichloromethane (5 mL) was added a solution of tribromoborane (5 mL) dropwise at room temperature. The mixture was refluxed for 3 hr. After cooling to room
temperature, the mixture was poured into iced water. The organic layer was separated, and the water layer was extracted by ethyl acetate (30 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate, filtered and evaporated to dryness. The residue was washed with ether to give the title compound (0.45 g) .
MS (ESI+) : [M+H] + 230.9
[1083]
B) 2- (2-Bromo-4-hydroxyphenyl) -N-methoxy-N-methylacetamide
A mixture of 2- (2-bromo-4-hydroxyphenyl) acetic acid (0.67 g) , HATU (1.33 g) , triethylamine (0.35 g) and N,0- dimethylhydroxylamine hydrochloride (0.34 g) in
dichloromethane (30 mL) was stirred overnight, to which water (30 mL) was added. The organic layer was separated. The water layer was extracted by ethyl acetate (20 mL x 3) . The combined organic. layer was dried over anhydrous sodium sulfate,
filtered and evaporated to dryness. The residue .was purified by silica gel column chromatography (petroleum ether/ethyl acetate) to afford the title compound (773 mg) .
XH NMR (CDCI3, 400 MHz): δ 3.27 (3H, s) , 3.79 (3H, s) , 3.85 (2H, s), 6.56 (1H, d, J = 8.0 Hz), 6.77 (1H, s) , 6.87 (1H, s) , 7.01 (1H, d, J = 8.4 Hz) .
[1084]
C) 2- (2-Bromo-4- (methoxymethoxy) phenyl) -N-methoxy-N- methylacetamide
A solution of 2- (2-bromo-4-hydroxyphenyl ) -N-methoxy-N- methylacetamide (1.37 g) in THF (5 mL) was slowly added to a suspension of sodium hydride (0.22 g) in THF (30 mL) at 0°C.
After stirring for 10 min, bromo (methoxy) methane (1.25 g) was added dropwise at 0°C. The mixture was stirred at 0°C for 2 hr. The mixture was poured into water and extracted with ethyl acetate (30 mL x 3) . The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated to dryness. The
residue was purified by silica gel column chromatography
(petroleum ether/ethyl acetate) to afford the title compound (1.34 g) .
XH NMR (DMSO, 400 MHz): δ 3.12 (3H, s) , 3.38 (3H, s) , 3.73 (3H, s), 3.82 (2H, s), 5.20 (2H, s) , 7.00 (1H, q) , 7.26 (2H, q) .
[1085]
D) 1- (2-Bromo-4- (methoxymethoxy) phenyl) propan-2-one
To a mixture of 2- (2-bromo-4- (methoxymethoxy) phenyl) -N- methoxy-N-methylacetamide (4.30 g) in ether (93 mL) was added methyl magnesium bromide (3 M in ether, 63 mL) dropwise at 0°C. After addition, the solution was stirred at 0°C for 1.5 hr. The mixture was poured into saturated aqueous ammonium chloride, and extracted with ethyl acetate (100 mL x 2) . The. organic phase was dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate) to afford the title compound (23 g) . XH NMR (CDCI3, 400 MHz): δ 2.13 (3H, s) , 3.40 (3H, s) , 3.73 (2H, s), 5.07 (2H, d, J = 3.6 Hz), 6.91 (1H, d, J = 2.8 Hz), 7.05
(1H, d, J = 8.4 Hz), 7.22 (1H, d, J = 2.4 Hz).
[1086]
E) 1- (2-Bromo-4- (methoxymethoxy) phenyl) -2- (5- (triisopropylsilyloxy) pyridin-2-yl) propan-2-ol
To a solution of 2-bromo-5- (triisopropylsilyloxy) pyridine (26.6 g) in ether (80 mL) at -78°C was added n-butyllithium (2.5 M in hexane, 32.2 mL) dropwise. After being stirred at the same temperature for 10 min, a solution of 1- (2-bromo-4- (methoxymethoxy) phenyl) propan-2-one (11 g) in diethylether (40 mL) was added dropwise. The mixture was stirred at -78 °C for 5 hr, and poured into iced saturated ammonium chloride and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified, by silica gel column chromatography (petroleum ether/ethyl acetate) to afford the title compound (9.6 g)..
aH NMR (CDCI3, 400 MHz) : δ 1.07-1.10 (18H, d, J = 8.8 Hz),
1.23-1.31 (6H, m) , 3.12-3.27 (2H, q, J = 7.2 Hz), 3.45 (3H, s) , 4.89 (1H, s), 5.11 (2H, s) , 6.83 (1H, dd, J = 8.4 Hz and 2.4 Hz) , 7.09 (1H, d, J = 8.8 Hz) , 7.16-7.22 (3H, m) , 8.10-8.12 (1H, m) .
[1087]
F) 2- (6- (Methoxymethoxy) -2-methyl-2, 3-dihydrobenzofuran-2-yl) - 5- (triisopropylsilyloxy) pyridine
A mixture of 1- (2-bromo-4- (methoxymethoxy) phenyl) -2- (5- (triisopropylsilyloxy) pyridin-2-yl) propan-2-ol (9.6 g) , copper iodide(I) (3.5 g) , cesium carbonate (5.1 g) in toluene (60 mL, containing ca. 0.6 mL DMF) was heated to reflux overnight. The mixture was filtrated and the solid was washed with ethyl acetate. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column
chromatography (petroleum ether/ethyl acetate) to afford the title compound (8 g) . MS (ESI+) : [M+H]+ 444.2
[1088]
G) 6- ( 6- (Methoxymethoxy) -2-methyl-2 , 3-dihydrobenzofuran-2- yl ) pyridin-3-ol
A mixture of 2- (6- (methoxymethoxy) -2-methyl-2, 3- dihydrobenzofuran-2-yl) -5- (triisopropylsilyloxy) yridine (8 g) and tetrabutylammonium fluoride (5.66 g) in THF (30 mL) was. stirred at ambient temperature for 30 min. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol) to afford the title compound (4.66 g) .
MS (ESI+) : [M+H]+ 288.0
[1089].
H) Diastereomer of 6- (6- (methoxymethoxy) -2-methyl-2, 3- dihydrobenzofuran-2-yl) pyridin-3-ol
The diastereomeric mixture of 6- ( 6- (methoxymethoxy) -2- methyl-2, 3-dihydrobenzofuran-2-yl) pyridin-3-ol was separated by preparative HPLC (column: CHIRALPAK AD-H, 4.6 x 250 mm, 5 jam, mobile phase: methanol) to afford the more polar isomer
(shorter retention time) .
MS (ESI+) : [M+H]+ 288.0.
100%de
[1090]
I) Diastereomer of tert-Butyl [ (IS) -2- ({ 6- [6- (methoxymethoxy) - 2-methyl-2, 3-dihydro-l-benzofuran-2-yl] pyridin-3-yl } oxy) -1- methylethyl] carbamate
A solution of diisopropyl azodicarboxylate (1.9 M in toluene, 2.20 mL) was added dropwise to a solution of
diastereomer of 6- (6- (methoxymethoxy) -2-methyl-2, 3- dihydrobenzofuran-2-yl) pyridin-3-ol (shorter retention time, 800 mg) , (S) -tert-butyl (l-hydroxypropan-2-yl) carbamate (976 mg) , and triphenylphosphine (1100 mg) in toluene (20 mL) at ambient temperature. The mixture was stirred at room
temperature for 2 hr. The mixture was concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The separated organic layer was washed with brine, dried over anhydrous magnesium sulfate, . and
concentrated under reduced pressure. The residue was purified by column chromatography (hexane/ethyl acetate) to give the title compound (1100 mg) .
XH NMR (300 MHz, DMSO-d6) δ 0.98 (3H, d, J = 6.7 Hz), 1.37 (9H, s), 1.68 (3H, s), 3.07-3.22 (2H, m) , 3.26-3.34 (2H, m) , 3.36
(3H, s), 3.37-3.60 (2H, m) , 5.12 (2H, s) , 6.40-6.58 (2H, m) , 7.03 (1H, d, J = 8.0 Hz), 7.13 (1H, dd, J = 8.6, 2.8 Hz), 7.36 (1H, d, J = 8.6 Hz), 8.09 (1H, d, J = 2.4 Hz).
[1091]
J) Diasteromer of 2- (5-{ [ (2S) -2-aminopropyl] oxy}pyridin-2-yl ) - 2-methyl-2, 3-dihydro-l-benzofuran-6-ol dihydrochloride
A solution of 4 M hydrogen chloride/ethyl acetate (10 mL) was added dropwise to a solution of diastereomer of tert-butyl [ (IS) -2- ( { 6- [6- (methoxymethoxy) -2-methyl-2 , 3-dihydro-l- benzofuran-2-yl] pyridin-3-yl } oxy) -1-methylethyl] carbamate
(1000 mg) in ethyl acetate (20 mL) at room temperature. The mixture was stirred at room temperature for 3 hr. The
resulting precipitate was collected by filtration to give the title compound (650 mg) .
XH NMR (300 MHz, DMSO-d6) δ 1.29 (3H, d, J = 6.7 Hz), 1.72 (3H, s), 3.20 (1H, d, J = 15.5 Hz), 3.47 (1H, d, J = 15.4 Hz), 3.53-3.71 (1H, m) , 4.08-4.18 (1H, m) , 4.20-4.30 (1H, m) , 6.25 (1H, dd, J = 7.9, 2.2 Hz), 6.33 (1H, d, J = 2.1 Hz), 6.90 (1H, d, J = 7.9 Hz), 7.43-7.65 (2H, m) , 8.24-8.48 (4H, m) .
[1092]
K) Diasteromer of N- [ (IS) -2-{ [6- (6-hydroxy-2-methyl-2, 3- dihydro-l-benzofuran-2-yl ) pyridin-3-yl] oxy} -1- methylethyl] acetamide
A solution of acetic anhydride (0.126 mL) was added dropwise to a solution of diastereomer of 2- (5-{ [ (2S) -2- aminopropyl] oxy}pyridin-2-yl) -2-methyl-2, 3-dihydro-l- benzofuran-6-ol (500 mg) in pyridine (15 mL) at ambient
temperature. After being stirred at ambient temperature for 2 hr, the mixture was diluted with methanol (15 mL) and 4 M sodium hydroxide (10 mL) . The mixture was stirred at ambient temperature for 15 hr. The organic solvent was removed under reduced pressure, and the aqueous solution was acidified with 4 M hydrochloric acid and extracted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (350 mg) .
MS (ESI+.) : [M+H]+ 343.1
[1093]
L) Diasteromer of N- [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -2- methyl-2 , 3-dihydro-l-benzofuran-2-yl] pyridin-3-yl } oxy) -1- methylethyl] acetamide
A mixture of (bromomethyl) cyclopropane (177 mg) , diastereomer of N- [ (IS) -2-{ [6- (6-hydroxy-2-methyl-2, 3-dihydro- l-benzofuran-2-yl) pyridin-3-yl] oxy} -1-methylethyl] acetamide (150 mg) and potassium carbonate (72.7 mg) in DMF (3 mL) was stirred at 80 °C for 3 hr. After cooling to room temperature, the mixture was concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The separated organic layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (NH, hexane/ethyl acetate) to give the title ■ compound (150 mg) .
[1094]
Example 118
Diasteromer of N- [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -2-methyl- 2, 3-dihydro-l-benzofuran-2-yl] pyridin-3-yl } oxy) -1- methylethyl] acetamide
[1095]
A) Diasteromer of 6- ( 6- (methoxymethoxy) -2-methyl-2 , 3- dihydrobenzofuran-2-yl) pyridin-3-ol The diastereomeric mixture of 6- ( 6- (methoxymethoxy) -2- methyl-2 , 3-dihydrobenzofuran-2-yl) pyridin-3-ol was separated by preparative HPLC (column: CHIRALPAK AD-H, 4.6 x 250 mm, 5 urn, mobile phase: methanol) to afford the less polar isomer
(longer retention time) .
MS (ESI+) : [M+H]+ 288.0.
100%de
[1096]
B) Diasteromer of N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -2- methyl-2, 3-dihydro-l-benzofuran-2-yl] pyridin-3-yl } oxy) -1- methylethyl] acetamide
By a method similar to Example 117, steps I, J, K and L, and using diastereomer of 6- ( 6- (methoxymethoxy) -2-methyl-2 , 3- dihydrobenzofuran-2-yl) pyridin-3-ol (longer retention time), the title compound was obtained.
[1097]
Example 119
Diastereomer of N- [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -2-ethyl- 2 , 3-dihydro-l-benzofuran-2-yl] pyridin-3-yl } oxy) -1- methylethyl] acetamide
[1098]
A) 1- (2-Bromo-4- (methoxymethoxy) phenyl) butan-2-one
By a method similar to Example 111, step D, and using ethylmagnesium bromide instead of methyl magnesium bromide, the title compound was obtained.
XH NMR (DMSO, 400 MHz): δ 0.95 (3H, t) , 2.38 (2H,m) , 3.32 (3H, s), 3.84 (2H, s), 5.20 (2H, s) , 6.99 (1H, s) , 7.22 (2H, s) .
[1099]
B) 6- (2-Ethyl-6- (methoxymethoxy) -2, 3-dihydro-l-benzofuran-2- yl ) pyridin-3-ol
By a method similar to Example 117, step E to G, and using 1- (2-bromo-4- (methoxymethoxy) phenyl) butan-2-one, the title compound was obtained.
MS (ESI+) : [M+H]+ 302.1.
[1100] C) Diastereomer of 6- (2-ethyl-6- (methoxymethoxy) -2, 3-dihydro- l-benzofuran-2-yl) pyridin-3-ol
The diastereomeric mixture of 6- (2-ethyl-6- (methoxymethoxy) -2 , 3-dihydro-l-benzofuran-2-yl) pyridin-3-ol ' was separated by preparative HPLC (column: CHIRALPAK AD-H, 4.6 x 250 mm, 5 μπι, mobile phase: .ethanol) to afford the more polar isomer (shorter retention time) .
MS (ESI+) : [M+H]+ 302.0.
100%de
[1101]
D) Diastereomer of N- [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -2- ethyl-2, 3-dihydro-l-benzofuran-2-yl] pyridin-3-yl } oxy) -1- methylethyl] acetamide
By a method similar to Example 117, steps I, J, K and L, and using diastereomer of 6- (2-ethyl-6- (methoxymethoxy) -2, 3- dihydro-l-benzofuran-2-yl ) pyridin-3-ol (shorter retention time) , the title compound was obtained.
[1102]
Example 120
Diastereomer of N- [ (IS) -2- ({ 6- [ 6- (cyclopropylmethoxy) -2-ethyl- 2, 3-dihydro-l-benzofuran-2-yl] pyridin-3-yl }oxy) -1- methylethyl] acetamide
[1103]
A) Diastereomer of 6- (2-ethyl-6- (methoxymethoxy) -2 , 3-dihydro- l-benzofuran-2-yl) pyridin-3-ol
The diastereomeric mixture of 6- (2-ethyl-6- (methoxymethoxy) -2 , 3-dihydro-l-benzofuran-2-yl ) pyridin-3-ol was separated by' preparative HPLC (column: CHIRALPAK AD-H, 4.6 x 250 mm, 5 urn, mobile phase: ethanol) to afford the less polar isomer (longer retention time) .
MS (ESI+) : [M+H]+ 302.0.
100%de
[1104]
B) Diastereomer of N- [ (IS) -2- ({ 6- [6- (cyclopropylmethoxy) -2- ethyl-2, 3-dihydro-l-benzofuran-2-yl] pyridin-3-yl } oxy) -1- methylethyl] acetamide
. By a method similar to Example 117, steps I, J, K and L, and using diastereomer of 6- (2-ethyl-6- (methoxymethoxy) -2, 3- dihydro-l-benzofuran-2-yl) pyridin-3-ol (longer retention time), the title compound was obtained.
[1105]
Example 121
Diastereomer of N- [ (IS) -2- ('{ 6- [2-cyclopropyl-6- (cyclopropylmethoxy) -2 , 3-dihydro-l-benzofuran-2-yl] pyridin-3- yl}oxy) -l-methylethyl] acetamide
[1106]
A) 2- (2-Bromo-4- (methoxymethoxy) phenyl) -1-cyclopropylethanone
By a method similar to Example 117, step D, and using ethylmagnesium bromide instead of cyclopropylmethyl magnesium bromide, the title compound was obtained.
MS (ESI+) : [M+H]+ 298.9.
[1107]
B) 6- (2-Cyclopropyl-6- (methoxymethoxy) -2, 3-dihydro-l- benzofuran-2-yl) pyridin-3-ol
By a method similar to Example 117, step E to G, and using 2- (2-bromo-4- (methoxymethoxy) phenyl) -1- cyclopropylethanone, the title compound was obtained.
MS (ESI+) : [M+H]+ 314.1.
[1108]
C) Diastereomer of 6- (2-cyclopropyl-6- (methoxymethoxy) -2 , 3- dihydro-l-benzofuran-2-yl) pyridin-3-ol
The diastereomeric mixture of 6- (2-cyclopropyl-6- (methoxymethoxy) -2 , 3-dihydro-l-benzofuran-2-yl ) pyridin-3-ol was separated by preparative' HPLC (column: CHIRALPAK AD-H, 4.6 x 250 mm, 5 μιτι, mobile phase: ethanol) to afford the more polar isomer (shorter retention time) .
MS (ESI+) : [M+H]+ 314.0.
100%de
[1109]
D) Diastereomer of N- [ (IS) -2- ( { 6- [2-cyclopropyl-6- (cyclopropylmethoxy) -2, 3-dihydro-l-benzofuran-2-yl ] pyridin-3- yl}oxy) -1-methylethyl] acetamide
By a method similar to Example 117, steps I, J, K and L, and using diastereomer of "6- (2-cyclopropyl-6- (methoxymethoxy) - 2 , 3-dihydro-l-benzofuran-2-yl ) pyridin-3-ol (shorter retention time) , the title compound was obtained.
[1110]
Example 122 .
Diastereomer of N- [ (IS) -2- ( { 6- [2-cyclopropyl-6- (cyclopropylmethoxy) -2, 3-dihydro-l-benzofuran-2-yl] pyridin-3- yl } oxy) -1-methylethyl] acetamide
[1111]
A) Diastereomer of 6- (2-cyclopropyl-6- (methoxymethoxy) -2 , 3- dihydro-l-benzofuran-2-yl) pyridin-3-ol
The diastereomeric mixture of 6- (2-cyclopropyl-6-
(methoxymethoxy) -2 , 3-dihydro-l-benzofuran-2-yl ) pyridin-3-ol was separated by preparative HPLC (column: CHIRALPAK AD-H, 4.6 x 250 mm, 5 μπι, mobile phase: ethanol) to afford the less polar isomer (longer retention time) .
MS '(ESI+): [ +H]+ 314.0.
100%de
[1112]
B) Diastereomer of N- [ (IS) -2- ( { 6- [2-cyclopropyl-6-
(cyclopropylmethoxy) -2, 3-dihydro-l-benzofuran-2-yl] pyridin-3- yl } oxy) -1-methylethyl] acetamide
By a method similar to Example 117, steps I, J, K and L, and using diastereomer of 6- (2-cyclopropyl-6- (methoxymethoxy) -
2 , 3-dihydro-l-benzofuran-2-yl ) pyridin-3-ol (longer retention time), the title compound was obtained.
[1113]
Example 123
N- [ (IS) -2-{4- [6- (cyclopropylmethoxy) pyrazolo [1, 5-a] pyridin-2- yl] -3, 5-difluorophenoxy} -1-methylethyl] acetamide
[1114]
A) tert-butyl [ (IS) -2- (4-bromo-3, 5-difluorophenoxy) -1- methylethyl] carbamate
To a solution of 4-bromo-3, 5-difluorophenol (5.0 g) , tert-butyl [ (IS) -2-hydroxy-l-methylethyl] carbamate (5 g) and triphenylphosphine (7.5 g) in THF (50 mL) was added
diisopropyl azodicarboxylate (1.9 in toluene, 14 mL)
dropwise at room temperature. The reaction mixture was stirred at 60 °C overnight and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to afford the title compound (5.1 g) . ¾ NMR (300 MHz, DMSO-d6) δ 1.10 (3H, d, J = 6.5 Hz), 1.33-1.42 (9H, m), 3.71-3.99 (3H, m) , 6.80-7.03 (3H, m) .
MS (ESI+) : [M+H]+ 266.9.
[1115]
B) tert-butyl [ (IS) -2- (4-ethynyl-3, 5-difluorophenoxy) -1- methylethyl] carbamate
A mixture of tert-butyl [ (IS) -2- (4-bromo-3, 5- difluorophenoxy) -1-methylethyl] carbamate (5.1 g) ,
ethynyl (trimethyl) silane (3.9 mL) , copper iodide (I) (0.26 g) , dichloropalladium - triphenylphosphine (1:2) (0.98 g) and triethylamine (3.9 -mL) in toluene (50 mL) was stirred at 100 °C overnight under Ar atmosphere. After cooling to room
temperature, the mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was dissolved in THF (50 mL) and tetrabutylammonium fluoride (1.0 M in THF, 28 mL) was added to the mixture. After stirring at room temperature for 1 hr, the mixture was
extracted with ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to afford the title compound (2.5 g) .
XH NMR (300 MHz, DMSO-d6) δ 1.10 (3H, d, J = 6.6 Hz), 1.37 (9H, s), 3.68-3.99 (3H, m) , 4.59 (1H, s) , 6.78-7.03 (3H, m) .
[1116]
C) tert-butyl [ (IS) -2- (4-{ [5- (cyclopropylmethoxy) pyridin-2- yl] ethynyl } -3, 5-difluorophenoxy) -l-methylethyl] carbamate
A mixture of tert-butyl [ (IS) -2- (4-ethynyl-3, 5- difluorophenoxy) -l-methylethyl] carbamate (2.5 g) , 2-bromo-5- (cyclopropylmethoxy) pyridine (1.8 g) , copper iodide (I) (0.15 g) , dichloropalladium-triphenylphosphine (1:2) (0.56 g) and triethylamine (2.2 mL) in . toluene (20 mL) was stirred at 100 °C overnight under argon atmosphere. After cooling to room temperature, the mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography
(hexane/ethyl acetate) to afford the title compound (1.3 g) .
XH NMR (300 MHz, DMSO-d6) δ 0.29-0.42 (2H, m) , 0.53-0.66 (2H, m) , l.ll' (3H, dd, J = 6.7, 1.7 Hz), 1.21-1.30 (1H, m) , 1.37 (9H, d, J = 1.4 Hz), 3.77-3.99 (5H, m) , 6.85-7.02 (3H, m) , 7.35-7.48 (1H, m) , 7.51-7.64 (1H, m) , 8.22-8.38 (1H, m) .
MS (ESI+) : [M+H]+ 459.2.
[1117] -
D) tert-butyl [( IS) -2- { 4- [ 6- (cyclopropylmethoxy) pyrazolo [ 1, 5- a] pyridin-2-yl] -3, 5-difluorophenoxy} -l-methylethyl] carbamate To an ice cold stirred solution of ethyl N-
( (mesitylsulfonyl).oxy) ethanimidoate (1.794 g) in THF (2 mL) was added perchloric acid (0.759 ml) dropwise. After stirring at 0 °C for 20 min, the mixture was poured into ice water. The precipitated solid was collected by filtration and washed with water. The solid was added to the solution of tert-butyl
[ (IS) -2- (4-{ [5- (cyclopropylmethoxy) pyridin-2-yl] ethynyl}-3, 5- difluorophenoxy) -l-methylethyl] carbamate (1.31 g) in THF (13 mL) at room temperature. The mixture was stirred at room temperature for 30 min. The mixture was concentrated under reduced pressure and the residue was dissolved in DMF (13 mL) . Potassium carbonate (0.790 g) was added to the mixture at room temperature and the reaction mixture was stirred at room temperature overnight. The mixture was extracted with ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to afford the title compound (130 mg) .
XH NMR (300 MHz, DMSO-d6) δ 0.24-0.41 (2H, m) , 0.52-0.67 (2H,m) , 1.12 (3H, d, J = 6.6 Hz), 1.19-1.31 (1H, m) , 1.39 (9H, s) , 3.76-4.06 (5H, m) , 6.69-6.78 (lH, m) , 6.80-6.99 (3H, m) , 7.01- 7.13 (1H, m), 7.58-7.70 (1H, m) , 8.34-8.42 (1H, m) .
MS (ESI+) : [M+H]+ 474.2.
[1118]
E) N- [ (IS) -2- { 4- [ 6- (cyclopropylmethoxy) pyrazolo [1, 5-a] pyridin- 2-yl] -3, 5-difluorophenoxy} -1-methylethyl] acetamide
A mixture of tert-butyl [ (IS) -2-{ 4- [6- (cyclopropylmethoxy) pyrazolo [1, 5-a] pyridin-2-yl] -3, 5- difluorophenoxy} -1-methylethyl] carbamate (130 mg) and 4 M hydrogen chloride-ethyl acetate (2 mL) was stirred at room temperature for 30 min. The mixture was concentrated under reduced pressure. To the residue were added pyridine (2 mL) and acetic anhydride (0.26 mL) . The mixture was stirred at room temperature for 30 min and concentrated under reduced pressure. The residue was purified by silica gel column
chromatography (NH, hexane/ethyl acetate) to afford the title compound (40 mg) .
1H NMR (300 MHz, DMSO-d6) δ 0.29-0.39 (2H, m) , 0.53-0.64 (2H, m) , 1.15 (3H, d, J = 6.7 Hz) , 1.20-1.33 (1H, m) , 1.82 (3H, s) , 3.83-3.94 (3H, m) , 3.96-4.16 (2H, m) , 6.70-6.78 (1H, m) , 6.89
(2H, d, J = 10.5 Hz), 7.08 (1H, dd, J = 9.6, 2.1 Hz), 7.64 (1H, d, J = 9.5 Hz) , 7.94 (1H, d, J = 7.5 Hz) , .8.33-8.43 (1H, m) .
Anal. Calcd for C22H23 3O3F2 : C, 63.60; H,5.58; Ν,ΙΟ.11. Found:
C, 63.47; H,5.59; N,9.95.
[1119]
Table 1-1 to Table 1-16 show compound names, structural formulas and measured values of MS of the Example compounds.
The measured values of MS generally show those in a positive mode (ESI+) , and those in a negative mode (ESI-) are accompanied by [M-H]~. In addition, when a fragment peak wherein a sodium ion (+Na) is added to a molecular ion peak observed in the positive mode (ESI+) , [M+Na] + is also shown .
[1120]
Table 1-1
Figure imgf000371_0001
[1121]
Table 1-2
Figure imgf000372_0001
[1122]
Table 1-3
Figure imgf000373_0001
[1123]
Table 1-4
Figure imgf000374_0001
Figure imgf000375_0001
[1124]
Table 1-5
Figure imgf000376_0001
[1125]
Table 1-6
Figure imgf000377_0001
[1126]
Table 1-7
Figure imgf000378_0001
N-[ (lS)-2-({2-[6-(cyclopro
methoxy ) -1 , 3-benzoxazol-2- 383.2 yl]pyrimidin-5-yl}oxy) -1- methylethyl] acetamide
[1127],
Table 1-8
Figure imgf000380_0001
[1128]
Table 1-9
Figure imgf000381_0001
Figure imgf000382_0001
[1129]
Table 1-10
Figure imgf000383_0001
Figure imgf000384_0001
[1130]
Table 1-11
Figure imgf000385_0001
N-[ (lS)-2-({6-[6- (cyclopropylmethoxy) [1,2,4]
triazolo [1, 5-a] pyridin-2- 382.3 yl] pyridin-3-yl}oxy) -1- methylethyl] acetaitiide
[1131]
Table 1-12
Figure imgf000387_0001
[1132]
Table 1-13
Figure imgf000388_0001
[1133]
Table 1-14
Figure imgf000389_0001
[1134]
Table 1-15
Figure imgf000390_0001
[1135]
Table 1-16
Figure imgf000391_0001
[1136]
Experimental Example 1
The ACC2 inhibitory action of the compound of the present invention was evaluated by the following method.
(1) Cloning of human ACC2 gene and preparation of recombinant Baculovirus
Human ACC2 gene was cloned by PCR using a human skeletal muscle cDNA library (Clontech) as a template and Primer 1 and Primer 2 shown below. Primer 1 and Primer 2 were prepared by adding Sail, Xbal restriction enzyme recognition sequences based on the information of the base sequence of human ACC2 gene (Genbank Accession U89344) .
Primer 1: 5' -AAAAGTCGACCCACCATGGTCTTGCTTCTTTGTCTATCTTG-3' (SEQ ID NO:l)
Primer 2: 5' -TTTTTCTAGATCAGGTAGAGGCCGGGCTGTCCATG-3' (SEQ ID NO:2) PCR was performed using Pyrobest DNA polymerase (TAKARA
BIO INC.). The obtained PCR product was cloned to pT7 Blue vector (Novagen) and after confirmation of the base sequence, digested with restriction enzymes Sail and Xbal. The obtained DNA fragment was inserted into pFAST-BacHTa (Invitrogen) digested with restriction enzymes Sail and Xbal to give expression plasmid ACC2/pFAST-BacHTa .
A plasmid for expression of ACC2 without a mitochondrial targeting sequence was prepared by PCR using the expression plasmid as a template, and Primer 3 (Sail restriction enzyme recognition sequence was added) and Primer 4, which are prepared by reference to the information of human ACC2 gene base sequence (Genbank Accession U89344).
Primer 3: 5' -CCAGGTCGACCCGCCAACGGGACTGGGACACAAGG-3' (SEQ ID NO: 3)
Primer 4: 5' -CGCACTCTCAGTTTCCCGGATTCCC-3' (SEQ ID NO: 4) PCR was performed using Pyrobest-DNA polymerase (TAKARA BIO INC.). The obtained PCR product was cloned to pT7 Blue vector (Novagen) and after confirmation of the base sequence, digested with restriction enzymes Sail and Aflll. The obtained DNA fragment was inserted into ACC2/ FAST-BacHTa digested with restriction enzymes Sail and Aflll to give expression plasmid ACC2mito7/pFAST-BacHTa .
Using the expression plasmid ACC2mito7/pFAST-BacHTa and BAC-TO-BAC Baculovirus Expression System (Invitrogen), virus stock BAC-ACC2 of recombinant Baculovirus (N terminal deleted (hereinafter Nd) ) was prepared.
[1137]
(2) Preparation of ACC2 (Nd) protein
SF-9 cells (Invitrogen) were inoculated to a medium (2 L) for insect cells (Sf-900IISFM medium (Invitrogen) containing 10% fetal bovine serum (Trace) , 50 mg/L Gentamicin
(Invitrogen), 0.1% Pluronic F-68 (Invitrogen)) at 0.5><106 cells/mL, and cultured with shaking in Wave Bioreactor (Wave) at 27°C, 20 rpm, rocking angle 6°, oxygen concentration 30%. On day 4 of the culture, 3 L of the medium for insect cells was added, the rocking angle was set to 8°, and the cells were further cultured. On day 5 of the culture, 100 mL of recombinant Baculovirus BAC-ACC2 (Nd) was added, 5 L of the medium for insect cells was further added, the rocking angle was set to 11°, and the cells were cultured for 3 days. The culture medium was centrifuged at 1000*g for 10 min to give virus-infected cells. The cells were washed with phosphate buffered saline (Invitrogen) and centrifuged under the same conditions. The obtained cells were cryopreserved at -80°C.
The cryopreserved cells were thawed in ice and suspended in 900 mL of 25 mM HEPES buffer- (pH 7.5) containing 10%
Glycerol, 0.13 M NaCl, 1 mM EDTA, 25 mM Sodium β- Glycerophosphate and 1 mM Sodium Orthovanadate, and
supplemented with Complete Protease Inhibitor (Nippon
Boehringer Ingelheim Co., Ltd.). The. obtained suspension was homogenized three times in a polytron · homogenizer (Kinematica) at 20,000 rpm for 30 sec. The obtained cell disruption
solution was clarified by centrifugation at 31000*g for 60 min, and filtered through a 0.45 urn filter. The filtrate was passed through a column packed with 60 mL of Ni-NTA Super Flow Gel (QUIAGEN) at a flow rate of about 5 mL/min. The column was washed with buffer A (50 mM HEPES (pH 7.5) containing 0.3 M NaCl) , further washed with buffer A containing 20 mM Imidazole, and eluted with buffer A containing 100 mM Imidazole. The eluate was concentrated with Vivaspin 20 (Vivascience) with a molecular weight cut off of 30K. The obtained concentrate was dialyzed against 50 mM HEPES (pH 7.5) containing 10 mM MgCl2, 2 mM Dithiothreitol, 10 mM Tripotassium Citrate and 0.3 M NaCl. The inner dialysate was filtered through a 0.22 μτη filter to give ACC2 (Nd) . The obtained ACC2 (Nd) was cryopreserved at - 80°C.
[1138]
(3) Measurement of ACC2 inhibitory activity
ACC2 (Nd) I I .1 mg/ml) obtained in the above-mentioned (2) was diluted with an enzyme reaction buffer (50 mM HEPES (pH
7.5), 10 mM MgCl2, 10 mM Tripottasium Citrate, 2 mM
Dithiothreitol, 0.75 mg/ml Fatty acid free BSA) to a
concentration of 6.4 μg/ml, and the mixture was added to each well of a 384 well assay plate (Nunc 265196) by 10 μΐ. A test compound dissolved in dimethyl sulfoxide (DMSO) was diluted with an enzyme reaction buffer and the resulting solution (5 μΐ) was added to each well. The mixture was incubated at 30°C for 20 min. Then, a substrate solution (50 mM KHC03, 200 μΜ ATP, 200 μΜ Acetyl-CoA, 5 μΐ) .was added to each well, and the mixture was reacted at 30°C for 20 min (test compound addition group) .
In addition, a reaction was performed in the same manner as above and without adding the test compound (test compound non-addition group) .
Furthermore, a reaction was performed in the same manner as above and without adding the test compound and Acetyl-CoA (control group) .
The reaction was quenched by adding a malachite green solution to each of the obtained reaction mixtures by 5 μΐ and stirring the mixtures. The obtained reaction mixture was left standing at room temperature for 20 min, and absorbance (620 nm) was measured . using wallacl420 (PerkinElmer Japan Co., Ltd.). The above-mentioned malachite green solution was prepared by mixing Solution A (0.12% malachite green solution, prepared with 5N H2S04, preserved at 4°C in shading) , Solution B (7.5% aqueous ammonium molybdate solution, prepared when in use) and Solution C (11% aqueous Tween 20 solution, preserved at room temperature) at a ratio of Solution A: Solution B:
Solution C=100:25:2 (volume ratio).
ACC2 inhibitory rate (%) was determined according to the following calculation formula.
(1- (absorbance of test compound addition group - absorbance of control group) ÷ (absorbance of test compound non-addition group - absorbance of control group) )xl00 The inhibitory rates (%) against ACC2 at 10 μΜ of the test compound are shown in Table 2-1 and Table 2-2.
[1139]
Table 2-1
Figure imgf000395_0001
[1140]
Table 2-2
Figure imgf000396_0001
[1141]
Experimental Example 2
Male F344/Jcl rats (CLEA Japan, Inc., Tokyo) purchased at 5 weeks of age were acclimated to the rearing environment, and, used for an experiment of malonyl CoA content measurement at 10 weeks of age. In the experiment of malonyl CoA content measurement, the body weight was measured in the morning
(8:00-11:00) 3 days before administration of a test compound, and the rats were divided into groups free of dispersion in the body weight between administration groups. The test compound was prepared as a 0.5% methyl cellulose (Wako) suspension to a dose of 5 mL/kg, in the afternoon (12:00- 17:00) of one day before administration by gavage, and administered by gavage according to the body weight on the day of test compound administration. The vehicle group was administered with a solvent (0.5% methyl cellulose) alone by gavage. The femoral muscle was rapidly removed 2 hr after the test compound administration, sliced into thin pieces (80-150 mg) , placed in an eppendorf tube, rapidly frozen in liquid nitrogen, and preserved at -80°C until use for the measurement of malonyl CoA content.
A sample homogenate for the malonyl CoA measurement was prepared by disrupting a frozen tissue with a measured weight in a Multi-beads shocker (MB400U, Yasui Kikai Corporation) , adding an extract (6% perchloric acid: aqueous di-n- butylammonium acetate solution (IPC-DBAA, 0.5 mol/L, TOKYO
CHEMICAL INDUSTRY CO., LTD. ) =1000 : 1 , 500 μΙ,)' containing an internal standard substance ( [13C3] -malonyl CoA lithium salt
(100 pmol/mL, Sigma-Aldrich) ) , and applying the mixture to the Multi-beads shocker again. The entire amount of the extract was centrifuged (13,000 rpm, 2 min) , and the supernatant was added to a solid phase extraction cartridge (OASIS HLB 1 cc/30 mg, WAT05882, Waters) to perform a solid phase extraction. The solid phase extraction cartridge used had previously undergone activation with solution A (500 μL, 50% acetonitrile) , and further, two times of equilibration with solution B (1 mL, 6% perchloric acid: IPC-DBAA=1000 : 1 ) . The sample was added to the solid phase cartridge, washed twice with ultrapure water (1 mL) , and eluted with solution A (500 μL) . This eluate was directly used for the LC/MS/MS analysis. The sample for analytical curve was added with malonyl CoA lithium salt with a known concentration (Sigma-Aldrich) , while regarding 100 μL of 4% aqueous BSA (w/v) solution as 100 mg of a tissue, added with an internal standard substance, like the tissue sample, and subjected to a solid phase extraction.
The HPLC for LC/MS/MS analysis was performed by using Prominence (SHIMADZU Corporation), and CAPCELL PAK C18 AQ (particle size; 3 μτη, inner diameter; 2.0 mm, length; 35 mm, Shiseido Co., Ltd.) as a separation column, and gradient mode of mobile phase (A) 10 mmol/L ammonium acetate/IPC-DBAA (100:1, v/v, pH 9.0), and mobile phase (B) acetonitrile . The gradient program included linear increase of mobile phase (B)
concentration from 5% at 0 min (start of analysis) to 35% in 2 min, and thereafter to 100% until 2.1 min, liquid supply at 100% until 6 min, decrease to 5% by.6.1 min, and liquid supply under the same conditions until the end of analysis (10 min) . Using a switching valve, the eluate of analysis time 2.0-6.0 min was introduced into MS/MS. The analysis was performed at a column temperature of 40°C and a sample injection volume of 10 μΐ.. The mass spectrometer used was API5000 (AB Sciex) and, using turboion spray as an ionization mode, ion was detected by selected reaction monitoring (SRM) in an anion mode. As the ion spray, zero air was used, and the ionization was performed at 4.5 kV. Nitrogen was used for collision-induced
decomposition of ion. As a monitor ion, a precursor ion and a fragment ion were set to malonyl CoA; m/z Q52.0→m/z 808.0 and [13C3] -malonyl CoA; m/z 855.0→m/z 810.0 Da, respectively. For quantitative calculation, a peak area ratio of internal
standard ( [13C3] -malonyl CoA) and malonyl CoA was used, and a . malonyl CoA concentration of each sample was calculated from the regression formula of standard analytical curve at each concentration ( 1/concentration weighted) . All values are shown in meanlstandard deviation, and Steel test was used for
statistical analysis. The results are shown in Table 3.
[1142]
Table 3
Malonyl-CoA content of femoral muscle at 2 hours after dosing
Figure imgf000398_0001
MeaniS.D., N=4-6, * P<0.05 (Steel test) Formulation Example 1 (production of capsule)
1) compound of Example 1 30 mg
2) finely divided powder cellulose 10 mg
3) lactose 19 mg
4) magnesium stearate 1 mg
total 60 mg
1), 2), 3) and 4) are mixed and filled' in a gelatin capsule.
[1144]
Formulation Example 2 (production of tablets)
1) compound of Example 1 30 g
2) lactose 50 g
3) cornstarch 15 g
4) calcium carboxymethylcellulose 44 g
5) magnesium stearate 1 g
1000 tablets total 140 g
The total amount of 1), 2) and 3) and 4) (30 g) is kneaded with water, vacuum dried, and sieved. The sieved powder is mixed with 4) (14 g) and 5) (1 g) , and the mixture is punched by a tableting machine, whereby 1000 tablets containing 30 mg of the compound of Example 1 per tablet are obtained.
Industrial Applicability
[1145]
The compound of the present invention has ACC (acetyl-CoA carboxylase) inhibitory action, and is useful for the
prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like.
[1146]
This application is based on patent application Nos.
266097/2010 and 175330/2011 filed in Japan, the contents of which are hereby" incorporated by reference.

Claims

A compound represented by the formula
Figure imgf000400_0001
wherein
R1 is a group represented by the formula: -COR2 wherein R2 is a hydrogen atom or a substituent, or an optionally, substituted 5- or 6-membered aromatic ring group;
R3 is a Ci-6 alkyl group optionally substituted by halogen atom(s), or an optionally substituted C3-6 cycloalkyl group; Ra and R4b are independently a hydrogen atom or a substituent; X is 0, CO, CR5aR5b wherein R5a and R5b are independently a hydrogen atom or a substituent, NR5c wherein R5c is a hydrogen atom or an optionally substituted Ci_6 alkyl group, S, SO, or s(0)2;
ring A is an optionally further substituted 5- or 6-membered aromatic ring;
for ring P and ring Q,
(1) ring P is an optionally further substituted 5-membered aromatic ring, ring Q is an optionally further substituted 6- membered ring, and ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic ring, or
(2) ring P is an optionally further substituted 5-membered non-aromatic ring, ring Q is an optionally further substituted 6-membered aromatic ring, and ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic ring; and
R6 is an optionally substituted Ci_6 alkyl group or an
optionally substituted C3-6 cycloalkyl group,
or a salt thereof.
2. The compound or salt of claim 1, wherein R1 is a group represented by the formula: -COR2
wherein
R2 is
5 (a) a Ci-6 alkyl group optionally substituted by 1 to 3
halogen atoms;
(b) a C -6 alkoxy group; or.
(c) an amino group optionally mono- or di-substituted by Ci_6 alkyl group (s) .
o
3. The compound or salt of claim 1, wherein the "optionally further substituted bicyclic aromatic ring" or "optionally
Figure imgf000401_0001
each of which is optionally further substituted by 1 to 4 substituents selected from
(1) a halogen atom,
(2) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(3) a C3- 6 cycloalkyl group optionally substituted by 1 halogen atoms, and
(4) a cyano group.
Figure imgf000402_0001
each of which is optionally further substituted by 1 to 4 substituents selected from
(1) a halogen atom,
(2) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(3) a C3-6 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, and
(4) a cyano group,
R3 is a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
R4a and R4b are each a hydrogen atom,
X is 0, CO or CH2,
R6 is a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom, and
(b) a C3-6 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, and
ring A is benzene, optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole, each of which is optionally substituted by 1 to 3 substituents selected from
(1) a halogen atom,
(2) a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms, (3) a Ci-6 alkoxy group, and
(4) a C7_i3 aralkyl group.
9. N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2-
5 yl]pyridin-3-yl}oxy) -1-methylethyl] acetamide or a salt thereof.
10. N- [ (IS) -2- ( { 6- [6- (cyclopropylmethoxy) -1, 3-benzoxazol-2- yl] -5-fluoropyridin-3-yl } oxy) -1-methylethyl] acetamide or a salt thereof.
10
11. N-[ (lS)-2-{ [6- (6-ethoxy-l,3-benzoxazol-2-yl)pyridin-3- yl] oxy} -1-methylethyl] acetamide or a salt thereof.
12. A medicament comprising the compound or salt of claim 1.
15 '
13. The medicament of claim 12, which is an acetyl-CoA
carboxylase inhibitor.
14. The medicament of claim 12, which is an agent for the
20 prophylaxis or treatment of obesity or diabetes.
15. A method of inhibiting acetyl-CoA carboxylase in -a mammal, which comprises administering an effective amount of the
compound or salt of claim 1 to the mammal.
25
16. A method for the prophylaxis or treatment of obesity or diabetes in a mammal, which comprises administering an
effective amount of the compound or salt of claim 1 to the mammal .
30
17. Use of the compound or salt of. claim 1 for production of an agent for the prophylaxis or treatment of obesity or
diabetes.
35 18. The compound or salt of claim 1 for use in the prophylaxis or treatment of obesity or diabetes.
PCT/JP2011/078010 2010-11-30 2011-11-29 Bicyclic compound WO2012074126A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN201180066388.XA CN103347872B (en) 2010-11-30 2011-11-29 Bicyclic compound
SG2013041546A SG190925A1 (en) 2010-11-30 2011-11-29 Bicyclic compound
AU2011337565A AU2011337565A1 (en) 2010-11-30 2011-11-29 Bicyclic compound
KR1020137016850A KR20140001965A (en) 2010-11-30 2011-11-29 Bicyclic compound
CA2819400A CA2819400A1 (en) 2010-11-30 2011-11-29 Bicyclic compound
BR112013013417A BR112013013417A2 (en) 2010-11-30 2011-11-29 compound, medicament, methods for inhibiting acetylco carboxylase in a mammal, and for prophylaxis or treatment of obesity or diabetes in a mammal, and use of a compound or salt
JP2013524677A JP5824517B2 (en) 2010-11-30 2011-11-29 Bicyclic compound
MX2013006113A MX2013006113A (en) 2010-11-30 2011-11-29 Bicyclic compound.
ES11802168.2T ES2536319T3 (en) 2010-11-30 2011-11-29 Bicyclic compounds such as acetyl-CoA carboxylase (ACC) inhibitors
EA201390794A EA201390794A1 (en) 2010-11-30 2011-11-29 BICYCLIC COMPOUND
EP11802168.2A EP2649062B1 (en) 2010-11-30 2011-11-29 Bicyclic compounds as inhibitors of acetyl-coa carboxylase (acc)
TNP2013000230A TN2013000230A1 (en) 2011-08-10 2013-05-29 Bicyclic compound
MA35965A MA34713B1 (en) 2010-11-30 2013-06-05 BICYCLIC COMPOUND

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010-266097 2010-11-30
JP2010266097 2010-11-30
JP2011175330 2011-08-10
JP2011-175330 2011-08-10

Publications (2)

Publication Number Publication Date
WO2012074126A1 true WO2012074126A1 (en) 2012-06-07
WO2012074126A9 WO2012074126A9 (en) 2013-06-06

Family

ID=45418740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/078010 WO2012074126A1 (en) 2010-11-30 2011-11-29 Bicyclic compound

Country Status (23)

Country Link
US (1) US8729102B2 (en)
EP (1) EP2649062B1 (en)
JP (1) JP5824517B2 (en)
KR (1) KR20140001965A (en)
CN (1) CN103347872B (en)
AR (1) AR084032A1 (en)
AU (1) AU2011337565A1 (en)
BR (1) BR112013013417A2 (en)
CA (1) CA2819400A1 (en)
CL (1) CL2013001520A1 (en)
CO (1) CO6751239A2 (en)
CR (1) CR20130281A (en)
DO (1) DOP2013000118A (en)
EA (1) EA201390794A1 (en)
EC (1) ECSP13012719A (en)
ES (1) ES2536319T3 (en)
MA (1) MA34713B1 (en)
MX (1) MX2013006113A (en)
PE (1) PE20140161A1 (en)
SG (1) SG190925A1 (en)
TW (1) TW201242951A (en)
UY (1) UY33756A (en)
WO (1) WO2012074126A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703758B2 (en) 2010-04-27 2014-04-22 Takeda Pharmaceutical Company Limited Bicyclic compound
CN104193731A (en) * 2014-08-27 2014-12-10 广东东阳光药业有限公司 Novel urea-substituted biphenyl compounds as well as composition and application thereof
WO2015036892A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
WO2015097713A1 (en) 2013-11-14 2015-07-02 Cadila Healthcare Limited Novel heterocyclic compounds
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
CN105008348A (en) * 2013-03-14 2015-10-28 赛隆制药股份公司 Pyrazolylbenzo [ D ] imidazole derivatives
CN105601626A (en) * 2015-11-04 2016-05-25 浙江大学 Preparation method of 2-substituted oxazoline-containing derivative
EP2928473A4 (en) * 2012-12-07 2016-06-08 Merck Sharp & Dohme Regioselective n-2 arylation of indazoles
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
CN104447725B (en) * 2014-10-22 2018-02-02 浙江大学 A kind of compound of chirality Bi containing imines Ding oxazolines and preparation method thereof
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
US10233156B2 (en) 2015-03-30 2019-03-19 Shionogi & Co., Ltd. 9-membered fused ring derivative
EP3355699A4 (en) * 2015-09-29 2019-06-19 OncoTherapy Science, Inc. Bicyclic compound and use thereof for inhibiting suv39h2
US10738057B2 (en) 2017-10-18 2020-08-11 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11059836B2 (en) 2014-08-29 2021-07-13 Chdi Foundation, Inc. Probes for imaging huntingtin protein
US11161834B2 (en) 2017-04-24 2021-11-02 Tesaro, Inc. Methods of manufacturing of niraparib
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
US11352340B2 (en) 2016-01-05 2022-06-07 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
WO2023090411A1 (en) 2021-11-19 2023-05-25 塩野義製薬株式会社 Pharmaceutical for treating heart disease or skeletal muscle disease
WO2023217989A1 (en) 2022-05-12 2023-11-16 Syngenta Crop Protection Ag Alkoxy heteroaryl- carboxamide or thioamide compounds
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024126650A1 (en) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Novel bicyclic-carboxamide compounds useful as pesticides

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6417401B2 (en) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー ACC inhibitors and uses thereof
AU2014262546B2 (en) 2013-05-10 2018-11-08 Gilead Apollo, Llc ACC inhibitors and uses thereof
CN105358154A (en) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc inhibitors and uses thereof
BR112015028214A2 (en) 2013-05-10 2017-07-25 Nimbus Apollo Inc acc inhibitors and uses thereof
PL3177612T3 (en) 2014-08-04 2022-08-08 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MX2022007265A (en) 2019-12-20 2022-09-09 Nuevolution As Compounds active towards nuclear receptors.
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
WO2001014372A2 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2002006234A1 (en) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Sulfone derivatives, process for their production and use thereof
WO2004039365A1 (en) 2002-11-01 2004-05-13 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
WO2004041266A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
WO2004106276A1 (en) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005030740A1 (en) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
WO2005058823A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
WO2005063725A1 (en) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
WO2005063729A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005087710A1 (en) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
WO2005095338A1 (en) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
WO2005113504A1 (en) 2004-05-21 2005-12-01 Takeda Pharmaceutical Company Limited Cyclic amide derivatives, and their production and use as antithrombotic agents
WO2006112549A1 (en) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2007013689A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
WO2007013694A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Phenoxyalkanoic acid compound
WO2007018314A2 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
WO2007028135A2 (en) 2005-09-01 2007-03-08 Takeda Pharmaceutical Company Limited Imidazopyridine compounds
WO2008001931A2 (en) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2008050821A1 (en) 2006-10-19 2008-05-02 Takeda Pharmaceutical Company Limited Indole compound
WO2008093639A1 (en) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited Pyrazole compound
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
WO2008136428A1 (en) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2010050445A1 (en) 2008-10-27 2010-05-06 武田薬品工業株式会社 Bicyclic compound
WO2011136385A1 (en) 2010-04-27 2011-11-03 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as acc inhibitors.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69828522T2 (en) * 1997-04-30 2005-12-15 Eli Lilly And Co., Indianapolis ANTITROMOMBOTIC AGENTS
JP4468810B2 (en) * 2002-07-24 2010-05-26 キューエルティー インコーポレーティッド Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
US20070219258A1 (en) * 2006-02-15 2007-09-20 Keyes Robert F Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
WO2012108478A1 (en) 2011-02-09 2012-08-16 武田薬品工業株式会社 Monocyclic compound

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
WO2001014372A2 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2002006234A1 (en) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Sulfone derivatives, process for their production and use thereof
WO2004039365A1 (en) 2002-11-01 2004-05-13 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
WO2004041266A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
WO2004106276A1 (en) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005030740A1 (en) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
WO2005058823A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
WO2005063729A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (en) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
WO2005087710A1 (en) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
WO2005095338A1 (en) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
WO2005113504A1 (en) 2004-05-21 2005-12-01 Takeda Pharmaceutical Company Limited Cyclic amide derivatives, and their production and use as antithrombotic agents
WO2006112549A1 (en) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2007013689A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
WO2007013694A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Phenoxyalkanoic acid compound
WO2007018314A2 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
WO2007028135A2 (en) 2005-09-01 2007-03-08 Takeda Pharmaceutical Company Limited Imidazopyridine compounds
WO2008001931A2 (en) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2008050821A1 (en) 2006-10-19 2008-05-02 Takeda Pharmaceutical Company Limited Indole compound
WO2008093639A1 (en) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited Pyrazole compound
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
WO2008136428A1 (en) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2010050445A1 (en) 2008-10-27 2010-05-06 武田薬品工業株式会社 Bicyclic compound
EP2351743A1 (en) * 2008-10-27 2011-08-03 Takeda Pharmaceutical Company Limited Bicyclic compound
WO2011136385A1 (en) 2010-04-27 2011-11-03 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as acc inhibitors.

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Comprehensive Organic Transformations", 1989, VCH. PUBLISHERS INC.
"Jikken Kagaku Kouza", vol. 20, THE CHEMICAL SOCIETY OF JAPAN, pages: 276 - 278
"ORGANIC FUNCTIONAL GROUP PREPARATIONS", 1989, ACADEMIC PRESS, INC.
"Part I: Diagnosis and Classification of Diabetes Mellitus", 1999, WORLD HEALTH ORGANIZATION, article "World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications"
"Protective Groups in Organic Synthesis", 1980, JOHN WILEY AND SONS
ANALYTICAL SCIENCES, vol. 10, no. 1, 1994, pages 17 - 23
IYAKUHIN NO KAIHATSU: "Design of Molecules", vol. 7, 1990, HIROKAWA SHOTEN, article "Development of Pharmaceuticals", pages: 163 - 198
JEFFREY W. CORBETT ET AL: "Inhibitors of Mammalian Acetyl-CoA Carboxylase", RECENT PATENTS ON CARDIOVASCULAR DRUG DISCOVERY, vol. 2, no. 3, 1 November 2007 (2007-11-01), pages 162 - 180, XP055002486, ISSN: 1574-8901, DOI: 10.2174/157489007782418928 *
JOURNAL OF THE CHEMICAL SOCIETY, 1937, pages 1530 - 1534
JOURNAL OF THE MEDICINAL CHEMISTRY, 2000, pages 3434 - 3442
JOURNAL OF THE MEDICINAL CHEMISTRY, 2006, pages 5282 - 5290
TETRAHEDRON LETTERS, 1980, pages 769 - 770
TETRAHEDRON LETTERS, 2001, pages 8345 - 8349
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 285, 2001, pages 2486 - 2497

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703758B2 (en) 2010-04-27 2014-04-22 Takeda Pharmaceutical Company Limited Bicyclic compound
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
US10815214B2 (en) 2012-12-07 2020-10-27 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
EP2928473A4 (en) * 2012-12-07 2016-06-08 Merck Sharp & Dohme Regioselective n-2 arylation of indazoles
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
US10435386B2 (en) 2012-12-07 2019-10-08 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
CN105008348A (en) * 2013-03-14 2015-10-28 赛隆制药股份公司 Pyrazolylbenzo [ D ] imidazole derivatives
WO2015036892A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
WO2015097713A1 (en) 2013-11-14 2015-07-02 Cadila Healthcare Limited Novel heterocyclic compounds
US10011609B2 (en) 2013-11-14 2018-07-03 Cadila Healthcare Limited Heterocyclic compounds
US10246470B2 (en) 2013-11-14 2019-04-02 Cadila Healthcare Limited Heterocyclic compounds
CN104193731A (en) * 2014-08-27 2014-12-10 广东东阳光药业有限公司 Novel urea-substituted biphenyl compounds as well as composition and application thereof
US11059836B2 (en) 2014-08-29 2021-07-13 Chdi Foundation, Inc. Probes for imaging huntingtin protein
CN104447725B (en) * 2014-10-22 2018-02-02 浙江大学 A kind of compound of chirality Bi containing imines Ding oxazolines and preparation method thereof
US10022387B2 (en) 2015-02-09 2018-07-17 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US10596184B2 (en) 2015-02-09 2020-03-24 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US10233156B2 (en) 2015-03-30 2019-03-19 Shionogi & Co., Ltd. 9-membered fused ring derivative
RU2702637C2 (en) * 2015-03-30 2019-10-09 Сионоги Энд Ко., Лтд. Benzimidazole or imidazopyridine derivatives useful for treating or preventing diseases associated with acc2
AU2021201573B2 (en) * 2015-09-29 2022-02-17 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting suv39h2
EP3355699A4 (en) * 2015-09-29 2019-06-19 OncoTherapy Science, Inc. Bicyclic compound and use thereof for inhibiting suv39h2
US10508109B2 (en) 2015-09-29 2019-12-17 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting SUV39H2
CN105601626A (en) * 2015-11-04 2016-05-25 浙江大学 Preparation method of 2-substituted oxazoline-containing derivative
US10472368B2 (en) 2015-11-06 2019-11-12 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US11773102B2 (en) 2015-11-06 2023-10-03 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US11091491B2 (en) 2015-11-06 2021-08-17 Incyte Corporation Heterocyclic compounds as PI3K-y inhibitors
US11952367B2 (en) 2016-01-05 2024-04-09 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
US11352340B2 (en) 2016-01-05 2022-06-07 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
US10479795B2 (en) 2016-06-24 2019-11-19 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors
US10975088B2 (en) 2016-06-24 2021-04-13 Incyte Corporation Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors
US12030885B2 (en) 2016-06-24 2024-07-09 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
US11161834B2 (en) 2017-04-24 2021-11-02 Tesaro, Inc. Methods of manufacturing of niraparib
US11629137B2 (en) 2017-04-24 2023-04-18 Tesaro, Inc. Methods of manufacturing of niraparib
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US10738057B2 (en) 2017-10-18 2020-08-11 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11225486B2 (en) 2017-10-18 2022-01-18 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
WO2023090411A1 (en) 2021-11-19 2023-05-25 塩野義製薬株式会社 Pharmaceutical for treating heart disease or skeletal muscle disease
WO2023217989A1 (en) 2022-05-12 2023-11-16 Syngenta Crop Protection Ag Alkoxy heteroaryl- carboxamide or thioamide compounds
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024126650A1 (en) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Novel bicyclic-carboxamide compounds useful as pesticides

Also Published As

Publication number Publication date
CN103347872A (en) 2013-10-09
CA2819400A1 (en) 2012-06-07
EP2649062B1 (en) 2015-04-08
AR084032A1 (en) 2013-04-17
MX2013006113A (en) 2013-11-01
MA34713B1 (en) 2013-12-03
TW201242951A (en) 2012-11-01
ES2536319T3 (en) 2015-05-22
CL2013001520A1 (en) 2013-10-18
CR20130281A (en) 2013-10-07
KR20140001965A (en) 2014-01-07
US20120142714A1 (en) 2012-06-07
AU2011337565A1 (en) 2013-07-11
CN103347872B (en) 2014-12-24
BR112013013417A2 (en) 2019-09-24
JP2013545718A (en) 2013-12-26
WO2012074126A9 (en) 2013-06-06
EP2649062A1 (en) 2013-10-16
SG190925A1 (en) 2013-07-31
US8729102B2 (en) 2014-05-20
AU2011337565A2 (en) 2013-07-11
EA201390794A1 (en) 2013-11-29
ECSP13012719A (en) 2013-12-31
CO6751239A2 (en) 2013-09-16
UY33756A (en) 2012-06-29
PE20140161A1 (en) 2014-02-19
JP5824517B2 (en) 2015-11-25
DOP2013000118A (en) 2013-09-30

Similar Documents

Publication Publication Date Title
EP2649062B1 (en) Bicyclic compounds as inhibitors of acetyl-coa carboxylase (acc)
US9238639B2 (en) Aromatic ring compound
US9133129B2 (en) Bicyclic compound
CN103025716B (en) Bicyclic compound derivatives and their use as acc inhibitors
EP2210876A1 (en) Heterocyclic compound
WO2012108478A1 (en) Monocyclic compound
EP2583965A1 (en) Heterocyclic ring compound
US9073864B2 (en) Aromatic ring compound
TW201350491A (en) Bicyclic compound
TW201332945A (en) Monocyclic compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11802168

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2819400

Country of ref document: CA

Ref document number: 2013524677

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013001520

Country of ref document: CL

Ref document number: 226628

Country of ref document: IL

Ref document number: 12013501099

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 0183313

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 001328-2013

Country of ref document: PE

Ref document number: MX/A/2013/006113

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2013-000281

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 20137016850

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13144

Country of ref document: GE

Ref document number: A201308168

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201390794

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2011337565

Country of ref document: AU

Date of ref document: 20111129

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013013417

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013013417

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130529